



US00RE44760E

(19) **United States**
 (12) **Reissued Patent**
Crooke et al.

(10) **Patent Number:** **US RE44,760 E**
 (45) **Date of Reissued Patent:** **Feb. 11, 2014**

(54) **ANTISENSE MODULATION OF
 APOLIPOPROTEIN B-EXPRESSION**

(71) Applicant: **Genzyme Corporation**, Cambridge, MA
 (US)

(72) Inventors: **Rosanne M. Crooke**, Carlsbad, CA
 (US); **Mark J. Graham**, San Clemente,
 CA (US); **Susan M. Freier**, San Diego,
 CA (US)

(73) Assignee: **Genzyme Corporation**, Cambridge, MA
 (US)

(21) Appl. No.: **13/629,214**

(22) Filed: **Sep. 27, 2012**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **7,803,930**
 Issued: **Sep. 28, 2010**
 Appl. No.: **10/920,612**
 Filed: **Aug. 17, 2004**

U.S. Applications:

(63) Continuation of application No. 10/712,795, filed on
 Nov. 13, 2003, now Pat. No. 7,511,131, and a continu-
 ation-in-part of application No. PCT/US03/15493,
 filed on May 15, 2003.

(60) Provisional application No. 60/426,234, filed on Nov.
 13, 2002.

(51) **Int. Cl.**
A61K 31/70 (2006.01)
A61K 48/00 (2006.01)
C07H 21/02 (2006.01)
C07H 21/04 (2006.01)

(52) **U.S. Cl.**
 USPC **435/455**; 536/24.5; 536/23.2; 536/24.1;
 536/24.3; 536/24.31; 536/24.33; 435/325;
 435/375; 435/377; 514/44 A

(58) **Field of Classification Search**
 None
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,220,006 A 6/1993 Ross et al.
 5,434,058 A 7/1995 Davidson et al.
 5,618,674 A 4/1997 Sanchez-Pescador et al.
 5,656,612 A 8/1997 Monia
 5,712,257 A 1/1998 Carter
 5,786,206 A 7/1998 Smith et al.
 5,801,154 A 9/1998 Baracchini et al.
 5,877,009 A 3/1999 Zannis et al.
 5,945,290 A 8/1999 Cowser
 5,998,148 A 12/1999 Bennett et al.
 6,010,849 A 1/2000 Edwards et al.
 6,033,910 A 3/2000 Monia et al.
 6,096,516 A 8/2000 Kwak et al.
 6,156,315 A 12/2000 Goldberg et al.
 6,172,216 B1 1/2001 Bennett et al.
 6,184,212 B1 2/2001 Miraglia et al.
 6,235,470 B1 5/2001 Sidransky
 6,359,124 B1 3/2002 Ecker et al.

6,448,079 B1 9/2002 Monia et al.
 6,500,672 B1 12/2002 Sladek et al.
 6,512,161 B1 1/2003 Rouy et al.
 6,534,277 B1 3/2003 Hancock et al.
 6,582,908 B2 6/2003 Fodor et al.
 6,660,737 B2 12/2003 Almstead et al.
 6,670,461 B1 12/2003 Wengel et al.
 6,852,536 B2 2/2005 Dobie et al.
 6,878,729 B2 4/2005 Almstead et al.
 6,949,367 B1 9/2005 Dempcy et al.
 7,407,943 B2 8/2008 Crooke et al.
 7,511,131 B2 3/2009 Crooke et al.
 7,598,227 B2 10/2009 Crooke et al.
 7,750,141 B2 7/2010 Crooke et al.
 7,803,930 B2 9/2010 Crooke et al.
 7,888,324 B2 2/2011 Crooke et al.
 2001/0053519 A1 12/2001 Fodor et al.
 2002/0068708 A1 6/2002 Wengel et al.
 2002/0123617 A1 9/2002 Starling et al.
 2003/0008373 A1 1/2003 Bartel et al.
 2003/0064950 A1 4/2003 Ntambi et al.
 2003/0083280 A1 5/2003 Crooke et al.
 2003/0087853 A1 5/2003 Crooke et al.
 2003/0215943 A1 11/2003 Crooke et al.
 2003/0228597 A1 12/2003 Cowser et al.
 2003/0228613 A1 12/2003 Bornarth et al.
 2004/0171566 A1 9/2004 Monia et al.
 2004/0208856 A1 10/2004 Crooke et al.
 2004/0209838 A1 10/2004 Monia et al.
 2004/0214325 A1 10/2004 Crooke et al.
 2004/0241651 A1 12/2004 Olek et al.
 2004/0266714 A1 12/2004 Freier et al.
 2005/0009088 A1 1/2005 Crooke et al.
 2005/0014713 A1 1/2005 Freier
 2005/0043524 A1 2/2005 Bhanot et al.
 2005/0130923 A1 6/2005 Bhat et al.
 2005/0164271 A1 7/2005 Bhanot et al.
 2005/0272680 A1 12/2005 Bhanot et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 332 435 9/1989
 EP 0 530 794 3/1993

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 60/159,462, filed Oct. 12, 1999, Eggerman et al.

(Continued)

Primary Examiner — Janet Epps-Smith

(74) *Attorney, Agent, or Firm* — Jones Day

(57) **ABSTRACT**

Antisense compounds, compositions and methods are pro-
 vided for modulating the expression of apolipoprotein B. The
 compositions comprise antisense compounds, particularly
 antisense oligonucleotides, targeted to nucleic acids encod-
 ing apolipoprotein B. Methods of using these compounds for
 modulation of apolipoprotein B expression and for treatment
 of diseases associated with expression of apolipoprotein B
 are provided.

58 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0287558	A1	12/2005	Crooke et al.
2006/0009410	A1	1/2006	Crooke et al.
2006/0025373	A1	2/2006	Bhanot et al.
2006/0035858	A1	2/2006	Geary et al.
2007/0031844	A1	2/2007	Khvorova et al.
2007/0087987	A1	4/2007	Monia et al.
2007/0238688	A1	10/2007	Bhanot et al.
2007/0238690	A1	10/2007	Bhanot et al.
2008/0146788	A1	6/2008	Bhat et al.
2008/0242629	A1	10/2008	Crooke et al.
2009/0306180	A1	12/2009	Bhanot et al.
2009/0326040	A1	12/2009	Geary et al.

FOREIGN PATENT DOCUMENTS

EP	0 911 344	4/1999
EP	1 239 051	9/2002
EP	1239051 A2 *	9/2002
JP	2002355074	12/2002
WO	WO 92/10590	6/1992
WO	WO 94/13794	6/1994
WO	WO 94/13794 A1	6/1994
WO	WO 97/20924	6/1997
WO	WO 97/35538 A2	10/1997
WO	WO 98/20166	5/1998
WO	WO 98/32846	7/1998
WO	WO 98/36641	8/1998
WO	WO 99/14226	3/1999
WO	WO 99/18237	4/1999
WO	WO 99/18986	4/1999
WO	WO 99/18986 A1	4/1999
WO	WO 99/35241	7/1999
WO	WO 00/00504	1/2000
WO	WO 00/56916	9/2000
WO	WO 00/56920	9/2000
WO	WO 01/12789	2/2001
WO	WO 01/30354	5/2001
WO	WO 01/30354 A1	5/2001
WO	WO 01/30395 A1	5/2001
WO	WO 01/52902	7/2001
WO	WO 0152902 A1 *	7/2001
WO	WO 01/72765 A1	10/2001
WO	WO 01/77384	10/2001
WO	WO 01/77384 A2 *	10/2001
WO	WO 02/26768	4/2002
WO	WO 03/011887	2/2003
WO	WO 03/074723	9/2003
WO	WO2003/074723 A2 *	9/2003
WO	WO 03/097097	11/2003
WO	WO 03/097662	11/2003
WO	WO 2004/044181	5/2004
WO	WO 2004/077384	9/2004
WO	WO 2004/093783	11/2004
WO	WO 2005/049621	6/2005
WO	WO 2006/020676 A2	2/2006
WO	WO 2007/031081 A2	3/2007
WO	WO 2007/090071 A2	8/2007
WO	WO 2007/131238 A2	11/2007
WO	WO 2007/134181	11/2007
WO	WO 2008/118883 A1	10/2008

OTHER PUBLICATIONS

Agrawal et al., "Antisense therapeutics: is it as simple as complementary base recognition?" *Molecular Medicine Today* (2000) 6: 72-81.

Bayarsaihan et al., "Single-strand-DNA-binding factors specifically recognize the pyrimidine element in the chick $\alpha 2(I)$ collagen gene promoter" *Biochem J.* (1996) 314:293-296.

Bennett et al., "Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides." *Journal of Immunology* (1994) 152(7):3530-3540.

Bennett et al., "Antisense Oligonucleotides as a Tool for Gene Functionalization and Target Validation," *Biochimica et Biophysica Acta* (1999) 1489:18-30.

Bonow, "Primary Prevention of Cardiovascular Disease: A Call to Action" *Circulation* (2002) 106:3140-3141.

Boren et al., "A simple and efficient method for making site-directed mutants, deletions, and fusions of large DNA such as PI and BAC clones" *Genome Research* (1996) 11:1123-1130.

Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," *Biochemistry* 41:4503-4510, (2002).

Branch et al., "A good antisense molecule is hard to find," *TIBS* (1998) 23:45-50.

Burnett, "Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia" *Current Opinion in Molecular Therapeutics* (2006) 8(5):461-467.

Campos et al., "Distinct patterns of lipoproteins with apoB defines by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia" *J. Lipid Res.* (2001) 42:1239-13491.

Chan et al., "Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration," *Metabolism Clin. and Experimental* (2002) 51(8):1041-1046.

Crooke, "Progress in Antisense Technology" *Ann. Rev. Med.* (2004) 55:61-95.

Crooke, "Antisense oligonucleotides as therapeutics for hyperlipidaemias" *Expert Opinion on Biological Therapy* (2005) 5(7):907-917.

Cuchel et al., "Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia" *New England Journal of Medicine* (2007) 356:148-156.

Dammerman et al., "An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms" *Proc. Natl. Acad. Sci. U. S. A.*, (1993) 90:4562-4566.

Davidson et al., "Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation" *Annu. Rev. Nutr.* (2000) 20:169-193.

Davis et al., "Atherosclerosis Is a Liver Disease of the Heart" *Arterioscler. Thromb. Vasc. Biol.* (2001) 21:887-898.

De Silva et al., "Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E" *J. Biol. Chem.* (1994) 269:2324-2335.

DeCatarina et al., "Fatty Acid Modulation of Endothelial Activation" *American Journal of Clinical Nutrition* (2000) 71 (suppl.):213S-223S.

Deeb et al., "Chromosomal localization of the human apolipoprotein B gene and detection of homologous RNA in monkey intestine" *Proc. Natl. Acad. Sci. USA* (1986) 83:419-422.

Deere et al., "Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition in *Escherichia coli*" *Antimicrobial Agents and Chemotherapy* (2005) 49:249-255.

Duivenvoorden et al., "Apolipoprotein C3 Deficiency Results in Diet-Induced Obesity and Aggravated Insulin Resistance in Mice" *Diabetes* (2005) 54:664-671.

Elias et al., "Decreased Production Rates of VLDL Triglycerides and ApoB-100 in Subjects Heterozygous for Familial Hypobetalipoproteinemia," *Metabolism of Triglycerides and ApoB-100 n FHBL, Arterioscler Therob Vasc Biol.*, (1999)9:2714-2721.

EMBL Accession No. A13426, Oct. 5, 1994.

EMBL Accession No. A23827, Apr. 2, 1995.

EMBL Accession No. A97152, Jan. 26, 2000.

EMBL Accession No. AR 152836, Aug. 9, 2001.

EMBL Accession No. L24258, Sep. 18, 1993.

EMBL Accession No. L27195, Jan. 6, 1994.

Farese et al., "Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes" *Proc. Natl. Acad. Sci. USA* (1995) 92:1774-1778.

Fluiter K., et al., "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides," *Nucleic Acids Research*, 2003, vol. 31, No. 3, pp. 953-962.

(56)

References Cited

OTHER PUBLICATIONS

- Frieden M., et al., "Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA," *Nucleic Acids Research*, Oxford University Press, Surrey, GB, vol. 31, No. 21, Nov. 1, 2003, pp. 6365-6372.
- Funatsu et al., "Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats" *Biochimica et Biophysica Acta* (2002) 1580:161-170.
- Ganji et al., "Niacin and cholesterol: role in cardiovascular disease (Review)" *The Journal of Nutritional Biochemistry* (2003) 14:293-305.
- Gautschi et al., "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins" *J. Natl Cancer Inst* (2001) 93:463-471.
- Geary et al., "Pharmacokinetics of a Tumor Necrosis Factor- α Phosphorothioate 2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide: Comparison Across Species," *Drug Metab Dispos* 2003;31:1419-1428.
- Genbank Accession No. NM_000384, Oct. 31, 2000, Huang et al.
- Geneseq Accession No. AAA07969, Jan. 29, 2001.
- Geneseq Accession No. AAA28208, Jan. 29, 2001.
- Geneseq Accession No. AAV39607, Sep. 28, 1998.
- Geneseq Accession No. AAX89306, Sep. 21, 1999. (from WO 99/35241).
- Gewirtz et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise" *PNAS USA* (1996) 93:3161-3163.
- Graham et al., "Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidemias" *AHA Abstracts* (2002) Abstract ID:20009.
- Graham et al., "Pharmacological Inhibition of PCSK9 in Hyperlipemic Mice Significantly Reduces Serum LDL-C While Increasing Hepatic Low-Density Lipoprotein Receptor Protein Abundance," *Arterioscler. Thromb. Vasc. Biol.* (Jun. 2007) vol. 27, No. 6, p. E36.
- Hajjar et al., "The role of lipoprotein(a) in atherogenesis and thrombosis" *Annu. Rev. Med.* (1996) 47:423-442.
- Hammond et al., "Post-transcriptional gene silencing by double-stranded RNA" *Nature Reviews Genetics* (2001) 2:110-119.
- Hertz et al., "Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-II" *J. Biol. Chem.* (1995) 270:13470-13475.
- Heymsfield, "Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults" *Archives of Internal Medicine* 160:1321-1326, (2002).
- Huang et al., "Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination" *Journal of Biological Chemistry* (1989) 264:11394-11400. (Genbank NM_000384).
- Iijima et al., "Red Wine Polyphenols Inhibit Vascular Smooth Muscle Cell Migration Through Two Distinct Signaling Pathways" *Circulation* (2002) 105(20):2404-2410.
- Innerarity et al., "Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding" *Proc. Natl. Acad. Sci. USA* (1987) 84:6919-6923.
- ISA, International Search Report for Application PCT/US00/29223 dated Dec. 26, 2000.
- ISA, International Search Report dated Oct. 22, 2003 for Application PCT/US03/15493.
- ISA, International Search Report dated Aug. 31, 2004 for Application CT/US03/36411.
- ISA, International Search Report dated Apr. 10, 2006 for Application PCT/US05/028342.
- ISA, Communication Relating to the Results of the Partial International Search dated Jan. 30, 2008 for Application PCT/US07/68401.
- ISA, International Search Report dated Apr. 21, 2008 for Application PCT/US07/68401.
- ISA, International Search Report dated Mar. 13, 2008 for Application PCT/US07/68403.
- ISA, International Search Report dated Mar. 13, 2008 for Application PCT/US07/68404.
- ISA, International Search Report dated Apr. 24, 2008 for Application PCT/US07/68410.
- ISA, International Search Report dated Apr. 24, 2008 for Application PCT/US07/68412.
- ISA, International Search Report dated Apr. 25, 2008 for Application PCT/US07/68415.
- ISA, International Search Report dated Jul. 28, 2008 for Application PCT/US08/058072.
- ISA, International Search Report dated May 25, 2010 for Application PCT/US10/27541.
- "Isis 301012" retrieved from the internet: URL: http://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_refid=1132978 [retrieved Nov. 29, 2012].
- Ito et al., "Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice" *Science* (1990) 249:790-793.
- James, W., "Towards gene-inhibition therapy; a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes," *Antiviral Chemistry and Chemotherapy*, Apr. 191, vol. 2, No. 4, pp. 191-214, (1991).
- Jen et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies" *Stem Cells* (2000) 18:307-319.
- Jong et al., "Role of ApoCs in Lipoprotein Metabolism—Functional Differences Between ApoC1, ApoC2, and ApoC3" *Arterioscler. Thromb. Vasc. Biol.* (1999) 19:472-484.
- Jover et al., "Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting" *Hepatology* (2001) 33(3):668-675.
- Karathanasis, "Apolipoprotein multigene family: tandem organization of human apolipoprotein A1, C111, and A1V genes" *Proc. Natl. Acad. Sci. U. S. A.* (1985) 82:6374-6378.
- Kardassis et al., "Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter" *Biochemistry* (2002) 41:1217-1228.
- Kardassis et al., "SMAD proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4" *J. Biol. Chem.* (2000) 275:41405-41414.
- Kastelein et al., "Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B" *Circulation* (2006) 114(16):1729-1735.
- Kawakami et al., "Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells," *Circulation* (2006) 113:691-700.
- Klein et al., "P284: Apoprotein C-III (ApoCIII) Protein Concentrations and Gene Polymorphisms in Type I Diabetes" *Arterioscler. Thromb. Vasc. Biol.* (2002) 22(5):A-50.
- Knopp, "Drug Treatment of Lipid Disorders" *New Engl J. Med* (1999) 341:498-511.
- Koba et al., "Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction" *Atherosclerosis* (2003) 170:131-140.
- Lai et al., "Association between obesity and hyperlipidemia among children." *Yale Journal of Biology and Medicine* (2001) 74:205-210.
- Latorra et al., "Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers," *Human Mutation* (2003) 22:79-85.
- Law et al., "Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2," *Proc. Natl. Acad. Sci. USA* (1985) 82:8340-8344.
- Lee et al., "LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic patients" *Arteriosclerosis, Thrombosis, and Vascular Biology* (2003) 23:853-858.
- Levy-Wilson et al., "Isolation and DNA sequence of full-length cDNA for human preapolipoprotein CIII" *DNA* (1984) 3:359-364.
- Li et al., "Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia" *J. Clin. Invest.* (1995) 96:2601-2605.
- Ma et al., "Synthetic oligonucleotides as therapeutics: the coming age," *Biotechnology Annual Review* (2000) 5:155-196.

(56)

References Cited

OTHER PUBLICATIONS

- Maeda et al., "Molecular cloning of a human apo-C-III variant: Thr 74—Ala74 mutation prevents O-glycosylation" *J. Lipid Res.* (1987) 28:1405-1409.
- Maeda et al., "Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia" *J. Biol. Chem.* (1994) 269:23610-23616.
- Maxwell et al., "Proprotein Convertase Subtilisin Kexin 9: The Third Locus Implicated in Autosomal Dominant Hypercholesterolemia," *Current Opinion in Lipidology*, 2005, vol. 16, pp. 167-172.
- McCormick et al., "Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl-terminal portion of human apoB100 are important for the assembly of lipoprotein," *J. Biol. Chem.* (1997) 272:23616-23622.
- Merki et al., "A second generation antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on apolipoprotein B-100 particles in lipoprotein(a)-transgenic mice," *J. Amer. Coll. Cardiol.* (2008) 51(1) Suppl. 1, A294.
- Merki et al., "Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on apolipoprotein B-100 particles in lipoprotein(a)-transgenic mice," *Circulation* (2008) 118:743-753.
- Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," *Nature Biotechnology*, Jun. 1997, Vol. 15, pp. 537-541.
- NCBI Search Results, (ISPH-0592) dated Oct. 30, 2007, *Mamm. Genome* 6 (3), 192-195 (1995).
- New England Biolabs, 1998/1999 Catalog, pp. 121 and 284.
- Nielsen, "Systemic Delivery: The Last Hurdle?" *Gene Therapy* (2005) 12:956-957.
- Nowak-Gottl et al., "Lipoprotein (a): its role in childhood thromboembolism," *Pediatrics* (1997) 99:1-3.
- Ogami et al., "Purification and characterization of a heat stable nuclear factor (CIII-B1 involved in the regulation of the human ApoC-III gene" *J. Biol. Chem.* (1991) 266:9640-9646.
- Olivieri et al., "ApoC-III polymorphisms and risk of coronary artery disease" *J. Lipid Res.* (2002) 43: 1450-1457.
- Olivieri et al., "Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin_Resistant" T-455C APOC3 Gene Polymorphisms in Heart Disease Patients: Example of Gene-Diet Interaction" *Clin. Chem.* (2005) 51(2):360-367.
- Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications" *Nature Rev. Drug Discov.* (2002) 1:503-514.
- Ostrander et al., "Dog (Clone: CXX.371) Primer for STS 371, 5' End, Sequence Tagged Site," EMBL XP002392182, Sep. 18, 1993.
- Ostrander et al., "Dog Primer for STS 610, 3' End, Sequence Tagged Site," EMBL XP002392183, Jan. 6, 1994.
- Parrish et al., "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," *Molecular Cell* (2000) 6:1077-1087.
- Petersen et al., "Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids," *Journal of the American Chemical Society* (2002) 124:5974-5982.
- Pittner et al., "Effects of PYY[3-36] in rodent models of diabetes and obesity" *Int. J. Obes. Relat. Metab. Disord.* (2004) 28:963-971.
- PR Newswire, "Isis Pharmaceuticals initiates phase I study of second-generation antisense drug for cardiovascular disease" New York, Dec. 29, 2003; Source: Isis Pharmaceuticals.
- PR Newswire, "Second generation antisense drug for cardiovascular disease demonstrates significant durable reductions in cholesterol" New York, Aug. 11, 2004; Source: Isis Pharmaceuticals.
- Protter et al., "Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo ACIII genes" *DNA* (1984) 3:449-456.
- Qidong, Tang et al., "The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells," *Zhongguo Dongmai Yinghua ZaZhi Bianjibu* (Chinese Journal of Arteriosclerosis) (1999) 7:315-318.
- Raspe et al., "Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription" *J. Lipid Res.* (2002) 43:2172-2179.
- Reynolds et al., "Rational siRNA design for RNA interference" *Nature Biotechnology* (2004) 22(3):326-330.
- Roglans et al., "Atorvastatin Treatment Induced Peroxisome Proliferator-Activated Receptor Alpha Expression and Decreased Plasma Nonesterified Fatty Acids and Liver Triglyceride in Fructose-Fed Rats" *Journal of Pharmacology and Experimental Therapeutics* (2002) 302:232-239.
- Rosenson, "Clinical Role of LDL and HDL Subclasses and Apolipoprotein Measurements," *ACC Current Journal Review*, 33-37 (2004).
- Rossi et al., "Introductory Remarks on the General Application of Antisense RNAs and Ribozymes," *Methods: A Companion to Methods in Enzymology* (1993) 5:1-5.
- Rubies-Prat et al., "Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension" *Clinical and Experimental Hypertension* (2001) 23:489-500.
- Sanghvi et al., "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides" *Antisense Research and Applications* (1993) pp. 273-288.
- Schoonjans et al., "3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase" *FEBS Lett.* (1999) 452:160-164.
- Senior, "Antisense inhibitor provides new treatment approach for hypercholesterolemia" *Drug Discovery Today* (2002) 7:840-841.
- Sewell et al., "Phase 1 Trial of Isis 104838, a 2'-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor- α ," *The Journal of Pharmacology and Experimental Therapeutics* (2002)303:1334-1343.
- Shachter, "Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism" *Curr. Opin. Lipidol.* (2001) 12:297-304.
- Sharpe et al., "Human apolipoproteins AI, AII, CII and CIII cDNA sequences and mRNA abundance" *Nucleic Acids Res.* (1984) 12:3917-3932.
- Simeonov et al., "Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection," *Nucleic Acids Research* (2002) 30:E91.
- Skrapari et al., "Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels," *Diabet Med* (2001) 18:781-785.
- Sniderman et al., "Substrate Delivery as a Determinant of Hepatic ApoB Secretion," *Arterioscler Thromb Vasc Biol.*, (1993)13:629-636.
- Tamm et al., "Antisense therapy in oncology: new hope for an old idea?" *The Lancet* (2001)358:489-497.
- Tanaka et al., "Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes," *Journal of Biological Chemistry* (1993) 268:12713-12718.
- Ugawa et al., "YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents" *British Journal of Pharmacology* (2003) 139:140-146.
- Vessby et al., "Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolemia," *Atherosclerosis* (1982) 44:61-71.
- Vu-Dac et al., "Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids," *J. Clin. Invest.* (1998) 102:625-632.
- Wimberly, "Rosuvastatin (Crestor) a new statin for the treatment of dyslipidemia" *PharmaNote* (2003) 19:1-6.
- Woolf et al., "Specificity of antisense oligonucleotides in vivo" *PNAS* (1992) 89:7305-7309.
- Yamamoto et al., "Overexpression of PACAP in Transgenic Mouse Pancreatic B-Cells Enhances Insulin Secretion and Ameliorates Streptozotocin-induced Diabetes" *Diabetes* (2003) 52:1155-1162.

(56)

References Cited

OTHER PUBLICATIONS

Yu et al., "Antisense oligonucleotide inhibition of DGAT2 expression reduced hepatic steatosis diet-induced obese mice," *Obesity Research* (2003) 11 (Suppl): A48.

Yu et al., "Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice," *Hepatology* (2005) 42(2):362-371.

Yu et al., "Pharmacokinetics and Pharmacodynamics of an Antisense Phosphorothioate Oligonucleotide Targeting Fas mRNA in Mice," *J. Pharmacol. Exp. Ther.* (2001) 296:388-395.

Parrish et al. *Molecular Cell* 2000, vol. 6, pp. 1077-1087.*

Hammond et al. Post-transcriptional gene silencing by double-stranded RNA. *Nature Genetics* 2001, vol. 2: 110-119.*

Enhanced allele-specific PCR discrimination in SNP genotyping using 3 locked nucleic acid (LNA) primers *Human Mutation* vol. 22, Issue 1, Date: Jul. 2003, pp. 79-85 David Latorra, Krista Campbell, Andreas Wolter, J. Michael Hurley.*

U.S. Appl. No. 60/159,462, Eggerman et al.

Katan et al., "Characteristics of Human Hypo- and Hyper-responders to Dietary Cholesterol," *American Journal of Epidemiology* 125(3):387-399 (1987).

Kim et al., Genetically modified mice for the study of apolipoprotein B.; *Journal of Lipid Research* 39: 703-723 (1998).

McCormick et al., "Transgenic Mice Expressing Human ApoB95 and ApoB97," *The Journal of Biological Chemistry* 272(38):23616-23622 (1997).

Nishina et al., "Synthetic low and high fat diets for the study of atherosclerosis in the mouse," *Journal of Lipid Research* 31:859-869 (1990).

Sandkamp et al., "Lipoprotein(a) Is an Independent Risk Factor for Myocardial Infarction at a Young Age," *Clin. Chem.* 36/1:20-23 (1990).

Seed et al., "Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary heart Disease in Patients with Familial Hypercholesterolemia," *The New England Journal of Medicine* 1494-1498 (1990).

Tang Quidong et al., "The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells," *Chinese Journal of Arteriosclerosis* 7(4):315-318 (1999).

Veniant et al., "Susceptibility to Atherosclerosis in Mice expressing Exclusively Apolipoprotein B48 or Apolipoprotein B100," *J. Clin. Invest* 100(1):180-188 (1997).

Chin, Andrew "On the Preparation and Utilization of Isolated and Purified Oligonucleotides." Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.

Eggerman et al. "Use of Oligonucleotides to Target Nucleic Acid Sequences Encoding Apolipoprotein B to Decrease Serum Apolipoprotein B and Cholesterol Levels" *Federal Register* vol. 65, No. 110 (2000).

Patil et al., DNA-based therapeutics and DNA delivery systems: A comprehensive review, 2005. *The AAPS Journal*, vol. 7, pp. E61-E77.

De Mesmaeker, et al. 1995. *Backbone Modifications in Oligonucleotides and Peptide Nucleic Acid Systems*. *Current Opinion in Structural Chemistry*, 5: 343-355.

Supplementary Partial European Search Report from PCT/US0224247 dated Jul. 27, 2006.

EMBL Accession No. A13429, Oct. 5, 1994.

EMBL Accession No. I13154, Aug. 2, 1995.

Tang, et al. 1999. The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells. *Chinese Journal of Arteriosclerosis*, vol. 7, No. 4.

Crooke et al., "Chapter 1: Basic Principles of Antisense Therapeutics" *Antisense Research and Applications* (1998) 131:1-50.

Advisory Action for U.S. Appl. No. 09/920,022 (ISPH-0592) dated Feb. 28, 2006.

Lemonidis, et al., "Abstracts of the 11th International Congress on Cardiovascular Pharmacotherapy. Montreal, Canada, May 18-21, 2002," Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 2002, vol. 16, Suppl. 1, P471, SP002565482.

Rojanasakul, Y., "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," *Advanced Drug Delivery Reviews*, (1996), vol. 18, pp. 115-131. XP002913878.

Smith et al., "Rational Selection of Antisense Oligonucleotide Sequences," *European Journal of Pharmaceutical Sciences*, (2000), vol. 11, No. 3, pp. 191-198, XP002372482.

EPO, European Search Report Dated Feb. 8, 2010 for Application No. 09015376.8.

* cited by examiner

ANTISENSE MODULATION OF APOLIPOPROTEIN B-EXPRESSION

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in *italics* indicates the additions made by reissue.

This application is a continuation of U.S. application Ser. No. 10/712,795, filed Nov. 13, 2003 now U.S. Pat. No. 7,511,131, U.S. application Ser. No. 10/712,795 claims priority to U.S. provisional Application Ser. No. 60/426,234, filed Nov. 13, 2002, and claims priority under 35 U.S.C. §365(a) to PCT application US03/15493, filed on May 15, 2003, both of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of apolipoprotein B. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding apolipoprotein B. Such compounds have been shown to modulate the expression of apolipoprotein B.

BACKGROUND OF THE INVENTION

Lipoproteins are globular, micelle-like particles that consist of a non-polar core of acylglycerols and cholesteryl esters surrounded by an amphiphilic coating of protein, phospholipid and cholesterol. Lipoproteins have been classified into five broad categories on the basis of their functional and physical properties: chylomicrons, which transport dietary lipids from intestine to tissues; very low density lipoproteins (VLDL); intermediate density lipoproteins (IDL); low density lipoproteins (LDL); all of which transport triacylglycerols and cholesterol from the liver to tissues; and high density lipoproteins (HDL), which transport endogenous cholesterol from tissues to the liver.

Lipoprotein particles undergo continuous metabolic processing and have variable properties and compositions. Lipoprotein densities increase without decreasing particle diameter because the density of their outer coatings is less than that of the inner core. The protein components of lipoproteins are known as apolipoproteins. At least nine apolipoproteins are distributed in significant amounts among the various human lipoproteins.

Apolipoprotein B (also known as ApoB, apolipoprotein B-100; ApoB-100, apolipoprotein B-48; ApoB-48 and Ag(x) antigen), is a large glycoprotein that serves an indispensable role in the assembly and secretion of lipids and in the transport and receptor-mediated uptake and delivery of distinct classes of lipoproteins. The importance of apolipoprotein B spans a variety of functions, from the absorption and processing of dietary lipids to the regulation of circulating lipoprotein levels (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193). This latter property underlies its relevance in terms of atherosclerosis susceptibility, which is highly correlated with the ambient concentration of apolipoprotein B-containing lipoproteins (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193).

Two forms of apolipoprotein B exist in mammals. ApoB-100 represents the full-length protein containing 4536 amino acid residues synthesized exclusively in the human liver (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-

193). A truncated form known as ApoB-48 is colinear with the amino terminal 2152 residues and is synthesized in the small intestine of all mammals (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193).

ApoB-100 is the major protein component of LDL and contains the domain required for interaction of this lipoprotein species with the LDL receptor. In addition, ApoB-100 contains an unpaired cysteine residue which mediates an interaction with apolipoprotein(a) and generates another distinct atherogenic lipoprotein called Lp(a) (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193).

In humans, ApoB-48 circulates in association with chylomicrons and chylomicron remnants and these particles are cleared by a distinct receptor known as the LDL-receptor-related protein (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193). ApoB-48 can be viewed as a crucial adaptation by which dietary lipid is delivered from the small intestine to the liver, while ApoB-100 participates in the transport and delivery of endogenous plasma cholesterol (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193).

The basis by which the common structural gene for apolipoprotein B produces two distinct protein isoforms is a process known as RNA editing. A site specific cytosine-to-uracil editing reaction produces a UAA stop codon and translational termination of apolipoprotein B to produce ApoB-48 (Davidson and Shelness, *Annu. Rev. Nutr.*, 2000, 20, 169-193).

Apolipoprotein B was cloned in 1985 (Law et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1985, 82, 8340-8344) and mapped to chromosome 2p23-2p24 in 1986 (Deeb et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1986, 83, 419-422).

Disclosed and claimed in U.S. Pat. No. 5,786,206 are methods and compositions for determining the level of low density lipoproteins (LDL) in plasma which include isolated DNA sequences encoding epitope regions of apolipoprotein B-100 (Smith et al., 1998).

Transgenic mice expressing human apolipoprotein B and fed a high-fat diet were found to develop high plasma cholesterol levels and displayed an 11-fold increase in atherosclerotic lesions over non-transgenic littermates (Kim and Young, *J. Lipid Res.*, 1998, 39, 703-723; Nishina et al., *J. Lipid Res.*, 1990, 31, 859-869).

In addition, transgenic mice expressing truncated forms of human apolipoprotein B have been employed to identify the carboxyl-terminal structural features of ApoB-100 that are required for interactions with apolipoprotein(a) to generate the Lp(a) lipoprotein particle and to investigate structural features of the LDL receptor-binding region of ApoB-100 (Kim and Young, *J. Lipid Res.*, 1998, 39, 703-723; McCormick et al., *J. Biol. Chem.*, 1997, 272, 23616-23622).

Apolipoprotein B knockout mice (bearing disruptions of both ApoB-100 and ApoB-48) have been generated which are protected from developing hypercholesterolemia when fed a high-fat diet (Farese et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1995, 92, 1774-1778; Kim and Young, *J. Lipid Res.*, 1998, 39, 703-723). The incidence of atherosclerosis has been investigated in mice expressing exclusively ApoB-100 or ApoB-48 and susceptibility to atherosclerosis was found to be dependent on total cholesterol levels. Whether the mice synthesized ApoB-100 or ApoB-48 did not affect the extent of the atherosclerosis, indicating that there is probably no major difference in the intrinsic atherogenicity of ApoB-100 versus ApoB-48 (Kim and Young, *J. Lipid Res.*, 1998, 39, 703-723; Veniant et al., *J. Clin. Invest.*, 1997, 100, 180-188).

Elevated plasma levels of the ApoB-100-containing lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, which may include hyperc-

hypercholesterolemia (Seed et al., N. Engl. J. Med., 1990, 322, 1494-1499), myocardial infarction (Sandkamp et al., Clin. Chem., 1990, 36, 20-23), and thrombosis (Nowak-Gottl et al., Pediatrics, 1997, 99, E11).

The plasma concentration of Lp(a) is strongly influenced by heritable factors and is refractory to most drug and dietary manipulation (Katan and Beynen, Am. J. Epidemiol., 1987, 125, 387-399; Vessby et al., Atherosclerosis, 1982, 44, 61-71). Pharmacologic therapy of elevated Lp(a) levels has been only modestly successful and apheresis remains the most effective therapeutic modality (Hajjar and Nachman, Annu. Rev. Med., 1996, 47, 423-442).

Disclosed and claimed in U.S. Pat. No. 6,156,315 and the corresponding PCT publication WO 99/18986 is a method for inhibiting the binding of LDL to blood vessel matrix in a subject, comprising administering to the subject an effective amount of an antibody or a fragment thereof, which is capable of binding to the amino-terminal region of apolipoprotein B, thereby inhibiting the binding of low density lipoprotein to blood vessel matrix (Goldberg and Pillarisetti, 2000; Goldberg and Pillarisetti, 1999).

Disclosed and claimed in U.S. Pat. No. 6,096,516 are vectors containing cDNA encoding murine recombinant antibodies which bind to human ApoB-100 for the purpose of for diagnosis and treatment of cardiovascular diseases (Kwak et al., 2000).

Disclosed and claimed in European patent application EP 911344 published Apr. 28, 1999 (and corresponding to U.S. Pat. No. 6,309,844) is a monoclonal antibody which specifically binds to ApoB-48 and does not specifically bind to ApoB-100, which is useful for diagnosis and therapy of hyperlipidemia and arterial sclerosis (Uchida and Kurano, 1998).

Disclosed and claimed in PCT publication WO 01/30354 are methods of treating a patient with a cardiovascular disorder, comprising administering a therapeutically effective amount of a compound to said patient, wherein said compound acts for a period of time to lower plasma concentrations of apolipoprotein B or apolipoprotein B-containing lipoproteins by stimulating a pathway for apolipoprotein B degradation (Fisher and Williams, 2001).

Disclosed and claimed in U.S. Pat. No. 5,220,006 is a cloned cis-acting DNA sequence that mediates the suppression of atherogenic apolipoprotein B (Ross et al., 1993).

Disclosed and claimed in PCT publication WO 01/12789 is a ribozyme which cleaves ApoB-100 mRNA specifically at position 6679 (Chan et al., 2001).

To date, strategies aimed at inhibiting apolipoprotein B function have been limited to Lp(a) apheresis, antibodies, antibody fragments and ribozymes. However, with the exception of Lp(a) apheresis, these investigative strategies are untested as therapeutic protocols. Consequently, there remains a long felt need for additional agents capable of effectively inhibiting apolipoprotein B function.

Antisense technology is emerging as an effective means of reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic and research applications involving modulation of apolipoprotein B expression.

The present invention provides compositions and methods for modulating apolipoprotein B expression, including inhibition of the alternative isoform of apolipoprotein B, ApoB-48.

SUMMARY OF THE INVENTION

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a

nucleic acid encoding apolipoprotein B, and which modulate the expression of apolipoprotein B. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of apolipoprotein B in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of apolipoprotein B by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

In particular, the invention provides a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

The invention further provides compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854, said active site being a region in said nucleic acid wherein binding of said compound to said site significantly inhibits apolipoprotein B expression as compared to a control.

The invention also provides a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, wherein the apolipoprotein B is encoded by a polynucleotide selected from the group consisting of: (a) SEQ ID NO: 3 and (b) a naturally occurring variant apolipoprotein B-encoding polynucleotide that hybridizes to the complement of the polynucleotide of (a) under stringent conditions, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

In another aspect the invention provides a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, wherein the apolipoprotein B is encoded by a polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 17, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

The invention also provides a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with an active site in said nucleic acid and inhibits expression of apolipoprotein B, said compound comprising at

5

least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854, said active site being a region in said nucleic acid wherein binding of said compound to said site significantly inhibits apolipoprotein B expression as compared to a control.

In another aspect the invention provides an oligonucleotide mimetic compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

In another aspect, the invention provides an antisense compound 8 to 50 nucleobases in length, wherein said compound specifically hybridizes with nucleotides 2920-3420 as set forth in SEQ ID NO:3 and inhibits expression of mRNA encoding human apolipoprotein B after 16 to 24 hours by at least 30% in 80% confluent HepG2 cells in culture at a concentration of 150 nM. In preferred embodiments, the antisense compound 8 to 50 nucleobases in length specifically hybridizes with nucleotides 3230-3288 as set forth in SEQ ID NO:3 and inhibits expression of mRNA encoding human apolipoprotein B after 16 to 24 hours by at least 30% in 80% confluent HepG2 cells in culture at a concentration of 150 nM. In another aspect, the compounds inhibits expression of mRNA encoding apolipoprotein B by at least 50%, after 16 to 24 hours in 80% confluent HepG2 cells in culture at a concentration of 150 nM.

In one aspect, the compounds of the invention are targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits expression of the long form of apolipoprotein B, ApoB-100. In another aspect, the compounds specifically hybridizes with said nucleic acid and inhibits expression of mRNA encoding apolipoprotein B by at least 5% in 80% confluent HepG2 cells in culture at an optimum concentration. In yet another aspect, the compounds inhibits expression of mRNA encoding apolipoprotein B by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or at least 50%.

In one aspect, the compounds are antisense oligonucleotides, and in one embodiment the compound has a sequence comprising SEQ ID NO: 224, the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 224, the compound comprises SEQ ID NO: 224, the compound consists essentially of SEQ ID NO: 224 or the compound consists of SEQ ID NO: 224.

In another aspect, the compound has a sequence comprising SEQ ID NO: 247, the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 247, the compound comprises SEQ ID NO: 247, the compound consists essentially of SEQ ID NO: 247 or the compound consists of SEQ ID NO: 247.

In another aspect, the compound has a sequence comprising SEQ ID NO: 319, the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 319, the compound comprises SEQ ID NO: 319, the compound consists essentially of SEQ ID NO: 319 or the compound consists of SEQ ID NO: 319.

6

In one embodiment, the compounds comprise at least one modified internucleoside linkage, and in another embodiment, the modified internucleoside linkage is a phosphorothioate linkage.

In another aspect, the compounds comprise at least one modified sugar moiety, and in one aspect, the modified sugar moiety is a 2-O-methoxyethyl sugar moiety.

In another embodiment, the compounds comprise at least one modified nucleobase, and in one aspect, the modified nucleobase is a 5-methylcytosine.

In yet another aspect, the compounds are chimeric oligonucleotides. Preferred chimeric compounds include those having one or more phosphorothioate linkages and further comprising 2'-methoxyethoxyl nucleotide wings and a ten nucleobase 2'-deoxynucleotide gap.

In another aspect, the compounds specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding an alternatively spliced form of apolipoprotein B.

The invention also provide compositions comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent. In one aspect, the composition further comprises a colloidal dispersion system, and in another aspect, the compound in the composition is an antisense oligonucleotide. In certain embodiments, the composition comprises an antisense compound of the invention hybridized to a complementary strand. Hybridization of the antisense strand can form one or more blunt ends or one or more overhanging ends. In some embodiments, the overhanging end comprises a modified base.

The invention further provides methods of inhibiting the expression of apolipoprotein B in cells or tissues comprising contacting said cells or tissues with a compound of the invention so that expression of apolipoprotein B is inhibited. Methods are also provided for treating an animal having a disease or condition associated with apolipoprotein B comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention so that expression of apolipoprotein B is inhibited. In various aspects, the condition is associated with abnormal lipid metabolism, the condition is associated with abnormal cholesterol metabolism, the condition is atherosclerosis, the condition is an abnormal metabolic condition, the abnormal metabolic condition is hyperlipidemia, the disease is diabetes, the diabetes is Type 2 diabetes, the condition is obesity, and/or the disease is cardiovascular disease.

The invention also provide methods of modulating glucose levels in an animal comprising administering to said animal a compound of the invention, and in one aspect, the animal is a human. In various embodiments, the glucose levels are plasma glucose levels, the glucose levels are serum glucose levels, and/or the animal is a diabetic animal.

The invention also provides methods of preventing or delaying the onset of a disease or condition associated with apolipoprotein B in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention. In one aspect, the animal is a human. In other aspects, the condition is an abnormal metabolic condition, the abnormal metabolic condition is hyperlipidemia, the disease is diabetes, the diabetes is Type 2 diabetes, the condition is obesity, the condition is atherosclerosis, the condition involves abnormal lipid metabolism, and/or the condition involves abnormal cholesterol metabolism.

The invention also provides methods of preventing or delaying the onset of an increase in glucose levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention. In one aspect, the animal is a human. In other

aspects, the glucose levels are serum glucose levels, and/or the glucose levels are plasma glucose levels.

The invention also provides methods of modulating serum cholesterol levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention. In one aspect, the animal is a human.

The invention also provides methods of modulating lipoprotein levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention. In one aspect, the animal is a human. In other aspects, the lipoprotein is VLDL, the lipoprotein is HDL, and/or the lipoprotein is LDL.

The invention also provides methods of modulating serum triglyceride levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of the invention. In one aspect, the animal is a human.

The invention also provides use of a compound of the invention for the manufacture of a medicament for the treatment of a disease or condition associated with apolipoprotein B expression, a medicament for the treatment of a condition associated with abnormal lipid metabolism, a medicament for the treatment of a condition associated with abnormal cholesterol metabolism, a medicament for the treatment of atherosclerosis, a medicament for the treatment of hyperlipidemia, a medicament for the treatment of diabetes, a medicament for the treatment of Type 2 diabetes, a medicament for the treatment of obesity, a medicament for the treatment of cardiovascular disease, a medicament for preventing or delaying the onset of increased glucose levels, a medicament for preventing or delaying the onset of increased serum glucose levels, a medicament for preventing or delaying the onset of increased plasma glucose levels, a medicament for the modulation of serum cholesterol levels, a medicament for the modulation of serum lipoprotein levels, a medicament for the modulation of serum VLDL levels, a medicament for the modulation of serum HDL levels, and/or a medicament for the modulation of serum LDL levels, a medicament for the modulation of serum triglyceride levels.

In another aspect, the invention provides methods of decreasing circulating lipoprotein levels comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. In another aspect, the invention provides methods of reducing lipoprotein transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. The invention also provides methods of reducing lipoprotein absorption/adsorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In another aspect, the invention contemplates methods of decreasing circulating triglyceride levels comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. Also provided are methods of reducing triglyceride transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. The invention further provides methods of reducing triglyceride absorption/adsorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In another aspect, the invention provides methods of decreasing circulating cholesterol levels, including cholesteryl esters and/or unesterified cholesterol, comprising the

step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. Also contemplated are methods of reducing cholesterol transport, including cholesteryl esters and/or unesterified cholesterol, comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. The invention also provides methods of reducing cholesterol absorption/adsorption, including cholesteryl esters and/or unesterified cholesterol, comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In another aspect, the invention provides methods of decreasing circulating lipid levels comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. The invention also provides methods of reducing lipid transport in plasma comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. In addition, the invention provides methods of reducing lipid absorption/adsorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

The invention further contemplates methods of decreasing circulating dietary lipid levels comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. Also provided are methods of reducing dietary lipid transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, as well as methods of reducing dietary lipid absorption/adsorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In another aspect, the invention provides methods of decreasing circulating fatty acid levels comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. The invention also provides methods of reducing fatty acid transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. Also contemplated are methods of reducing fatty acid absorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

The invention also provides methods of decreasing circulating acute phase reactants comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. In another aspect, the invention provides methods of reducing acute phase reactants transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, as well as methods of reducing acute phase reactants absorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In another aspect, the invention provides methods of decreasing circulating chylomicrons comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, methods of reducing chylomicron transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein

tein B expression, and methods of reducing chylomicron absorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

The invention further provides methods of decreasing circulating chylomicron remnant particles comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, methods of reducing chylomicron remnant transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, and methods of reducing chylomicron remnant absorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

The invention further contemplates methods of decreasing circulating VLDL, IDL, LDL, and/or HDL comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression. Likewise, the invention provides methods of reducing VLDL, IDL, LDL, and/or HDL transport comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression, in addition to methods of reducing VLDL, IDL, LDL, and/or HDL absorption comprising the step of administering to an individual an amount of a compound of the invention sufficient to reduce apolipoprotein B expression.

In still another aspect, the invention provides methods of treating a condition associated with apolipoprotein B expression comprising the step of administering to an individual an amount of a compound of the invention sufficient to inhibit apolipoprotein B expression, said condition selected from hyperlipoproteinemia, familial type 3 hyperlipoproteinemia (familial dysbetalipoproteinemia), and familial hyperalphalipoproteinemia; hyperlipidemia, mixed hyperlipidemias, multiple lipoprotein-type hyperlipidemia, and familial combined hyperlipidemia; hypertriglyceridemia, familial hypertriglyceridemia, and familial lipoprotein lipase; hypercholesterolemia, familial hypercholesterolemia, polygenic hypercholesterolemia, and familial defective apolipoprotein B; cardiovascular disorders including atherosclerosis and coronary artery disease; peripheral vascular disease; von Gierke's disease (glycogen storage disease, type I); lipodystrophies (congenital and acquired forms); Cushing's syndrome; sexual ateliotic dwarfism (isolated growth hormone deficiency); diabetes mellitus; hyperthyroidism; hypertension; anorexia nervosa; Werner's syndrome; acute intermittent porphyria; primary biliary cirrhosis; extrahepatic biliary obstruction; acute hepatitis; hepatoma; systemic lupus erythematosus; monoclonal gammopathies (including myeloma, multiple myeloma, macroglobulinemia, and lymphoma); endocrinopathies; obesity; nephrotic syndrome; metabolic syndrome; inflammation; hypothyroidism; uremia (hyperurecemia); impotence; obstructive liver disease; idiopathic hypercalcemia; dysglobulinemia; elevated insulin levels; Syndrome X; Dupuytren's contracture; and Alzheimer's disease and dementia.

The invention also provides methods of reducing the risk of a condition comprising the step of administering to an individual an amount of a compound of the invention sufficient to inhibit apolipoprotein B expression, said condition selected from pregnancy; intermittent claudication; gout; and mercury toxicity and amalgam illness.

The invention further provides methods of inhibiting cholesterol particle binding to vascular endothelium comprising the step of administering to an individual an amount of a

compound of the invention sufficient to inhibit apolipoprotein B expression, and as a result, the invention also provides methods of reducing the risk of: (i) cholesterol particle oxidation; (ii) monocyte binding to vascular endothelium; (iii) monocyte differentiation into macrophage; (iv) macrophage ingestion of oxidized lipid particles and release of cytokines (including, but limited to IL-1, TNF-alpha, TGF-beta); (v) platelet formation of fibrous fibrofatty lesions and inflammation; (vi) endothelium lesions leading to clots; and (vii) clots leading to myocardial infarction or stroke, also comprising the step of administering to an individual an amount of a compound of the invention sufficient to inhibit apolipoprotein B expression.

The invention also provides methods of reducing hyperlipidemia associated with alcoholism, smoking, use of oral contraceptives, use of glucocorticoids, use of beta-adrenergic blocking agents, or use of isotretinoin (13-cis-retinoic acid) comprising the step of administering to an individual an amount of a compound of the invention sufficient to inhibit apolipoprotein B expression.

In certain aspects, the invention provides an antisense oligonucleotide compound 8 to 50 nucleobases in length comprising at least 8 contiguous nucleotides of SEQ ID NO:247 and having a length from at least 12 or at least 14 to 30 nucleobases.

In a further aspect, the invention provides an antisense oligonucleotide compound 20 nucleobases in length having a sequence of nucleobases as set forth in SEQ ID NO:247 and comprising 5-methylcytidine at nucleobases 2, 3, 5, 9, 12, 15, 17, 19, and 20, wherein every internucleoside linkage is a phosphothioate linkage, nucleobases 1-5 and 16-20 comprise a 2'-methoxyethoxyl modification, and nucleobases 6-15 are deoxynucleotides.

In another aspect, the invention provides a compound comprising a first nucleobase strand, 8 to 50 nucleobases in length and comprising a sequence of at least 8 contiguous nucleobases of the sequence set forth in SEQ ID NO:3, hybridized to a second nucleobase strand, 8 to 50 nucleobases in length and comprising a sequence sufficiently complementary to the first strand so as to permit stable hybridization, said compound inhibiting expression of mRNA encoding human apolipoprotein B after 16 to 24 hours by at least 30% or by at least 50% in 80% confluent HepG2 cells in culture at a concentration of 100 nM.

Further provided is a vesicle, such as a liposome, comprising a compound or composition of the invention

Preferred methods of administration of the compounds or compositions of the invention to an animal are intravenously, subcutaneously, or orally. Administrations can be repeated.

In another aspect, the invention provides a method of reducing lipoprotein(a) secretion by hepatocytes comprising (a) contacting hepatocytes with an amount of a composition comprising a non-catalytic compound 8 to 50 nucleobases in length that specifically hybridizes with mRNA encoding human apolipoprotein B and inhibits expression of the mRNA after 16 to 24 hours by at least 30% or at least 50% in 80% confluent HepG2 cells in culture at a concentration of 150 nM, wherein said amount is effective to inhibit expression of apolipoprotein B in the hepatocytes; and (b) measuring lipoprotein(a) secretion by the hepatocytes.

The invention further provides a method of treating a condition associated with apolipoprotein B expression in a primate, such as a human, comprising administering to the primate a therapeutically or prophylactically effective amount of a non-catalytic compound 8 to 50 nucleobases in length that specifically hybridizes with mRNA encoding human apolipoprotein B and inhibits expression of the

mRNA after 16 to 24 hours by at least 30% or by at least 50% in 80% confluent HepG2 cells in culture at a concentration of 150 nM.

The invention provides a method of reducing apolipoprotein B expression in the liver of an animal, comprising administering to the animal between 2 mg/kg and 20 mg/kg of a non-catalytic compound 8 to 50 nucleobases in length that specifically hybridizes with mRNA encoding human apolipoprotein B by at least 30% or by at least 50% in 80% confluent HepG2 cells in culture at a concentration of 150 nM.

Also provided is a method of making a compound of the invention comprising specifically hybridizing in vitro a first nucleobase strand comprising a sequence of at least 8 contiguous nucleobases of the sequence set forth in SEQ ID NO:3 to a second nucleobase strand comprising a sequence sufficiently complementary to said first strand so as to permit stable hybridization.

The invention further provides use of a compound of the invention in the manufacture of a medicament for the treatment of any and all conditions disclosed herein.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding apolipoprotein B, ultimately modulating the amount of apolipoprotein B produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding apolipoprotein B. As used herein, the terms "target nucleic acid" and "nucleic acid encoding apolipoprotein B" encompass DNA encoding apolipoprotein B, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of apolipoprotein B. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding apolipoprotein B. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the

present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding apolipoprotein B, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aber-

rant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, 2000, 480, 17-24; Celis, et al., *FEBS Lett.*, 2000, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, 2000, 286, 91-98; Larson, et al., *Cytometry*, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (reviewed in (To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. Thus, this term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages (RNA and DNA) as well as oligonucleotides having non-naturally-occurring portions which function similarly (oligonucleotide mimetics). Oligonucleotide mimetics are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12, about 14, about 20 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS)

oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression. In preferred embodiments, the antisense compound is non-catalytic oligonucleotide, i.e., is not dependent on a catalytic property of the oligonucleotide for its modulating activity. Antisense compounds of the invention can include double-stranded molecules wherein a first strand is stably hybridized to a second strand.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—O—CH₂—, —CH₂—N(CH₃)—O—CH₂— [known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—CH₂—N(CH₃)—N(CH₃)—CH₂— and —O—N(CH₃)—CH₂—CH₂— [wherein the native phosphodiester backbone is represented as —O—P—O—CH₂—] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucle-

otides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O—CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON (CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O—CH₂—O—CH₂—N(CH₂)₂, also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (—CH₂—)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O—CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂—CH=CH₂), 2'-O-allyl (2'-O—CH₂—CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine

and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrimido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyl-adenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate

groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmitoyl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation,

increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active

form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 and U.S. Pat. No. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucuronic acid, gluconic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts

formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of apolipoprotein B is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding apolipoprotein B, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding apolipoprotein B can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of apolipoprotein B in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline)

negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polymorithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their

preparation are described in detail in U.S. application Ser. No. 08/886,829 (filed Jul. 1, 1997), Ser. No. 09/108,673 (filed Jul. 1, 1998), Ser. No. 09/256,515 (filed Feb. 23, 1999), Ser. No. 09/082,624 (filed May 21, 1998) and Ser. No. 09/315,298 (filed May 20, 1999) each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μ m in diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a

bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs*:

Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C 12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligo-

nucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accu-

mulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into

liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klivanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Pat. Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S.

Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising anti-sense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Non-ionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: Remington's *Pharmaceutical Sciences*, 18th

Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laurth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacycloalkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705, 188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced

when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Pulsatile Delivery

The compounds of the present invention may also be administered by pulsatile delivery. "Pulsatile delivery" refers to a pharmaceutical formulations that delivers a first pulse of drug combined with a penetration enhancer and a second pulse of penetration enhancer to promote absorption of drug which is not absorbed upon release with the first pulse of penetration enhancer.

One embodiment of the present invention is a delayed release oral formulation for enhanced intestinal drug absorption, comprising:

(a) a first population of carrier particles comprising said drug and a penetration enhancer, wherein said drug and said penetration enhancer are released at a first location in the intestine; and

(b) a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix, wherein the penetration enhancer is released at a second

location in the intestine downstream from the first location, whereby absorption of the drug is enhanced when the drug reaches the second location.

Alternatively, the penetration enhancer in (a) and (b) is different.

This enhancement is obtained by encapsulating at least two populations of carrier particles. The first population of carrier particles comprises a biologically active substance and a penetration enhancer, and the second (and optionally additional) population of carrier particles comprises a penetration enhancer and a delayed release coating or matrix.

A "first pass effect" that applies to orally administered drugs is degradation due to the action of gastric acid and various digestive enzymes. One means of ameliorating first pass clearance effects is to increase the dose of administered drug, thereby compensating for proportion of drug lost to first pass clearance. Although this may be readily achieved with i.v. administration by, for example, simply providing more of the drug to an animal, other factors influence the bioavailability of drugs administered via non-parenteral means. For example, a drug may be enzymatically or chemically degraded in the alimentary canal or blood stream and/or may be impermeable or semipermeable to various mucosal membranes.

It is also contemplated that these pharmaceutical compositions are capable of enhancing absorption of biologically active substances when administered via the rectal, vaginal, nasal or pulmonary routes. It is also contemplated that release of the biologically active substance can be achieved in any part of the gastrointestinal tract.

Liquid pharmaceutical compositions of oligonucleotide can be prepared by combining the oligonucleotide with a suitable vehicle, for example sterile pyrogen free water, or saline solution. Other therapeutic compounds may optionally be included.

The present invention also contemplates the use of solid particulate compositions. Such compositions preferably comprise particles of oligonucleotide that are of respirable size. Such particles can be prepared by, for example, grinding dry oligonucleotide by conventional means, for example with a mortar and pestle, and then passing the resulting powder composition through a 400 mesh screen to segregate large particles and agglomerates. A solid particulate composition comprised of an active oligonucleotide can optionally contain a dispersant which serves to facilitate the formation of an aerosol, for example lactose.

In accordance with the present invention, oligonucleotide compositions can be aerosolized. Aerosolization of liquid particles can be produced by any suitable means, such as with a nebulizer. See, for example, U.S. Pat. No. 4,501,729. Nebulizers are commercially available devices which transform solutions or suspensions into a therapeutic aerosol mist either by means of acceleration of a compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation. Suitable nebulizers include those sold by Blair® under the name PARI LC PLUS, PARI DURANE 2000, PARI-BABY Size, PARI PRONEB Compressor with LC PLUS, PARI WALKHALER Compressor/Nebulizer System, PARI LC PLUS Reusable Nebulizer, and PARI LC Jet+® Nebulizer.

Exemplary formulations for use in nebulizers consist of an oligonucleotide in a liquid, such as sterile, pyrogen free water, or saline solution, wherein the oligonucleotide comprises up to about 40% w/w of the formulation. Preferably, the oligonucleotide comprises less than 20% w/w. If desired, further

additives such as preservatives (for example, methyl hydroxybenzoate) antioxidants, and flavoring agents can be added to the composition.

Solid particles comprising an oligonucleotide can also be aerosolized using any solid particulate medicament aerosol generator known in the art. Such aerosol generators produce respirable particles, as described above, and further produce reproducible metered dose per unit volume of aerosol. Suitable solid particulate aerosol generators include insufflators and metered dose inhalers. Metered dose inhalers are used in the art and are useful in the present invention.

Preferably, liquid or solid aerosols are produced at a rate of from about 10 to 150 liters per minute, more preferably from about 30 to 150 liters per minute, and most preferably about 60 liters per minute.

Enhanced bioavailability of biologically active substances is also achieved via the oral administration of the compositions and methods of the present invention. The term "bioavailability" refers to a measurement of what portion of an administered drug reaches the circulatory system when a non-parenteral mode of administration is used to introduce the drug into an animal.

Penetration enhancers include, but are not limited to, members of molecular classes such as surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactant molecules. (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Carriers are inert molecules that may be included in the compositions of the present invention to interfere with processes that lead to reduction in the levels of bioavailable drug.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan,

cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

Combination Therapy

The invention also provides methods of combination therapy, wherein one or more compounds of the invention and one or more other therapeutic/prophylactic compounds are administered treat a condition and/or disease state as described herein. In various aspects, the compound(s) of the invention and the therapeutic/prophylactic compound(s) are co-administered as a mixture or administered individually. In one aspect, the route of administration is the same for the

compound(s) of the invention and the therapeutic/prophylactic compound(s), while in other aspects, the compound(s) of the invention and the therapeutic/prophylactic compound(s) are administered by a different routes. In one embodiment, the dosages of the compound(s) of the invention and the therapeutic/prophylactic compound(s) are amounts that are therapeutically or prophylactically effective for each compound when administered individually. Alternatively, the combined administration permits use of lower dosages than would be required to achieve a therapeutic or prophylactic effect if administered individually, and such methods are useful in decreasing one or more side effects of the reduced-dose compound.

In one aspect, a compound of the present invention and one or more other therapeutic/prophylactic compound(s) effective at treating a condition are administered wherein both compounds act through the same or different mechanisms. Therapeutic/prophylactic compound(s) include, but are not limited to, bile salt sequestering resins (e.g., cholestyramine, colestipol, and colessevelam hydrochloride), HMGCoA-reductase inhibitors (e.g., lovastatin, cerivastatin, pravastatin, atorvastatin, simvastatin, and fluvastatin), nicotinic acid, fibric acid derivatives (e.g., clofibrate, gemfibrozil, fenofibrate, bezafibrate, and ciprofibrate), probucol, neomycin, dextrothyroxine, plant-stanol esters, cholesterol absorption inhibitors (e.g., ezetimibe), implitapide, inhibitors of bile acid transporters (apical sodium-dependent bile acid transporters), regulators of hepatic CYP7a, estrogen replacement therapeutics (e.g., tamoxifen), and anti-inflammatories (e.g., glucocorticoids).

Accordingly, the invention further provides use of a compound of the invention and one or more other therapeutic/prophylactic compound(s) as described herein in the manufacture of a medicament for the treatment and/or prevention of a disease or condition as described herein.

Targeted Delivery

In another aspect, methods are provided to target a compound of the invention to a specific tissue, organ or location in the body. Exemplary targets include liver, lung, kidney, heart, and atherosclerotic plaques within a blood vessel. Methods of targeting compounds are well known in the art.

In one embodiment, the compound is targeted by direct or local administration. For example, when targeting a blood vessel, the compound is administered directly to the relevant portion of the vessel from inside the lumen of the vessel, e.g., single balloon or double balloon catheter, or through the adventitia with material aiding slow release of the compound, e.g., a pluronic gel system as described by Simons et al., *Nature* 359: 67-70 (1992). Other slow release techniques for local delivery of the compound to a vessel include coating a stent with the compound. Methods of delivery of antisense compounds to a blood vessel are disclosed in U.S. Pat. No. 6,159,946, which is incorporated by reference in its entirety.

When targeting a particular tissue or organ, the compound may be administered in or around that tissue or organ. For example, U.S. Pat. No. 6,547,787, incorporated herein by reference in its entirety, discloses methods and devices for targeting therapeutic agents to the heart. In one aspect, administration occurs by direct injection or by injection into a blood vessel associated with the tissue or organ. For example, when targeting the liver, the compound may be administered by injection or infusion through the portal vein.

In another aspect, methods of targeting a compound are provided which include associating the compound with an agent that directs uptake of the compound by one or more cell types. Exemplary agents include lipids and lipid-based structures such as liposomes generally in combination with an

organ- or tissue-specific targeting moiety such as, for example, an antibody, a cell surface receptor, a ligand for a cell surface receptor, a polysaccharide, a drug, a hormone, a hapten, a special lipid and a nucleic acid as described in U.S. Pat. No. 6,495,532, the disclosure of which is incorporated herein by reference in its entirety. U.S. Pat. No. 5,399,331, the disclosure of which is incorporated herein by reference in its entirety, describes the coupling of proteins to liposomes through use of a crosslinking agent having at least one maleimido group and an amine reactive function; U.S. Pat. Nos. 4,885,172, 5,059,421 and 5,171,578, the disclosures of which are incorporated herein by reference in their entirety, describe linking proteins to liposomes through use of the glycoprotein streptavidin and coating targeting liposomes with polysaccharides. Other lipid based targeting agents include, for example, micelle and crystalline products as described in U.S. Pat. No. 6,217,886, the disclosure of which is incorporated herein by reference in its entirety.

In another aspect, targeting agents include porous polymeric microspheres which are derived from copolymeric and homopolymeric polyesters containing hydrolyzable ester linkages which are biodegradable, as described in U.S. Pat. No. 4,818,542, the disclosure of which is incorporated herein by reference in its entirety. Typical polyesters include polyglycolic (PGA) and polylactic (PLA) acids, and copolymers of glycolide and L(-lactide) (PGL), which are particularly suited for the methods and compositions of the present invention in that they exhibit low human toxicity and are biodegradable. The particular polyester or other polymer, oligomer, or copolymer utilized as the microspheric polymer matrix is not critical and a variety of polymers may be utilized depending on desired porosity, consistency, shape and size distribution. Other biodegradable or bioerodable polymers or copolymers include, for example, gelatin, agar, starch, arabinogalactan, albumin, collagen, natural and synthetic materials or polymers, such as, poly(ϵ -caprolactone), poly(ϵ -caprolactone-CO-lactic acid), poly(ϵ -caprolactone-CO-glycolic acid), poly(β -hydroxy butyric acid), polyethylene oxide, polyethylene, poly(alkyl-2-cyanoacrylate), (e.g., methyl, ethyl, butyl), hydrogels such as poly(hydroxyethyl methacrylate), polyamides (e.g., polyacrylamide), poly(amino acids) (i.e., L-leucine, L-aspartic acid, β -methyl-L-aspartate, β -benzyl-L-aspartate, glutamic acid), poly(2-hydroxyethyl DL-aspartamide), poly(ester urea), poly(L-phenylalanine/ethylene glycol/1,6-diisocyanatohexane) and poly(methyl methacrylate). The exemplary natural and synthetic polymers suitable for targeted delivery are either readily available commercially or are obtainable by condensation polymerization reactions from the suitable monomers or, comonomers or oligomers.

In still another embodiment, U.S. Pat. No. 6,562,864, the disclosure of which is incorporated herein by reference in its entirety, describes catechins, including epi and other carbocationic isomers and derivatives thereof, which as monomers, dimers and higher multimers can form complexes with nucleophilic and cationic bioactive agents for use as delivery agents. Catechin multimers have a strong affinity for polar proteins, such as those residing in the vascular endothelium, and on cell/organelle membranes and are particularly useful for targeted delivery of bioactive agents to select sites in vivo. In treatment of vascular diseases and disorders, such as atherosclerosis and coronary artery disease, delivery agents include substituted catechin multimers, including amidated catechin multimers which are formed from reaction between catechin and nitrogen containing moieties such as ammonia.

Other targeting strategies of the invention include ADEPT (antibody-directed enzyme prodrug therapy), GDEPT (gene-

directed EPT) and VDEPT (virus-directed EPT) as described in U.S. Pat. No. 6,433,012, the disclosure of which is incorporated herein by reference in its entirety.

The present invention further provides medical devices and kits for targeted delivery, wherein the device is, for example, a syringe, stent, or catheter. Kits include a device for administering a compound and a container comprising a compound of the invention. In one aspect, the compound is preloaded into the device. In other embodiments, the kit provides instructions for methods of administering the compound and dosages. U.S. patents describing medical devices and kits for delivering antisense compounds include U.S. Pat. Nos. 6,368,356; 6,344,035; 6,344,028; 6,287,285; 6,200,304; 5,824,049; 5,749,915; 5,674,242; 5,670,161; 5,609,629; 5,593,974; and 5,470,307 (all incorporated herein by reference in their entirety).

While the present invention has been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham Mass. or Glen Research, Inc. Sterling Va.). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Pat. No. 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., Nucleic Acids Research, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling Va. or ChemGenes, Needham Mass.).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., J. Med. Chem., 1993, 36, 831-841] and U.S. Pat. No. 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2 -displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected

41

9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups.

Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., Helvetica Chimica Acta, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60° C. at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4° C.).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160° C. After heating for 48 hours at 155-160° C., the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the

42

filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35° C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using Teac/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-21-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5° C. and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10° C., and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture

43

was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in Teac (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1×300 mL of NaHCO₃ and 2×300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with Teac to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2×200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100° C. for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in Teac (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2×300 mL) and saturated NaCl (2×300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using Teac/hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1×300 mL) and saturated NaCl (3×300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using Teac/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites]

44

side amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 mL) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2×1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to -10° C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3×200 mL) and dried (40° C., 1 mm Hg, 24 h) to 149 g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160° C. was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100° C.) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2 kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mmol) was mixed with triphenylphosphine (11.63 g, 44.36 mmol) and N-hydroxyphthal-

45

imide (7.24 g, 44.36 mmol). It was then dried over P_2O_5 under high vacuum for two days at 40° C. The reaction mixture was flushed with argon and dry THF (369.8 mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-[(2-phthalimidoxymethyl)-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-[(2-phthalimidoxymethyl)-5'-t-butylidiphenylsilyl-5-methyluridine (3.1 g, 4.5 mmol) was dissolved in dry CH_2Cl_2 (4.5 mL) and methylhydrazine (300 mL, 4.64 mmol) was added dropwise at -10° C. to 0° C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH_2Cl_2 and the combined organic phase was washed with water, brine and dried over anhydrous Na_2SO_4 . The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-tert-Butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine (1.77 g, 3.12 mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.39 g, 6.13 mmol) was added to this solution at 10° C. under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10° C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH_2Cl_2). Aqueous $NaHCO_3$ solution (5%, 10 mL) was added and extracted with ethyl acetate (2x20 mL). Ethyl acetate phase was dried over anhydrous Na_2SO_4 , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL). Formaldehyde (20% w/w, 30 mL, 3.37 mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10° C. in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mmol) was added and reaction mixture stirred at 10° C. for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% $NaHCO_3$ (25 mL) solution was added and extracted with ethyl acetate (2x25 mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH_2Cl_2 to get 5'-O-tert-butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6 g, 80%).

2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91 mL, 24.0 mmol) was dissolved in dry THF and triethylamine (1.67 mL, 12 mmol,

46

dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40 g, 2.4 mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH_2Cl_2). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH_2Cl_2 to get 2'-O-(dimethylaminooxyethyl)-5-methyluridine (766 mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P_2O_5 under high vacuum overnight at 40° C. It was then co-evaporated with anhydrous pyridine (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol), 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH_2Cl_2 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and dried over P_2O_5 under high vacuum overnight at 40° C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous $NaHCO_3$ (40 mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%).

2'-(Aminooxyethoxy) Nucleoside Amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopu-

rine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2'-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2'-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2'-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalimidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE)
nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl
uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155° C. for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3×200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2×200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added

to a solution of 5'-O-ditriethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

Oligonucleotide Synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in *Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications*, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]—[2'-deoxy]—[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]—[2'-deoxy]—[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]—[2'-deoxy]—[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]—[2'-deoxy Phosphorothioate]—[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]—[2'-deoxy phosphorothioate]—[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55° C. for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis—96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipetors.

Oligonucleotide Analysis—96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Cell Culture and Oligonucleotide Treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 7 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 Cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 Cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF Cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville Md.) supplemented as

HEK Cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville Md.). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville Md.) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

HepG2 Cells:

The human hepatoblastoma cell line HepG2 was obtained from the American Type Culture Collection (Manassas, Va.). HepG2 cells were routinely cultured in Eagle's MEM supplemented with 10% fetal calf serum, non-essential amino acids, and 1 mM sodium pyruvate (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

AML12 Cells:

The AML12 (alpha mouse liver 12) cell line was established from hepatocytes from a mouse (CD1 strain, line MT42) transgenic for human TGF alpha. Cells are cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium with 0.005 mg/mL insulin, 0.005 mg/mL transferrin, 5 ng/mL selenium, and 40 ng/mL dexamethasone, and 90%; 10% fetal bovine serum. For subculturing, spent medium is removed and fresh media of 0.25% trypsin, 0.03% EDTA solution is added. Fresh trypsin solution (1 to 2 mL) is added and the culture is left to sit at room temperature until the cells detach.

Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Primary Mouse Hepatocytes:

Primary mouse hepatocytes were prepared from CD-1 mice purchased from Charles River Labs (Wilmington, Mass.) and were routinely cultured in Hepatocyte Attachment Media (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco/Life Technologies, Gaithersburg, Md.), 250 nM dexamethasone (Sigma), and 10 nM bovine insulin (Sigma). Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 10000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells are plated onto 100 mm or other standard tissue culture plates coated with rat tail collagen (200 ug/mL) (Becton Dickinson) and treated similarly using appropriate volumes of medium and oligonucleotide.

Hep3B Cells:

The human hepatocellular carcinoma cell line Hep3B was obtained from the American Type Culture Collection (Manassas, Va.). Hep3B cells were routinely cultured in Dulbecco's MEM high glucose supplemented with 10% fetal calf serum, L-glutamine and pyridoxine hydrochloride (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 24-well plates (Falcon-Primaria #3846) at a density of 50,000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Rabbit Primary Hepatocytes:

Primary rabbit hepatocytes were purchased from Invitro Technologies (Gaithersburg, Md.) and maintained in Dulbecco's modified Eagle's medium (Gibco). When purchased, the cells had been seeded into 96-well plates for use in RT-PCR analysis and were confluent.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly using appropriate volumes of medium and oligonucleotide.

HeLa Cells:

The human epitheloid carcinoma cell line HeLa was obtained from the American Tissue Type Culture Collection (Manassas, Va.). HeLa cells were routinely cultured in DMEM, high glucose (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Corporation, Carlsbad, Calif.). Cells were seeded into 24-well plates (Falcon-Primaria #3846) at a density of 50,000 cells/well for use in RT-PCR analysis. Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells 96-well plates (Falcon-Primaria #3872) at a density of 5,000 cells/well for use in RT-PCR analysis. For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Human Mammary Epithelial Cells:

Normal human mammary epithelial cells (HMECs) were obtained from the American Tissue Culture Collection (Manassas Va.). HMECs were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #353872, BD Biosciences, Bedford, Mass.) at a density of 7000 cells/well for use in RT-PCR analysis. For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with Antisense Compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCAAGGA, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-ras. The

concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-ras (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-ras mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 5 nM to 300 nM.

Example 10

Analysis of Oligonucleotide Inhibition of Apolipoprotein B Expression

Antisense modulation of apolipoprotein B expression can be assayed in a variety of ways known in the art. For example, apolipoprotein B mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.

Protein levels of apolipoprotein B can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to apolipoprotein B can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Poly(A)+ mRNA Isolation

Poly(A)+ mRNA was isolated according to Miura et al., Clin. Chem., 1996, 42, 1758-1764. Other methods for poly (A)+ mRNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribo-nucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C. was added to each well, the plate was incubated on a 90° C. hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia Calif.) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIA-VAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia Calif.). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Real-Time Quantitative PCR Analysis of Apolipoprotein B mRNA Levels

Quantitation of apolipoprotein B mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exo-nuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, Calif. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1 \times TAQMAN™ buffer A, 5.5 mM MgCl₂, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°

C. Following a 10 minute incubation at 95° C. to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L. J., et al, Analytical Biochemistry, 1998, 265, 368-374.

In this assay, 175 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:2865 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 25 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480 nm and emission at 520 nm.

Probes and primers to human apolipoprotein B were designed to hybridize to a human apolipoprotein B sequence, using published sequence information (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). For human apolipoprotein B the PCR primers were: forward primer: TGCTAAAGGCACATATGGCCT (SEQ ID NO: 4) reverse primer: CTCAGGTTGGACTCTCCAT-TGAG (SEQ ID NO: 5) and the PCR probe was: FAM-CTTGTCAGAGGGATCCTAACACTGGCCG-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. For human GAPDH the PCR primers were: forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7) reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCCGT-TCTCAGCC-TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Probes and primers to mouse apolipoprotein B were designed to hybridize to a mouse apolipoprotein B sequence, using published sequence information (GenBank accession number M35186, incorporated herein as SEQ ID NO: 10). For mouse apolipoprotein B the PCR primers were: forward primer: CGTGGGCTCCAGCATTCTA (SEQ ID NO: 11) reverse primer: AGTCATTCTGCCTTTGCGTC (SEQ ID NO: 12) and the PCR probe was: FAM-CCAATG-GTCGGGCACTGCTCAA-TAMRA SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. For mouse GAPDH the PCR primers were: forward primer: GGCAAAT-TCAACGGCACAGT (SEQ ID NO: 14) reverse primer: GGGTCTCGTCTCCTGGAAGAT (SEQ ID NO: 15) and the PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCT-TGTCATC-TAMRA 3' (SEQ ID NO: 16) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 14

Northern Blot Analysis of Apolipoprotein B mRNA Levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNA-ZOL™ (TEL-TEST "B" Inc., Friendswood, Tex.). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AM-RESCO, Inc. Solon, Ohio). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, Tex.). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc. La Jolla, Calif.) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer's recommendations for stringent conditions.

To detect human apolipoprotein B, a human apolipoprotein B specific probe was prepared by PCR using the forward primer TGCTAAAGGCACATATGGCCT (SEQ ID NO: 4) and the reverse primer CTCAGGTTGGACTCTCATTGAG (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

To detect mouse apolipoprotein B, a human apolipoprotein B specific probe was prepared by PCR using the forward primer CGTGGGCTCCAGCATTCTA (SEQ ID NO: 11) and the reverse primer AGTCATTCTGCCTTTGCGTC (SEQ ID NO: 12). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap

In accordance with the present invention, a series of oligonucleotides was designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HepG2 cells were treated with 150 nM of the compounds in Table 1. If present, "N.D." indicates "no data".

TABLE 1

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
147780	5'UTR	3	1	CCGCAGGTCCCGTGGGAAT	40	17
147781	5'UTR	3	21	ACCGAGAAGGGCACTCAGCC	35	18
147782	5'UTR	3	71	GCCTCGGCCTCGCGGCCCTG	67	19
147783	Start Codon	3	114	TCCATCGCCAGCTGCGGTGG	N.D.	20
147784	Coding	3	151	CAGCGCCAGCAGCGCCAGCA	70	21
147785	Coding	3	181	GCCCCGCCAGCAGCAGCAGCA	29	22
147786	Coding	3	321	CTTGAATCAGCAGTCCCAGG	34	23
147787	Coding	3	451	CTTCAGCAAGGCTTTGCCCT	N.D.	24
147788	Coding	3	716	TTTCTGTTGCCACATTGCCC	95	25
147789	Coding	3	911	GGAAGAGGTGTTGCTCCTTG	24	26
147790	Coding	3	951	TGTGCTACCATCCCATACTT	33	27
147791	Coding	3	1041	TCAAATGCGAGGCCCATCTT	N.D.	28
147792	Coding	3	1231	GGACACCTCAATCAGCTGTG	26	29
147793	Coding	3	1361	TCAGGGCCACCAGGTAGGTG	N.D.	30
147794	Coding	3	1561	GTAATCTTCATCCCCAGTGC	47	31
147795	Coding	3	1611	TGCTCCATGGTTTGCCCAT	N.D.	32
147796	Coding	3	1791	GCAGCCAGTCGCTTATCTCC	8	33
147797	Coding	3	2331	GTATAGCCAAAGTGGTCCAC	N.D.	34
147798	Coding	3	2496	CCCAGGAGCTGGAGGTCATG	N.D.	35
147799	Coding	3	2573	TTGAGCCCTTCCTGATGACC	N.D.	36
147800	Coding	3	2811	ATCTGGACCCCACTCCTAGC	N.D.	37
147801	Coding	3	2842	CAGACCCGACTCGTGGAAGA	38	38
147802	Coding	3	3367	GCCCTCAGTAGATTCATCAT	N.D.	39
147803	Coding	3	3611	GCCATGCCACCCTCTTGGAA	N.D.	40
147804	Coding	3	3791	AACCCACGTGCCGAAAGTC	N.D.	41
147805	Coding	3	3841	ACTCCAGATGCCTTCTGAA	N.D.	42
147806	Coding	3	4281	ATGTGGTAACGAGCCGAAG	100	43
147807	Coding	3	4391	GGCGTAGAGACCATCACAT	25	44
147808	Coding	3	4641	GTGTTAGGATCCCTCTGACA	N.D.	45
147809	Coding	3	5241	CCCAGTGATAGCTCTGTGAG	60	46
147810	Coding	3	5355	ATTTCAAGCATATGAGCCCAT	0	47
147811	Coding	3	5691	CCCTGAACCTTAGCAACAGT	N.D.	48
147812	Coding	3	5742	GCTGAAGCCAGCCAGCGAT	N.D.	49
147813	Coding	3	5891	ACAGCTGCCCAGTATGTTCT	N.D.	50
147814	Coding	3	7087	CCCAATAAGATTATAACAA	34	51
147815	Coding	3	7731	TGGCCTACCAGAGACAGGTA	45	52
147816	Coding	3	7841	TCATACGTTTAGCCCAATCT	100	53

TABLE 1-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
147817	Coding	3	7901	GCATGGTCCCAAGGATGGTC	0	54
147818	Coding	3	8491	AGTGATGGAAGCTGCGATAC	30	55
147819	Coding	3	9181	ATGAGCATCATGCCTCCCAG	N.D.	56
147820	Coding	3	9931	GAACACATAGCCGAATGCCG	100	57
147821	Coding	3	10263	GTGGTGCCCTCTAATTGTGA	N.D.	58
147822	Coding	3	10631	CCCGAGAAAGAACCGAACCC	N.D.	59
147823	Coding	3	10712	TGCCCTGCAGCTTCACTGAA	19	60
147824	Coding	3	11170	GAAATCCCATAAGCTCTTGT	N.D.	61
147825	Coding	3	12301	AGAAGCTGCCTCTTCTTCCC	72	62
147826	Coding	3	12401	TCAGGGTGAGCCCTGTGTGT	80	63
147827	Coding	3	12471	CTAATGGCCCCCTTGATAAAC	13	64
147828	Coding	3	12621	ACGTTATCCTTGAGTCCCTG	12	65
147829	Coding	3	12741	TATATCCCAGGTTTCCCCGG	64	66
147830	Coding	3	12801	ACCTGGGACAGTACCGTCCC	N.D.	67
147831	3'UTR	3	13921	CTGCCTACTGCAAGGCTGGC	0	68
147832	3'UTR	3	13991	AGAGACCTTCCGAGCCCTGG	N.D.	69
147833	3'UTR	3	14101	ATGATACACAATAAAGACTC	25	70

As shown in Table 1, SEQ ID NOs 17, 18, 19, 21, 23, 25, 27, 31, 38, 43, 46, 51, 52, 53, 55, 57, 62, 63 and 66 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention. As apolipoprotein B exists in two forms in mammals (ApoB-48 and ApoB-100) which are colinear at the amino terminus, antisense oligonucleotides targeting nucleotides 1-6530 hybridize to both forms, while those targeting nucleotides 6531-14121 are specific to the long form of apolipoprotein B.

Example 16

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap-Dose Response Study

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 15 were further investigated in dose-response studies. Treatment doses were 50, 150 and 250 nM. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 2.

TABLE 2

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap			
ISIS #	Percent Inhibition		
	50 nM	150 nM	250 nM
147788	54	63	72
147806	23	45	28
147816	25	81	65
147820	10	0	73

Example 17

Antisense Inhibition of Mouse Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap

In accordance with the present invention, a series of oligonucleotides was designed to target different regions of the mouse apolipoprotein B RNA, using published sequence (GenBank accession number M35186, incorporated herein as SEQ ID NO: 10). The oligonucleotides are shown in Table 3. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 3 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxy-

ethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse apolipoprotein B mRNA levels in primary mouse hepatocytes by

quantitative real-time PCR as described in other examples herein. Primary mouse hepatocytes were treated with 150 nM of the compounds in Table 3. Data are averages from two experiments. If present, "N.D." indicates "no data".

TABLE 3

Inhibition of mouse apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
147475	Coding	10	13	ATTGTATGTGAGAGGTGAGG	79	71
147476	Coding	10	66	GAGGAGATTGGATCTTAAGG	13	72
147477	Coding	10	171	CTTCAAATTGGGACTCTCCT	N.D.	73
147478	Coding	10	211	TCCAGGAATTGAGCTTGTGC	78	74
147479	Coding	10	238	TTCAGGACTGGAGGATGAGG	N.D.	75
147480	Coding	10	291	TCTCACCTCATGCTCCATT	54	76
147481	Coding	10	421	TGACTGTCAAGGGTGAGCTG	24	77
147482	Coding	10	461	GTCCAGCCTAGGAACACTCA	59	78
147483	Coding	10	531	ATGTCAATGCCACATGTCCA	N.D.	79
147484	Coding	10	581	TTCATCCGAGAAGTTGGGAC	49	80
147485	Coding	10	601	ATTGGGACGAATGTATGCC	64	81
147486	Coding	10	711	AGTTGAGGAAGCCAGATTCA	N.D.	82
147487	Coding	10	964	TTCCAGTCAGCTTTAGTGG	73	83
147488	Coding	10	1023	AGCTTGCTTGTGGGCACGG	72	84
147489	Coding	10	1111	CCTATACTGGCTTCTATGTT	5	85
147490	Coding	10	1191	TGAACTCCGTGTAAGGCAAG	N.D.	86
147491	Coding	10	1216	GAGAAATCCTTCAGTAAGGG	71	87
147492	Coding	10	1323	CAATGGAATGCTTGTCAGT	68	88
147493	Coding	10	1441	GCTTCATTATAGGAGGTGGT	41	89
147494	Coding	10	1531	ACAAC TGGGATAGTGTAGCC	84	90
147495	Coding	10	1631	GTTAGGACCAAGGATGTGA	0	91
147496	Coding	10	1691	ACCATGGAAAACTGGCAACT	19	92
147497	Coding	10	1721	TGGGAGGAAAACTTGAATA	N.D.	93
147498	Coding	10	1861	TGGGCAACGATATCTGATTG	0	94
147499	Coding	10	1901	CTGCAGGCGTCAGTGACAA	29	95
147500	Coding	10	1932	GCATCAGACGTGATGTTCCC	N.D.	96
147501	Coding	10	2021	CTTGGTTAACTAATGGTGC	18	97
147502	Coding	10	2071	ATGGGAGCATGGAGGTGGC	16	98
147503	Coding	10	2141	AATGGATGATGAAACAGTGG	26	99
147504	Coding	10	2201	ATCAATGCCTCCTGTTCAG	N.D.	100
147505	Coding	10	2231	GGAAGTGAGACTTCTAAGC	76	101
147506	Coding	10	2281	AGGAAGGAACCTTGATATT	58	102
147507	Coding	10	2321	ATTGGCTTCATTGGCAACAC	81	103

TABLE 3-continued

Inhibition of mouse apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
147759	Coding	10	1	AGGTGAGGAAGTTGGAATTC	19	104
147760	Coding	10	121	TTGTTCCCTGAAGTTGTTAC	N.D	105
147761	Coding	10	251	GTTTCATGGATTCCTTCAGGA	45	106
147762	Coding	10	281	ATGCTCCATTCTCACATGCT	46	107
147763	Coding	10	338	TGCGACTGTGTCTGATTTC	34	108
147764	Coding	10	541	GTCCCTGAAGATGTCAATGC	97	109
147765	Coding	10	561	AGGCCAGTTCATGACCCT	59	110
147766	Coding	10	761	GGAGCCACGTGCTGAGATT	59	111
147767	Coding	10	801	CGTCCTTGAGCAGTGCCCGA	5	112
147768	Coding	10	1224	CCCATATGGAGAAATCCTTC	24	113
147769	Coding	10	1581	CATGCCTGGAAGCCAGTGTC	89	114
147770	Coding	10	1741	GTGTTGAATCCCTTGAAATC	67	115
147771	Coding	10	1781	GGTAAAGTTGCCCATGGCTG	68	116
147772	Coding	10	1041	GTTATAAAGTCCAGCATTGG	78	117
147773	Coding	10	1931	CATCAGACGTGATGTTCCCT	85	118
147774	Coding	10	1956	TGGCTAGTTTCAATCCCCTT	84	119
147775	Coding	10	2002	CTGTCATGACTGCCCTTAC	52	120
147776	Coding	10	2091	GCTTGAAGTTCATTGAGAAT	92	121
147777	Coding	10	2291	TTCCTGAGAAAGGAAGAAC	N.D	122
147778	Coding	10	2331	TCAGATATACATTGGCTTCA	14	123

As shown in Table 3, SEQ ID Nos 71, 74, 76, 78, 81, 83, 84, 87, 88, 90, 101, 102, 103, 109, 111, 111, 114, 115, 116, 117, 118, 119, 120 and 121 demonstrated at least 50% inhibition of mouse apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

Example 18

Antisense Inhibition Mouse Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap—Dose Response Study

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 17 were further investigated in dose-response studies. Treatment doses were 50, 150 and 300 nM. The compounds were analyzed for their effect on mouse apolipoprotein B mRNA levels in primary hepatocytes cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 4.

TABLE 4

Inhibition of mouse apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap			
ISIS #	Percent Inhibition		
	50 nM	150 nM	300 nM
147483	56	88	89
147764	48	84	90
147769	3	14	28
147776	0	17	44

Example 19

Western Blot Analysis of Apolipoprotein B Protein Levels

Western blot analysis (immunoblot analysis) was carried out using standard methods. Cells were harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels were run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to apolipoprotein B was used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands were visualized using a PHOSPHO-

67

RIMAGER™ (Molecular Dynamics, Sunnyvale Calif.) or the ECL+ chemiluminescent detection system (Amersham Biosciences, Piscataway, N.J.).

Example 20

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) in C57BL/6 mice: Lean Animals vs. High Fat Fed Animals.

C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate antisense oligonucleotides as potential lipid lowering compounds in lean versus high fat fed mice.

Male C57BL/6 mice were divided into two matched groups; (1) wild-type control animals (lean animals) and (2) animals receiving a high fat diet (60% kcal fat). Control animals received saline treatment and were maintained on a normal rodent diet. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline or 50 mg/kg ISIS 147764 (SEQ ID No: 109) for six weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, liver enzyme levels and serum glucose levels.

The results of the comparative studies are shown in Table 5.

TABLE 5

Effects of ISIS 147764 treatment on apolipoprotein B mRNA, cholesterol, lipid, triglyceride, liver enzyme and glucose levels in lean and high fat mice.									
Percent Change									
Treatment	Lipoproteins						Liver Enzymes		
Group	mRNA	CHOL	VLDL	LDL	HDL	TRIG	AST	ALT	GLUC
Lean-control	-73	-63	No change	-64	-44	-34	Slight decrease	No change	No change
High Fat Group	-87	-67	No change	-87	-65	No change	Slight decrease	Slight increase	-28

It is evident from these data that treatment with ISIS 147764 lowered cholesterol as well as LDL and HDL lipoproteins and serum glucose in both lean and high fat mice and that the effects demonstrated are, in fact, due to the inhibition of apolipoprotein B expression as supported by the decrease in mRNA levels. No significant changes in liver enzyme levels were observed, indicating that the antisense oligonucleotide was not toxic to either treatment group.

Example 21

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on High Fat Fed Mice; 6 Week Timecourse Study

In accordance with the present invention, a 6-week timecourse study was performed to further investigate the effects of ISIS 147764 on lipid and glucose metabolism in high fat fed mice.

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of treatment with the antisense oligonucleotide, ISIS 147764. Control animals received saline treatment (50 mg/kg). A subset of animals received a daily oral dose (20 mg/kg) atorvastatin calcium (Lipitor®, Pfizer Inc.). All mice, except atorvastatin-treated animals, were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or

68

saline (50 mg/kg) for six weeks. Serum cholesterol and lipoproteins were analyzed at 0, 2 and 6 week interim timepoints. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver, cholesterol, lipoprotein, triglyceride, liver enzyme (AST and ALT) and serum glucose levels as well as body, liver, spleen and fat pad weights.

Example 22

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) in High Fat Fed Mice—mRNA Expression in Liver

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on mRNA expression. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver. ISIS 147764 showed a dose-response effect, reducing mRNA levels by 15, 75 and 88% at doses of 5, 25 and 50 mg/kg, respectively.

Liver protein samples collected at the end of the treatment period were subjected to immunoblot analysis using an anti-

body directed to mouse apolipoprotein B protein (Gladstone Institute, San Francisco, Calif.). These data demonstrate that treatment with ISIS 147764 decreases apolipoprotein B protein expression in liver in a dose-dependent manner, in addition to reducing mRNA levels.

Example 23

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum Cholesterol and Triglyceride Levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum cholesterol and triglyceride levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

Serum cholesterol levels were measured at 0, 2 and 6 weeks and this data is shown in Table 6. Values in the table are expressed as percent inhibition and are normalized to the saline control.

In addition to serum cholesterol, at study termination, animals were sacrificed 48 hours after the final injections and evaluated for triglyceride levels.

Mice treated with ISIS 147764 showed a reduction in both serum cholesterol (240 mg/dL for control animals and 225,

125 and 110 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) and triglycerides (115 mg/dL for control animals and 125, 150 and 85 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) to normal levels by study end. These data were also compared to the effects of atorvastatin calcium at an oral dose of 20 mg/kg which showed only a minimal decrease in serum cholesterol of 20 percent at study termination.

TABLE 6

Percent Inhibition of mouse apolipoprotein B cholesterol levels by ISIS 147764				
time	Percent Inhibition			
	Saline	5 mg/kg	25 mg/kg	50 mg/kg
0 weeks	0	0	0	0
2 weeks	0	5	12	20
6 weeks	0	10	45	55

Example 24

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Lipoprotein Levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on lipoprotein (VLDL, LDL and HDL) levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

Lipoprotein levels were measured at 0, 2 and 6 weeks and this data is shown in Table 7. Values in the table are expressed as percent inhibition and are normalized to the saline control. Negative values indicate an observed increase in lipoprotein levels.

These data were also compared to the effects of atorvastatin calcium at a daily oral dose of 20 mg/kg at 0, 2 and 6 weeks.

These data demonstrate that at a dose of 50 mg/kg, ISIS 147764 is capable of lowering all categories of serum lipoproteins investigated to a greater extent than atorvastatin.

TABLE 7

Percent Inhibition of mouse apolipoprotein B lipoprotein levels by ISIS 147764 as compared to atorvastatin						
Lipo-protein	Time (weeks)	Percent Inhibition				
		Dose				
		Saline	5 mg/kg	25 mg/kg	50 mg/kg	atorvastatin (20 mg/kg)
VLDL	0	0	0	0	0	0
	2	0	25	30	40	15
	6	0	10	-30	15	-5
LDL	0	0	0	0	0	0
	2	0	-30	10	40	10
	6	0	-10	55	90	-10
HDL	0	0	0	0	0	0
	2	0	5	10	10	15
	6	0	10	45	50	20

Example 25

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum AST and ALT Levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on liver enzyme (AST and ALT) levels. Increased levels of the liver enzymes ALT and AST indicate toxicity and liver damage. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks. AST and ALT levels were measured at 6 weeks.

Mice treated with ISIS 147764 showed no significant change in AST levels over the duration of the study compared to saline controls (105, 70 and 80 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 65 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 85 IU/L.

ALT levels were increased by all treatments with ISIS 147764 over the duration of the study compared to saline controls (50, 70 and 100 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 25 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 40 IU/L.

Example 26

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Serum Glucose Levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum glucose levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

At study termination, animals were sacrificed 48 hours after the final injections and evaluated for serum glucose levels. ISIS 147764 showed a dose-response effect, reducing serum glucose levels to 225, 190 and 180 mg/dL at doses of 5, 25 and 50 mg/kg, respectively compared to the saline control of 300 mg/dL. Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had serum glucose levels of 215 mg/dL. These data demonstrate that ISIS 147764 is capable of reducing serum glucose levels in high fat fed mice.

Example 27

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) on Body, Spleen, Liver and Fat Pad Weight

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on body, spleen, liver and fat pad weight. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

At study termination, animals were sacrificed 48 hours after the final injections and body, spleen, liver and fat pad weights were measured. These data are shown in Table 8. Values are expressed as percent change in body weight or organ weight compared to the saline-treated control animals. Data

71

from mice treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table. Negative values indicated a decrease in weight.

TABLE 8

Effects of antisense inhibition of mouse apolipoprotein B on body and organ weight				
Tissue	Percent Change			
	Dose			Atorvastatin
	5 mg/kg	25 mg/kg	50 mg/kg	
Total Body Wt.	5	5	-4	1
Spleen	10	10	46	10
Liver	18	70	80	15
Fat	10	6	-47	7

These data show a decrease in fat over the dosage range of ISIS 147764 counterbalanced by an increase in both spleen and liver weight with increased dose to give an overall decrease in total body weight.

Example 28

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147764) in B6.129P-ApoE^{tm1Unc} Knockout Mice: Lean Animals vs. High Fat Fed Animals.

B6.129P-ApoE^{tm1Unc} knockout mice (herein referred to as ApoE knockout mice) obtained from The Jackson Laboratory (Bar Harbor, Me.), are homozygous for the ApoE^{tm1Unc} mutation and show a marked increase in total plasma cholesterol levels that are unaffected by age or sex. These animals present with fatty streaks in the proximal aorta at 3 months of age. These lesions increase with age and progress to lesions with less lipid but more elongated cells, typical of a more advanced stage of pre-atherosclerotic lesion.

The mutation in these mice resides in the apolipoprotein E (ApoE) gene. The primary role of the ApoE protein is to transport cholesterol and triglycerides throughout the body. It stabilizes lipoprotein structure, binds to the low density lipoprotein receptor (LDLR) and related proteins, and is present in a subclass of HDLs, providing them the ability to bind to LDLR. ApoE is expressed most abundantly in the liver and brain. Female B6.129P-ApoE^{tm1Unc} knockout mice (ApoE knockout mice) were used in the following studies to evaluate antisense oligonucleotides as potential lipid lowering compounds.

Female ApoE knockout mice ranged in age from 5 to 7 weeks and were placed on a normal diet for 2 weeks before study initiation. ApoE knockout mice were then fed ad libitum a 60% fat diet, with 0.15% added cholesterol to induce dyslipidemia and obesity. Control animals were maintained on a high-fat diet with no added cholesterol. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline, 50 mg/kg of a control antisense oligonucleotide (ISIS 29837; TCGATCTCCTTTTATGCGCCG; SEQ ID NO. 124) or 5, 25 or 50 mg/kg ISIS 147764 (SEQ ID No: 109) for six weeks.

The control oligonucleotide is a chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

72

At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver by RT-PCR methods verified by Northern Blot analysis, glucose levels, cholesterol and lipid levels by HPLC separation methods and triglyceride and liver enzyme levels (performed by LabCorp Preclinical Services; San Diego, Calif.). Data from ApoE knockout mice treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table for comparison.

The results of the comparative studies are shown in Table 9. Data are normalized to saline controls.

TABLE 9

Effects of ISIS 147764 treatment on apolipoprotein B mRNA, cholesterol, glucose, lipid, triglyceride and liver enzyme levels in ApoE knockout mice.						
		Percent Inhibition				
		Dose				
		Control	5 mg/kg	25 mg/kg	50 mg/kg	atorvastatin (20 mg/kg)
mRNA		0	2	42	70	10
Glucose Levels (mg/dL)						
Glucose		225	195	209	191	162
Cholesterol Levels (mg/dL)						
Cholesterol		1750	1630	1750	1490	938
Lipoprotein Levels (mg/dL)						
Lipo-protein	HDL	51	49	62	61	42
	LDL	525	475	500	325	250
	VLDL	1190	1111	1194	1113	653
Liver Enzyme Levels (IU/L)						
Liver Enzymes	AST	55	50	60	85	75
	ALT	56	48	59	87	76

It is evident from these data that treatment with ISIS 147764 lowered glucose and cholesterol as well as all lipoproteins investigated (HDL, LDL and VLDL) in ApoE knockout mice. Further, these decreases correlated with a decrease in both protein and RNA levels of apolipoprotein B, demonstrating an antisense mechanism of action. No significant changes in liver enzyme levels were observed, indicating that the antisense oligonucleotide was not toxic to either treatment group.

Example 29

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap: Additional Oligonucleotides

In accordance with the present invention, another series of oligonucleotides was designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 10. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 10 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleo-

side (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2

cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HepG2 cells were treated with 150 nM of the compounds in Table 10. If present, "N.D." indicates "no data".

TABLE 10

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap							
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	
270965	5'UTR	3	199	TTCTCTTCGGCCCTGGCGC	75	124	
270986	coding	3	299	CTCCACTGGAACCTCAGCC	0	125	
270997	exon:exon junction	3	359	CCTCCAGCTCAACCTTGACG	0	126	
270988	coding	3	429	GGGTTGAAGCCATACACCTC	6	127	
270989	exon:exon junction	3	509	CCAGCTTGAGCTCATACCTG	64	128	
270990	coding	3	584	CCCTCTTGATGTTTACAGGATG	42	129	
270991	coding	3	669	GAGCAGTTTCCATACACGGT	21	130	
270992	coding	3	699	CCCTTCTCGTCTTGACGGT	8	131	
270993	coding	3	756	TTGAAGCGATCACACTGCCC	69	132	
270994	coding	3	799	GCCTTTGATGAGAGCAAGTG	51	133	
270995	coding	3	869	TCCTCTTAGCGTCCAGTGTG	40	134	
270996	coding	3	1179	CCTCTCAGCTCAGTAACCAG	0	135	
270997	coding	3	1279	GCACTGAGGCTGTCCACACT	24	136	
270998	coding	3	1419	CGCTGATCCCTCGCCATGTT	1	137	
270999	coding	3	1459	GTGACCGCGTGGCTCAGCG	76	138	
271000	coding	3	1499	GCAGCTCCTGGGTCCCTGTA	22	139	
271001	coding	3	1859	CCCATGGTAGAATTGGACA	53	140	
271002	exon:exon junction	3	2179	AATCTCGATGAGGTCAGCTG	48	141	
271003	coding	3	2299	GACACCATCAGGAACCTTGAC	46	142	
271004	coding	3	2459	GCTCCTCTCCCAAGATGCGG	10	143	
271005	coding	3	2518	GGCACCCATCAGAAGCAGCT	32	144	
271006	coding	3	2789	AGTCCGAATGATGATGCCC	42	145	
271007	coding	3	2919	CTGAGCAGCTTGACTGGTCT	26	146	
271008	coding	3	3100	CCCGGTCAGCGGATAGTAGG	37	147	
271010	exon:exon junction	3	3449	TGTCACAACCTAGGTGGCCC	57	148	
271011	coding	3	3919	GTCTGGCAATCCCATGTTCT	51	149	
271012	coding	3	4089	CCCACAGACTTGAAGTGGAG	55	150	
271013	coding	3	4579	GAACTGCCCATCAATCTTGA	19	151	
271014	coding	3	5146	CCCAGAGAGGCCAAGCTCTG	54	152	
271015	coding	3	5189	TGTGTTCCCTGAAGCGGCCA	43	153	
271016	coding	3	5269	ACCCAGAATCATGGCCTGAT	19	154	
271017	coding	3	6049	GGTGCCTGTCTGCTCAGCTG	30	155	

TABLE 10-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
271018	coding	3	6520	ATGTGAAACTTGCTCTCTCCC	44	156
271019	coding	3	6639	TATGTCTGCAGTTGAGATAG	15	157
271020	coding	3	6859	TTGAATCCAGGATGCAGTAC	35	158
271021	coding	3	7459	GAGTCTCTGAGTCACCTCAC	38	159
271022	coding	3	7819	GATAGAATATTGCTCTGCAA	100	160
271023	coding	3	7861	CCCTTGCTCTACCAATGCTT	44	161
271025	coding	3	8449	TCCATTCCCTATGTCAGCAT	16	162
271026	coding	3	8589	GACTCCTTCAGAGCCAGCGG	39	163
271027	coding	3	8629	CCCATGCTCCGTTCTCAGGT	26	164
271028	coding	3	8829	CGCAGGTCAGCCTGACTAGA	98	165
271030	coding	3	9119	CAGTTAGAACACTGTGGCCC	52	166
271031	coding	3	10159	CAGTGTGATGACACTTGATT	49	167
271032	coding	3	10301	CTGTGGCTAACTTCAATCCC	22	168
271033	coding	3	10349	CAGTACTGTTATGACTACCC	34	169
271034	coding	3	10699	CACTGAAGACCGTGTGCTCT	35	170
271035	coding	3	10811	TCGTACTGTGCTCCAGAGG	23	171
271036	coding	3	10839	AAGAGGCCCTCTAGCTGTAA	95	172
271037	coding	3	11039	AAGACCCAGAATGAATCCGG	23	173
271038	coding	3	11779	GTCTACCTCAAAGCGTGCAG	29	174
271039	coding	3	11939	TAGAGGCTAACGTACCATCT	4	175
271041	coding	3	12149	CCATATCCATGCCCCACGGTG	37	176
271042	coding	3	12265	AGTTTCCTCATCAGATTCCC	57	177
271043	coding	3	12380	CCCAGTGGTACTTGTTGACA	68	178
271044	coding	3	12526	CCCAGTGGTGCCACTGGCTG	22	179
271045	coding	3	12579	GTCAACAGTTCCTGGTACAG	19	180
271046	coding	3	12749	CCCTAGTGTATATCCCAGGT	61	181
271048	coding	3	13009	CTGAAGATTACGTAGCACCT	7	182
271049	coding	3	13299	GTCCAGCCAATACTACTTGG	54	183
271050	coding	3	13779	CCTGGAGCAAGCTTCATGTA	42	184
281586	exon:exon junction	3	229	TGGACAGACCAGGCTGACAT	80	185
281587	coding	3	269	ATGTGTACTTCCGAGGTGC	77	186
281588	coding	3	389	TCTTCAGGATGAAGCTGCAG	80	187
281589	coding	3	449	TCAGCAAGGCTTTGCCCTCA	90	188
281590	coding	3	529	CTGCTTCCCTTCTGGAATGG	84	189
281591	coding	3	709	TGCCACATTGCCCTTCCTCG	90	190
281592	coding	3	829	GCTGATCAGAGTTGACAAGG	56	191
281593	coding	3	849	TACTGACAGGACTGGCTGCT	93	192

TABLE 10-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
281594	coding	3	889	GATGGCTTCTGCCACATGCT	74	193
281595	coding	3	1059	GATGTGGATTGGTGCTCTC	76	194
281596	coding	3	1199	TGACTGCTTCATCACTGAGG	77	195
281597	coding	3	1349	GGTAGGTGACCACATCTATC	36	196
281598	coding	3	1390	TCGCAGCTGCTGTGCTGAGG	70	197
281599	exon:exon junction	3	1589	TTCCAATGACCCGCAGAATC	74	198
281600	coding	3	1678	GATCATCAGTGATGGCTTTG	52	199
281601	coding	3	1699	AGCCTGGATGGCAGCTTTCT	83	200
281602	coding	3	1749	GTCTGAAGAAGAACCTCCTG	84	201
281603	coding	3	1829	TATCTGCCTGTGAAGGACTC	82	202
281604	coding	3	1919	CTGAGTTCAAGATATTGGCA	78	203
281605	exon:exon junction	3	2189	CTTCCAAGCCAATCTCGATG	82	204
281606	coding	3	2649	TGCAACTGTAATCCAGCTCC	86	205
281607	exon:exon junction	3	2729	CCAGTTCAGCCTGCATGTTG	84	206
281608	coding	3	2949	GTAGAGACCAAATGTAATGT	62	207
281609	coding	3	3059	CGTTGGAGTAAGCGCCTGAG	70	208
281610	exon:exon junction	3	3118	CAGCTCTAATCTGGTGTCCT	69	209
281611	coding	3	3189	CTGTCCTCTCTCTGGAGCTC	93	210
281612	coding	3	3289	CAAGGTCATACTCTGCCGAT	83	211
281613	coding	3	3488	GTATGGAAATAACACCCTTG	70	212
281614	coding	3	3579	TAAGCTGTAGCAGATGAGTC	63	213
281615	coding	3	4039	TAGATCTCTGGAGGATTTGC	81	214
281616	coding	3	4180	GTCTAGAACACCCAGGAGAG	66	215
281617	coding	3	4299	ACCACAGAGTCAGCCTTCAT	89	216
281618	coding	3	4511	AAGCAGACATCTGTGGTCCC	90	217
281619	coding	3	4660	CTCTCCATTGAGCCGCCAG	96	218
281620	coding	3	4919	CCTGATATTGAGAACGCAGC	89	219
281621	coding	3	5009	CAGTGCCTAAGATGTCAGCA	53	220
281622	coding	3	5109	AGCACCAGGAGACTACACTT	88	221
281623	coding	3	5212	CCCATCCAGACTGAATTTTG	59	222
281624	coding	3	5562	GGTTCTAGCCGTAGTTTCCC	75	223
281625	coding	3	5589	AGGTTACCAGCCACATGCAG	94	224
281626	coding	3	5839	ATGTGCATCGATGGTCATGG	88	225
281627	coding	3	5869	CCAGAGAGCGAGTTTCCCAT	82	226
281628	coding	3	5979	CTAGACACGAGATGATGACT	81	227

TABLE 10-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
281629	coding	3	6099	TCCAAGTCCTGGCTGTATTC	83	228
281630	coding	3	6144	CGTCCAGTAAGCTCCACGCC	82	229
281631	coding	3	6249	TCAACGGCATCTCTCATCTC	88	230
281632	coding	3	6759	TGATAGTGCTCATCAAGACT	75	231
281633	coding	3	6889	GATTCTGATTGGTACTTAG	73	232
281634	coding	3	7149	CTCTCGATTAACATCATGGAC	81	233
281635	coding	3	7549	ATACACTGCAACTGTGGCCT	89	234
281636	coding	3	7779	GCAAGAGTCCACCAATCAGA	68	235
281637	coding	3	7929	AGAGCCTGAAGACTGACTTC	74	236
281638	coding	3	8929	TCCCTCATCTGAGAATCTGG	66	237
281640	coding	3	10240	CAGTGCATCAATGACAGATG	87	238
281641	coding	3	10619	CCGAACCCCTTGACATCTCCT	72	239
281642	coding	3	10659	GCCTCACTAGCAATAGTTCC	59	240
281643	coding	3	10899	GACATTGCCATGGAGAGAG	61	241
281644	coding	3	11209	CTGTCTCCTACCAATGCTGG	26	242
281645	exon:exon junction	3	11979	TCTGCACTGAAGTCACGGTG	78	243
281646	coding	3	12249	TCCCGGACCCTCAACTCAGT	76	244
281648	3'UTR	3	13958	GCAGGTCCAGTTCATATGTG	81	245
281649	3'UTR	3	14008	GCCATCCTTCTGAGTTCAGA	76	246
301012	exon:exon junction	3	3249	GCCTCAGTCTGCTTCGCACC	87	247
301013	5'UTR	3	3	CCCCGCAGGTCCCGGTGGGA	82	248
301014	5'UTR	3	6	CAGCCCCGCAGGTCCCGGTG	88	249
301015	5'UTR	3	23	CAACCGAGAAGGGCACTCAG	53	250
301016	5'UTR	3	35	CCTCAGCGGCAGCAACCGAG	62	251
301017	5'UTR	3	36	TCCTCAGCGGCAGCAACCGA	47	252
301018	5'UTR	3	37	CTCCTCAGCGGCAGCAACCG	45	253
301019	5'UTR	3	39	GGCTCCTCAGCGGCAGCAAC	70	254
301020	5'UTR	3	43	GGCGGGCTCCTCAGCGGCAG	85	255
301021	5'UTR	3	116	GGTCCATCGCCAGCTGCGGT	89	256
301022	Start Codon	3	120	GGCGGGTCCATCGCCAGCTG	69	257
301023	Stop Codon	3	13800	TAGAGGATGATAGTAAGTTC	69	258
301024	3'UTR	3	13824	AAATGAAGATTTCTTTTAAA	5	259
301025	3'UTR	3	13854	TATGTGAAAGTTCAATTGGA	76	260
301026	3'UTR	3	13882	ATATAGGCAGTTTGAATTTT	57	261
301027	3'UTR	3	13903	GCTCACTGTATGGTTTATC	89	262

TABLE 10-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301028	3'UTR	3	13904	GGCTCACTGTATGGTTTTAT	93	263
301029	3'UTR	3	13908	GGCTGGCTCACTGTATGGTT	90	264
301030	3'UTR	3	13909	AGGCTGGCTCACTGTATGGT	90	265
301031	3'UTR	3	13910	AAGGCTGGCTCACTGTATGG	90	266
301032	3'UTR	3	13917	CTACTGCAAGGCTGGCTCAC	63	267
301033	3'UTR	3	13922	ACTGCCTACTGCAAGGCTGG	77	268
301034	3'UTR	3	13934	TGCTTATAGTCTACTGCCTA	88	269
301035	3'UTR	3	13937	TTCTGCTTATAGTCTACTGC	82	270
301036	3'UTR	3	13964	TTTGGTGCAGGTCCAGTTCA	88	271
301037	3'UTR	3	13968	CAGCTTTGGTGCAGGTCCAG	90	272
301038	3'UTR	3	13970	GCCAGCTTTGGTGCAGGTCC	86	273
301039	3'UTR	3	13974	TGGTGCCAGCTTTGGTGCAG	73	274
301040	3'UTR	3	13978	GCCCTGGTGCAGCTTTGGT	74	275
301041	3'UTR	3	13997	GAGTTCAGAGACCTTCCGAG	85	276
301042	3'UTR	3	14012	AAATGCCATCCTTCTGAGTT	81	277
301043	3'UTR	3	14014	AAAAATGCCATCCTTCTGAG	81	278
301044	3'UTR	3	14049	AAAATAACTCAGATCCTGAT	76	279
301045	3'UTR	3	14052	AGCAAAATAACTCAGATCCT	90	280
301046	3'UTR	3	14057	AGTTTAGCAAAATAACTCAG	80	281
301047	3'UTR	3	14064	TCCCCCAAGTTTAGCAAAAT	56	282
301048	3'UTR	3	14071	TTCTCCTCCCCCAAGTTTA	67	283
301217	3'UTR	3	14087	AGACTCCATTATTTGTGTTCC	81	284

Example 30

Antisense Inhibition of Apolipoprotein B—Gene Walk

In accordance with the present invention, a “gene walk” was conducted in which another series of oligonucleotides was designed to target the regions of the human apolipoprotein B RNA (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3) which are near the target site of SEQ ID Nos 224 or 247. The oligonucleotides are shown in Table 11. “Target site” indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 11

are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting often 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide “wings”. The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Treatment doses were 50 nM and 150 nM and are indicated in Table 11. Data are averages from two experiments. If present, “N.D.” indicates “no data”.

TABLE 11

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Gene walk							
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	SEQ ID NO
308589	exon:exon junction	3	3230	CTTCTGCTTGAGTTACAAAC	94	20	285

TABLE 11-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Gene walk							
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	SEQ ID NO
308590	exon:exon junction	3	3232	ACCTTCTGCTTGAGTTACAA	98	26	286
308591	exon:exon junction	3	3234	GCACCTTCTGCTTGAGTTAC	92	76	287
308592	exon:exon junction	3	3236	TCGCACCTTCTGCTTGAGTT	96	49	288
308593	exon:exon junction	3	3238	CTTCGCACCTTCTGCTTGAG	80	41	289
308594	exon:exon junction	3	3240	TGCTTCGCACCTTCTGCTTG	88	57	290
308595	exon:exon junction	3	3242	TCTGCTTCGCACCTTCTGCT	82	60	291
308596	exon:exon junction	3	3244	AGTCTGCTTCGCACCTTCTG	94	81	292
308597	exon:exon junction	3	3246	TCAGTCTGCTTCGCACCTTC	91	66	293
308598	exon:exon junction	3	3248	CCTCAGTCTGCTTCGCACCT	85	59	294
308599	exon:exon junction	3	3250	AGCCTCAGTCTGCTTCGCAC	94	79	295
308600	coding	3	3252	GTAGCCTCAGTCTGCTTCGC	89	72	296
308601	coding	3	3254	TGGTAGCCTCAGTCTGCTTC	91	63	297
308602	coding	3	3256	CATGGTAGCCTCAGTCTGCT	92	83	298
308603	coding	3	3258	GTCATGGTAGCCTCAGTCTG	97	56	299
308604	coding	3	3260	ATGTCATGGTAGCCTCAGTC	90	73	300
308605	coding	3	3262	GAATGTCATGGTAGCCTCAG	81	50	301
308606	coding	3	3264	TTGAATGTCATGGTAGCCTC	97	54	302
308607	coding	3	3266	ATTTGAATGTCATGGTAGCC	77	9	303
308608	coding	3	3268	ATATTTGAATGTCATGGTAG	85	70	304
308609	coding	3	5582	CAGCCACATGCAGCTTCAGG	96	78	305
308610	coding	3	5584	ACCAGCCACATGCAGCTTCA	90	40	306
308611	coding	3	5586	TTACCAGCCACATGCAGCTT	95	59	307
308612	coding	3	5588	GGTTACCAGCCACATGCAGC	90	75	308
308613	coding	3	5590	TAGGTTACCAGCCACATGCA	87	43	309
308614	coding	3	5592	TTTAGGTTACCAGCCACATG	92	74	310
308615	coding	3	5594	CTTTTAGGTTACCAGCCACA	85	45	311
308616	coding	3	5596	TCCTTTTAGGTTACCAGCCA	81	39	312
308617	coding	3	5598	GCTCCTTTTAGGTTACCAGC	87	77	313
308618	coding	3	5600	AGGCTCCTTTTAGGTTACCA	77	61	314
308619	coding	3	5602	GTAGGCTCCTTTTAGGTTAC	74	69	315
308620	coding	3	5604	TGGTAGGCTCCTTTTAGGTT	88	69	316
308621	coding	3	5606	TTGGTAGGCTCCTTTTAGG	91	56	317

85

As shown in Tables 10 and 11, SEQ ID Nos 124, 128, 129, 132, 133, 134, 138, 140, 141, 142, 144, 145, 147, 148, 149, 150, 152, 153, 155, 156, 158, 159, 160, 161, 163, 165, 166, 167, 169, 170, 172, 176, 177, 178, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, and 317 demonstrated

86

of a central “gap” region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide “wings”. The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HepG2 cells were treated with 150 nM of the compounds in Table 12. If present, “N.D.” indicates “no data”.

TABLE 12

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap					
ISIS # REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
271009 coding	318	3121	GCCTCAGTCTGCTTCGCGCC	75	319
271024 coding	318	8031	GCTCACTGTTTACGATCTGG	27	320
271029 coding	318	8792	TGAGAATCTGGGCGAGGCC	N.D.	321
271040 coding	318	11880	GTCCTTCATATTTGCCATCT	0	322
271047 coding	318	12651	CCTCCCTCATGAACATAGTG	32	323
281639 coding	318	9851	GACGTCAGAACCTATGATGG	38	324
281647 coding	318	12561	TGAGTGAGTCAATCAGCTTC	73	325

at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. More preferred are SEQ ID Nos 224, 247, and 262. The target regions to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Tables 10 and 11. “Target site” indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 31

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap: Targeting GenBank Accession Number M14162.1

In accordance with the present invention, another series of oligonucleotides was designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number M14162.1, incorporated herein as SEQ ID NO: 318). The oligonucleotides are shown in Table 12. “Target site” indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 12 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed

Example 32

Antisense Inhibition of Human Apolipoprotein B—Gene Walk Targeting GenBank Accession Number M14162.1

In accordance with the present invention, a “gene walk” was conducted in which another series of oligonucleotides was designed to target the regions of the human apolipoprotein B RNA (GenBank accession number M14162.1, incorporated herein as SEQ ID NO: 318) which are near the target site of SEQ ID NO: 319. The oligonucleotides are shown in Table 13. “Target site” indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 13 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide “wings”. The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Treatment doses were 50 nM and 150 nM and are indicated in Table 13. Data are averages from two experiments. If present, “N.D.” indicates “no data”.

TABLE 13

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap							
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	SEQ ID NO
308622	coding	318	3104	GCCTTCTGCTTGAGTTACAA	87	25	326
308623	coding	318	3106	GCGCCTTCTGCTTGAGTTAC	71	62	327
308624	coding	318	3108	TCGCGCCTTCTGCTTGAGTT	89	69	328
308625	coding	318	3110	CTTCGCGCCTTCTGCTTGAG	83	64	329
308626	coding	318	3116	AGTCTGCTTCGCGCCTTCTG	94	38	330
308627	coding	318	3118	TCAGTCTGCTTCGCGCCTTC	89	67	331
308628	coding	318	3120	CCTCAGTCTGCTTCGCGCCT	92	61	332
308629	coding	318	3122	AGCCTCAGTCTGCTTCGCGC	95	77	333

As shown in Tables 12 and 13, SEQ ID Nos 319, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, and 333 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. More preferred is SEQ ID NO: 319. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Tables 12 and 13. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 33

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap—Targeting the Genomic Sequence

In accordance with the present invention, another series of oligonucleotides was designed to target different regions of

the human apolipoprotein B RNA, using published sequence (the complement of nucleotides 39835 to 83279 of the sequence with GenBank accession number NT_022227.9, representing a genomic sequence, incorporated herein as SEQ ID NO: 334). The oligonucleotides are shown in Table 14. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 14 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HepG2 cells were treated with 150 nM of the oligonucleotides in Table 14. If present, "N.D." indicates "no data".

TABLE 14

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301049	intron:exon junction	334	904	TCTGTAAGACAGGAGAAAGA	41	335
301050	intron:exon junction	334	913	ATTTCCTCTTCTGTAAGACA	22	336
301051	exon:intron junction	334	952	GATGCCTTACTTGGACAGAC	27	337
301052	intron	334	1945	AGAAATAGCTCTCCCAAGGA	13	338
301053	intron:exon junction	334	1988	GTCGCATCTTCTAACGTGGG	45	339
301054	exon:intron junction	334	2104	TCCTCCATACCTTGACAGTTG	0	340
301055	intron	334	2722	TGGCTCATGTCTACCATATT	49	341
301056	intron	334	2791	CAGTTGAAATGCAGCTAATG	35	342
301057	intron	334	3045	TGCAGACTAGGAGTGAAAGT	30	343
301058	intron	334	3117	AGGAGGATGTCTCTTTATTG	27	344

TABLE 14-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301059	intron	334	3290	ATCAGAGCACCAAGGGAAT	12	345
301060	intron:exon junction	334	3381	CCAGCTCAACCTGAGAATTC	17	346
301061	exon:intron junction	334	3527	CATGACTTACCTGGACATGG	52	347
301062	intron	334	3566	CCTCAGCGGACACACACA	21	348
301063	intron	334	3603	GTCAATCCGTGCCTGGTGC	41	349
301064	intron	334	3864	CAGTGCCTCTGGGACCCAC	60	350
301065	intron	334	3990	AGCTGCAGTGGCCGATCAGC	50	351
301066	intron	334	4251	GACCTCCCCAGCCCGTGA	61	352
301067	intron	334	4853	TCTGATCACCATACATTACA	45	353
301068	intron	334	5023	ATTTCCCACTGGGTACTCTC	44	354
301069	intron	334	5055	GGCTGAAGCCCATGCTGACT	44	355
301070	intron	334	5091	GTTGGACAGTCATTCTTTTG	38	356
301071	intron	334	5096	CACCTGTGTGGACAGTCATTC	48	357
301072	intron	334	5301	ATTTTAAATTACAGTAGATA	43	358
301073	intron	334	5780	CTGTTCTCCACCCATATCAG	37	359
301074	intron:exon junction	334	6353	GAGCTCATACCTGTCCGAGA	75	360
301075	intron	334	6534	TTCAAGGGCCACTGCTATCA	52	361
301076	intron	334	6641	CCAGTATTTACGCAATCC	36	362
301077	intron	334	6661	GGCAGGAGGAACCTCGGGCA	55	363
301078	intron	334	6721	TTTTAAAATTAGACCAACC	22	364
301079	intron	334	6727	TGACTGTTTTAAAATTAGAC	20	365
301080	intron	334	6788	CCCAGCAAACACAGGTGAAG	25	366
301081	intron	334	7059	GAGTGTGGTCTTGCTAGTGC	46	367
301082	intron	334	7066	CTATGCAGAGTGTGGTCTTG	41	368
301083	intron	334	7189	AGAAGATGCAACCACATGTA	29	369
301084	intron:exon junction	334	7209	ACACGGTATCCTATGGAGGA	49	370
301085	exon:intron junction	334	7365	TGGGACTTACCATGCCTTTG	11	371
301086	intron	334	7702	GGTTTTGCTGCCCTACATCC	30	372
301087	intron	334	7736	ACAAGGAGTCCTTGTGCAGA	40	373
301088	intron	334	8006	ATGTTCACTGAGACAGGCTG	41	374
301089	intron	334	8215	GAAGGTCCATGGTTCATCTG	0	375
301090	intron	334	8239	ATTAGACTGGAAGCATCCTG	39	376
301091	intron	334	8738	GAGATTGGAGACGAGCATTT	35	377
301092	exon:intron junction	334	8881	CATGACCTACTTGTAGGAGA	22	378
301093	intron	334	9208	TGGATTGGATACACAAGTT	42	379
301094	intron	334	9244	ACTCAATATATATTCATTGA	22	380
301095	intron	334	9545	CAAGGAAGCACACCATGTCA	38	381

TABLE 14-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301096	intron:exon junction	334	9563	ATACTTATTCCTGGTAACCA	24	382
301097	intron	334	9770	GGTAGCCAGAACACCAGTGT	50	383
301098	intron	334	9776	ACTAGAGGTAGCCAGAACAC	34	384
301099	intron	334	10149	ACCACCTGACATCACAGGTT	24	385
301100	intron	334	10341	TACTGTGACCTATGCCAGGA	55	386
301101	intron	334	10467	GGAGGTGCTACTGTTGACAT	42	387
301102	intron	334	10522	TCCAGACTTGTCTGAGTCTA	47	388
301103	intron	334	10547	TCTAAGAGGTAGAGCTAAAG	7	389
301104	intron	334	10587	CCAGAGATGAGCAACTTAGG	38	390
301105	intron	334	10675	GGCCATGTAAATTGCTCATC	7	391
301106	intron	334	10831	AAAGAACTATCCTGTATTC	12	392
301107	intron:exon junction	334	10946	TTCTTAGTACCTGGAAGATG	23	393
301108	exon:intron junction	334	11166	CATTAGATACCTGGACACCT	29	394
301109	intron	334	11337	GTTTCATGGAAGCTCAGCGCA	44	395
301110	intron	334	11457	CTGGACAGCACCTGCAATAG	35	396
301111	intron	334	11521	TGAAGGGTAGAGAAATCATA	9	397
301112	exon:intron junction	334	12111	GGAAACTCACTTGTGACCG	25	398
301113	intron	334	12155	AGGTGCAAGATGTTCCCTCTG	46	399
301114	intron	334	12162	TGCACAGAGGTGCAAGATGT	16	400
301115	intron	334	12221	CACAAGAGTAAGGAGCAGAG	39	401
301116	intron	334	12997	GATGGATGGTGAGAAATTAC	33	402
301117	intron	334	13025	TAGACAATTGAGACTCAGAA	39	403
301118	intron	334	13057	ATGTGCACACAAGACATAG	33	404
301119	intron	334	13634	ACATACAAATGGCAATAGGC	33	405
301120	intron	334	13673	TAGGCAAAGGACATGAATAG	30	406
301121	coding	334	14448	TTATGATAGCTACAGAATAA	29	407
301122	exon:intron junction	334	14567	CTGAGATTACCCGCAGAATC	32	408
301123	intron	334	14587	GATGTATGTCATATAAAAGA	26	409
301124	intron:exon junction	334	14680	TTTCCAATGACCTGCATTGA	48	410
301125	intron	334	15444	AGGGATGGTCAATCTGGTAG	57	411
301126	intron	334	15562	GGCTAATAAATAGGGTAGTT	22	412
301127	intron	334	15757	TCCTAGAGCACTATCAAGTA	41	413
301128	intron:exon junction	334	15926	CCTCCTGGTCTGCAGTCAA	56	414
301129	intron	334	16245	CATTTGCACAAGTGTGTT	35	415
301130	intron	334	16363	CTGACACACCATGTTATTAT	10	416
301131	intron:exon junction	334	16399	CTTTTTCAGACTAGATAAGA	0	417

TABLE 14-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301132	exon:intron junction	334	16637	TCACACTTACCTCGATGAGG	29	418
301133	intron	334	17471	AAGAAAATGGCATCAGGTTT	13	419
301134	intron:exon junction	334	17500	CCAAGCCAATCTGAGAAAGA	25	420
301135	exon:intron junction	334	17677	AAATACACACCTGCTCATGT	20	421
301136	exon:intron junction	334	17683	CTTCACAAATACACACCTGC	20	422
301137	intron	334	18519	AGTGAAGTTTGGTCTCATT	41	423
301138	intron	334	18532	TTGCTAGCTTCAAAGTGGAA	44	424
301139	intron	334	18586	TCAAGAATAAGCTCCAGATC	41	425
301140	intron	334	18697	GCATACAAGTCACATGAGGT	34	426
301141	intron	334	18969	TACAAGGTGTTTCTTAAGAA	38	427
301142	intron	334	19250	ATGCAGCCAGGATGGGCCTA	54	428
301143	intron:exon junction	334	19340	TTACCATATCCTGAGAGTTT	55	429
301144	intron	334	19802	GCAAAGGTAGAGGAAGGTAT	32	430
301145	intron	334	19813	AAGGACCTTCAGCAAAGGTA	36	431
301146	intron	334	20253	CATAGGAGTACATTTATATA	23	432
301147	intron	334	20398	ATTATGATAAAATCAATTTT	19	433
301148	intron	334	20567	AGAAATTTCACTAGATAGAT	31	434
301149	intron	334	20647	AGCATATTTTGATGAGCTGA	44	435
301150	intron	334	20660	GAAAGGAAGGACTAGCATAT	39	436
301151	intron:exon junction	334	20772	CCTCTCCAATCTGTAGACCC	28	437
301152	intron	334	21316	CTGGATAACTCAGACCTTTG	40	438
301153	intron	334	21407	AGTCAGAAAACAACCTATTC	11	439
301154	intron:exon junction	334	21422	CAGCCTGCATCTATAAGTCA	31	440
301155	exon:intron junction	334	21634	AAAGAATTACCCCTCCACTGA	33	441
301156	intron	334	21664	TCTTTCAAACCTGGCTAGGCA	39	442
301157	intron	334	21700	GCCTGGCAAAATCTGCAGG	37	443
301158	intron	334	22032	CTACCTCAAATCAATATGTT	28	444
301159	intron	334	22048	TGCTTTACCTACCTAGCTAC	36	445
301160	intron	334	22551	ACCTTGTGTGTCTCACTCAA	49	446
301161	intron	334	22694	ATGCATTCCCTGACTAGCAC	34	447
301162	intron	334	22866	CATCTCTGAGCCCCTTACCA	24	448
301163	intron	334	22903	GCTGGGCATGCTCTCTCCCC	51	449
301164	intron	334	22912	GCTTTCGCAGCTGGGCATGC	55	450
301165	intron	334	23137	ACTCCTTTCTATACCTGGCT	47	451
301166	intron	334	23170	ATTCTGCCTCTTAGAAAGTT	38	452
301167	intron	334	23402	CCAAGCCTCTTTACTGGGCT	29	453
301168	intron	334	23882	CACTCATGACCAGACTAAGA	35	454

TABLE 14-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301169	intron	334	23911	ACCTCCCAGAAGCCTTCCAT	22	455
301170	intron	334	24184	TTCATATGAAATCTCCTACT	40	456
301171	intron	334	24425	TATTTAATTTACTGAGAAAC	7	457
301172	intron:exon junction	334	24559	TAATGTGTTGCTGGTGAAGA	35	458
301173	exon:intron junction	334	24742	CATCTCTAACCTGGTGTCCC	21	459
301174	intron	334	24800	GTGCCATGCTAGGTGGCCAT	37	460
301175	intron	334	24957	AGCAAATTGGGATCTGTGCT	29	461
301176	intron	334	24991	TCTGGAGGCTCAGAAACATG	57	462
301177	intron	334	25067	TGAAGACAGGAGCCACCTA	40	463
301178	intron	334	25152	AGGATTCCTCAAGACTTTGGA	38	464
301179	intron:exon junction	334	25351	CAGCTCTAATCTAAAGACAT	22	465
301180	exon:intron junction	334	25473	GAATACTCACCTTCTGCTTG	6	466
301181	intron	334	26047	ATCTCTCTGTCTCATCTTC	28	467
301182	intron	334	26749	CCAACTCCCCCTTCTTTGT	37	468
301183	intron	334	26841	TCTGGGCCAGGAAGACACGA	68	469
301184	intron	334	27210	TATTGTGTGCTGGGCACTGC	52	470
301185	intron:exon junction	334	27815	TGCTTCGCACCTGGACGAGT	51	471
301186	exon:intron junction	334	28026	CCTTCTTTACCTTAGGTGGC	37	472
301187	intron	334	28145	GCTCTCTCTGCCACTCTGAT	47	473
301188	intron	334	28769	AACTTCTAAAGCCAACATTC	27	474
301189	intron:exon junction	334	28919	TGTGTCACAACATATGGTAAA63	475	
301190	exon:intron junction	334	29095	AGACACATACCATAATGCCA	22	476
301191	intron:exon junction	334	29204	TTCTCTTCATCTGAAAATAC	21	477
301192	intron	334	29440	TGAGGATGTAATTAGCACTT	27	478
301193	intron:exon junction	334	29871	AGCTCATTGCCTACAAAATG	31	479
301194	intron	334	30181	GTTCTCATGTTTACTAATGC	40	480
301195	intron	334	30465	GAATTGAGACAACCTTGATTT	26	481
301196	intron:exon junction	334	30931	CCGGCCATCGCTGAAATGAA	54	482
301197	exon:intron junction	334	31305	CATAGCTCACCTTGACATT	28	483
301198	intron	334	31325	CGGTGCACCCTTTACCTGAG	28	484
301199	intron:exon junction	334	31813	TCTCCAGATCCTAACATAAA	19	485
301200	intron	334	39562	TTGAATGACACTAGATTTTC	37	486

TABLE 14-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301201	intron	334	39591	AAAATCCATTTTCTTTAAAG	12	487
301202	intron	334	39654	CAGCTCACACTTATTTTAAA	7	488
301203	intron:exon junction	334	39789	GTTCCCAAACTGTATAGGA	36	489
301204	exon:intron junction	334	39904	AGCTCCATACTGAAGTCCTT	37	490
301205	intron	334	39916	CAATTCAATAAAAGCTCCAT	31	491
301206	intron	334	39938	GTTTTCAAAAGGTATAAGGT	28	492
301207	intron:exon junction	334	40012	TTCCCATTCCTCGAAAGCAG	13	493
301208	exon:intron junction	334	40196	TGGTATTACCTGAGGGCTG	21	494
301209	intron	334	40412	ATAAATAATAGTGCTGATGG	39	495
301210	intron	334	40483	CTATGGCTGAGCTTGCCTAT	33	496
301211	intron	334	40505	CTCTCTGAAAAATATACCCCT	17	497
301212	intron	334	40576	TTGATGTATCTCATCTAGCA	41	498
301213	intron	334	40658	TAGAACCATGTTTGGTCTTC	35	499
301214	intron	334	40935	TTTCTCTTTATCACATGCC	29	500
301215	intron	334	41066	TATAGTACACTAAACTTCA	1	501
301216	intron:exon junction	334	41130	CTGGAGAGGACTAAACAGAG	49	502

35

As shown in Table 14, SEQ ID Nos 335, 339, 341, 342, 343, 347, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 367, 368, 370, 372, 373, 374, 376, 377, 379, 381, 383, 384, 386, 387, 388, 390, 395, 396, 399, 401, 402, 403, 404, 405, 406, 408, 410, 411, 413, 414, 415, 423, 424, 425, 426, 427, 428, 429, 430, 431, 434, 435, 436, 438, 440, 441, 442, 443, 445, 446, 447, 449, 450, 451, 452, 454, 456, 458, 460, 462, 463, 464, 468, 469, 470, 471, 472, 473, 475, 479, 480, 482, 486, 489, 490, 491, 495, 496, 498, 499, and 502 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 14. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 34

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap—Targeting GenBank Accession Number

In accordance with the present invention, another series of oligonucleotides was designed to target different regions of the human apolipoprotein B RNA, using published sequence (the complement of the sequence with GenBank accession number AI249040.1, incorporated herein as SEQ ID NO: 503). The oligonucleotides are shown in Table 15. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 15 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HepG2 cells were treated with 150 nM of the oligonucleotides in Table 15. If present, "N.D." indicates "no data".

TABLE 15

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap					
ISIS # REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301218 3'UTR	503	484	ACATTTTATCAATGCCCTCG	23	504
301219 3'UTR	503	490	GCCAGAACATTTTATCAATG	35	505
301220 3'UTR	503	504	AGAGGTTTTGCTGTGCCAGA	51	506
301221 3'UTR	503	506	CTAGAGGTTTTGCTGTGCCA	61	507
301222 3'UTR	503	507	TCTAGAGGTTTTGCTGTGCC	14	508
301223 3'UTR	503	522	AATCACACTATGTGTTCTAG	26	509
301224 3'UTR	503	523	AAATCACACTATGTGTTCTA	33	510
301225 3'UTR	503	524	TAAATCACACTATGTGTTCT	3	511
301226 3'UTR	503	526	CTTAAATCACACTATGTGTT	39	512
301227 3'UTR	503	536	TATTCTGTACTTAAATCAC	23	513

As shown in Table 15, SEQ ID Nos 505, 506, 507, 510, and 512 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 15. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 35 Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap—Variation in Position of the Gap

In accordance with the present invention, a series of antisense compounds was designed to target different regions of the human apolipoprotein B RNA, using published sequences (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). The compounds are shown in Table

16. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 16 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length. The "gap" region consists of 2'-deoxynucleotides, which is flanked on one or both sides (5' and 3' directions) by "wings" composed of 2'-methoxyethyl (2'-MOE)nucleotides. The number of 2'-MOE nucleotides on either side of the gap varies such that the total number of 2'-MOE nucleotides always equals 10 and the total length of the chimeric oligonucleotide is 20 nucleotides. The exact structure of each oligonucleotide is designated in Table 16 as the "gap structure" and the 2'-deoxynucleotides are in bold type. A designation of 8~10~2, for instance, indicates that the first (5'-most) 8 nucleotides and the last (3'-most) 2 nucleotides are 2'-MOE nucleotides and the 10 nucleotides in the gap are 2'-deoxynucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels by quantitative real-time PCR as described in other examples herein. Data, shown in Table 16, are averages from three experiments in which HepG2 cells were treated with the antisense oligonucleotides of the present invention at doses of 50 nM and 150 nM. If present, "N.D." indicates "no data".

TABLE 16

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a variable deoxy gap							
ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	gap structure	SEQ ID NO
308631	3	5589	AGGTTACCAGCCACATGCAG	94	74	0~10~10	224
308632	3	3249	GCCTCAGTCTGCTTCGCACC	97	41	0~10~10	247
308634	3	5589	AGGTTACCAGCCACATGCAG	67	45	10~10~0	224
308635	3	3249	GCCTCAGTCTGCTTCGCACC	93	69	10~10~0	247

TABLE 16-continued

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a variable deoxy gap							
ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	gap structure	SEQ ID NO
308637	3	5589	AGGTTACCAGCCACATGCAG	95	79	1~10~9	224
308638	3	3249	GCCTCAGTCTGCTTCGCACC	94	91	1~10~9	247
308640	3	5589	AGGTTACCAGCCACATGCAG	96	76	2~10~8	224
308641	3	3249	GCCTCAGTCTGCTTCGCACC	89	77	2~10~8	247
308643	3	5589	AGGTTACCAGCCACATGCAG	96	56	3~10~7	224
308644	3	3249	GCCTCAGTCTGCTTCGCACC	93	71	3~10~7	247
308646	3	5589	AGGTTACCAGCCACATGCAG	76	50	4~10~6	224
308647	3	3249	GCCTCAGTCTGCTTCGCACC	86	53	4~10~6	247
308649	3	5589	AGGTTACCAGCCACATGCAG	91	68	6~10~4	224
308650	3	3249	GCCTCAGTCTGCTTCGCACC	94	74	6~10~4	247
308652	3	5589	AGGTTACCAGCCACATGCAG	95	73	7~10~3	224
308653	3	3249	GCCTCAGTCTGCTTCGCACC	89	73	7~10~3	247
308655	3	5589	AGGTTACCAGCCACATGCAG	83	84	8~10~2	224
305656	3	3249	GCCTCAGTCTGCTTCGCACC	97	37	8~10~2	247
308658	3	5589	AGGTTACCAGCCACATGCAG	78	86	9~10~1	224
308659	3	3249	GCCTCAGTCTGCTTCGCACC	93	70	9~10~1	247
308660	3	3254	TGGTAGCCTCAGTCTGCTTC	92	72	2~10~8	514
308662	3	3254	TGGTAGCCTCAGTCTGCTTC	83	76	8~10~2	514

As shown in Table 16, SEQ ID Nos 224, 247, and 514 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay at both doses. These data suggest that the oligonucleotides are effective with a number of variations in the gap placement. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 16. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 8 is the species in which each of the preferred target segments was found.

Example 36

Antisense Inhibition of Human Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides Having 2'-MOE Wings and a Deoxy Gap—Variation in Position of the Gap of SEQ ID Nos: 319 and 515

In accordance with the present invention, a series of antisense compounds was designed based on SEQ ID Nos 319 and 515, with variations in the gap structure. The compounds are shown in Table 17. "Target site" indicates the first (5'-

most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 17 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length. The "gap" region consists of 2'-deoxynucleotides, which is flanked on one or both sides (5' and 3' directions) by "wings" composed of 2'-methoxyethyl (2'-MOE)nucleotides. The number of 2'-MOE nucleotides on either side of the gap varies such that the total number of 2'-MOE nucleotides always equals 10 and the total length of the chimeric oligonucleotide is 20 nucleotides. The exact structure of each oligonucleotide is designated in Table 17 as the "gap structure" and the 2'-deoxynucleotides are in bold type. A designation of 8~10~2, for instance, indicates that the first (5'-most) 8 nucleotides and the last (3'-most) 2 nucleotides are 2'-MOE nucleotides and the 10 nucleotides in the gap are 2'-deoxynucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels by quantitative real-time PCR as described in other examples herein. Data, shown in Table 17, are averages from three experiments in which HepG2 cells were treated with the antisense oligonucleotides of the present invention at doses of 50 nM and 150 nM. If present, "N.D." indicates "no data".

TABLE 17

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a variable deoxy gap							
ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nm	% INHIB 50 nm	gap structure	SEQ ID NO
308630	318	3121	GCCTCAGTCTGCTTCGCGCC	89	69	0~10~10	319
308633	318	3121	GCCTCAGTCTGCTTCGCGCC	83	66	10~10~0	319
308636	318	3121	GCCTCAGTCTGCTTCGCGCC	91	81	1~10~9	319
308639	318	3121	GCCTCAGTCTGCTTCGCGCC	94	86	2~10~8	319
308642	318	3121	GCCTCAGTCTGCTTCGCGCC	95	85	3~10~7	319
308645	318	3121	GCCTCAGTCTGCTTCGCGCC	98	57	4~10~6	319
308648	318	3121	GCCTCAGTCTGCTTCGCGCC	89	78	6~10~4	319
308651	318	3121	GCCTCAGTCTGCTTCGCGCC	88	87	7~10~3	319
308654	318	3121	GCCTCAGTCTGCTTCGCGCC	90	81	8~10~2	319
308657	318	3121	GCCTCAGTCTGCTTCGCGCC	78	61	9~10~1	319
308661	318	3116	AGTCTGCTTCGCGCCTTCTG	91	70	2~10~8	515
308663	318	3116	AGTCTGCTTCGCGCCTTCTG	84	44	8~10~2	515

As shown in Table 17, SEQ ID Nos 319 and 515 demonstrated at least 44% inhibition of human apolipoprotein B³⁰ expression in this assay for either dose. These data suggest that the compounds are effective with a number of variations in gap placement. The target regions to which these preferred sequences are complementary are herein preferred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred

target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 17. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

TABLE 18

Sequence and position of preferred target segments identified in apolipoprotein B.							
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO	
187342	3	199	GCGCCAGGGCCGAAGAGGAA	124	<i>H. sapiens</i>	516	
187346	3	509	CAGGTATGAGCTCAAGCTGG	128	<i>H. sapiens</i>	517	
187347	3	584	CATCCTGAACATCAAGAGGG	129	<i>H. sapiens</i>	518	
187350	3	756	GGGCAGTGTGATCGCTTCAA	132	<i>H. sapiens</i>	519	
187351	3	799	CACTTGCTCTCATCAAAGGC	133	<i>H. sapiens</i>	520	
187352	3	869	CACACTGGACGCTAAGAGGA	134	<i>H. sapiens</i>	521	
187356	3	1459	CGCTGAGCCACGCGGTCAAC	138	<i>H. sapiens</i>	522	
187358	3	1859	TGTCCAAATTCTACCATGGG	140	<i>H. sapiens</i>	523	
187359	3	2179	CAGCTGACCTCATCGAGATT	141	<i>H. sapiens</i>	524	
187360	3	2299	GTCAAGTTCCTGATGGTGTC	142	<i>H. sapiens</i>	525	
107362	3	2518	AGCTGCTTCTGATGGGTGCC	144	<i>H. sapiens</i>	526	
187363	3	2789	GGGCATCATCATTCGGACT	145	<i>H. sapiens</i>	527	
187365	3	3100	CCTACTATCCGCTGACCGGG	147	<i>H. sapiens</i>	528	
187367	3	3449	GGGCCACCTAAGTTGTGACA	148	<i>H. sapiens</i>	529	

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV SEQ ID NO	COMP OF ACTIVE IN	SEQ ID NO
187368	3	3919	AGAACATGGGATTGCCAGAC	149	<i>H. sapiens</i>	530
187369	3	4089	CTCCACTTCAAGTCTGTGGG	150	<i>H. sapiens</i>	531
187371	3	5146	CAGAGCTTGGCCTCTCTGGG	152	<i>H. sapiens</i>	532
187372	3	5189	TGGCCGCTTCAGGGAACACA	153	<i>H. sapiens</i>	533
187374	3	6049	CAGCTGAGCAGACAGGCACC	155	<i>H. sapiens</i>	534
187375	3	6520	GGGAGAGACAAGTTTCACAT	156	<i>H. sapiens</i>	535
187377	3	6859	GTACTGCATCCTGGATTCAA	158	<i>H. sapiens</i>	536
187378	3	7459	GTGAGGTGACTCAGAGACTC	159	<i>H. sapiens</i>	537
187379	3	7819	TTGCAGAGCAATATTCTATC	160	<i>H. sapiens</i>	538
187380	3	7861	AAGCATTGGTAGAGCAAGGG	161	<i>H. sapiens</i>	539
187383	3	8589	CCGCTGGCTCTGAAGGAGTC	163	<i>H. sapiens</i>	540
187385	3	8829	TCTAGTCAGGCTGACCTGCG	165	<i>H. sapiens</i>	541
187387	3	9119	GGGCCACAGTGTCTAACTG	166	<i>H. sapiens</i>	542
187388	3	10159	AATCAAGTGTCATCACACTG	167	<i>H. sapiens</i>	543
187390	3	10349	GGGTAGTCATAACAGTACTG	169	<i>H. sapiens</i>	544
187391	3	10699	AGAGCACACGGTCTTCAGTG	170	<i>H. sapiens</i>	545
187393	3	10839	TTACAGCTAGAGGGCCTCTT	172	<i>H. sapiens</i>	546
187398	3	12149	CACCGTGGGCATGGATATGG	176	<i>H. sapiens</i>	547
187399	3	12265	GGGAATCTGATGAGGAACT	177	<i>H. sapiens</i>	548
187400	3	12380	TGTCAACAAGTACCACTGGG	178	<i>H. sapiens</i>	549
187403	3	12749	ACCTGGGATATACACTAGGG	181	<i>H. sapiens</i>	550
187406	3	13299	CCAAGTATAGTTGGCTGGAC	183	<i>H. sapiens</i>	551
187407	3	13779	TACATGAAGCTTGCTCCAGG	184	<i>H. sapiens</i>	552
197724	3	229	ATGTCAGCCTGGTCTGTCCA	185	<i>H. sapiens</i>	553
197725	3	269	GCACCTCCGGAAGTACACAT	186	<i>H. sapiens</i>	554
197726	3	389	CTGCAGCTTCATCCTGAAGA	187	<i>H. sapiens</i>	555
197727	3	449	TGAGGGCAAAGCCTTGCTGA	188	<i>H. sapiens</i>	556
197728	3	529	CCATTCCAGAAGGGAAGCAG	189	<i>H. sapiens</i>	557
197729	3	709	CGAGGAAGGGCAATGTGGCA	190	<i>H. sapiens</i>	558
197730	3	829	CCTTGTCAACTCTGATCAGC	191	<i>H. sapiens</i>	559
197731	3	849	AGCAGCCAGTCCTGTCACTA	192	<i>H. sapiens</i>	560
197732	3	889	AGCATGTGGCAGAAGCCATC	193	<i>H. sapiens</i>	561
197733	3	1059	GAGAGCACCAAATCCACATC	194	<i>H. sapiens</i>	562
197734	3	1199	CCTCAGTGATGAAGCAGTCA	195	<i>H. sapiens</i>	563
197735	3	1349	GATAGATGTGGTCACCTACC	196	<i>H. sapiens</i>	564
197736	3	1390	CCTCAGCACAGCAGCTGCGA	197	<i>H. sapiens</i>	565
197737	3	1589	GATTCTCGGGTCATTGGAA	198	<i>H. sapiens</i>	566

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
197738	3	1678	CAAAGCCATCACTGATGATC	199	<i>H. sapiens</i>	567
197739	3	1699	AGAAAGCTGCCATCCAGGCT	200	<i>H. sapiens</i>	568
197740	3	1749	CAGGAGGTTCTTCTTCAGAC	201	<i>H. sapiens</i>	569
197741	3	1829	GAGTCCTTCACAGGCAGATA	202	<i>H. sapiens</i>	570
197742	3	1919	TGCCAATATCTTGAACCTAG	203	<i>H. sapiens</i>	571
197743	3	2189	CATCGAGATTGGCTTGGAG	204	<i>H. sapiens</i>	572
197744	3	2649	GGAGCTGGATTACAGTTGCA	205	<i>H. sapiens</i>	573
197745	3	2729	CAACATGCAGGCTGAACCTGG	206	<i>H. sapiens</i>	574
197746	3	2949	ACATTACATTTGGTCTCTAC	207	<i>H. sapiens</i>	575
197747	3	3059	CTCAGGCGCTTACTCCAACG	208	<i>H. sapiens</i>	576
197748	3	3118	GGGACACCAGATTAGAGCTG	209	<i>H. sapiens</i>	577
197749	3	3189	GAGCTCCAGAGAGAGGACAG	210	<i>H. sapiens</i>	578
197750	3	3289	ATCGGCAGAGTATGACCTTG	211	<i>H. sapiens</i>	579
197751	3	3488	CAAGGGTGTATTTCATAC	212	<i>H. sapiens</i>	580
197752	3	3579	GACTCATCTGCTACAGCTTA	213	<i>H. sapiens</i>	581
197753	3	4039	GCAAATCCTCCAGAGATCTA	214	<i>H. sapiens</i>	582
197754	3	4180	CTCTCCTGGGTGTTCTAGAC	215	<i>H. sapiens</i>	583
197755	3	4299	ATGAAGGCTGACTCTGTGGT	216	<i>H. sapiens</i>	584
197756	3	4511	GGGACCACAGATGTCTGCTT	217	<i>H. sapiens</i>	585
197757	3	4660	CTGGCCGGCTCAATGGAGAG	218	<i>H. sapiens</i>	586
197758	3	4919	GCTGCGTTCTGAATATCAGG	219	<i>H. sapiens</i>	587
197759	3	5009	TGCTGACATCTTAGGCACTG	220	<i>H. sapiens</i>	588
197760	3	5109	AAGTGTAAGTCTCCTGGTGCT	221	<i>H. sapiens</i>	589
197761	3	5212	CAAAATTCAGTCTGGATGGG	222	<i>H. sapiens</i>	590
197762	3	5562	GGGAAACTACGGCTAGAACC	223	<i>H. sapiens</i>	591
197763	3	5589	CTGCATGTGGCTGGTAACCT	224	<i>H. sapiens</i>	592
197764	3	5839	CCATGACCATCGATGCACAT	225	<i>H. sapiens</i>	593
197765	3	5869	ATGGGAAACTCGCTCTCTGG	226	<i>H. sapiens</i>	594
197766	3	5979	AGTCATCATCTCGTGTCTAG	227	<i>H. sapiens</i>	595
197767	3	6099	GAATACAGCCAGGACTTGGA	228	<i>H. sapiens</i>	596
197768	3	6144	GGCGTGGAGCTTACTGGACG	229	<i>H. sapiens</i>	597
197769	3	6249	GAGATGAGAGATGCCGTTGA	230	<i>H. sapiens</i>	598
197770	3	6759	AGTCTTGATGAGCACTATCA	231	<i>H. sapiens</i>	599
197771	3	6889	CTAAGTACCAAATCAGAATC	232	<i>H. sapiens</i>	600
197772	3	7149	GTCCATGAGTTAATCGAGAG	233	<i>H. sapiens</i>	601
197773	3	7549	AGGCCACAGTTGCAGTGAT	234	<i>H. sapiens</i>	602
197774	3	7779	TCTGATTGGTGGACTCTTGC	235	<i>H. sapiens</i>	603

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
197775	3	7929	GAAGTCAGTCTTCAGGCTCT	236	<i>H. sapiens</i>	604
197776	3	8929	CCAGATTCTCAGATGAGGGA	237	<i>H. sapiens</i>	605
197770	3	10240	CATCTGTCATTGATGCACTG	238	<i>H. sapiens</i>	606
197779	3	10619	AGGAGATGTCAAGGGTTCGG	239	<i>H. sapiens</i>	607
197780	3	10659	GGAACTATTGCTAGTGAGGC	240	<i>H. sapiens</i>	608
197781	3	10899	CTCTCTCCATGGCAAATGTC	241	<i>H. sapiens</i>	609
197783	3	11979	CACCGTGACTTCAGTGCAGA	243	<i>H. sapiens</i>	610
197784	3	12249	ACTGAGTTGAGGGTCCGGGA	244	<i>H. sapiens</i>	611
197786	3	13958	CACATATGAACTGGACCTGC	245	<i>H. sapiens</i>	612
197787	3	14008	TCTGAACTCAGAAGGATGGC	246	<i>H. sapiens</i>	613
216825	3	3249	GGTGCGAAGCAGACTGAGGC	247	<i>H. sapiens</i>	614
216826	3	3	TCCCACCGGACCTGCGGGG	248	<i>H. sapiens</i>	615
216827	3	6	CACCGGGACCTGCGGGGCTG	249	<i>H. sapiens</i>	616
216828	3	23	CTGAGTGCCCTTCTCGGTTG	250	<i>H. sapiens</i>	617
216829	3	35	CTCGGTTGCTGCCGCTGAGG	251	<i>H. sapiens</i>	618
216830	3	36	TCGGTTGCTGCCGCTGAGGA	252	<i>H. sapiens</i>	619
216831	3	37	CGGTTGCTGCCGCTGAGGAG	253	<i>H. sapiens</i>	620
216832	3	39	GTTGCTGCCGCTGAGGAGCC	254	<i>H. sapiens</i>	621
216833	3	43	CTGCCGCTGAGGAGCCCGCC	255	<i>H. sapiens</i>	622
216834	3	116	ACCGCAGCTGGCGATGGACC	256	<i>H. sapiens</i>	623
216835	3	120	CAGCTGGCGATGGACCCGCC	257	<i>H. sapiens</i>	624
216836	3	13800	GAACTTACTATCATCCTCTA	258	<i>H. sapiens</i>	625
216838	3	13854	TCCAATTGAACTTTCACATA	260	<i>H. sapiens</i>	626
216839	3	13882	AAAATTCAAATGCCTATAT	261	<i>H. sapiens</i>	627
216840	3	13903	GATAAAACCATACAGTGAGC	262	<i>H. sapiens</i>	628
216841	3	13904	ATAAAACCATACAGTGAGCC	263	<i>H. sapiens</i>	629
216842	3	13908	AACCATACAGTGAGCCAGCC	264	<i>H. sapiens</i>	630
216843	3	13909	ACCATACAGTGAGCCAGCCT	265	<i>H. sapiens</i>	631
216844	3	13910	CCATACAGTGAGCCAGCCTT	266	<i>H. sapiens</i>	632
216845	3	13917	GTGAGCCAGCCTTGCACTAG	267	<i>H. sapiens</i>	633
216846	3	13922	CCAGCCTTGCACTAGGCAGT	268	<i>H. sapiens</i>	634
216847	3	13934	TAGGCAGTAGACTATAAGCA	269	<i>H. sapiens</i>	635
216848	3	13937	GCAGTAGACTATAAGCAGAA	270	<i>H. sapiens</i>	636
216849	3	13964	TGAACTGGACCTGCACCAAA	271	<i>H. sapiens</i>	637
216850	3	13968	CTGGACCTGCACCAAAGCTG	272	<i>H. sapiens</i>	638
216851	3	13970	GGACCTGCACCAAAGCTGGC	273	<i>H. sapiens</i>	639
216852	3	13974	CTGCACCAAAGCTGGCACCA	274	<i>H. sapiens</i>	640

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
216853	3	13978	ACCAAAGCTGGCACCAGGGC	275	<i>H. sapiens</i>	641
216854	3	13997	CTCGGAAGGTCTCTGAACTC	276	<i>H. sapiens</i>	642
216855	3	14012	AACTCAGAAGGATGGCATT	277	<i>H. sapiens</i>	643
216856	3	14014	CTCAGAAGGATGGCATTTTT	278	<i>H. sapiens</i>	644
216857	3	14049	ATCAGGATCTGAGTTATTTT	279	<i>H. sapiens</i>	645
216858	3	14052	AGGATCTGAGTTATTTTGCT	280	<i>H. sapiens</i>	646
216859	3	14057	CTGAGTTATTTTGCTAACT	281	<i>H. sapiens</i>	647
216860	3	14064	ATTTTGCTAACTTGGGGGA	282	<i>H. sapiens</i>	648
216861	3	14071	TAACTTGGGGGAGGAGGAA	283	<i>H. sapiens</i>	649
217030	3	14087	GGAACAAATAAATGGAGTCT	284	<i>H. sapiens</i>	650
224316	3	3230	GTTTGTAAGTCAAGCAGAAG	285	<i>H. sapiens</i>	651
224317	3	3232	TTGTAAGTCAAGCAGAAGGT	286	<i>H. sapiens</i>	652
224318	3	3234	GTAAGTCAAGCAGAAGGTGC	287	<i>H. sapiens</i>	653
224319	3	3236	AACTCAAGCAGAAGGTGCGA	288	<i>H. sapiens</i>	654
224320	3	3238	CTCAAGCAGAAGGTGCGAAG	289	<i>H. sapiens</i>	655
224321	3	3240	CAAGCAGAAGGTGCGAAGCA	290	<i>H. sapiens</i>	656
224322	3	3242	AGCAGAAGGTGCGAAGCAGA	291	<i>H. sapiens</i>	657
224323	3	3244	CAGAAGGTGCGAAGCAGACT	292	<i>H. sapiens</i>	658
224324	3	3246	GAAGGTGCGAAGCAGACTGA	293	<i>H. sapiens</i>	659
224325	3	3248	AGGTGCGAAGCAGACTGAGG	294	<i>H. sapiens</i>	660
224326	3	3250	GTGCGAAGCAGACTGAGGCT	295	<i>H. sapiens</i>	661
224327	3	3252	GCGAAGCAGACTGAGGCTAC	296	<i>H. sapiens</i>	662
224328	3	3254	GAAGCAGACTGAGGCTACCA	297	<i>H. sapiens</i>	663
224329	3	3256	AGCAGACTGAGGCTACCATG	298	<i>H. sapiens</i>	664
224330	3	3258	CAGACTGAGGCTACCATGAC	299	<i>H. sapiens</i>	665
224331	3	3260	GACTGAGGCTACCATGACAT	300	<i>H. sapiens</i>	666
224332	3	3262	CTGAGGCTACCATGACATTC	301	<i>H. sapiens</i>	667
224333	3	3264	GAGGCTACCATGACATTCAA	302	<i>H. sapiens</i>	668
224334	3	3266	GGCTACCATGACATTCAAAT	303	<i>H. sapiens</i>	669
224335	3	3268	CTACCATGACATTCAAATAT	304	<i>H. sapiens</i>	670
224336	3	5582	CCTGAAGCTGCATGTGGCTG	305	<i>H. sapiens</i>	671
224337	3	5584	TGAAGCTGCATGTGGCTGGT	306	<i>H. sapiens</i>	672
224338	3	5586	AAGCTGCATGTGGCTGGTAA	307	<i>H. sapiens</i>	673
224339	3	5588	GCTGCATGTGGCTGGTAACC	308	<i>H. sapiens</i>	674
224340	3	5590	TGCATGTGGCTGGTAACCTA	309	<i>H. sapiens</i>	675
224341	3	5592	CATGTGGCTGGTAACCTAAA	310	<i>H. sapiens</i>	676
224342	3	5594	TGTGGCTGGTAACCTAAAAG	311	<i>H. sapiens</i>	677

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
224343	3	5596	TGGCTGGTAACCTAAAAGGA	312	<i>H. sapiens</i>	678
224344	3	5598	GCTGGTAACCTAAAAGGAGC	313	<i>H. sapiens</i>	679
224345	3	5600	TGGTAACCTAAAAGGAGCCT	314	<i>H. sapiens</i>	680
224346	3	5602	GTAACCTAAAAGGAGCCTAC	315	<i>H. sapiens</i>	681
224347	3	5604	AACCTAAAAGGAGCCTACCA	316	<i>H. sapiens</i>	682
224348	3	5606	CCTAAAAGGAGCCTACCAA	317	<i>H. sapiens</i>	683
187366	318	3121	GGCGCGAAGCAGACTGAGGC	319	<i>H. sapiens</i>	684
187404	318	12651	CACATATGTTTCATGAGGGAGG	323	<i>H. sapiens</i>	685
197777	318	9851	CCATCATAGGTTCTGACGTC	324	<i>H. sapiens</i>	686
197785	318	12561	GAAGCTGATTGACTCACTCA	325	<i>H. sapiens</i>	687
224349	318	3104	TTGTAACCTCAAGCAGAAGGC	326	<i>H. sapiens</i>	688
224350	318	3106	GTAACCTCAAGCAGAAGGCGC	327	<i>H. sapiens</i>	689
224351	318	3108	AACTCAAGCAGAAGGCGCGA	328	<i>H. sapiens</i>	690
224352	318	3110	CTCAAGCAGAAGGCGCGAAG	329	<i>H. sapiens</i>	691
224353	318	3116	CAGAAGGCGCGAAGCAGACT	330	<i>H. sapiens</i>	692
224354	318	3118	GAAGGCGCGAAGCAGACTGA	331	<i>H. sapiens</i>	693
224355	318	3120	AGGCGCGAAGCAGACTGAGG	332	<i>H. sapiens</i>	694
224356	318	3122	GCGCGAAGCAGACTGAGGCT	333	<i>H. sapiens</i>	695
224328	3	3254	GAAGCAGACTGAGGCTACCA	514	<i>H. sapiens</i>	696
224353	318	3116	CAGAAGGCGCGAAGCAGACT	515	<i>H. sapiens</i>	697
216862	334	904	TCTTTCTCCTGTCTTACAGA	335	<i>H. sapiens</i>	698
216866	334	1988	CCCACGTTAGAAGATGCGAC	339	<i>H. sapiens</i>	699
216868	334	2722	AATATGGTAGACATGAGCCA	341	<i>H. sapiens</i>	700
216869	334	2791	CATTAGCTGCATTTCAACTG	342	<i>H. sapiens</i>	701
216870	334	3045	ACTTTCACCTCCTAGTCTGCA	343	<i>H. sapiens</i>	702
216874	334	3527	CCATGTCCAGGTAAGTCATG	347	<i>H. sapiens</i>	703
216876	334	3603	GCACCAGGCACGGATGTGAC	349	<i>H. sapiens</i>	704
216877	334	3864	GTGGGGTCCAGAGGCACTG	350	<i>H. sapiens</i>	705
216878	334	3990	GCTGATCGGCCACTGCAGCT	351	<i>H. sapiens</i>	706
216879	334	4251	TCCACGTGGCTGGGGAGGTC	352	<i>H. sapiens</i>	707
216880	334	4853	TGTAATGTATGGTGATCAGA	353	<i>H. sapiens</i>	708
216881	334	5023	GAGAGTACCCAGTGGGAAAT	354	<i>H. sapiens</i>	709
216882	334	5055	AGTCAGCATGGGCTTCAGCC	355	<i>H. sapiens</i>	710
216883	334	5091	CAAAAGAATGACTGTCCAAC	356	<i>H. sapiens</i>	711
216884	334	5096	GAATGACTGTCCAACAAGTO	357	<i>H. sapiens</i>	712
216885	334	5301	TATCTACTGTAATTTAAAT	358	<i>H. sapiens</i>	713
216886	334	5780	CTGATATGGGTGGAGAACAG	359	<i>H. sapiens</i>	714

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
216887	334	6353	TCTGGGACAGGTATGAGCTC	360	<i>H. sapiens</i>	715
216888	334	6534	TGATAGCAGTGGCCCTTGAA	361	<i>H. sapiens</i>	716
216889	334	6641	GGATTGGCGTGAATACTGG	362	<i>H. sapiens</i>	717
216890	334	6661	TGCCCAGAGTTCCTCCTGCC	363	<i>H. sapiens</i>	718
216894	334	7059	GCACTAGCAAGACCACACTC	367	<i>H. sapiens</i>	719
216895	334	7066	CAAGACCACACTCTGCATAG	368	<i>H. sapiens</i>	720
216897	334	7209	TCCTCCATAGGATACCGTGT	370	<i>H. sapiens</i>	721
216899	334	7702	GGATGTAGGGCAGCAAAACC	372	<i>H. sapiens</i>	722
216900	334	7736	TCTGCACAAGGACTCCTTGT	373	<i>H. sapiens</i>	723
216901	334	8006	CAGCCTGTCTCAGTGAACAT	374	<i>H. sapiens</i>	724
216903	334	8239	CAGGATGCTTCCAGTCTAAT	376	<i>H. sapiens</i>	725
216904	334	8738	AAATGCTCGTCTCCAATCTC	377	<i>H. sapiens</i>	726
216906	334	9208	AACTTGTTATCCAAATCCA	379	<i>H. sapiens</i>	727
216908	334	9545	TGACATGGTGTGCTTCCTTG	381	<i>H. sapiens</i>	728
216910	334	9770	ACACTGGTGTCTGGCTACC	383	<i>H. sapiens</i>	729
216911	334	9776	GTGTTCTGGCTACCTCTAGT	384	<i>H. sapiens</i>	730
216913	334	10341	TCCTGGCATAGGTCACAGTA	386	<i>H. sapiens</i>	731
216914	334	10467	ATGTCAACAGTAGCACCTCC	387	<i>H. sapiens</i>	732
216915	334	10522	TACACTCAGACAAGTCTGGA	388	<i>H. sapiens</i>	733
216917	334	10587	CCTAAGTTGCTCATCTCTGG	390	<i>H. sapiens</i>	734
216922	334	11337	TGCGCTGAGTTCATGAAAC	395	<i>H. sapiens</i>	735
216923	334	11457	CTATTGCAGGTGCTCTCCAG	396	<i>H. sapiens</i>	736
216926	334	12155	CAGAGGAACATCTTGACCT	399	<i>H. sapiens</i>	737
216928	334	12221	CTCTGCTCCTTACTCTTGTG	401	<i>H. sapiens</i>	738
216929	334	12987	GTAATTCTCACCATCCATC	402	<i>H. sapiens</i>	739
216930	334	13025	TTCTGAGTCTCAATTGTCTA	403	<i>H. sapiens</i>	740
216931	334	13057	CTATGTCCTTGTGTGCACAT	404	<i>H. sapiens</i>	741
216932	334	13634	GCCTATTGCCATTTGTATGT	405	<i>H. sapiens</i>	742
216933	334	13673	CTATTCATGTCCTTTGCCTA	406	<i>H. sapiens</i>	743
216935	334	14567	GATTCTGCGGTAATCTCAG	408	<i>H. sapiens</i>	744
216937	334	14680	TCAATGCAGGTCATTGGAAA	410	<i>H. sapiens</i>	745
216938	334	15444	CTACCAGATTGACCATCCCT	411	<i>H. sapiens</i>	746
216940	334	15757	TACTTGATAGTGCTCTAGGA	413	<i>H. sapiens</i>	747
216941	334	15926	TTGACTGCAGGACCAGGAGG	414	<i>H. sapiens</i>	748
216942	334	16245	AACAAACACTTGTGCAAATG	415	<i>H. sapiens</i>	749
216950	334	18519	AATGAGACCAAACCTTCCACT	423	<i>H. sapiens</i>	750
216951	334	18532	TTCCACTTTGAAGCTAGCAA	424	<i>H. sapiens</i>	751

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
216952	334	18586	GATCTGGAGCTTATTCTTGA	425	<i>H. sapiens</i>	752
216953	334	18697	ACCTCATGTGACTTGTATGC	426	<i>H. sapiens</i>	753
216954	334	18969	TTCTTAAGAAACACCTTGTA	427	<i>H. sapiens</i>	754
216955	334	19250	TAGGCCCATCCTGGCTGCAT	428	<i>H. sapiens</i>	755
216956	334	19340	AAACTCTCAGGATATGGTAA	429	<i>H. sapiens</i>	756
216957	334	19802	ATACCTTCCTCTACCTTTGC	430	<i>H. sapiens</i>	757
216958	334	19813	TACCTTTGCTGAAGGTCCTT	431	<i>H. sapiens</i>	758
216961	334	20567	ATCTATCTAGTGAAATTCT	434	<i>H. sapiens</i>	759
216962	334	20647	TCAGCTCATCAAATATGCT	435	<i>H. sapiens</i>	760
216963	334	20660	ATATGCTAGTCCTTCCTTTC	436	<i>H. sapiens</i>	761
216965	334	21316	CAAAGGTCTGAGTTATCCAG	438	<i>H. sapiens</i>	762
216967	334	21422	TGACTTATAGATGCAGGCTG	440	<i>H. sapiens</i>	763
216968	334	21634	TCAGTGGAGGGTAATTCTTT	441	<i>H. sapiens</i>	764
216969	334	21664	TGCCTAGCCAGTTTGAAAGA	442	<i>H. sapiens</i>	765
216970	334	21700	CCTGCAGAAATTTGCCAGGC	443	<i>H. sapiens</i>	766
216972	334	22048	GTAGCTAGGTAGGTAAAGCA	445	<i>H. sapiens</i>	767
216973	334	22551	TTGAGTGAGACACACAAGGT	446	<i>H. sapiens</i>	768
216974	334	22694	GTGCTAGTCAGGGAATGCAT	447	<i>H. sapiens</i>	769
216976	334	22903	GGGGAGAGAGCATGCCCAGC	449	<i>H. sapiens</i>	770
216977	334	22912	GCATGCCCAGCTGCGAAAGC	450	<i>H. sapiens</i>	771
216978	334	23137	AGCCAGGTATAGAAAGGAGT	451	<i>H. sapiens</i>	772
216979	334	23170	AACTTTCTAAGAGGCAGAAT	452	<i>H. sapiens</i>	773
216981	334	23882	TCTTAGTCTGGTCATGAGTG	454	<i>H. sapiens</i>	774
216983	334	24184	AGTAGGAGATTTTCATATGAA	456	<i>H. sapiens</i>	775
216985	334	24559	TCTTCACCAGCAACACATTA	458	<i>H. sapiens</i>	776
216987	334	24800	ATGGCCACCTAGCATGGCAC	460	<i>H. sapiens</i>	777
216989	334	24991	CATGTTTCTGAGCCTCCAGA	462	<i>H. sapiens</i>	778
216990	334	25067	TAGGTGGCTCCCTGTCTTCA	463	<i>H. sapiens</i>	779
216991	334	25152	TCCAAAGTCTTGGGAATCCT	464	<i>H. sapiens</i>	780
216995	334	26749	ACAAAGAAAGGGGAGTTGG	468	<i>H. sapiens</i>	781
216996	334	26841	TCGTGTCTTCTTGCCCGAGA	469	<i>H. sapiens</i>	782
216997	334	27210	GCAGTGCCCGAGCACACAATA	470	<i>H. sapiens</i>	783
216998	334	27815	ACTCGTCCAGGTGCGAAGCA	471	<i>H. sapiens</i>	784
216999	334	28026	GCCACCTAAGGTAAAGAAGG	472	<i>H. sapiens</i>	785
217000	334	28145	ATCAGAGTGGCAGAGAGAGC	473	<i>H. sapiens</i>	786
217002	334	28919	TTTACCATAGTTGTGACACA	475	<i>H. sapiens</i>	787
217006	334	29871	CATTTTGTAGGCAATGAGCT	479	<i>H. sapiens</i>	788

TABLE 18-continued

Sequence and position of preferred target segments identified in apolipoprotein B.						
SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV	COMP OF SEQ ID NO	SEQ ID NO
217007	334	30181	GCATTAGTAAACATGAGAAC	480	<i>H. sapiens</i>	789
217009	334	30931	TTCATTTTCAGCGATGGCCGG	482	<i>H. sapiens</i>	790
217013	334	39562	GAAAATCTAGTGTCATTCAA	486	<i>H. sapiens</i>	791
217016	334	39789	TCCTATACAGTTTGGGAAC	489	<i>H. sapiens</i>	792
217017	334	39904	AAGGACTTCAGTATGGAGCT	490	<i>H. sapiens</i>	793
217018	334	39916	ATGGAGCTTTTATTGAATTG	491	<i>H. sapiens</i>	794
217022	334	40412	CCATCAGCACTATTATTAT	495	<i>H. sapiens</i>	795
217023	334	40483	ATAGGCAAGCTCAGCCATAG	496	<i>H. sapiens</i>	796
217025	334	40576	TGCTAGATGAGATACATCAA	498	<i>H. sapiens</i>	797
217026	334	40658	GAAGACCAACATGGTTCTA	499	<i>H. sapiens</i>	798
217029	334	41130	CTCTGTTTAGTCCTCTCCAG	502	<i>H. sapiens</i>	799
217032	503	490	CATTGATAAAATGTTCTGGC	505	<i>H. sapiens</i>	800
217033	503	504	TCTGGCACAGCAAAACCTCT	506	<i>H. sapiens</i>	801
217034	503	506	TGGCACAGCAAAACCTCTAG	507	<i>H. sapiens</i>	802
217037	503	523	TAGAACACATAGTGTGATTT	510	<i>H. sapiens</i>	803
217039	503	526	AACACATAGTGTGATTTAAG	512	<i>H. sapiens</i>	804

As these “preferred target segments” have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to there referred target segments and consequently inhibit the expression of apolipoprotein B.

According to the present invention, antisense compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other short oligomeric compounds which hybridize to at least a portion of the target nucleic acid.

Example 37

Antisense Inhibition of Human Apolipoprotein B Expression—Dose Response of Oligonucleotides

In accordance with the present invention, 12 oligonucleotides described in Examples 29 and 31 were further investigated in a dose response study. The control oligonucleotides used in this study were ISIS 18076 (SEQ ID NO: 805) and ISIS 13650 (SEQ ID NO: 806).

All compounds in this study, including the controls, were chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide “wings”. The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotides. All cytidine residues are 5-methylcytidines.

In the dose-response experiment, with mRNA levels as the endpoint, HepG2 cells were treated with the antisense oligonucleotides or the control oligonucleotides at doses of 37, 75, 150, and 300 nM oligonucleotide. Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments with mRNA levels in the treatment groups being normalized to an untreated control group. The data are shown in Table 19.

TABLE 19

Inhibition of apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Dose Response

ISIS #	% inhibition				SEQ ID NO
	Dose				
	37 nM	75 nM	150 nM	300 nM	
271009	82	91	94	96	319
281625	62	76	84	94	224
301014	75	90	96	98	249
301027	80	90	95	96	262
301028	70	79	85	92	263
301029	54	67	79	85	264
301030	64	75	87	92	265
301031	61	82	92	96	266
301034	73	87	93	97	269
301036	67	83	92	95	271
301037	73	85	69	96	272
301045	77	86	94	98	280

Antisense Inhibition of Human Apolipoprotein B Expression—Dose Response—Lower Dose Range

In accordance with the present invention, seven oligonucleotides described in Examples 29, 31, 35, and 36 were further investigated in a dose response study. The control oligonucleotides used in this study were ISIS 18076 (SEQ ID NO: 805), ISIS 13650 (SEQ ID NO: 806), and ISIS 129695 (SEQ ID NO: 807).

All compounds in this study, including the controls, were chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotides. All cytidine residues are 5-methylcytidines.

In the dose-response experiment, with mRNA levels as the endpoint, HepG2 cells were treated with the antisense oligonucleotides or the control oligonucleotides at doses of 12.5, 37, 75, 150, and 300 nM oligonucleotide. Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments with mRNA levels in the treatment groups being normalized to an untreated control group. The data are shown in Table 20.

TABLE 20

Inhibition of apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Dose Response						
ISIS #	% inhibition					SEQ ID #
	12.5 nM	37 nM	75 nM	150 nM	300 nM	
271009	67	86	92	94	95	319
281625	44	66	83	85	94	224
301012	63	79	90	92	95	247
368638	42	73	91	96	97	247
308642	59	84	91	97	98	319
308651	57	76	84	90	88	319
308658	29	61	73	78	90	224

Example 39

RNA Synthesis

In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5'-hydroxyl in combination with an acid-labile orthoester protecting group on the 2'-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.

Following this procedure for the sequential protection of the 5'-hydroxyl in combination with protection of the 2'-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5'-direction) at the 3'-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5'-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5'-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S_2Na_2) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55°C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2'-groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

The 2'-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, Colo.), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product.

Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., J. Am. Chem. Soc., 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc., 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. Tetrahedron Lett., 1981, 22, 1859-1862; Dahl, B. J., et al., Acta Chem. Scand., 1990, 44, 639-641; Reddy, M. P., et al., Tetrahedron Lett., 1994, 25, 4311-4314; Wincott, F. et al., Nucleic Acids Res., 1995, 23, 2677-2684; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2301-2313; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2315-2331).

RNA antisense compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, Colo.). Once synthesized, complementary RNA antisense compounds can then be stably annealed by methods known in the art to form double stranded (duplexed) antisense compounds. For example, duplexes can be formed by combining 30 μ l of each of the complementary strands of RNA oligonucleotides (50 μ M RNA oligonucleotide solution) and 15 μ l of 5 \times annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90°C., then 1 hour at 37°C. The

123

resulting duplexed antisense compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.

Example 40

Design and Screening of Duplexed Antisense Compounds Targeting Apolipoprotein B

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements are designed to target apolipoprotein B. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide described herein. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. The antisense and sense strands of the duplex comprise from about 17 to 25 nucleotides, or from about 19 to 23 nucleotides. Alternatively, the antisense and sense strands comprise 20, 21 or 22 nucleotides.

For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG (SEQ ID NO: 893) and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

```

cgagaggcggacgggac-   Antisense Strand
cgTT                  (SEQ ID NO: 894)
|||||
TTgctctcgctgcctggc   Complement (SEQ. ID NO: 895)

```

In another embodiment, a duplex comprising an antisense strand having the same sequence CGAGAGGCGGACGGGACCG (SEQ ID NO: 893) may be prepared with blunt ends (no single stranded overhang) as shown:

```

cgagaggcggacgggacgg   Antisense Strand
|||||                  (SEQ ID NO: 893)
gctctcgctgcctggc      Complement (SEQ. ID NO: 896)

```

RNA strands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, Colo.). Once synthesized, the complementary strands are stably annealed. The single strands are aliquoted and diluted to a concentration of 50 uM. Once diluted, 30 uL of each strand is combined with 15 uL of a 5x solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2 mM magnesium acetate. The final volume is 75 uL. This solution is incubated for 1 minute at 90° C. and then centrifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37° C. at which time the dsRNA duplexes are used in experimentation. The final concentration of the dsRNA duplex is 20 uM. This solution can be stored frozen (-20° C.) and freeze-thawed up to 5 times.

Once prepared, the duplexed antisense compounds are evaluated for their ability to modulate apolipoprotein B expression.

When cells reached 80% confluency, they are treated with duplexed antisense compounds of the invention. For cells grown in 96-well plates, wells are washed once with 200 uL OPTI-MEM-1 reduced-serum medium (Gibco BRL) and

124

then treated with 130 uL of OPTI-MEM-1 containing 12 uM LIPOFECTIN (Gibco BRL) and the desired duplex antisense compound at a final concentration of 200 nM. After 5 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after treatment, at which time RNA is isolated and target reduction measured by RT-PCR.

Example 41

Design of Phenotypic Assays and In Vivo Studies for the use of Apolipoprotein B Inhibitors
Phenotypic Assays

Once apolipoprotein B inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition. Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of apolipoprotein B in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, Oreg.; PerkinElmer, Boston, Mass.), protein-based assays including enzymatic assays (Panvera, LLC, Madison, Wis.; BD Biosciences, Franklin Lakes, N.J.; Oncogene Research Products, San Diego, Calif.), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, Mich.), triglyceride accumulation (Sigma-Aldrich, St. Louis, Mo.), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, Calif.; Amersham Biosciences, Piscataway, N.J.).

In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with apolipoprotein B inhibitors identified from the in vitro studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the apolipoprotein B inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

In Vivo Studies

The individual subjects of the in vivo studies described herein are warm-blooded vertebrate animals, which includes humans.

The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study.

To account for the psychological effects of receiving treatments, volunteers are randomly given placebo or apolipoprotein B inhibitor. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are administering is a apolipoprotein B inhibitor or a placebo. Using this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

Volunteers receive either the apolipoprotein B inhibitor or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study period. Such measurements include the levels of nucleic acid molecules encoding apolipoprotein B or apolipoprotein B protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and apolipoprotein B inhibitor treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the apolipoprotein B inhibitor show positive trends in their disease state or condition index at the conclusion of the study.

Antisense Inhibition of Rabbit Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides having 2'-MOE Wings and a Deoxy Gap

In accordance with the present invention, a series of oligonucleotides was designed to target different regions of rabbit apolipoprotein B, using published sequences (GenBank accession number X07480.1, incorporated herein as SEQ ID NO: 808, GenBank accession number M17780.1, incorporated herein as SEQ ID NO: 809, and a sequence was derived using previously described primers (Tanaka, Journ. Biol. Chem., 1993, 268, 12713-12718) representing an mRNA of the rabbit apolipoprotein B, incorporated herein as SEQ ID NO: 810). The oligonucleotides are shown in Table 21. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 21 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on rabbit apolipoprotein B mRNA levels in primary rabbit hepatocytes by quantitative real-time PCR as described in other examples herein. Primary rabbit hepatocytes were treated with 150 nM of the compounds in Table 21. For rabbit apolipoprotein B the PCR primers were:
forward primer: AAGCACCCCCAATGTCACC (SEQ ID NO: 811)
reverse primer: GGGATGGCAGAGCCAATGTA (SEQ ID NO: 812) and the PCR probe was: FAM-TCCTGGAT-TCAAGCTTCTATGTGCCTTCA-TAMRA (SEQ ID NO: 813) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. Data are averages from two experiments. If present, "N.D." indicates "no data".

TABLE 21

Inhibition of rabbit apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap					
ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
233149	808	1	TGCTTGGAGAAGGTAAGATC	0	814
233150	810	1	GC GTTGTCTCCGATGTTCTG	20	815
233151	809	13	TAATCATTAACCTTGCTGTGG	20	816
233152	808	22	TCAGCACGTAGCAATGCATT	0	817
233153	808	31	GCCTGATACTCAGCACGTAG	0	818
233154	809	31	CAATTGAATGTACTCAGATA	18	819
233155	808	51	ACCTCAGTGACTTGTAATCA	47	820
233156	809	51	CACTGGAACTTGCTCTCC	23	821
233157	809	71	AGTAGTTAGTTTCTCCTTGG	0	822
233159	808	121	TCAGTGCCCAAGATGTCAGC	0	823
233160	810	121	ATTGGAATAATGTATCCAGG	81	824

TABLE 21-continued

Inhibition of rabbit apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap					
ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
233161	809	130	TTGGCATTATCCAATGCAGT	28	825
233162	808	151	GTTGCCTTGTGAGCAGCAGT	0	826
233163	810	151	ATTGTGAGTGGAGATACTTC	80	827
233164	809	171	CATATGTCTGAAGTTGAGAC	8	828
233165	808	181	GTAGATACTCCATTTTGGCC	0	829
233166	810	181	GGATCACATGACTGAATGCT	82	830
233167	808	201	TCAAGCTGGTTGTTGCACTG	28	831
233168	808	211	GGACTGTACCTCAAGCTGGT	0	832
233169	808	231	GCTCATTTCTCCAGCATCAGG	14	833
233170	809	251	TTGATCTATAATACTAGCTA	23	834
233172	810	282	ATGGAAGACTGGCAGCTCTA	86	835
233173	808	301	TTGTGTTCTTGAAGCGGCC	3	836
233174	809	301	TGTGCACGGATATGATAACG	21	837
233175	810	306	GACCTTGAGTAGATTCTTGG	90	838
233176	810	321	GAAATCTGGAAGAGAGACCT	62	839
233177	808	331	GTAGCTTTCCCATCTAGGCT	0	840
233178	808	346	GATAACTCTGTGAGGGTAGC	0	841
233179	810	371	ATGTTGCCCATGGCTGGAAT	65	842
233180	809	381	AAGATGCAGTACTACTTCCA	13	843
233181	808	382	GCACCCAGAATCATGGCCTG	0	844
233182	809	411	CTTGATACTTGGTATCCACA	59	845
233183	810	411	CAGTGTAATGATCGTTGATT	88	846
233184	810	431	TAAAGTCCAGCATTGGTATT	69	847
233185	810	451	CAACAATGTCTGATTGGTTA	73	848
233186	810	473	GAAGAGGAAGAAAGGATATG	60	849
233187	810	481	TGACAGATGAAGAGGAAGAA	66	850
233188	810	500	TTGTAAGTAGTGCATCAAT	74	851
233189	809	511	GCCTCAATCTGTTGTTTCAG	46	852
233190	810	520	ACTTGAGCGTGCCCTCTAAT	69	853
233191	809	561	GAAATGGAATTGTAGTTCTC	31	854

Example 43

Antisense Inhibition of Rabbit Apolipoprotein B Expression by Chimeric Phosphorothioate Oligonucleotides having 2'-MOE Wings and a Deoxy gap-Dose Response Study

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 42 was further investigated in dose-response studies. Treatment doses were 10, 50,

150 and 300 nM. ISIS 233160 (SEQ ID NO: 824), ISIS 233166 (SEQ ID NO: 830), ISIS 233172 (SEQ ID NO: 835), ISIS 233175 (SEQ ID NO: 838), and ISIS 233183 (SEQ ID NO: 846) were analyzed for their effect on rabbit apolipoprotein B mRNA levels in primary rabbit hepatocytes by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 22.

TABLE 22

Inhibition of rabbit apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap				
ISIS #	Percent Inhibition			
	300 nM	150 nM	50 nM	10 nM
233160	80	74	67	33
233166	73	79	81	66
233172	84	81	76	60
233175	93	90	85	67
233183	80	81	71	30

Example 44

Effects of Antisense Inhibition of Apolipoprotein B in LDLr^{-/-} Mice—Dose Response

LDL receptor-deficient mice (LDLr^{-/-} mice), a strain that cannot edit the apolipoprotein B mRNA and therefore synthesize exclusively apolipoprotein B-100, have markedly elevated LDL cholesterol and apolipoprotein B-100 levels and develop extensive atherosclerosis.

LDLr^{-/-} mice, purchased from Taconic (Germantown, N.Y.) were used to evaluate antisense oligonucleotides for their potential to lower apolipoprotein B mRNA or protein levels, as well as phenotypic endpoints associated with apolipoprotein B. LDLr^{-/-} mice were separated into groups of males and females. LDLr^{-/-} mice were dosed intraperitoneally twice a week for six weeks with either 10, 25, or 50 mg/kg of ISIS 147764 (SEQ ID NO: 109) or ISIS 270906 (SEQ ID NO: 856) which is a 4 base mismatch of ISIS 147764, or with saline, or 20 mg/kg of Atorvastatin. At study termination animals were sacrificed and evaluated for several phenotypic markers.

ISIS 147764 was able to lower cholesterol, triglycerides, and mRNA levels in a dose-dependent manner in both male and female mice while the 4-base mismatch ISIS 270906 was not able to do this. The results of the study are summarized in Table 23.

TABLE 23

Effects of ISIS 147764 treatment in male and female LDLr-/mice on apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.								
	Dose	Liver Enzymes IU/L		Lipoproteins mg/dL				mRNA %
ISIS No.	mg/kg	AST	ALT	CHOL	HDL	LDL	TRIG	control
Males								
Saline		68.4	26.6	279.2	125.4	134.7	170.6	100.0
147764	10	57.6	29.8	314.2	150.0	134.7	198.6	61.7
	25	112.6	78.8	185.0	110.6	66.2	104.2	30.7
	50	163.6	156.8	165.6	107.8	51.2	113.4	16.6
270906	50	167.4	348.0	941.0	244.2	541.9	844.8	N.D.
Atorvastatin	20	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	110.9
Females								
Saline		65.0	23.4	265.8	105.8	154.9	121.4	100.0
147764	10	82.0	27.2	269.6	121.0	127.8	140.8	64.2
	25	61.4	32.2	175.8	99.5	68.9	100.4	41.3
	50	134.6	120.4	138.2	92.2	45.9	98.0	18.5
270906	50	96.0	88.6	564.6	200.0	310.0	240.4	N.D.
Atorvastatin	20	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	109.0

Example 45

Effects of Antisense Inhibition of Apolipoprotein B in Cynomolgus Monkeys

Cynomolgus monkeys fed an atherogenic diet develop atherosclerosis with many similarities to atherosclerosis of human beings. Female Cynomolgus macaques share several similarities in lipoproteins and the cardiovascular system with humans. In addition to these characteristics, there are similarities in reproductive biology. The Cynomolgus female has a 28-day menstrual cycle like that of women. Plasma hormone concentrations have been measured throughout the Cynomolgus menstrual cycle, and the duration of the follicular and luteal phases, as well as plasma estradiol and progesterone concentrations across the cycle, are also remarkably similar to those in women.

Cynomolgus monkeys (male or female) can be used to evaluate antisense oligonucleotides for their potential to lower apolipoprotein B mRNA or protein levels, as well as phenotypic endpoints associated with apolipoprotein B including, but not limited to cardiovascular indicators, atherosclerosis, lipid diseases, obesity, and plaque formation. One study could include normal and induced hypercholesterolemic monkeys fed diets that are normal or high in lipid and cholesterol. Cynomolgus monkeys can be dosed in a variety of regimens, one being subcutaneously with 10-20 mg/kg of the oligomeric compound for 1-2 months. Parameters that may be observed during the test period could include: total plasma cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, arterial wall cholesterol content, and coronary intimal thickening.

Example 46

Sequencing of Cynomolgus Monkey (*Macaca fascicularis*) Apolipoprotein B Preferred Target Segment

In accordance with the present invention, a portion of the cynomolgus monkey apolipoprotein B mRNA not available in the art, was amplified. Positions 2920 to 3420 of the human apolipoprotein B mRNA sequence (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3) contain the preferred target segment to which ISIS 301012

131

hybridizes and the corresponding segment of cynomolgus monkey apolipoprotein B mRNA was amplified and sequenced. The site to which ISIS 301012 hybridizes in the human apolipoprotein B was amplified by placing primers at 5' position 2920 and 3' position 3420. The cynomolgus monkey hepatocytes were purchased from In Vitro Technologies (Gaithersburg, Md.). The 500 bp fragments were produced using human and cynomolgus monkey 1° hepatocyte cDNA and were produced by reverse transcription of purified total RNA followed by 40 rounds of PCR amplification. Following gel purification of the human and cynomolgus amplicons, the forward and reverse sequencing reactions of each product were performed by Retrogen (Invitrogen kit was used to create the single-stranded cDNA and provided reagents for Amplitaq PCR reaction). This cynomolgus monkey sequence is incorporated herein as SEQ ID NO: 855 and is 96% identical to positions 2920 to 3420 of the human apolipoprotein B mRNA.

Example 47

Effects of Antisense Inhibition of Human Apolipoprotein B Gene (ISIS 281625 and 301012) in C57BL/6NTac-TgN (APOB100) Transgenic Mice

C57BL/6NTac-TgN(APOB100) transgenic mice have the human apolipoprotein B gene "knocked-in". These mice express high levels of human apolipoprotein B100 resulting in mice with elevated serum levels of LDL cholesterol. These mice are useful in identifying and evaluating compounds to reduce elevated levels of LDL cholesterol and the risk of atherosclerosis. When fed a high fat cholesterol diet, these mice develop significant foam cell accumulation underlying the endothelium and within the media, and have significantly more complex atherosclerotic lesions than control animals.

C57BL/6NTac-TgN(APOB100) mice were divided into two groups—one group receiving oligonucleotide treatment and control animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg ISIS 281625 (SEQ ID No: 224) or ISIS 301012 (SEQ ID No: 247) for eight weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, and liver enzyme levels. In addition, the endogenous mouse apolipoprotein B levels in liver were measured to evaluate any effects of these antisense oligonucleotides targeted to the human apolipoprotein B.

Upon treatment with either ISIS 281625 or ISIS 301012, the AST and ALT levels were increased, yet did not exceed normal levels (~300 IU/L). Cholesterol levels were slightly increased relative to saline treatment, while triglyceride levels were slightly decreased. Treatment with either of these oligonucleotides targeted to the human apolipoprotein B which is expressed in these mice markedly decreased the mRNA levels of the human apolipoprotein, while the levels of the endogenous mouse apolipoprotein B were unaffected, indicating that these oligonucleotides exhibit specificity for the human apolipoprotein B. The results of the comparative studies are shown in Table 24.

132

TABLE 24

Effects of ISIS 281625 and 301012 treatment in mice on apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.

	ISIS No.		
	SALINE	281625	301012
Liver Enzymes IU/L			
AST	70.3	265.8	208.4
ALT	32.8	363.8	137.4
Lipoproteins mg/dL			
CHOL	109.5	152.0	145.1
HDL	67.3	84.6	98.6
LDL	30.2	49.8	36.6
TRIG	194.5	171.1	157.8
mRNA % control			
human mRNA	100.0	45.2	23.7
mouse mRNA	100.0	111.0	94.6

Following 2 and 4 weeks of ISIS 301012 treatment, LDL-cholesterol levels were significantly reduced to 22 mg/dL and 17 mg/dL, respectively.

Apolipoprotein B protein levels in liver were also evaluated at the end of the 8 week treatment period. Liver protein was isolated and subjected to immunoblot analysis using antibodies specific for human or mouse apolipoprotein B protein (US Biologicals, Swampscott, Mass. and Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., respectively). Immunoblot analysis of liver protein samples reveals a reduction in the expression of both forms of human apolipoprotein B, apolipoprotein B-100 and apolipoprotein B-48. Mouse apolipoprotein B levels in liver were not significantly changed, as judged by immunoblot analysis.

Serum samples were also collected at 2, 4, 6 and 8 weeks and were evaluated for human apolipoprotein B expression by using a human apolipoprotein B specific ELISA kit (ALerCHEK Inc., Portland, Me.). Quantitation of serum human apolipoprotein B protein by ELISA revealed that treatment with ISIS 281625 reduced serum human apolipoprotein B protein by 31, 26, 11 and 26% at 2, 4, 6 and 8 weeks, respectively, relative to saline-treated animals. Treatment with ISIS 301012 reduced serum human apolipoprotein B protein by 70, 87, 81 and 41% at 2, 4, 6 and 8 weeks, respectively, relative to saline-treated control animals. Serum from transgenic mice was also subjected to immunoblot analysis using both human and mouse specific apolipoprotein B antibodies (US Biologicals, Swampscott, Mass. and Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., respectively). Immunoblot analysis of serum samples taken from animals shows a similar pattern of human apolipoprotein B expression, with a significant reduction in serum apolipoprotein B protein after 2, 4 and 6 weeks of treatment and a slight reduction at 8 weeks. Mouse apolipoprotein B in serum was not significantly changed, as judged by immunoblot analysis.

Example 48

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 233172, 233175, 281625, 301012, and 301027) in C57BL/6 Mice

C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate the toxicity in mice of several antisense oligonucleotides targeted to human or rabbit apolipoprotein B.

133

C57BL/6 mice were divided into two groups—one group receiving oligonucleotide treatment and control animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg of one of several oligonucleotides for two weeks. The antisense oligonucleotides used in the present study were ISIS 233172 (SEQ ID NO: 835) and ISIS 233175 (SEQ ID NO: 838), both targeted to rabbit apolipoprotein B, and ISIS 281625 (SEQ ID NO: 224), ISIS 301012 (SEQ ID NO: 247), and ISIS 301027 (SEQ ID NO: 262), targeted to human apolipoprotein B. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for liver enzyme levels, body weight, liver weight, and spleen weight.

The levels of liver enzymes in mice were decreased relative to saline treatment for three of the antisense oligonucleotide. However, the rabbit oligonucleotide ISIS 233175 and the human oligonucleotide ISIS 301027 both elicited drastically increased levels of these liver enzymes, indicating toxicity. For all of the oligonucleotides tested, the change in weight of body, liver, and spleen were minor. The results of the comparative studies are shown in Table 25.

TABLE 25

Effects of antisense oligonucleotides targeted to human or rabbit apolipoprotein B mouse apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.						
	ISIS No.					
	SALINE	233172	233175	281625	301012	301027
Liver Enzymes						
AST IU/L	104.5	94.3	346.7	89.5	50.6	455.3
ALT IU/L	39.5	43.3	230.2	36.2	21.2	221.3
Weight						
BODY	21.2	21.3	21.5	20.9	21.3	21.2
LIVER	1.1	1.3	1.4	1.2	1.1	1.3
SPLEEN	0.1	0.1	0.1	0.1	0.1	0.1

Example 49

Time Course Evaluation of Oligonucleotide at two Different Doses

C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate the toxicity in mice of several antisense oligonucleotides targeted to human apolipoprotein B.

Female C57BL/6 mice were divided into two groups—one group receiving oligonucleotide treatment and control animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg or 50 mg/kg of ISIS 281625 (SEQ ID NO: 224), ISIS 301012 (SEQ ID NO: 247), or ISIS 301027 (SEQ ID NO: 262). After 2 weeks, a blood sample was taken from the tail of the mice and evaluated for liver enzyme. After 4 weeks, and study termination, animals were sacrificed and evaluated for liver enzyme levels.

For ISIS 281625 and ISIS 301012, AST and ALT levels remained close to those of saline at either dose after 2 weeks. After 4 weeks, AST and ALT levels showed a moderate increase over saline treated animals for the lower dose, but a large increase at the higher dose. ISIS 301027, administered at either dose, showed a small increase in AST and ALT levels

134

after 2 weeks and a huge increase in AST and ALT levels after 4 weeks. The results of the studies are summarized in Table 26.

TABLE 26

AST and ALT levels in mice treated with ISIS 281625, 301012, or 301027 after 2 and 4 weeks					
ISIS No.	Dose (mg/kg)	AST (IU/L)		ALT (IU/L)	
		2 weeks	4 weeks	2 weeks	4 weeks
		SALINE			
261625	25	40.8	75	21.2	31.8
	50	44.4	152.4	30.8	210.4
301012	25	37.2	89.8	22.4	24.8
	50	38.4	107.4	23.2	29.2
301027	25	55.4	537.6	27.2	311.2
	50	64	1884	34.8	1194

Example 50

Effects of Antisense Inhibition of Apolipoprotein B (ISIS 147483 and 147764) in ob/ob Mice

Leptin is a hormone produced by fat that regulates appetite. Deficiencies in this hormone in both humans and non-human animals leads to obesity. ob/ob mice have a mutation in the leptin gene which results in obesity and hyperglycemia. As such, these mice are a useful model for investigation of obesity and diabetes and treatments designed to treat these conditions.

Ob/ob mice receiving a high fat, high cholesterol diet (60% kcal fat supplemented with 0.15% cholesterol) were treated with one of several oligonucleotides to evaluate their effect on apolipoprotein B-related phenotypic endpoints in ob/ob mice. After overnight fasting, mice from each group were dosed intraperitoneally twice a week with 50 mg/kg of ISIS 147483 (SEQ ID NO: 79), or 147764 (SEQ ID NO: 109), or the controls ISIS 116847 (SEQ ID NO: 857), or 141923 (SEQ ID NO: 858), or saline for six weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, liver enzyme levels, serum glucose levels, and PTEN levels.

ISIS 147483 and 147764 were both able to lower apolipoprotein B mRNA levels, as well as glucose, cholesterol, and triglyceride levels. The results of the comparative studies are shown in Table 27.

TABLE 27

Effects of ISIS 147483 and 147764 treatment in ob/ob mice on apolipoprotein B mRNA, cholesterol, lipid, triglyceride, liver enzyme, glucose, and PTEN levels.						
			ISIS No.			
		SALINE	116847	141923	147483	147764
Glucose mg/dL		269.6	135.5	328.5	213.2	209.2
Liver Enzymes						
IU/L	AST	422.3	343.2	329.3	790.2	406.5
	ALT	884.3	607.5	701.7	941.7	835.0
Lipoproteins						
mg/dL	CHOL	431.9	287.5	644.3	250.0	286.3
	TRIG	128.6	196.5	196.5	99.8	101.2

135

TABLE 27-continued

Effects of ISIS 147483 and 147764 treatment in ob/ob mice on apolipoprotein B mRNA, cholesterol, lipid, triglyceride, liver enzyme, glucose, and PTEN levels.						
		ISIS No.				
		SALINE	116847	141923	147483	147764
mRNA	% control					
	ApoB	100.0	77.0	100.0	25.2	43.1
	PTEN	100.0	20.0	113.6	143.2	115.3

Example 51

Antisense Inhibition of Apolipoprotein B in High Fat Fed Mice: Time-Dependent Effects

In a further embodiment of the invention, the inhibition of apolipoprotein B mRNA in mice was compared to liver oligonucleotide concentration, total cholesterol, LDL-cholesterol and HDL-cholesterol. Male C57BL/6 mice receiving a high fat diet (60% fat) were evaluated over the course of 6 weeks for the effects of treatment with twice weekly intraperitoneal injections of 50 mg/kg ISIS 147764 (SEQ ID NO: 109) or 50 mg/kg of the control oligonucleotide ISIS 141923 (SEQ ID NO: 858). Control animals received saline treatment. Animals were sacrificed after 2 days, 1, 2, 4 and 6 weeks of treatment. Each treatment group at each time point consisted of 8 mice.

Target expression in liver was measured by real-time PCR as described by other examples herein and is expressed as percent inhibition relative to saline treated mice. Total, LDL- and HDL-cholesterol levels were measured by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.) and are presented in mg/dL. Results from saline-treated animals are shown for comparison. Intact oligonucleotide in liver tissue was measured by capillary gel electrophoresis and is presented as micrograms of oligonucleotide per gram of tissue. All results are the average of 8 animals and are shown in Table 28.

TABLE 28

Correlation between liver drug concentration, apolipoprotein B mRNA expression and serum lipids during ISIS 147764 treatment						
		Treatment period				
	ISIS #	2 days	1 week	2 weeks	4 weeks	6 weeks
% Inhibition	141923	9	4	7	0	0
apolipoprotein B mRNA	147764	50	57	73	82	88
Intact oligonucleotide ug/g	141923	58	61	152	261	631
	147764	85	121	194	340	586
Total cholesterol	saline	105	152	144	180	191
	141923	99	146	152	169	225
mg/dL LDL-cholesterol	147764	101	128	121	75	73
	saline	8	32	28	50	46
mg/dL HDL-cholesterol	141923	8	27	27	38	56
	147764	7	19	14	7	7
HDL-cholesterol	saline	74	117	114	127	141
mg/dL	141923	70	116	122	128	166
	147764	76	107	105	66	64

These results illustrate that inhibition of apolipoprotein B mRNA by ISIS 147764 occurred within 2 days of treatment, increased with successive treatments and persisted for 6 weeks of treatment. Quantitation of liver oligonucleotide lev-

136

els reveals a strong correlation between the extent of target inhibition and liver drug concentration. Furthermore, at 1, 2, 3 and 4 weeks of treatment, a inverse correlation between inhibition of target mRNA and cholesterol levels (total, HDL and LDL) is observed, with cholesterol levels lowering as percent inhibition of apolipoprotein B mRNA becomes greater. Serum samples were subjected to immunoblot analysis using an antibody to detect mouse apolipoprotein B protein (Gladstone Institute, San Francisco, Calif.). The expression of protein follows the same pattern as that of the mRNA, with apolipoprotein B protein in serum markedly reduced within 48 hours and lowered throughout the 6 week treatment period.

The oligonucleotide treatments described in this example were duplicated to investigate the extent to which effects of ISIS 147764 persist following cessation of treatment. Mice were treated as described, and sacrificed 1, 2, 4, 6 and 8 weeks following the cessation of oligonucleotide treatment. The same parameters were analyzed and the results are shown in Table 29.

TABLE 29

Correlation between liver drug concentration, apolipoprotein B mRNA expression, and serum lipids after cessation of dosing						
		Treatment period				
	ISIS #	1 week	2 weeks	4 weeks	6 weeks	8 weeks
% Inhibition	141923	15	2	7	11	7
	147764	82	78	49	37	19
apolipoprotein B mRNA						
Intact	141923	297	250	207	212	128
oligonucleotide	147764	215	168	124	70	43
ug/g						
Total	saline	114	144	195	221	160
cholesterol	141923	158	139	185	186	151
mg/dL	147764	69	67	111	138	135
LDL-	saline	21	24	34	37	22
cholesterol	141923	24	24	32	32	24
mg/dL	147764	14	14	18	24	21
HDL-	saline	86	109	134	158	117
cholesterol	141923	121	105	135	136	108
mg/dL	147764	51	49	79	100	94

These data demonstrate that after termination of oligonucleotide treatment, the effects of ISIS 147764, including apolipoprotein B mRNA inhibition, and cholesterol lowering, persist for up to 8 weeks. Immunoblot analysis demonstrates that apolipoprotein B protein levels follow a pattern similar that observed for mRNA expression levels.

Example 52

Effects of Antisense Inhibition of Human Apolipoprotein B Gene by 301012 in C57BL/6NTac-TgN(APOB100) Transgenic Mice: Dosing Study

C57BL/6Tac-TgN(APOB100) transgenic mice have the human apolipoprotein B gene "knocked-in". These mice express high levels of human apolipoprotein B resulting in mice with elevated serum levels of LDL cholesterol. These mice are useful in identifying and evaluating compounds to reduce elevated levels of LDL cholesterol and the risk of atherosclerosis. When fed a high fat cholesterol diet, these mice develop significant foam cell accumulation underlying the endothelium and within the media, and have significantly more complex atherosclerotic plaque lesions than control animals.

137

A long-term study of inhibition of human apolipoprotein B by ISIS 301012 in C57BL/6NTac-TgN(APOB100) mice (Taconic, Germantown, N.Y.) was conducted for a 3 month period. Mice were dosed intraperitoneally twice a week with 10 or 25 mg/kg ISIS 301012 (SEQ ID No: 247) for 12 weeks. Saline-injected animals served as controls. Each treatment group comprised 4 animals.

After 2, 4, 6, 8 and 12 weeks of treatment, serum samples were collected for the purpose of measuring human apolipoprotein B protein. Serum protein was quantitated using an ELISA kit specific for human apolipoprotein B (ALerCHEK Inc., Portland, Me.). The data are shown in Table 30 and each result represents the average of 4 animals. Data are normalized to saline-treated control animals.

TABLE 30

Reduction of human apolipoprotein B protein in transgenic mouse serum following ISIS 331012 treatment					
Dose of oligonucleotide mg/kg	% Reduction in human apolipoprotein B protein in serum				
	2 weeks	4 weeks	6 weeks	8 weeks	12 weeks
10	76	78	73	42	85
25	80	87	86	47	79

These data illustrate that following 2, 4, 6 or 12 weeks of treatment with ISIS 301012, the level of human apolipoprotein B protein in serum from transgenic mice is lowered by approximately 80%, demonstrating that in addition to inhibiting mRNA expression, ISIS 301012 effectively inhibits human apolipoprotein B protein expression in mice carrying the human apolipoprotein B transgene. Apolipoprotein B protein in serum was also assessed by immunoblot analysis using an antibody directed to human apolipoprotein B protein (US Biologicals, Swampscott, Mass.). This analysis shows that the levels human apolipoprotein B protein, both the apolipoprotein B-100 and apolipoprotein B-48 forms, are lowered at 2, 4, 6 and 12 weeks of treatment. Immunoblot analysis using a mouse apolipoprotein B specific antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) reveals no significant change in the expression of the mouse protein in serum.

At the beginning of the treatment (start) and after 2, 4, 6 and 8 weeks of treatment, serum samples were collected and total, LDL- and HDL-cholesterol levels were measured by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.), and these data are presented in Table 31. Results are presented as mg/dL in serum and represent the average of 4 animals. Results from the saline control animals are also shown.

TABLE 31

Effects of ISIS 301012 on serum lipids in human apolipoprotein B transgenic mice						
	Treatment	Treatment period				
		Start	2 weeks	4 weeks	6 weeks	8 weeks
Total cholesterol mg/dL	Saline	120	110	129	121	126
	10	115	97	111	120	122
	25	107	101	107	124	147
HDL-cholesterol mg/dL	Saline	67	61	69	62	64
	10	70	69	78	72	79
	25	64	73	76	80	91
LDL-	Saline	39	41	50	45	47

138

TABLE 31-continued

Effects of ISIS 301012 on serum lipids in human apolipoprotein B transgenic mice						
	Treatment	Treatment period				
		Start	2 weeks	4 weeks	6 weeks	8 weeks
cholesterol mg/dL	10	35	20	23	37	33
	25	33	19	19	37	44

These data demonstrate that LDL-cholesterol is lowered by treatment with 10 or 25 mg/kg of ISIS 147764 during the first 4 weeks of treatment.

The study was terminated forty eight hours after the final injections in the eighth week of treatment, when animals were sacrificed and evaluated for target mRNA levels in liver, apolipoprotein B protein levels in liver and serum cholesterol and liver enzyme levels. In addition, the expression of endogenous mouse apolipoprotein B levels in liver was measured to evaluate any effects of ISIS 301012 on mouse apolipoprotein B mRNA expression.

Human and mouse apolipoprotein B mRNA levels in livers of animals treated for 12 weeks were measured by real-time PCR as described herein. Each result represents the average of data from 4 animals. The data were normalized to saline controls and are shown in Table 32.

TABLE 32

Effects of ISIS 301012 on human and mouse apolipoprotein B mRNA levels in transgenic mice		
mRNA species measured	% Inhibition Dose of ISIS 301012	
	10 mg/kg	25 mg/kg
human apolipoprotein B	65	75
mouse apolipoprotein B	6	6

These data demonstrate that following 12 weeks of treatment with ISIS 301012, human apolipoprotein B mRNA is reduced by as much as 75% in the livers of transgenic mice, whereas mouse liver apolipoprotein B mRNA was unaffected. Furthermore, ELISA analysis of apolipoprotein B protein in livers of transgenic mice reveals an 80% and 82% reduction in the human protein following 10 and 20 mg/kg ISIS 301012, respectively. Immunoblot analysis using an antibody directed to human apolipoprotein B also demonstrates a reduction in the expression of human apolipoprotein B, both the apolipoprotein B-100 and apolipoprotein B-48 forms, in the livers of transgenic mice. Immunoblot analysis using an antibody directed to mouse apolipoprotein B protein (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) reveals that expression of the mouse protein in liver does not change significantly.

ALT and AST levels in serum were also measured using the Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.) and showed that following treatment with ISIS 301012, the AST and ALT levels were increased, yet did not exceed normal levels (~ 300 IU/L), indicating a lack of toxicity due to ISIS 301012 treatment.

Assessment of In vitro Immunostimulatory Effects of ISIS 301012

Immunostimulatory activity is defined by the production of cytokines upon exposure to a proinflammatory agent. In a further embodiment of the invention, ISIS 301012 was tested for immunostimulatory, or proinflammatory, activity. These studies were performed by MDS Pharma Services (Saint Germain sur l'Arbresle, France). Whole blood was collected from naive B6C3F1 mice, which had not been knowingly exposed to viral, chemical or radiation treatment. Cultured blood cells were exposed to 0.5, 5 or 50 μ M of ISIS 301012 for a period of 14 to 16 hours. Antisense oligonucleotides known to possess proinflammatory activity served as positive controls. Each treatment was performed in triplicate. At the end of the treatment period, supernatants were collected and cytokine analysis was performed using a flow cytometry method with the mouse Inflammation CBA kit (Becton Dickinson, Franklin Lakes, N.J.). The results revealed that ISIS 301012 does not stimulate the release of any of the tested cytokines, which were interleukin-12p70 (IL-12p70), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1) and interleukin-10 (IL-10). Thus, ISIS 301012 does not possess immunostimulatory activity, as determined by the in vitro immunostimulatory assay.

Example 54

Comparative Genomic Analysis of Apolipoprotein B

In accordance with the present invention, a comparative genomic analysis of apolipoprotein B sequences from human, mouse and monkey was performed and illustrated that apolipoprotein B sequences are conserved across species. The organization of human and mouse apolipoprotein B genes is also highly conserved. The human and mouse genes are comprised of 29 and 26 exons, respectively. The mouse mRNA is approximately 81% homologous to the human sequence. The complete sequence and gene structure of the apolipoprotein B gene in non-human primates have not been identified. However, as illustrated in Example 46, a 500 base pair fragment which contains the ISIS 301012 target sequence exhibits approximately 96% identity to the human sequence.

The binding site for ISIS 301012 lies within the coding region, within exon 22 of the human apolipoprotein B mRNA. When the ISIS 301012 binding sites from human, mouse and monkey were compared, significant sequence diversity was observed. Although the overall sequence conservation between human and monkey over a 500 nucleotide region was approximately 96%, the ISIS 301012 binding site of the monkey sequence contains 2 mismatches relative to the human sequence. Likewise, though the mouse apolipoprotein B mRNA sequence is approximately 81% homologous to human, within the ISIS 301012 binding site, 5 nucleotides are divergent. The sequence comparisons for the ISIS 301012 binding site for human, mouse and monkey apolipoprotein B sequences are shown in Table 33. Mismatched nucleotides relative to the ISIS 301012 target sequence are underlined.

TABLE 33

Comparison of ISIS 301012 binding site among human, monkey and mouse apolipoprotein B sequences		
Species	# Mismatches	ISIS 301012 target sequence
Human	0	agggtcggaagcagactgagg
Monkey	2	agggtgtaagcagactgagg
Mouse	5	aggagtcgagcagctggaag

The target sequence to which the mouse antisense oligonucleotide ISIS 147764 hybridizes lies within exon 24 of the mouse apolipoprotein B gene. The sequence comparisons for the ISIS 147764 binding site in mouse and human apolipoprotein B sequences are shown in Table 34. Mismatched nucleotides relative to the ISIS 147764 target sequence are underlined.

TABLE 34

Comparison of ISIS 147764 binding site between mouse and human apolipoprotein B sequences		
Species	# Mismatches	ISIS 147764 binding site
Human	5	gcattgacatcttcaggagac
Mouse	0	gcattgacatcttcaggaaa

Example 55

BLAST Analysis of ISIS 301012

In accordance with the present invention, the number of regions in the human genome to which ISIS 301012 will hybridize with perfect complementarity was determined. Percent complementarity of an antisense compound with a region of a target nucleic acid was determined using BLAST programs (basic local alignment search tools) and Power-BLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). This analysis assessed sequence complementarity in genomic or pre-mRNA regions and in coding sequences.

In genomic regions, ISIS 301012 shows perfect sequence complementarity to the apolipoprotein B gene only. No target sequences with one mismatch relative to ISIS 301012 were found. Two mismatches are found between the ISIS 301012 target sequence and the heparanase gene, and 3 mismatches are found between the ISIS 301012 target sequence and 28 unique genomic sites.

In RNA sequences, perfect sequence complementarity is found between ISIS 301012 and the apolipoprotein B mRNA and three expressed sequence tags that bear moderate similarity to a human apolipoprotein B precursor. A single mismatch is found between ISIS 301012 and an expressed sequence tag similar to the smooth muscle form of myosin light chain.

Example 56

Antisense Inhibition of Apolipoprotein B in Primary Human Hepatocytes: Dose Response Studies

In accordance with the present invention, antisense oligonucleotides targeted to human apolipoprotein B were tested in dose response studies in primary human hepatocytes. Pre-plated primary human hepatocytes were purchased from Invitro Technologies (Baltimore, Md.). Cells were cultured in

141

high-glucose DMEM (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Corporation, Carlsbad, Calif.), 100 units/mL and 100 µg/mL streptomycin (Invitrogen Corporation, Carlsbad, Calif.).

Human primary hepatocytes were treated with ISIS 301012 (SEQ ID NO: 247) at 10, 50, 150 or 300 nM. Untreated cells and cells treated with the scrambled control oligonucleotide ISIS 113529 (CTCTTACTGTGCTGTG-GACA, SEQ ID NO: 859) served as two groups of control cells. ISIS 113529 is a chimeric oligonucleotide ("gapmer") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidines are 5-methylcytidines.

Oligonucleotides were introduced into cells through LIPOFECTIN-mediated transfection as described by other examples herein. Cells were harvested both 24 and 48 hours after treatment with oligonucleotide, and both RNA and protein were isolated. Additionally, the culture media from treated cells was collected for ELISA analysis of apolipoprotein B protein secretion.

Apolipoprotein B mRNA expression was determined by real-time PCR of RNA samples as described by other examples herein. Each result represents 6 experiments. The data are normalized to untreated control cells and are shown in Table 35.

TABLE 35

Inhibition of apolipoprotein B mRNA by antisense oligonucleotides in human primary hepatocytes			
Dose of oligonucleotide	Treatment (hours)	% Inhibition of apolipoprotein B mRNA	
		ISIS #	
		301012	113529
10 nM	24	65	N.D.
	48	33	N.D.
50 nM	24	75	N.D.
	48	48	N.D.
150 nM	24	90	16
	48	78	5
300 nM	24	89	10
	48	72	18

These data demonstrate that ISIS 301012 inhibits apolipoprotein B expression in a dose-dependent manner in human primary hepatocytes.

Apolipoprotein secreted from into the cultured cell media was measured in the samples treated with 50 and 150 nM of oligonucleotide, using a target protein specific ELISA kit (ALerCHEK Inc., Portland, Me.). Each result represents 3 experiments. The data are normalized to untreated control cells and are shown in Table 36.

TABLE 36

Inhibition of apolipoprotein B protein secretion from human primary hepatocytes by ISIS 301012			
Dose	Treatment (hours)	% Change in apolipoprotein B protein secretion	
		ISIS #	
		301012	113529
150 nM	24	-57	+6
	48	-75	+4

142

TABLE 36-continued

Inhibition of apolipoprotein B protein secretion from human primary hepatocytes by ISIS 301012			
Dose	Treatment (hours)	% Change in apolipoprotein B protein secretion	
		ISIS #	
		301012	113529
300 nM	24	-41	-2
	48	-48	-5

Protein samples from 50, 150 and 300 nM doses after 24 hours and 150 and 300 nM doses after 48 hours were subjected to immunoblot analysis as described by other examples herein, using a human apolipoprotein B protein specific antibody purchased from US Biological (Swampscott, Mass.). Immunoblot analysis further demonstrates that apolipoprotein B protein in human hepatocytes is reduced in a dose-dependent manner following antisense oligonucleotide treatment with ISIS 301012.

An additional experiment was performed to test the effects of ISIS 271009 (SEQ ID NO: 319), ISIS 281625 (SEQ ID NO: 224) and ISIS 301027 (SEQ ID NO: 262) on human apolipoprotein B mRNA in human primary hepatocytes. Cells were cultured as described herein and treated with 5, 10, 50 or 150 nM of ISIS 271009, ISIS 281625 or ISIS 301027 for a period of 24 hours. The control oligonucleotides ISIS 13650 (SEQ ID NO: 806) and ISIS 113529 (SEQ ID NO: 859) were used at 50 or 150 nM. Human apolipoprotein B mRNA expression was evaluated by real-time PCR as described by other examples herein. Apolipoprotein B protein secreted into the cultured cell media was measured in the samples treated with 50 and 150 nM of oligonucleotide, using a target protein specific ELISA kit (ALerCHEK Inc., Portland, Me.).

The data, shown in Table 37, represent the average 2 experiments and are normalized to untreated control cells. Where present, a "+" indicates that gene expression was increased.

TABLE 37

Antisense inhibition of human apolipoprotein B mRNA by ISIS 271009, ISIS 281625 and ISIS 301027						
	Oligo-nucleotide dose	ISIS 271009	ISIS 281625	ISIS 301027	ISIS 13650	ISIS 113529
% Inhibition of apolipoprotein B mRNA expression	5 nM	+4	8	11	N.D.	N.D.
	10 nM	5	22	37	N.D.	N.D.
	50 nM	52	49	50	38	0
	150 nM	81	52	70	26	14
% Inhibition of apolipoprotein B protein secretion	50 nM	17	18	21	N.D.	N.D.
	150 nM	32	18	32	+18	+1

These data demonstrate that ISIS 271009, ISIS 281625 and ISIS 301027 inhibit apolipoprotein B mRNA expression in a dose-dependent manner in human primary hepatocytes. ISIS 271009 and ISIS 301027 inhibit the secretion of apolipoprotein B protein from cells in a dose-dependent manner.

Example 57

Effects of apolipoprotein B-100 Antisense Oligonucleotides on Apolipoprotein(a) Expression

Lipoprotein(a) [Lp(a)] contains two disulfide-linked distinct proteins, apolipoprotein(a) and apolipoprotein B (Rainwater and Kammerer, J. Exp. Zool., 1998, 282, 54-61). In accordance with the present invention, antisense oligonucle-

143

otides targeted to apolipoprotein B were tested for effects on the expression of the apolipoprotein(a) component of the lipoprotein(a) particle in primary human hepatocytes.

Primary human hepatocytes (InVitro Technologies, Baltimore, Md.), cultured and transfected as described herein, were treated with 5, 10, 50 or 150 nM of ISIS 271009 (SEQ ID NO: 319), 281625 (SEQ ID NO: 224), 301012 (SEQ ID NO: 247) or 301027 (SEQ ID NO: 262). Cells were also treated with 50 or 150 nM of the control oligonucleotides ISIS 113529 (SEQ ID NO: 859) or ISIS 13650 (SEQ ID NO: 806). Untreated cells served as a control. Following 24 hours of oligonucleotide treatment, apolipoprotein(a) mRNA expression was measured by quantitative real-time PCR as described in other examples herein.

Probes and primers to human apolipoprotein(a) were designed to hybridize to a human apolipoprotein(a) sequence, using published sequence information (GenBank accession number NM_005577.1, incorporated herein as SEQ ID NO: 860). For human apolipoprotein(a) the PCR primers were: forward primer: CAGCTCCTTATTGTTATACGAGGGA (SEQ ID NO: 861)

reverse primer: TGCGTCTGAGCATTGCGT (SEQ ID NO: 862) and the PCR probe was: FAM-CCCGGTGTCAG-GTGGGAGTACTGC-TAMRA (SEQ ID NO: 863) where FAM is the fluorescent dye and TAMRA is the quencher dye.

Data are the average of three experiments and are expressed as percent inhibition relative to untreated controls. The results are shown in Table 38. A "+" or "-" preceding the number indicates that apolipoprotein(a) expression was increased or decreased, respectively, following treatment with antisense oligonucleotides.

TABLE 38

Effects of apolipoprotein B antisense oligonucleotides on apolipoprotein(a) expression						
Oligo-nucleotide	% Change in apolipoprotein(a) mRNA expression following antisense inhibition of apolipoprotein B					
	ISIS #					
Dose	271009	281625	301012	301027	13650	113529
5 nM	+70	-9	+34	-16	N.D.	N.D.
10 nM	+31	-23	+86	-45	N.D.	N.D.
50 nM	+25	-34	+30	-39	-68	+14
150 nM	-47	+32	+38	-43	-37	-9

These results illustrate that ISIS 301012 did not inhibit the expression of apolipoprotein(a) in human primary hepatocytes. ISIS 271009 inhibited apolipoprotein(a) expression at the highest dose. ISIS 281625 and ISIS 301027 decreased the levels of apolipoprotein(a) mRNA.

Example 58

Inhibition of Lipoprotein(a) Particle Secretion with Antisense Oligonucleotides Targeted to Apolipoprotein B-100

In accordance with the present invention, the secretion of lipoprotein(a) particles, which are comprised of one apolipoprotein(a) molecule covalently linked to one apolipoprotein B molecule, was evaluated in primary human hepatocytes treated with antisense oligonucleotides targeted to the apolipoprotein B component of lipoprotein(a).

Primary human hepatocytes (InVitro Technologies, Baltimore, Md.), cultured and transfected as described herein, were treated for 24 hours with 50 or 150 nM of ISIS 271009 (SEQ ID NO: 319), 281625 (SEQ ID NO: 224), 301012 (SEQ ID NO: 247) or 301027 (SEQ ID NO: 262). Cells were also

144

treated with 150 nM of the control oligonucleotides ISIS 113529 (SEQ ID NO: 859) or ISIS 13650 (SEQ ID NO: 806). Untreated cells served as a control. Following 24 hours of oligonucleotide treatment, the amount of lipoprotein(a) in the culture medium collected from the treated cells was measured using a commercially available ELISA kit (ALerCHECK Inc., Portland, Me.). The results are the average of three experiments and are expressed as percent change in lipoprotein(a) secretion relative to untreated controls. The data are shown in Table 39. A "+" or "-" preceding the number indicates that lipoprotein(a) particle secretion was increased or decreased, respectively, following treatment with antisense oligonucleotides targeted to apolipoprotein B.

TABLE 39

Inhibition of lipoprotein(a) particle secretion with antisense oligonucleotides targeted to apolipoprotein B						
Oligo-nucleotide	% Change in lipoprotein(a) secretion					
	ISIS #					
Dose	271009	281625	301012	301027	13650	113529
50 nM	-25	-26	-27	-33	N.D.	N.D.
150 nM	-42	-24	-37	-44	+14	+14

These data demonstrate that antisense inhibition of apolipoprotein B, a component of the lipoprotein(a) particle, can reduce the secretion of lipoprotein(a) from human primary hepatocytes. In addition, this reduction in lipoprotein(a) secretion is not necessarily concomitant with a decrease in apolipoprotein(a) mRNA expression, as shown in Example 57.

Example 59

Mismatched and Truncated Derivatives of ISIS 301012

As demonstrated herein, ISIS 301012 (SEQ ID NO: 247) reduces apolipoprotein B mRNA levels in cultured human cell lines as well as in human primary hepatocytes. In a further embodiment of the invention, a study was performed using nucleotide sequence derivatives of ISIS 301012. A series of oligonucleotides containing from 1 to 7 base mismatches, starting in the center of the ISIS 301012 sequence, was designed. This series was designed to introduce the consecutive loss of Watson-Crick base pairing between ISIS 301012 and its target mRNA sequence. These compounds are shown in Table 40. The antisense compounds with mismatched nucleotides relative to ISIS 301012 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide.

An additional derivative of ISIS 301012 was designed, comprising the ISIS 301012 sequence with 2'MOE nucleotides throughout the oligonucleotide (uniform 2'-MOE). This compound is 20 nucleotides in length, with phosphorothioate linkages throughout the oligonucleotide. This compound is also shown in Table 40.

HepG2 cells were treated with 50 or 150 nM of the compounds in Table 40 for a 24 hour period, after which RNA was isolated and target expression was measured by real-time PCR as described herein. Untreated cells served as controls. The results are shown in Tables 40 and are normalized to untreated control samples.

TABLE 40

Effects of ISIS 301012 mismatched oligonucleotides and a uniform 2'MOE oligonucleotide on apolipoprotein B expression in HepG2 cells					
ISIS #	SEQUENCE	# Mismatches	% Change in apolipoprotein B mRNA expression Dose of oligonucleotide		SEQ ID
			50	150	
301012	GCCTCAGTCTGCTTCGCACC	0	-44	-75	247
Mismatch Series, chimeric oligonucleotides					
332770	GCCTCAGTCTTCTTCGCACC	1	+7	-22	864
332771	GCCTCAGTCTTATTCGCACC	2	+37	+37	865
332772	GCCTCAGTATTATTCGCACC	3	+99	+84	866
332773	GCCTCATTATATTCGCACC	4	+75	+80	867
332774	GCCTCATTATATTAGCACC	5	+62	+66	868
332775	GCCTCATTATATTATCACC	6	-1	+10	869
332776	GCCTAATTATATTATCACC	7	+10	+20	870
Uniform 2'-MOE oligonucleotide					
332769	GCCTCAGTCTGCTTCGCACC	0	-11	-14	247

The results of treatment of HepG2 cells with the compounds in Table 40 reveals that none of the compounds displays the dose-dependent inhibition observed following treatment with the parent ISIS 301012 sequence. ISIS 332770, which has only a single thymidine to cytosine substitution in the center of the oligonucleotide, was 3-fold less potent than ISIS 301012. Further nucleotide substitutions abrogated antisense inhibition of apolipoprotein B expression.

Phosphorothioate chimeric oligonucleotides are metabolized in vivo predominantly by endonucleolytic cleavage. In accordance with the present invention, a series of oligonucleotides was designed by truncating the ISIS 301012 sequence in 1 or 2 base increments from the 5' and/or 3' end. The truncated oligonucleotides represent the possible products that result from endonucleolytic cleavage. These compounds are shown in Table 41. The compounds in Table 41 are chimeric oligonucleotides ("gapmers") of varying lengths, composed of a central "gap" region consisting of 2'-deoxynucleotides, which is flanked on both ends by 2'-methoxyethyl

(2'-MOE)nucleotides. The exact structure of each chimeric oligonucleotide is designated in Table 41 as the "chimera structure". For example, a designation of 4~10~4 indicates that the first 4 (5' most) and last 4 (3' most) nucleotides are 2'-MOE nucleotides, and the 10 nucleotides in the gap are 2'-deoxynucleotides. 2'-MOE nucleotides are indicated by bold type. The internucleoside (backbone) linkages are phosphodiester (P=O) between underscored nucleotides; all other internucleoside linkages are phosphorothioate (P=S).

These compounds were tested for their ability to reduce the expression of apolipoprotein B mRNA. HepG2 cells were treated with 10, 50 or 150 nM of each antisense compound in Table 41 for a 24 hour period, after which RNA was isolated and target expression was measured by real-time PCR as described herein. Untreated cells served as controls. The results are shown in Tables 41 and are normalized to untreated control samples.

TABLE 41

Effect of ISIS 301012 truncation mutants on apolipoprotein B expression in HepG2 cells									
ISIS #	Target SEQ ID NO	Target Site	SEQUENCE	Chimeric structure	% Change in apolipoprotein B mRNA expression Dose of oligonucleotide			SEQ ID	
					10	50	150		
301012	3	3249	GCCTCAGTCTGCTTCGCACC	5~10~5	-51	-72	-92	247	
331022	3	3249	GCCTCAGTCTGCTTCGCAC	5~10~4	-33	-49	-87	871	
332777	3	3249	GCCTCAGTCTGCTTCGCA	5~10~3	-27	-53	-80	872	
332778	3	3249	GCCTCAGTCTGCTTC	5~10~0	-11	-20	-58	873	
332780	3	3248	CCTCAGTCTGCTTCGCAC	4~10~4	-3	-43	-74	874	

TABLE 41-continued

Effect of ISIS 301012 truncation mutants on apolipoprotein B expression in HepG2 cells								
ISIS #	Target SEQ ID NO	Target Site	SEQUENCE	Chimeric structure	% Change in apolipoprotein B mRNA expression Dose of oligonucleotide			SEQ ID NO
					10	50	150	
332781	3	3247	CTCAGTCTGCTTCGCA	3~10~3	-9	-35	-60	875
332782	3	3246	TCAGTCTGCTTCGC	2~10~2	-16	-16	-69	876
332784	3	3249	GCCTCAGTCT	5~5~0	+12	-1	+7	877
332785	3	3238	GCTTCG CACC	0~5~5	+5	-2	-4	878

The results in Table 41 illustrate that inhibition of apolipoprotein B is dependent upon sequence length, as well as upon sequence complementarity and dose, as demonstrated in Table 41, but truncated versions of ISIS 301012 are to a certain degree capable of inhibiting apolipoprotein B mRNA expression.

Example 60

Design and Screening of dsRNAs Targeting Human Apolipoprotein B

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements were designed to target apolipoprotein B and are shown in Table 42. All compounds in Table 42 are oligoribonucleotides 20 nucleotides in

length with phosphodiester internucleoside linkages (backbones) throughout the compound. The compounds were prepared with blunt ends. Table 41 shows the antisense strand of the dsRNA, and the sense strand is synthesized as the complement of the antisense strand. These sequences are shown to contain uracil (U) but one of skill in the art will appreciate that uracil (U) is generally replaced by thymine (T) in DNA sequences. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. A subset of the compounds in Table 42 are the RNA equivalents of DNA antisense oligonucleotides described herein, and, where applicable, this is noted by the ISIS # of the DNA oligonucleotide in the column "RNA equivalent of ISIS #".

TABLE 42

dsRNAs targeted to human apolipoprotein B							
ISIS #	Region	Target SEQ ID NO	Target Site	Sequence	SEQ ID NO	RNA equivalent of ISIS #	
342855	coding	3	3249	GCCUCAGUCUGCUUCGCACC	247	301012	
342856	3' UTR	3	13903	GCUCACUGUAUGGUUUUAUC	262	301027	
342857	coding	3	5589	AGGUUACCAGCCACAUGCAG	224	308361	
342858	coding	3	669	GAGCAGUUCCAUAACACGGU	130	270991	
342859	coding	3	1179	CCUCUCAGCUCAGUAACCGAG	135	270996	
342860	coding	3	2331	GUAUAGCCAAAGUGGUCCAC	34	147797	
342861	coding	3	3579	UAAGCUGUAGCAGAUGAGUC	213	281614	
342862	5' UTR	3	6	CAGCCCCGCAGGUCCCGGUG	249	301014	
342863	5' UTR	3	116	GGUCCAUCGCCAGCUGCGGU	256	301021	
342864	3' UTR	3	13910	AAGGCUGGCUCACUGUAUGG	266	301031	
342865	3' UTR	3	13970	GCCAGCUUUGGUGCAGGUCC	273	301038	
342866	coding	3	426	UUGAAGCCAUAACCCUCUUU	879	none	
342867	coding	3	3001	UGACCAGGACUGCCUGUUCU	880	none	
342868	coding	3	5484	GAAUAGGGCUGUAGCUGUAA	881	none	

TABLE 42-continued

dsRNAs targeted to human apolipoprotein B						
ISIS #	Region	Target SEQ ID NO	Target Site	Sequence	SEQ ID NO	RNA equivalent of ISIS #
342869	coding	3	6662	UAUACUGAUCAAAUUGUAUC	882	none
342870	coding	3	8334	UGGAAUUCUGGUAUGUGAAG	883	none
342871	coding	3	9621	AAAUCAAUGAUUGCUUUGU	883	none
342872	coding	3	10155	GUGAUGACACUUGAUUUAAA	885	none
342873	coding	3	12300	GAAGCUGCCUCUUCUCCCA	886	none
342874	coding	3	13629	GAGAGUUGGUCUGAAAAAUC	887	none

The dsRNA compounds in Table 42 were tested for their effects on human apolipoprotein mRNA in HepG2 cells. HepG2 cells were treated with 100 nM of dsRNA compounds mixed with 5 µg/mL LIPOFECTIN (Invitrogen Corporation, Carlsbad, Calif.) for a period of 16 hours. In the same experiment, HepG2 cells were also treated with 150 nM of subset of the antisense oligonucleotides described herein mixed with 3.75 µg/mL LIPOFECTIN; these compounds are listed in Table 43. Control oligonucleotides included ISIS 18078 (GT-GCGCGCGAGCCCGAAATC, SEQ ID NO: 888), ISIS 18078 is a chimeric oligonucleotide ("gapmer") 20 nucleotides in length, composed of a central "gap" region consisting of 9 2'-deoxynucleotides, which is flanked on the 5' and 3' ends by a five-nucleotide "wing" and a six-nucleotide "wing", respectively. The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidines are 5-methylcytidines. The duplex of ISIS 263188 (CUUCUGGCAUCCGGUUUAGTT, SEQ ID NO: 889) and its complement was also used as a control. ISIS 263188 is an oligoribonucleotide 21 nucleotides in length with the 2 nucleotides on the 3' end being oligodeoxyribonucleotides (TT) and with phosphodiester internucleoside linkages (backbones) throughout the compound.

Cells were treated for 4 hours, after which human apolipoprotein B mRNA expression was measured as described by examples herein. Results were normalized to untreated control cells, which were not treated with LIPOFECTIN or oligonucleotide. Data are the average of 4 experiments and are presented in Table 43.

TABLE 43

Inhibition of apolipoprotein B mRNA by dsRNAs in HepG2 cells			
ISIS #	Dose	% Inhibition	SEQ ID #
342855	100 nM	53	247
342856	100 nM	34	262
342857	100 nM	55	224
342858	100 nM	44	130
342859	100 nM	23	135
342860	100 nM	34	34
342861	100 nM	42	213
342862	100 nM	16	249
342863	100 nM	34	256
342864	100 nM	53	266
342865	100 nM	50	273
342866	100 nM	12	879
342867	100 nM	26	880
342868	100 nM	36	881

TABLE 43-continued

Inhibition of apolipoprotein B mRNA by dsRNAs in HepG2 cells			
ISIS #	Dose	% Inhibition	SEQ ID #
342869	100 nM	78	882
342870	100 nM	71	883
342871	100 nM	9	883
342872	100 nM	2	885
342873	100 nM	53	886
342874	100 nM	73	887
281625	150 nM	79	224
301012	150 nM	77	247
301014	150 nM	88	249
301021	150 nM	67	256
301027	150 nM	79	262
301028	150 nM	85	263
301029	150 nM	77	264
301030	150 nM	70	265
301031	150 nM	73	266
301037	150 nM	80	272
301038	150 nM	84	273
301045	150 nM	77	280
263188	150 nM	26	888
18078	150 nM	13	889

Example 61

Antisense Inhibition of Apolipoprotein B in Cynomolgous Monkey Primary Hepatocytes

As demonstrated in Example 46, the region containing the target site to which ISIS 301012 hybridizes shares 96% identity with the corresponding region of Cynomolgus monkey apolipoprotein B mRNA sequence. ISIS 301012 contains two mismatched nucleotides relative to the Cynomolgous monkey apolipoprotein B mRNA sequence to which it hybridizes. In a further embodiment of the invention, oligonucleotides were designed to target regions of the monkey apolipoprotein B mRNA, using the partial Cynomolgous monkey apolipoprotein B sequence described herein (SEQ ID NO: 855) and an additional portion of Cynomolgous monkey apolipoprotein B RNA sequence, incorporated herein as SEQ ID NO: 890. The target site indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. For ISIS 326358 (GCCTCAGTCTGCTT-TACACC, SEQ ID NO: 891) the target site is nucleotide 168 of SEQ ID NO: 855 and for ISIS 315089 (AGATTACCAGC-CATATGCAG, SEQ ID NO: 892) the target site is nucleotide 19 of SEQ ID NO: 890. ISIS 326358 and ISIS 315089 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten

151

2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. ISIS 326358 and ISIS 315089 are the Cynomolgous monkey equivalents of the human apolipoprotein B antisense oligonucleotides ISIS 301012 (SEQ ID NO: 247) and ISIS 281625 (SEQ ID NO: 224), respectively.

Antisense inhibition by ISIS 301012 was compared to that of ISIS 326358, which is a perfect match to the Cynomolgous monkey apolipoprotein B sequence to which ISIS 301012 hybridizes. The compounds were analyzed for their effect on Cynomolgous monkey apolipoprotein B mRNA levels in primary Cynomolgous monkey hepatocytes purchased from In Vitro Technologies (Gaithersburg, Md.). Pre-plated primary Cynomolgous monkey hepatocytes were purchased from In Vitro Technologies (Baltimore, Md.). Cells were cultured in high-glucose DMEM (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Corporation, Carlsbad, Calif.), 100 units/mL and 100 µg/mL streptomycin (Invitrogen Corporation, Carlsbad, Calif.).

Primary Cynomolgous monkey hepatocytes were treated with 10, 50, 150 or 300 nM of antisense oligonucleotides for 48 hours. ISIS 113529 (SEQ ID NO: 859) was used as a control oligonucleotide. Untreated cells also served as a control. Cynomolgous monkey apolipoprotein B mRNA levels were quantitated by real-time PCR using the human apolipoprotein B and GAPDH primers and probes described by other examples herein. The results, shown in Table 44, are the average of 6 experiments and are expressed as percent inhibition of apolipoprotein B mRNA normalized to untreated control cells.

TABLE 44

Inhibition of Cynomolgous monkey apolipoprotein B mRNA by ISIS 301012 and ISIS 326358				
Dose of oligonucleotide	Time of treatment (hours)	% Inhibition of apolipoprotein B mRNA ISIS #		
		326358	301012	113529
10 nM	24	35	24	N.D.
	48	85	76	N.D.
50 nM	24	66	60	N.D.
	48	88	77	N.D.
150 nM	24	61	56	5
	48	82	88	42
300 nM	24	64	61	19
	48	87	86	13

These data demonstrate that both ISIS 326359 and ISIS 301012 (despite two mismatches with the Cynomolgous monkey apolipoprotein B sequence) can inhibit the expression of apolipoprotein B mRNA in cynomolgous monkey primary hepatocytes, in a dose- and time-dependent manner.

Apolipoprotein B protein secreted from primary Cynomolgous hepatocytes treated with 150 and 300 nM of oligonucleotide was measured by ELISA using an apolipoprotein B protein specific kit (ALerCHEK Inc., Portland, Me.). Each result represents the average of 3 experiments. The data are normalized to untreated control cells and are shown in Table 45.

152

TABLE 45

Reduction in apolipoprotein B protein secreted from Cynomolgous monkey hepatocytes following antisense oligonucleotide treatment				
Dose of oligonucleotide	Time of treatment (hours)	% Reduction in secreted apolipoprotein B protein ISIS #		
		326358	301012	113529
150 nM	24	21	31	11
	48	29	25	18
300 nM	24	17	10	12
	48	35	17	8

These results demonstrate that antisense inhibition by ISIS 301012 and ISIS 326358 leads to a decrease in the secretion of apolipoprotein B protein from cultured primary Cynomolgous hepatocytes.

Additionally, protein was isolated from oligonucleotide-treated primary Cynomolgous monkey hepatocytes and subjected to immunoblot analysis to further assess apolipoprotein B protein expression. Immunoblotting was performed as described herein, using an antibody to human apolipoprotein B protein (US Biologicals, Swampscott, Mass.). Immunoblot analysis of apolipoprotein B expression following antisense oligonucleotide treatment with ISIS 326358 and ISIS 301012 reveals a substantial reduction in apolipoprotein B expression.

In a further embodiment of the invention, antisense inhibition by ISIS 281625 was compared to that by ISIS 315089, which is a perfect match to the Cynomolgous monkey apolipoprotein B sequence to which ISIS 281625 hybridizes. Primary Cynomolgous monkey hepatocytes, cultured as described herein, were treated with 10, 50, 150 or 300 nM of ISIS 315089 or ISIS 281625 for 24 hours. Cells were treated with the control oligonucleotide ISIS 13650 (SEQ ID NO: 806) at 150 and 300 nM or ISIS 113529 (SEQ ID NO: 859) at 300 nM. Untreated cells also served as a control. Cynomolgous monkey apolipoprotein B mRNA levels in primary Cynomolgous monkey hepatocytes was quantitated using real-time PCR with human primers and probe as described by other examples herein. The results, shown in Table 46, are the average of 3 experiments and are expressed as percent inhibition of apolipoprotein B mRNA normalized to untreated control cells. Where present, a "+" preceding the value indicates that mRNA expression was increased.

TABLE 46

Antisense inhibition of apolipoprotein B mRNA expression in Cynomolgous monkey hepatocytes				
Dose of oligonucleotide	% Inhibition of apolipoprotein B mRNA ISIS #			
	315089	281625	13650	113529
10 nM	70	+5	N.D.	N.D.
50 nM	83	41	N.D.	N.D.
150 nM	81	35	+50	N.D.
300 nM	82	69	33	28

These data demonstrate that both ISIS 315089 and ISIS 281625 can inhibit the expression of apolipoprotein B mRNA in Cynomolgous monkey primary hepatocytes, in a dose-dependent manner.

Apolipoprotein B protein secreted primary Cynomolgous hepatocytes treated with 50 and 150 nM of ISIS 315089 and ISIS 281625 was measured by ELISA using an apolipoprotein-

153

tein B protein specific kit (ALerCHEK Inc., Portland, Me.). Each result represents the average of 3 experiments. The data are normalized to untreated control cells and are shown in Table 47.

TABLE 47

Reduction in apolipoprotein B protein secreted from Cynomolgous monkey hepatocytes following antisense oligonucleotide treatment				
Dose of oligonucleotide	% Reduction of monkey apolipoprotein B protein secretion			
	ISIS #			
	315089	281625	13650	113529
50 nM	11	6	16	N.D.
150 nM	25	13	13	12

These results demonstrate that antisense inhibition by 150 nM of ISIS 315089 leads to a decrease in the secretion of apolipoprotein B protein from cultured primary Cynomolgous hepatocytes.

ISIS 271009 (SEQ ID NO: 319) and ISIS 301027 (SEQ ID NO: 262) were also tested for their effects on apolipoprotein B mRNA and protein expression in Cynomolgous primary hepatocytes. Cells, cultured as described herein, were treated with 10, 50 and 150 nM of ISIS 271009 or ISIS 301027 for 24 hours. Cells were treated with the control oligonucleotide ISIS 113529 (SEQ ID NO: 859) at 150 nM. Untreated cells also served as a control. Cynomolgous monkey apolipoprotein B mRNA levels in primary Cynomolgous monkey hepatocytes was quantitated using real-time PCR with human primers and probe as described by other examples herein. The results, shown in Table 48, are the average of 2 experiments and are expressed as percent inhibition of apolipoprotein B mRNA normalized to untreated control cells.

TABLE 48

Antisense inhibition of apolipoprotein B mRNA expression in Cynomolgous monkey hepatocytes			
Dose of oligonucleotide	% Inhibition of apolipoprotein B mRNA		
	ISIS #		
	271009	301027	113529
10 nM	42	40	N.D.
50 nM	66	54	N.D.
150 nM	69	67	11

These data demonstrate that both ISIS 271009 and ISIS 301027 can inhibit the expression of apolipoprotein B mRNA in Cynomolgous monkey primary hepatocytes, in a dose-dependent manner.

Apolipoprotein B protein secreted from primary Cynomolgous hepatocytes treated with 50 and 150 nM of ISIS 271009 and ISIS 301027 was measured by ELISA using an apolipoprotein B protein specific kit (ALerCHEK Inc., Portland, Me.). Each result represents the average of 3 experiments. The data are shown as percent reduction in secreted protein, normalized to untreated control cells, and are shown in Table 49. Where present, a "+" indicates that protein secretion was increased.

154

TABLE 49

Reduction in apolipoprotein B protein secreted from Cynomolgous monkey hepatocytes following antisense oligonucleotide treatment				
Dose of oligonucleotide	% Reduction of monkey apolipoprotein B protein secretion			
	ISIS #			
	271009	301027	13650	113529
50 nM	+30	25	N.D.	N.D.
150 nM	26	31	+1	15

These results demonstrate that antisense inhibition by ISIS 315089 and ISIS 281625 leads to a decrease in the secretion of apolipoprotein B protein from cultured primary Cynomolgous hepatocytes.

Example 62

20 Methods for Evaluating Hepatic Steatosis

Hepatic steatosis refers to the accumulation of lipids in the liver, or "fatty liver", which is frequently caused by alcohol consumption, diabetes and hyperlipidemia. Livers of animals treated with antisense oligonucleotides targeted to apolipoprotein B were evaluated for the presence of steatosis. Steatosis is assessed by histological analysis of liver tissue and measurement of liver triglyceride levels.

Tissue resected from liver is immediately immersed in Tissue Tek OCT embedding compound (Ted Pella, Inc., Redding, Calif.) and frozen in a 2-methyl-butane dry ice slurry. Tissue sections are cut at a thickness of 4-5 μ m and then fixed in 5% neutral-buffered formalin. Tissue sections are stained with hematoxylin and eosin following standard histological procedures to visualize nuclei and cytoplasm, respectively, and oil red O according to the manufacturer's instructions (Newcomers Supply, Middleton, Wis.) to visualize lipids.

Alternatively, tissues are fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned at a thickness of 4-5 μ m, deparaffinized and stained with hematoxylin and eosin, all according to standard histological procedures.

Quantitation of liver triglyceride content is also used to assess steatosis. Tissue triglyceride levels are measured using a Triglyceride GPO Assay (Sigma-Aldrich, St. Louis, Mo.).

Example 63

Effects of Antisense Inhibition by ISIS 301012 in Lean Mice: Long-Term Study

In accordance with the present invention, the toxicity of ISIS 301012 (SEQ ID NO: 247) is investigated in a long-term, 3 month study in mice. Two-month old male and female CD-1 mice (Charles River Laboratories, Wilmington, Mass.) are dosed with 2, 5, 12.5, 25 or 50 mg/kg of ISIS 301012 twice per week for first week, and every 4 days thereafter. The mice are maintained on a standard rodent diet. Saline and control oligonucleotide animals serve as controls and are injected on the same schedule. Each treatment group contains 6 to 10 mice of each sex, and each treatment group is duplicated, one group for a 1 month study termination, the other for a 3 month study termination. After the 1 or 3 month treatment periods, the mice are sacrificed and evaluated for target expression in liver, lipid levels in serum and indicators of toxicity. Liver samples are procured, RNA is isolated and apolipoprotein B mRNA expression is measured by real-time PCR as described in other examples herein. Serum lipids, including total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, are evaluated by routine clinical analysis using an Olym-

pus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). Ratios of LDL-cholesterol to HDL-cholesterol and total cholesterol to HDL-cholesterol are also calculated. Analyses of serum ALT and AST, inflammatory infiltrates in tissue and basophilic granules in tissue provide an assessment of toxicities related to the treatment. Hepatic steatosis, or accumulation of lipids in the liver, is assessed by routine histological analysis with oil red O stain and measurement of liver tissue triglycerides using a Triglyceride GPO Assay (Sigma-Aldrich, St. Louis, Mo.).

The toxicity study also includes groups of animals allowed to recover following cessation of oligonucleotide treatment. Both male and female CD-1 mice (Charles River Laboratories, Wilmington, Mass.) are treated with 5, 10, 50 mg/kg of ISIS 301012 twice per week for the first week and every 4 days thereafter. Saline and, control oligonucleotide injected animals serve as controls. Each treatment group includes 6 animals per sex. After 3 months of treatment, animals remain untreated for an additional 3 months, after which they are sacrificed. The same parameters are evaluated as in the mice sacrificed immediately after 3 months of treatment.

After one month of treatment, real-time PCR quantitation reveals that mouse apolipoprotein B mRNA levels in liver are reduced by 53%. Additionally, the expected dose-response toxicities were observed. ALT and AST levels, measured by routine clinical procedures on an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.), are increased in mice treated with 25 or 50 mg/kg of ISIS 301012. Tissues were prepared for analysis by routine histological procedures. Basophilic granules in liver and kidney tissue were observed at doses of ISIS 301012 above 12.5 mg/kg. Mild lymphohistiocytic infiltrates were observed in various tissues at doses greater than 12.5 mg/kg of ISIS 301012. Staining of tissue sections with oil red O reveals no steatosis present following the oligonucleotide treatments.

Example 64

Effects of Antisense Inhibition by ISIS 301012 in Lean CYNOMOLGOUS Monkeys: Long-term Study

As discussed in Example 45, Cynomolgus monkeys (male or female) are used to evaluate antisense oligonucleotides for their potential to lower apolipoprotein B mRNA or protein levels, as well as phenotypic endpoints associated with apolipoprotein B including, but not limited to cardiovascular indicators, atherosclerosis, lipid diseases, obesity, and plaque formation. Accordingly, in a further embodiment of the invention, ISIS 301012 (SEQ ID NO: 247) is investigated in a long-term study for its effects on apolipoprotein B expres-

sion and serum lipids in Cynomolgous monkeys. Such a long-term study is also used to evaluate the toxicity of antisense compounds.

Male and female Cynomolgous monkeys are treated with 2, 4 or 12 mg/kg of ISIS 301012 intravenously or 2 or 20 mg/kg subcutaneously at a frequency of every two days for the first week, and every 4 days thereafter, for 1 and 3 month treatment periods. Saline-treated animals serve as controls. Each treatment group includes 2 to 3 animals of each sex.

At a one month interval and at the 3 month study termination, the animals are sacrificed and evaluated for target expression in liver, lipid levels in serum and indicators of toxicity. Liver samples are procured, RNA is isolated and apolipoprotein B mRNA expression is measured by real-time PCR as described in other examples herein. Serum lipids, including total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, are evaluated by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). Ratios of LDL-cholesterol to HDL-cholesterol and total cholesterol to HDL-cholesterol are also calculated. Analyses of serum ALT and AST, inflammatory infiltrates in tissue and basophilic granules in tissue provide an assessment of toxicities related to the treatment. Hepatic steatosis, or accumulation of lipids in the liver, is assessed by routine histological analysis with oil red O stain and measurement of liver tissue triglycerides using a Triglyceride GPO Assay (Sigma-Aldrich, St. Louis, Mo.).

Additional treatment groups consisting of 2 animals per sex are treated with saline (0 mg/kg), 12 or 20 mg/kg ISIS 301012 at a frequency of every two days for the first week, and every 4 days thereafter, for a 3 month period. Following the treatment period, the animals receive no treatment for an additional three months. These treatment groups are for the purpose of studying the effects of apolipoprotein B inhibition 3 months after cessation of treatment. At the end of the 3 month recovery period, animals are sacrificed and evaluated for the same parameters as the animals sacrificed immediately after 1 and 3 months of treatment.

The results from the one month interval of the long term treatment are shown in Table 50 and are normalized to saline-treated animals for mRNA and to untreated baseline values for lipid levels. Total cholesterol, LDL-cholesterol, HDL-cholesterol, LDL particle concentration and triglyceride levels in serum were measured by nuclear magnetic resonance spectroscopy by Liposcience (Raleigh, N.C.). Additionally, the concentration of intact oligonucleotide in liver was measured by capillary gel electrophoresis and is presented as micrograms of oligonucleotide per gram of liver tissue. Each result represents the average of data from 4 animals (2 males and 2 females).

TABLE 50

Effects of antisense inhibition by ISIS 301012 in lean Cynomolgous monkeys						
	Intravenous delivery			Subcutaneous injection		
	Saline	2 mg/kg	4 mg/kg	12 mg/kg	3.5 mg/kg	20 mg/kg
apolipoprotein B expression		-45	-76	-96	N.D.	-94
% change normalized to saline						
antisense oligonucleotide		92	179	550	N.D.	855
concentration $\mu\text{g/g}$						
Lipid parameters, % change						
normalized to untreated						
baseline value						
Total cholesterol	+1	-6	-2	-2	+5	-5
LDL-cholesterol	+17	+15	+9	+3	-4	-16
HDL-cholesterol	-11	-23	-15	-8	+13	+5

TABLE 50-continued

	Intravenous delivery				Subcutaneous injection	
	Saline	2 mg/kg	4 mg/kg	12 mg/kg	3.5 mg/kg	20 mg/kg
LDL/HDL	+62	+94	+38	+44	-15	-19
Total cholesterol/HDL	+30	+44	+22	+21	-7	-10
Triglyceride	+37	+26	+32	+15	+1	-3
LDL Particle concentration	+15	+8	+8	-11	-14	-21

These data show that ISIS 301012 inhibits apolipoprotein B expression in a dose-dependent manner in a primate species and concomitantly lowers lipid levels at higher doses of ISIS 301012. Furthermore, these results demonstrate that antisense oligonucleotide accumulates in the liver in a dose-dependent manner.

Hepatic steatosis, or accumulation of lipids in the liver, was not observed following 4 weeks of treatment with the doses indicated. Expected dose-related toxicities were observed at the higher doses of 12 and 20 mg/kg, including a transient 1.2-1.3 fold increase in activated partial thromboplastin time (APTT) during the first 4 hours and basophilic granules in the liver and kidney (as assessed by routine histological examination of tissue samples). No functional changes in kidney were observed.

In a similar experiment, male and female Cynomolgous monkeys received an intravenous dose of ISIS 301012 at 4 mg/kg, every two days for the first week and every 4 days thereafter. Groups of animals were sacrificed after the first dose and the fourth dose, as well as 11, 15 and 23 days following the fourth and final dose. Liver RNA was isolated and apolipoprotein B mRNA levels were evaluated by real-time PCR as described herein. The results of this experiment demonstrate a 40% reduction in apolipoprotein B mRNA expression after a single intravenous dose of 4 mg/kg ISIS 301012. Furthermore, after 4 doses of ISIS 301012 at 4 mg/kg, target mRNA was reduced by approximately 85% and a 50% reduction in target mRNA was sustained for up to 16 days following the cessation of antisense oligonucleotide treatment.

Example 65

Microarray Analysis: Gene Expression Patterns in Lean Versus High-fat Fed Mice

Male C57Bl/6 mice were divided into the following groups, consisting of 5 animals each: (1) mice on a lean diet, injected with saline (lean control); (2) mice on a high fat diet; (3) mice on a high fat diet injected with 50 mg/kg of the control oligonucleotide 141923 (SEQ ID NO: 858); (4) mice on a high fat diet given 20 mg/kg atorvastatin calcium (Lipitor®, Pfizer Inc.); (5) mice on a high fat diet injected with 10, 25 or 50 mg/kg ISIS 147764 (SEQ ID NO: 109). Saline and oligonucleotide treatments were administered intraperitoneally twice weekly for 6 weeks. Atorvastatin was administered daily for 6 weeks. At study termination, liver samples were isolated from each animal and RNA was isolated for Northern blot qualitative assessment, DNA microarray and quantitative real-time PCR. Northern blot assessment and quantitative real-time PCR were performed as described by other examples herein.

For DNA microarray analysis, hybridization samples were prepared from 10 µg of total RNA isolated from each mouse liver according to the Affymetrix Expression Analysis Tech-

nical Manual (Affymetrix, Inc., Santa Clara, Calif.). Samples were hybridized to a mouse gene chip containing approximately 22,000 genes, which was subsequently washed and double-stained using the Fluidics Station 400 (Affymetrix, Inc., Santa Clara, Calif.) as defined by the manufacturer's protocol. Stained gene chips were scanned for probe cell intensity with the GeneArray scanner (Affymetrix, Inc., Santa Clara, Calif.). Signal values for each probe set were calculated using the Affymetrix Microarray Suite v5.0 software (Affymetrix, Inc., Santa Clara, Calif.). Each condition was profiled from 5 biological samples per group, one chip per sample. Fold change in expression was computed using the geometric mean of signal values as generated by Microarray Suite v5.0. Statistical analysis utilized one-way ANOVA followed by 9 pair-wise comparisons. All groups were compared to the high fat group to determine gene expression changes resulting from ISIS 147764 treatment. Microarray data was interpreted using hierarchical clustering to visualize global gene expression patterns.

The results of the microarray analysis reveal that treatment with ISIS 147764 drives the gene expression profile in high fat fed mice to the profile observed in lean mice. Real-time PCR analysis confirmed the reduction in mRNA expression for the following genes involved in the lipid metabolism: hepatic lipase, fatty acid synthase ATP-binding cassette, subfamily D (ALD) member 2, intestinal fatty acid binding protein 2, stearyl CoA desaturase-1 and HMG CoA reductase.

Mouse apolipoprotein B mRNA and serum cholesterol levels, measured as described herein, were evaluated to confirm antisense inhibition by ISIS 147764 and ISIS 147483. Both mRNA and cholesterol levels were lowered in a dose-dependent manner following treatment with ISIS 147764 or ISIS 147483, as demonstrated in other examples herein. The 50 mg/kg dose of ISIS 147483 increased ALT and AST levels. The 10, 25 and 50 mg/kg doses of ISIS 147764 and the 10 and 25 mg/kg doses of ISIS 147483 did not significantly elevate ALT or AST levels.

Example 66

Evaluation of Hepatic Steatosis in Animals Treated with Apolipoprotein B Antisense Oligonucleotides

Livers of animals treated with antisense oligonucleotides targeted to apolipoprotein B were evaluated for the presence of steatosis. Steatosis is assessed by histological analysis of liver tissue and measurement of liver triglyceride levels.

Evaluation of Steatosis in High Fat Fed Animals Treated with ISIS 147764 for 6 Weeks

Liver tissue from ISIS 147764 (SEQ ID NO: 109) and control-treated animals described in Example 21 was evaluated for steatosis at study termination following 6 weeks of treatment. Tissue sections were stained with oil red O and hematoxylin to visualize lipids and nuclei, respectively. Tissue sections were also stained with hematoxylin and eosin to

159

visualize nuclei and cytoplasm, respectively. Histological analysis of tissue sections stained by either method reveal no difference in steatosis between saline treated and ISIS 147764 treated animals, demonstrating that a 6 week treatment with ISIS 147764 does not lead to accumulation of lipids in the liver.

Evaluation of Steatosis Following Long-term Treatment with Apolipoprotein B Inhibitor in High-fat Fed Animals

Male C57Bl/6 mice were treated with twice weekly intraperitoneal injections of 25 mg/kg ISIS 147764 (SEQ ID NO: 109) or 25 mg/kg ISIS 141923 (SEQ ID NO: 858) for 6, 12 and 20 weeks. Saline treated animals served as controls. Each treatment group contained 4 animals. Animals were sacrificed at 6, 12 and 20 weeks and liver tissue was procured for histological analysis and measurement of tissue triglyceride content. The results reveal no significant differences in liver tissue triglyceride content when ISIS 147764 treated animals are compared to saline treated animals. Furthermore, histological analysis of liver tissue section demonstrates that steatosis is reduced at 12 and 20 weeks following treatment of high fat fed mice with ISIS 147764, in comparison to saline control animals that received a high fat diet.

Evaluation of Steatosis in Lean Mice

The accumulation of lipids in liver tissue was also evaluated in lean mice. Male C67Bl/6 mice (Charles River Laboratories (Wilmington, Mass.) at 6 to 7 weeks of age were maintained on a standard rodent diet and were treated twice weekly with intraperitoneal injections of 25 or 50 mg/kg 147764 (SEQ ID NO: 109) or 147483 (SEQ ID NO: 79) for 6 weeks. Saline treated animals served as controls. Each treatment group was comprised of 4 animals. Animals were sacrificed after the 6 week treatment period, at which point liver tissue and serum were collected.

Apolipoprotein B mRNA levels were measured by real-time PCR as described by other examples herein. The data, shown in Table 51, represent the average of 4 animals and are presented as inhibition relative to saline treated controls. The results demonstrate that both ISIS 147483 and ISIS 147764 inhibit apolipoprotein B mRNA expression in lean mice in a dose-dependent manner.

TABLE 51

Antisense inhibition of apolipoprotein B mRNA in lean mice				
	Treatment and dose			
	ISIS 147483		ISIS 147764	
	25 mg/kg	50 mg/kg	25 mg/kg	50 mg/kg
% inhibition apolipoprotein B mRNA	79	91	48	77

Total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in serum were measured by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). The liver enzymes ALT and AST in serum were also measured using the Olympus Clinical Analyzer. These results demonstrate that ISIS 147764 lowers serum lipids relative to saline-treated control animals ALT and AST levels do not exceed the normal range for mice (300 IU/L), indicating a lack of treatment-associated toxicity. The results are the average of data from 4 animals and are shown in Table 52.

160

TABLE 52

Serum lipids and liver enzyme levels in lean mice treated with ISIS 147764 and ISIS 147483					
	Treatment and dose				
	ISIS 147483		ISIS 147764		
	Saline	25 mg/kg	50 mg/kg	25 mg/kg	50 mg/kg
Serum lipids					
Total cholesterol mg/dL	164	153	183	114	57
LDL-cholesterol mg/dL	25	26	39	29	18
HDL-cholesterol mg/dL	127	117	131	79	38
Triglycerides mg/dL	121	138	127	80	30
Liver enzymes					
ALT IU/L	105	73	57	47	48
AST IU/L	109	78	72	81	101

Liver tissue was prepared by routine histological methods to evaluate steatosis, as described herein. Examination of tissue samples stained with oil red O or hematoxylin and eosin reveals that treatment of lean mice with apolipoprotein B antisense oligonucleotides does not result in steatosis.

Six Month Study to Further Evaluate Steatosis in Mice Treated with Apolipoprotein B Antisense Oligonucleotides

A long-term treatment of mice with antisense oligonucleotides targeted to apolipoprotein B is used to evaluate the toxicological and pharmacological effects of extended treatment with antisense compounds. Both male and female C57Bl/6 mice at 2 months of age are treated with 2, 5, 25 or 50 mg/kg of apolipoprotein B antisense oligonucleotide. Treatments are administered intraperitoneally every 2 days for the first week and every 4 days thereafter. Mice treated with saline alone or control oligonucleotide serve as control groups. Each treatment group contains 25 to 30 mice. After 6 months of treatment, a subset of the mice in each treatment group is sacrificed. The remaining mice are allowed a 3 month recovery period without treatment, after which they are sacrificed. Apolipoprotein B mRNA expression in liver is measured by real-time PCR as described by other methods herein. Liver tissue is also prepared for measurement of triglyceride content using a Triglyceride GPO Assay (Sigma-Aldrich, St. Louis, Mo.). Serum is collected and evaluated for lipid content, including total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride, using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). The liver enzymes ALT and AST are also measured in serum, also using the clinical analyzer. Serum samples are subjected to immunoblot analysis using an antibody directed to apolipoprotein B (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.). Liver, kidney and other tissues are prepared by routine procedures for histological analyses. Tissues are evaluated for the presence of basophilic granules and inflammatory infiltrates. Steatosis is evaluated by oil red O stain of liver tissue sections.

Example 67

A Mouse Model for Atherosclerotic Plaque Formation: Human Apolipoprotein R Transgenic Mice Lacking the LDL Receptor Gene

The LDL receptor is responsible for clearing apolipoprotein B-containing LDL particles. Without the LDL receptor, animals cannot effectively clear apolipoprotein B-containing

LDL particles from the plasma. Thus the serum levels of apolipoprotein B and LDL cholesterol are markedly elevated. Mice expressing the human apolipoprotein B transgene (TgN-hApoB +/+) and mice deficient for the LDL receptor (LDLr -/-) are both used as animal models of atherosclerotic plaque development. When the LDL receptor deficiency genotype is combined with a human apolipoprotein B transgenic genotype (TgN-hApoB +/+; LDLr -/-), atherosclerotic plaques develop rapidly. In accordance with the present invention, mice of this genetic background are used to investigate the ability of compounds to prevent atherosclerosis and plaque formation.

Male TgN-hApoB +/+;LDLr -/- mice are treated twice weekly with 10 or 20 mg/kg of human apolipoprotein B antisense oligonucleotides for 12 weeks. Control groups are treated with saline or control oligonucleotide. Serum total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides are measured at 2, 4, 6, 8 and 12 weeks by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). Serum human apolipoprotein B protein is measured at 2, 4, 6, 8 and 12 weeks using an ELISA kit (ALerCHEK Inc., Portland, Me.). Human and mouse apolipoprotein mRNA in liver is measured at 12 weeks. The results of the 12 week study serve to evaluate the pharmacological behavior of ISIS 301012 in a doubly transgenic model.

Additionally, a four month study is performed in TgN-hApoB +/+;LDLr -/- mice, with treatment conditions used in the 12 week study. Mice are treated for 4 months with antisense oligonucleotides targeted to human apolipoprotein B to evaluate the ability of such compounds to prevent atherosclerotic plaque formation. At the end of the 4 month treatment period, mice are anesthetized and perfused with 10% formalin. The perfused arterial tree is isolated and examined for the presence of atherosclerotic plaques. Sections of the arterial tree are embedded in paraffin and prepared for histological analysis using routine methods. Serum total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides are measured at 2, 4, 6, 8, 12 and 16 weeks by routine clinical analysis using an Olympus Clinical Analyzer (Olympus America Inc., Melville, N.Y.). Serum human apolipoprotein B protein is measured at 2, 4, 6, 8, 12 and 16 weeks using an ELISA kit (ALerCHEK Inc., Portland, Me.). Human and mouse apolipoprotein mRNA in liver at 16 weeks is measured by real-time PCR.

Example 68

Rabbit Models for Study of Atherosclerotic Plaque Formation

The Watanabe heritable hyperlipidemic (WHHL) strain of rabbit is used as a model for atherosclerotic plaque formation. New Zealand white rabbits on a high-fat diet are also used as a model of atherosclerotic plaque formation. Treatment of WHHL or high fat fed New Zealand white rabbits with apolipoprotein B antisense compounds is used to test their potential as therapeutic or prophylactic treatments for atherosclerotic plaque disease. Rabbits are injected with 5, 10, 25 or 50 mg/kg of antisense oligonucleotides targeted to apolipoprotein B. Animals treated with saline alone or a control oligonucleotide serve as controls. Throughout the treatment, serum samples are collected and evaluated for apolipoprotein B protein levels by ELISA (kit from ALerCHEK Inc., Portland, Me.) and serum lipids (cholesterol, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol, triglycerides) by routine clinical analysis. Liver tissue triglyceride content is measured using a Triglyceride GPO Assay (Sigma-Aldrich, St.

Louis, Mo.). Liver, kidney, heart, aorta and other tissues are procured and processed for histological analysis using routine procedures. Liver and kidney tissues are examined for evidence of basophilic granules and inflammatory infiltrates. Liver tissue is evaluated for steatosis using oil red O stain. Additionally, aortic sections stained with oil red O stain and hematoxylin are examined to evaluate the formation of atherosclerotic lesions.

Example 69

Oral Delivery of Apolipoprotein B Inhibitors

Oligonucleotides may be formulated for delivery in vivo in an acceptable dosage form, e.g. as parenteral or non-parenteral formulations. Parenteral formulations include intravenous (IV), subcutaneous (SC), intraperitoneal (IP), intravitreal and intramuscular (IM) formulations, as well as formulations for delivery via pulmonary inhalation, intranasal administration, topical administration, etc. Non-parenteral formulations include formulations for delivery via the alimentary canal, e.g. oral administration, rectal administration, intrajejunal instillation, etc. Rectal administration includes administration as an enema or a suppository. Oral administration includes administration as a capsule, a gel capsule, a pill, an elixir, etc.

In some embodiments, an oligonucleotide may be administered to a subject via an oral route of administration. The subject may be an animal or a human (man). An animal subject may be a mammal, such as a mouse, rat, mouse, a rat, a dog, a guinea pig, a monkey, a non-human primate, a cat or a pig. Non-human primates include monkeys and chimpanzees. A suitable animal subject may be an experimental animal, such as a mouse, rat, mouse, a rat, a dog, a monkey, a non-human primate, a cat or a pig.

In some embodiments, the subject may be a human. In certain embodiments, the subject may be a human patient in need of therapeutic treatment as discussed in more detail herein. In certain embodiments, the subject may be in need of modulation of expression of one or more genes as discussed in more detail herein. In some particular embodiments, the subject may be in need of inhibition of expression of one or more genes as discussed in more detail herein. In particular embodiments, the subject may be in need of modulation, i.e. inhibition or enhancement, of apolipoprotein B in order to obtain therapeutic indications discussed in more detail herein.

In some embodiments, non-parenteral (e.g. oral) oligonucleotide formulations according to the present invention result in enhanced bioavailability of the oligonucleotide. In this context, the term "bioavailability" refers to a measurement of that portion of an administered drug which reaches the circulatory system (e.g. blood, especially blood plasma) when a particular mode of administration is used to deliver the drug. Enhanced bioavailability refers to a particular mode of administration's ability to deliver oligonucleotide to the peripheral blood plasma of a subject relative to another mode of administration. For example, when a non-parenteral mode of administration (e.g. an oral mode) is used to introduce the drug into a subject, the bioavailability for that mode of administration may be compared to a different mode of administration, e.g. an IV mode of administration. In some embodiments, the area under a compound's blood plasma concentration curve (AUCO) after non-parenteral (e.g. oral, rectal, intrajejunal) administration may be divided by the area under the drug's plasma concentration curve after intravenous (i.v.) administration (AUC_{iv}) to provide a dimensionless quotient (relative bioavailability, RB) that represents fraction

of compound absorbed via the non-parenteral route as compared to the IV route. A composition's bioavailability is said to be enhanced in comparison to another composition's bioavailability when the first composition's relative bioavailability (RB_1) is greater than the second composition's relative bioavailability (RB_2).

In general, bioavailability correlates with therapeutic efficacy when a compound's therapeutic efficacy is related to the blood concentration achieved, even if the drug's ultimate site of action is intracellular (van Berge-Henegouwen et al., *Gastroenterol.*, 1977, 73, 300). Bioavailability studies have been used to determine the degree of intestinal absorption of a drug by measuring the change in peripheral blood levels of the drug after an oral dose (DiSanto, Chapter 76 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 1451-1458).

In general, an oral composition's bioavailability is said to be "enhanced" when its relative bioavailability is greater than the bioavailability of a composition substantially consisting of pure oligonucleotide, i.e. oligonucleotide in the absence of a penetration enhancer.

Organ bioavailability refers to the concentration of compound in an organ. Organ bioavailability may be measured in test subjects by a number of means, such as by whole-body radiography. Organ bioavailability may be modified, e.g. enhanced, by one or more modifications to the oligonucleotide, by use of one or more carrier compounds or excipients, etc. as discussed in more detail herein. In general, an increase in bioavailability will result in an increase in organ bioavailability.

Oral oligonucleotide compositions according to the present invention may comprise one or more "mucosal penetration enhancers," also known as "absorption enhancers" or simply as "penetration enhancers." Accordingly, some embodiments of the invention comprise at least one oligonucleotide in combination with at least one penetration enhancer. In general, a penetration enhancer is a substance that facilitates the transport of a drug across mucous membrane(s) associated with the desired mode of administration, e.g. intestinal epithelial membranes. Accordingly it is desirable to select one or more penetration enhancers that facilitate the uptake of an oligonucleotide, without interfering with the activity of the oligonucleotide, and in a such a manner the oligonucleotide can be introduced into the body of an animal without unacceptable side-effects such as toxicity, irritation or allergic response.

Embodiments of the present invention provide compositions comprising one or more pharmaceutically acceptable penetration enhancers, and methods of using such compositions, which result in the improved bioavailability of oligonucleotides administered via non-parenteral modes of administration. Heretofore, certain penetration enhancers have been used to improve the bioavailability of certain drugs. See Muranishi, *Crit. Rev. Ther. Drug Carrier Systems*, 1990, 7, 1 and Lee et al., *Crit. Rev. Ther. Drug Carrier Systems*, 1991, 8, 91. It has been found that the uptake and delivery of oligonucleotides, relatively complex molecules which are known to be difficult to administer to animals and man, can be greatly improved even when administered by non-parenteral means through the use of a number of different classes of penetration enhancers.

In some embodiments, compositions for non-parenteral administration include one or more modifications from naturally-occurring oligonucleotides (i.e. full-phosphodiester deoxyribosyl or full-phosphodiester ribosyl oligonucleotides). Such modifications may increase binding affinity, nuclease stability, cell or tissue permeability, tissue distribu-

tion, or other biological or pharmacokinetic property. Modifications may be made to the base, the linker, or the sugar, in general, as discussed in more detail herein with regards to oligonucleotide chemistry. In some embodiments of the invention, compositions for administration to a subject, and in particular oral compositions for administration to an animal or human subject, will comprise modified oligonucleotides having one or more modifications for enhancing affinity, stability, tissue distribution, or other biological property.

Suitable modified linkers include phosphorothioate linkers. In some embodiments according to the invention, the oligonucleotide has at least one phosphorothioate linker. Phosphorothioate linkers provide nuclease stability as well as plasma protein binding characteristics to the oligonucleotide. Nuclease stability is useful for increasing the in vivo lifetime of oligonucleotides, while plasma protein binding decreases the rate of first pass clearance of oligonucleotide via renal excretion. In some embodiments according to the present invention, the oligonucleotide has at least two phosphorothioate linkers. In some embodiments, wherein the oligonucleotide has exactly n nucleosides, the oligonucleotide has from one to $n-1$ phosphorothioate linkages. In some embodiments, wherein the oligonucleotide has exactly n nucleosides, the oligonucleotide has $n-1$ phosphorothioate linkages. In other embodiments wherein the oligonucleotide has exactly n nucleoside, and n is even, the oligonucleotide has from 1 to $n/2$ phosphorothioate linkages, or, when n is odd, from 1 to $(n-1)/2$ phosphorothioate linkages. In some embodiments, the oligonucleotide has alternating phosphodiester (PO) and phosphorothioate (PS) linkages. In other embodiments, the oligonucleotide has at least one stretch of two or more consecutive PO linkages and at least one stretch of two or more PS linkages. In other embodiments, the oligonucleotide has at least two stretches of PO linkages interrupted by at least one PS linkage.

In some embodiments, at least one of the nucleosides is modified on the ribosyl sugar unit by a modification that imparts nuclease stability, binding affinity or some other beneficial biological property to the sugar. In some cases, the sugar modification includes a 2'-modification, e.g. the 2'-OH of the ribosyl sugar is replaced or substituted. Suitable replacements for 2'-OH include 2'-F and 2'-arabino-F. Suitable substitutions for OH include 2'-O-alkyl, e.g. 2-O-methyl, and 2'-O-substituted alkyl, e.g. 2'-O-methoxyethyl, 2'-O-aminopropyl, etc. In some embodiments, the oligonucleotide contains at least one 2'-modification. In some embodiments, the oligonucleotide contains at least 2 2'-modifications. In some embodiments, the oligonucleotide has at least one 2'-modification at each of the termini (i.e. the 3'- and 5'-terminal nucleosides each have the same or different 2'-modifications). In some embodiments, the oligonucleotide has at least two sequential 2'-modifications at each end of the oligonucleotide. In some embodiments, oligonucleotides further comprise at least one deoxynucleoside. In particular embodiments, oligonucleotides comprise a stretch of deoxynucleosides such that the stretch is capable of activating RNase (e.g. RNase H) cleavage of an RNA to which the oligonucleotide is capable of hybridizing. In some embodiments, a stretch of deoxynucleosides capable of activating RNase-mediated cleavage of RNA comprises about 6 to about 16, e.g. about 8 to about 16 consecutive deoxynucleosides.

Oral compositions for administration of non-parenteral oligonucleotide compositions of the present invention may be formulated in various dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The term "alimentary delivery" encompasses e.g. oral, rectal, endoscopic and sublingual/buccal adminis-

tration. A common requirement for these modes of administration is absorption over some portion or all of the alimentary tract and a need for efficient mucosal penetration of the nucleic acid(s) so administered.

Delivery of a drug via the oral mucosa, as in the case of buccal and sublingual administration, has several desirable features, including, in many instances, a more rapid rise in plasma concentration of the drug than via oral delivery (Harvey, Chapter 35 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, page 711).

Endoscopy may be used for drug delivery directly to an interior portion of the alimentary tract. For example, endoscopic retrograde cystopancreatography (ERCP) takes advantage of extended gastroscopy and permits selective access to the biliary tract and the pancreatic duct (Hirahata et al., Gan To Kagaku Ryoho, 1992, 19(10 Suppl.), 1591). Pharmaceutical compositions, including liposomal formulations, can be delivered directly into portions of the alimentary canal, such as, e.g., the duodenum (Somogyi et al., Pharm. Res., 1995, 12, 149) or the gastric submucosa (Akamo et al., Japanese J. Cancer Res., 1994, 85, 652) via endoscopic means. Gastric lavage devices (Inoue et al., Artif. Organs, 1997, 21, 28) and percutaneous endoscopic feeding devices (Pennington et al., Ailment Pharmacol. Ther., 1995, 9, 471) can also be used for direct alimentary delivery of pharmaceutical compositions.

In some embodiments, oligonucleotide formulations may be administered through the anus into the rectum or lower intestine. Rectal suppositories, retention enemas or rectal catheters can be used for this purpose and may be preferred when patient compliance might otherwise be difficult to achieve (e.g., in pediatric and geriatric applications, or when the patient is vomiting or unconscious). Rectal administration can result in more prompt and higher blood levels than the oral route. (Harvey, Chapter 35 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, page 711). Because about 50% of the drug that is absorbed from the rectum will bypass the liver, administration by this route significantly reduces the potential for first-pass metabolism (Benet et al., Chapter 1 In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996).

One advantageous method of non-parenteral administration of oligonucleotide compositions is oral delivery. Some embodiments employ various penetration enhancers in order to effect transport of oligonucleotides and other nucleic acids across mucosal and epithelial membranes. Penetration enhancers may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Accordingly, some embodiments comprise oral oligonucleotide compositions comprising at least one member of the group consisting of surfactants, fatty acids, bile salts, chelating agents, and non-chelating surfactants. Further embodiments comprise oral oligonucleotide compositions comprising at least one fatty acid, e.g. capric or lauric acid, or combinations or salts thereof. Other embodiments comprise methods of enhancing the oral bioavailability of an oligonucleotide, the method comprising co-administering the oligonucleotide and at least one penetration enhancer.

Other excipients that may be added to oral oligonucleotide compositions include surfactants (or "surface-active agents"), which are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the

solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the alimentary mucosa and other epithelial membranes is enhanced. In addition to bile salts and fatty acids, surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and perfluorochemical emulsions, such as FC-43 (Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

Fatty acids and their derivatives which act as penetration enhancers and may be used in compositions of the present invention include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tripalmitate, monolein (1-monoleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines and mono- and di-glycerides thereof and/or physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1; El-Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651).

In some embodiments, oligonucleotide compositions for oral delivery comprise at least two discrete phases, which phases may comprise particles, capsules, gel-capsules, microspheres, etc. Each phase may contain one or more oligonucleotides, penetration enhancers, surfactants, bioadhesives, effervescent agents, or other adjuvant, excipient or diluent. In some embodiments, one phase comprises at least one oligonucleotide and at least one penetration enhancer. In some embodiments, a first phase comprises at least one oligonucleotide and at least one penetration enhancer, while a second phase comprises at least one penetration enhancer. In some embodiments, a first phase comprises at least one oligonucleotide and at least one penetration enhancer, while a second phase comprises at least one penetration enhancer and substantially no oligonucleotide. In some embodiments, at least one phase is compounded with at least one degradation retardant, such as a coating or a matrix, which delays release of the contents of that phase. In some embodiments, at least one phase In some embodiments, a first phase comprises at least one oligonucleotide, at least one penetration enhancer, while a second phase comprises at least one penetration enhancer and a release-retardant. In particular embodiments, an oral oligonucleotide comprises a first phase comprising particles containing an oligonucleotide and a penetration enhancer, and a second phase comprising particles coated with a release-retarding agent and containing penetration enhancer.

A variety of bile salts also function as penetration enhancers to facilitate the uptake and bioavailability of drugs. The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996, pages 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid

(sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (CDCA, sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: Remington's *Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579).

In some embodiments, penetration enhancers useful in some embodiments of present invention are mixtures of penetration enhancing compounds. One such penetration enhancer is a mixture of UDCA (and/or CDCA) with capric and/or lauric acids or salts thereof e.g. sodium. Such mixtures are useful for enhancing the delivery of biologically active substances across mucosal membranes, in particular intestinal mucosa. Other penetration enhancer mixtures comprise about 5-95% of bile acid or salt(s) UDCA and/or CDCA with 5-95% capric and/or lauric acid. Particular penetration enhancers are mixtures of the sodium salts of UDCA, capric acid and lauric acid in a ratio of about 1:2:2 respectively. Another such penetration enhancer is a mixture of capric and lauric acid (or salts thereof) in a 0.01:1 to 1:0.01 ratio (mole basis). In particular embodiments capric acid and lauric acid are present in molar ratios of e.g. about 0.1:1 to about 1:0.1, in particular about 0.5:1 to about 1:0.5.

Other excipients include chelating agents, i.e. compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the alimentary and other mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315). Chelating agents of the invention include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, lauric acid and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1; Buur et al., *J. Control Rel.*, 1990, 14, 43).

As used herein, non-chelating non-surfactant penetration enhancers may be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary and other mucosal membranes (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1). This class of penetration enhancers includes, but is not limited to, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents

such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al., U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), can be used.

Some oral oligonucleotide compositions also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which may be inert (i.e., does not possess biological activity per se) or may be necessary for transport, recognition or pathway activation or mediation, or is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177).

A "pharmaceutical carrier" or "excipient" may be a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, EXPLOTAB); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Oral oligonucleotide compositions may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 897

<210> SEQ ID NO 1
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 1

tccgtcatcg ctctcaggg 20

<210> SEQ ID NO 2
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 2

atgcattctg cccccaagga 20

<210> SEQ ID NO 3
 <211> LENGTH: 14121
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (129)..(13820)

<400> SEQUENCE: 3

attcccaccg ggacctgcgg ggctgagtg ccttctcggt tgctgccgct gaggagcccg 60

cccagccagc cagggccgag aggccgaggg caggccgcag cccaggagcc gccccaccgc 120

agctggcg atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg 170
 Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu
 1 5 10

cct gcg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa 218
 Pro Ala Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu
 15 20 25 30

atg ctg gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc 266
 Met Leu Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe
 35 40 45

aag cac ctg cgg aag tac aca tac aac tat gag gct gag agt tcc agt 314
 Lys His Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser
 50 55 60

gga gtc cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc 362
 Gly Val Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys
 65 70 75

aag gtt gag ctg gag gtt ccc cag ctg tgc agc ttc atc ctg aag acc 410
 Lys Val Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr
 80 85 90

agc cag tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa 458
 Ser Gln Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys
 95 100 105 110

gcc ttg ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg 506
 Ala Leu Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met
 115 120 125

tcc agg tat gag ctg aag ctg gcc att cca gaa ggg aag cag gtt ttc 554
 Ser Arg Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe
 130 135 140

ctt tac ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg 602

-continued

Leu	Tyr	Pro	Glu	Lys	Asp	Glu	Pro	Thr	Tyr	Ile	Leu	Asn	Ile	Lys	Arg	
		145					150					155				
ggc	atc	att	tct	gcc	ctc	ctg	gtt	ccc	cca	gag	aca	gaa	gaa	gcc	aag	650
Gly	Ile	Ile	Ser	Ala	Leu	Leu	Val	Pro	Pro	Glu	Thr	Glu	Glu	Ala	Lys	
	160					165				170						
caa	gtg	ttg	ttt	ctg	gat	acc	gtg	tat	gga	aac	tgc	tcc	act	cac	ttt	698
Gln	Val	Leu	Phe	Leu	Asp	Thr	Val	Tyr	Gly	Asn	Cys	Ser	Thr	His	Phe	
	175				180					185					190	
acc	gtc	aag	acg	agg	aag	ggc	aat	gtg	gca	aca	gaa	ata	tcc	act	gaa	746
Thr	Val	Lys	Thr	Arg	Lys	Gly	Asn	Val	Ala	Thr	Glu	Ile	Ser	Thr	Glu	
				195					200					205		
aga	gac	ctg	ggg	cag	tgt	gat	cgc	ttc	aag	ccc	atc	cgc	aca	ggc	atc	794
Arg	Asp	Leu	Gly	Gln	Cys	Asp	Arg	Phe	Lys	Pro	Ile	Arg	Thr	Gly	Ile	
		210					215						220			
agc	cca	ctt	gct	ctc	atc	aaa	ggc	atg	acc	cgc	ccc	ttg	tca	act	ctg	842
Ser	Pro	Leu	Ala	Leu	Ile	Lys	Gly	Met	Thr	Arg	Pro	Leu	Ser	Thr	Leu	
		225					230					235				
atc	agc	agc	agc	cag	tcc	tgt	cag	tac	aca	ctg	gac	gct	aag	agg	aag	890
Ile	Ser	Ser	Ser	Gln	Ser	Cys	Gln	Tyr	Thr	Leu	Asp	Ala	Lys	Arg	Lys	
	240					245					250					
cat	gtg	gca	gaa	gcc	atc	tgc	aag	gag	caa	cac	ctc	ttc	ctg	cct	ttc	938
His	Val	Ala	Glu	Ala	Ile	Cys	Lys	Glu	Gln	His	Leu	Phe	Leu	Pro	Phe	
	255				260				265						270	
tcc	tac	aac	aat	aag	tat	ggg	atg	gta	gca	caa	gtg	aca	cag	act	ttg	986
Ser	Tyr	Asn	Asn	Lys	Tyr	Gly	Met	Val	Ala	Gln	Val	Thr	Gln	Thr	Leu	
				275					280					285		
aaa	ctt	gaa	gac	aca	cca	aag	atc	aac	agc	cgc	ttc	ttt	ggt	gaa	ggt	1034
Lys	Leu	Glu	Asp	Thr	Pro	Lys	Ile	Asn	Ser	Arg	Phe	Phe	Gly	Glu	Gly	
			290					295					300			
act	aag	aag	atg	ggc	ctc	gca	ttt	gag	agc	acc	aaa	tcc	aca	tca	cct	1082
Thr	Lys	Lys	Met	Gly	Leu	Ala	Phe	Glu	Ser	Thr	Lys	Ser	Thr	Ser	Pro	
		305					310					315				
cca	aag	cag	gcc	gaa	gct	gtt	ttg	aag	act	ctc	cag	gaa	ctg	aaa	aaa	1130
Pro	Lys	Gln	Ala	Glu	Ala	Val	Leu	Lys	Thr	Leu	Gln	Glu	Leu	Lys	Lys	
		320				325					330					
cta	acc	atc	tct	gag	caa	aat	atc	cag	aga	gct	aat	ctc	ttc	aat	aag	1178
Leu	Thr	Ile	Ser	Glu	Gln	Asn	Ile	Gln	Arg	Ala	Asn	Leu	Phe	Asn	Lys	
				340					345						350	
ctg	gtt	act	gag	ctg	aga	ggc	ctc	agt	gat	gaa	gca	gtc	aca	tct	ctc	1226
Leu	Val	Thr	Glu	Leu	Arg	Gly	Leu	Ser	Asp	Glu	Ala	Val	Thr	Ser	Leu	
				355					360					365		
ttg	cca	cag	ctg	att	gag	gtg	tcc	agc	ccc	atc	act	tta	caa	gcc	ttg	1274
Leu	Pro	Gln	Leu	Ile	Glu	Val	Ser	Ser	Pro	Ile	Thr	Leu	Gln	Ala	Leu	
			370					375					380			
gtt	cag	tgt	gga	cag	cct	cag	tgc	tcc	act	cac	atc	ctc	cag	tgg	ctg	1322
Val	Gln	Cys	Gly	Gln	Pro	Gln	Cys	Ser	Thr	His	Ile	Leu	Gln	Trp	Leu	
		385					390					395				
aaa	cgt	gtg	cat	gcc	aac	ccc	ctt	ctg	ata	gat	gtg	gtc	acc	tac	ctg	1370
Lys	Arg	Val	His	Ala	Asn	Pro	Leu	Leu	Ile	Asp	Val	Val	Thr	Tyr	Leu	
		400				405					410					
gtg	gcc	ctg	atc	ccc	gag	ccc	tca	gca	cag	cag	ctg	cga	gag	atc	ttc	1418
Val	Ala	Leu	Ile	Pro	Glu	Pro	Ser	Ala	Gln	Gln	Leu	Arg	Glu	Ile	Phe	
		415			420					425					430	
aac	atg	gcg	agg	gat	cag	cgc	agc	cga	gcc	acc	ttg	tat	gcg	ctg	agc	1466
Asn	Met	Ala	Arg	Asp	Gln	Arg	Ser	Arg	Ala	Thr	Leu	Tyr	Ala	Leu	Ser	
				435					440					445		
cac	gcg	gtc	aac	aac	tat	cat	aag	aca	aac	cct	aca	ggg	acc	cag	gag	1514
His	Ala	Val	Asn	Asn	Tyr	His	Lys	Thr	Asn	Pro	Thr	Gly	Thr	Gln	Glu	
			450					455					460			
ctg	ctg	gac	att	gct	aat	tac	ctg	atg	gaa	cag	att	caa	gat	gac	tgc	1562

-continued

Leu	Leu	Asp	Ile	Ala	Asn	Tyr	Leu	Met	Glu	Gln	Ile	Gln	Asp	Asp	Cys	
		465					470					475				
act	ggg	gat	gaa	gat	tac	acc	tat	ttg	att	ctg	cgg	gtc	att	gga	aat	1610
Thr	Gly	Asp	Glu	Asp	Tyr	Thr	Tyr	Leu	Ile	Leu	Arg	Val	Ile	Gly	Asn	
		480					485				490					
atg	ggc	caa	acc	atg	gag	cag	tta	act	cca	gaa	ctc	aag	tct	tca	atc	1658
Met	Gly	Gln	Thr	Met	Glu	Gln	Leu	Thr	Pro	Glu	Leu	Lys	Ser	Ser	Ile	
		495				500				505					510	
ctc	aaa	tgt	gtc	caa	agt	aca	aag	cca	tca	ctg	atg	atc	cag	aaa	gct	1706
Leu	Lys	Cys	Val	Gln	Ser	Thr	Lys	Pro	Ser	Leu	Met	Ile	Gln	Lys	Ala	
				515					520				525			
gcc	atc	cag	gct	ctg	cgg	aaa	atg	gag	cct	aaa	gac	aag	gac	cag	gag	1754
Ala	Ile	Gln	Ala	Leu	Arg	Lys	Met	Glu	Pro	Lys	Asp	Lys	Asp	Gln	Glu	
			530					535					540			
gtt	ctt	ctt	cag	act	ttc	ctt	gat	gat	gct	tct	ccg	gga	gat	aag	cga	1802
Val	Leu	Leu	Gln	Thr	Phe	Leu	Asp	Asp	Ala	Ser	Pro	Gly	Asp	Lys	Arg	
		545					550					555				
ctg	gct	gcc	tat	ctt	atg	ttg	atg	agg	agt	cct	tca	cag	gca	gat	att	1850
Leu	Ala	Ala	Tyr	Leu	Met	Leu	Met	Arg	Ser	Pro	Ser	Gln	Ala	Asp	Ile	
		560					565					570				
aac	aaa	att	gtc	caa	att	cta	cca	tgg	gaa	cag	aat	gag	caa	gtg	aag	1898
Asn	Lys	Ile	Val	Gln	Ile	Leu	Pro	Trp	Glu	Gln	Asn	Glu	Gln	Val	Lys	
		575				580				585					590	
aac	ttt	gtg	gct	tcc	cat	att	gcc	aat	atc	ttg	aac	tca	gaa	gaa	ttg	1946
Asn	Phe	Val	Ala	Ser	His	Ile	Ala	Asn	Ile	Leu	Asn	Ser	Glu	Glu	Leu	
			595					600					605			
gat	atc	caa	gat	ctg	aaa	aag	tta	gtg	aaa	gaa	gct	ctg	aaa	gaa	tct	1994
Asp	Ile	Gln	Asp	Leu	Lys	Lys	Leu	Val	Lys	Glu	Ala	Leu	Lys	Glu	Ser	
			610					615					620			
caa	ctt	cca	act	gtc	atg	gac	ttc	aga	aaa	ttc	tct	cgg	aac	tat	caa	2042
Gln	Leu	Pro	Thr	Val	Met	Asp	Phe	Arg	Lys	Phe	Ser	Arg	Asn	Tyr	Gln	
		625					630					635				
ctc	tac	aaa	tct	gtt	tct	ctt	cca	tca	ctt	gac	cca	gcc	tca	gcc	aaa	2090
Leu	Tyr	Lys	Ser	Val	Ser	Leu	Pro	Ser	Leu	Asp	Pro	Ala	Ser	Ala	Lys	
		640					645				650					
ata	gaa	ggg	aat	ctt	ata	ttt	gat	cca	aat	aac	tac	ctt	cct	aaa	gaa	2138
Ile	Glu	Gly	Asn	Leu	Ile	Phe	Asp	Pro	Asn	Asn	Tyr	Leu	Pro	Lys	Glu	
		655				660				665					670	
agc	atg	ctg	aaa	act	acc	ctc	act	gcc	ttt	gga	ttt	gct	tca	gct	gac	2186
Ser	Met	Leu	Lys	Thr	Thr	Leu	Thr	Ala	Phe	Gly	Phe	Ala	Ser	Ala	Asp	
			675					680					685			
ctc	atc	gag	att	ggc	ttg	gaa	gga	aaa	ggc	ttt	gag	cca	aca	ttg	gaa	2234
Leu	Ile	Glu	Ile	Gly	Leu	Glu	Gly	Lys	Gly	Phe	Glu	Pro	Thr	Leu	Glu	
			690					695					700			
gct	ctt	ttt	ggg	aag	caa	gga	ttt	ttc	cca	gac	agt	gtc	aac	aaa	gct	2282
Ala	Leu	Phe	Gly	Lys	Gln	Gly	Phe	Phe	Pro	Asp	Ser	Val	Asn	Lys	Ala	
		705					710					715				
ttg	tac	tgg	gtt	aat	ggg	caa	gtt	cct	gat	ggg	gtc	tct	aag	gtc	tta	2330
Leu	Tyr	Trp	Val	Asn	Gly	Gln	Val	Pro	Asp	Gly	Val	Ser	Lys	Val	Leu	
		720					725				730					
gtg	gac	cac	ttt	ggc	tat	acc	aaa	gat	gat	aaa	cat	gag	cag	gat	atg	2378
Val	Asp	His	Phe	Gly	Tyr	Thr	Lys	Asp	Asp	Lys	His	Glu	Gln	Asp	Met	
		735				740				745					750	
gta	aat	gga	ata	atg	ctc	agt	gtt	gag	aag	ctg	att	aaa	gat	ttg	aaa	2426
Val	Asn	Gly	Ile	Met	Leu	Ser	Val	Glu	Lys	Leu	Ile	Lys	Asp	Leu	Lys	
			755					760					765			
tcc	aaa	gaa	gtc	ccg	gaa	gcc	aga	gcc	tac	ctc	cgc	atc	ttg	gga	gag	2474
Ser	Lys	Glu	Val	Pro	Glu	Ala	Arg	Ala	Tyr	Leu	Arg	Ile	Leu	Gly	Glu	
			770					775					780			
gag	ctt	ggg	ttt	gcc	agt	ctc	cat	gac	ctc	cag	ctc	ctg	gga	aag	ctg	2522

-continued

Glu	Leu	Gly	Phe	Ala	Ser	Leu	His	Asp	Leu	Gln	Leu	Leu	Gly	Lys	Leu	
		785					790					795				
ctt	ctg	atg	ggt	gcc	cgc	act	ctg	cag	ggg	atc	ccc	cag	atg	att	gga	2570
Leu	Leu	Met	Gly	Ala	Arg	Thr	Leu	Gln	Gly	Ile	Pro	Gln	Met	Ile	Gly	
	800					805				810						
gag	gtc	atc	agg	aag	ggc	tca	aag	aat	gac	ttt	ttt	ctt	cac	tac	atc	2618
Glu	Val	Ile	Arg	Lys	Gly	Ser	Lys	Asn	Asp	Phe	Phe	Leu	His	Tyr	Ile	
	815				820				825						830	
ttc	atg	gag	aat	gcc	ttt	gaa	ctc	ccc	act	gga	gct	gga	tta	cag	ttg	2666
Phe	Met	Glu	Asn	Ala	Phe	Glu	Leu	Pro	Thr	Gly	Ala	Gly	Leu	Gln	Leu	
			835					840					845			
caa	ata	tct	tca	tct	gga	gtc	att	gct	ccc	gga	gcc	aag	gct	gga	gta	2714
Gln	Ile	Ser	Ser	Ser	Gly	Val	Ile	Ala	Pro	Gly	Ala	Lys	Ala	Gly	Val	
		850					855					860				
aaa	ctg	gaa	gta	gcc	aac	atg	cag	gct	gaa	ctg	gtg	gca	aaa	ccc	tcc	2762
Lys	Leu	Glu	Val	Ala	Asn	Met	Gln	Ala	Glu	Leu	Val	Ala	Lys	Pro	Ser	
	865						870				875					
gtg	tct	gtg	gag	ttt	gtg	aca	aat	atg	ggc	atc	atc	att	ccg	gac	ttc	2810
Val	Ser	Val	Glu	Phe	Val	Thr	Asn	Met	Gly	Ile	Ile	Ile	Pro	Asp	Phe	
	880				885						890					
gct	agg	agt	ggg	gtc	cag	atg	aac	acc	aac	ttc	ttc	cac	gag	tcg	ggt	2858
Ala	Arg	Ser	Gly	Val	Gln	Met	Asn	Thr	Asn	Phe	Phe	His	Glu	Ser	Gly	
	895				900				905					910		
ctg	gag	gct	cat	gtt	gcc	cta	aaa	gct	ggg	aag	ctg	aag	ttt	atc	att	2906
Leu	Glu	Ala	His	Val	Ala	Leu	Lys	Ala	Gly	Lys	Leu	Lys	Phe	Ile	Ile	
			915						920					925		
cct	tcc	cca	aag	aga	cca	gtc	aag	ctg	ctc	agt	gga	ggc	aac	aca	tta	2954
Pro	Ser	Pro	Lys	Arg	Pro	Val	Lys	Leu	Leu	Ser	Gly	Gly	Asn	Thr	Leu	
		930					935						940			
cat	ttg	gtc	tct	acc	acc	aaa	acg	gag	gtg	atc	cca	cct	ctc	att	gag	3002
His	Leu	Val	Ser	Thr	Thr	Lys	Thr	Glu	Val	Ile	Pro	Pro	Leu	Ile	Glu	
	945					950						955				
aac	agg	cag	tcc	tgg	tca	gtt	tgc	aag	caa	gtc	ttt	cct	ggc	ctg	aat	3050
Asn	Arg	Gln	Ser	Trp	Ser	Val	Cys	Lys	Gln	Val	Phe	Pro	Gly	Leu	Asn	
	960				965					970						
tac	tgc	acc	tca	ggc	gct	tac	tcc	aac	gcc	agc	tcc	aca	gac	tcc	gcc	3098
Tyr	Cys	Thr	Ser	Gly	Ala	Tyr	Ser	Asn	Ala	Ser	Ser	Thr	Asp	Ser	Ala	
	975				980				985					990		
tcc	tac	tat	ccg	ctg	acc	ggg	gac	acc	aga	tta	gag	ctg	gaa	ctg	agg	3146
Ser	Tyr	Tyr	Pro	Leu	Thr	Gly	Asp	Thr	Arg	Leu	Glu	Leu	Glu	Leu	Arg	
			995					1000					1005			
cct	aca	gga	gag	att	gag	cag	tat	tct	gtc	agc	gca	acc	tat	gag	ctc	3194
Pro	Thr	Gly	Glu	Ile	Glu	Gln	Tyr	Ser	Val	Ser	Ala	Thr	Tyr	Glu	Leu	
		1010					1015					1020				
cag	aga	gag	gac	aga	gcc	ttg	gtg	gat	acc	ctg	aag	ttt	gta	act	caa	3242
Gln	Arg	Glu	Asp	Arg	Ala	Leu	Val	Asp	Thr	Leu	Lys	Phe	Val	Thr	Gln	
	1025					1030						1035				
gca	gaa	ggt	gcg	aag	cag	act	gag	gct	acc	atg	aca	ttc	aaa	tat	aat	3290
Ala	Glu	Gly	Ala	Lys	Gln	Thr	Glu	Ala	Thr	Met	Thr	Phe	Lys	Tyr	Asn	
	1040				1045				1050							
cgg	cag	agt	atg	acc	ttg	tcc	agt	gaa	gtc	caa	att	ccg	gat	ttt	gat	3338
Arg	Gln	Ser	Met	Thr	Leu	Ser	Ser	Glu	Val	Gln	Ile	Pro	Asp	Phe	Asp	
	1055				1060				1065					1070		
gtt	gac	ctc	gga	aca	atc	ctc	aga	gtt	aat	gat	gaa	tct	act	gag	ggc	3386
Val	Asp	Leu	Gly	Thr	Ile	Leu	Arg	Val	Asn	Asp	Glu	Ser	Thr	Glu	Gly	
			1075					1080					1085			
aaa	acg	tct	tac	aga	ctc	acc	ctg	gac	att	cag	aac	aag	aaa	att	act	3434
Lys	Thr	Ser	Tyr	Arg	Leu	Thr	Leu	Asp	Ile	Gln	Asn	Lys	Lys	Ile	Thr	
		1090					1095					1100				
gag	gtc	gcc	ctc	atg	ggc	cac	cta	agt	tgt	gac	aca	aag	gaa	gaa	aga	3482

Glu	Val	Ala	Leu	Met	Gly	His	Leu	Ser	Cys	Asp	Thr	Lys	Glu	Glu	Arg	
		1105					1110					1115				
aaa	atc	aag	ggt	gtt	att	tcc	ata	ccc	cgt	ttg	caa	gca	gaa	gcc	aga	3530
Lys	Ile	Lys	Gly	Val	Ile	Ser	Ile	Pro	Arg	Leu	Gln	Ala	Glu	Ala	Arg	
		1120				1125					1130					
agt	gag	atc	ctc	gcc	cac	tgg	tcg	cct	gcc	aaa	ctg	ctt	ctc	caa	atg	3578
Ser	Glu	Ile	Leu	Ala	His	Trp	Ser	Pro	Ala	Lys	Leu	Leu	Leu	Gln	Met	
		1135			1140				1145					1150		
gac	tca	tct	gct	aca	gct	tat	ggc	tcc	aca	gtt	tcc	aag	agg	gtg	gca	3626
Asp	Ser	Ser	Ala	Thr	Ala	Tyr	Gly	Ser	Thr	Val	Ser	Lys	Arg	Val	Ala	
				1155				1160						1165		
tgg	cat	tat	gat	gaa	gag	aag	att	gaa	ttt	gaa	tgg	aac	aca	ggc	acc	3674
Trp	His	Tyr	Asp	Glu	Glu	Lys	Ile	Glu	Phe	Glu	Trp	Asn	Thr	Gly	Thr	
			1170				1175						1180			
aat	gta	gat	acc	aaa	aaa	atg	act	tcc	aat	ttc	cct	gtg	gat	ctc	tcc	3722
Asn	Val	Asp	Thr	Lys	Lys	Met	Thr	Ser	Asn	Phe	Pro	Val	Asp	Leu	Ser	
		1185				1190					1195					
gat	tat	cct	aag	agc	ttg	cat	atg	tat	gct	aat	aga	ctc	ctg	gat	cac	3770
Asp	Tyr	Pro	Lys	Ser	Leu	His	Met	Tyr	Ala	Asn	Arg	Leu	Leu	Asp	His	
		1200				1205					1210					
aga	gtc	cct	gaa	aca	gac	atg	act	ttc	cgg	cac	gtg	ggt	tcc	aaa	tta	3818
Arg	Val	Pro	Glu	Thr	Asp	Met	Thr	Phe	Arg	His	Val	Gly	Ser	Lys	Leu	
		1215			1220				1225					1230		
ata	gtt	gca	atg	agc	tca	tgg	ctt	cag	aag	gca	tct	ggg	agt	ctt	cct	3866
Ile	Val	Ala	Met	Ser	Ser	Trp	Leu	Gln	Lys	Ala	Ser	Gly	Ser	Leu	Pro	
			1235					1240					1245			
tat	acc	cag	act	ttg	caa	gac	cac	ctc	aat	agc	ctg	aag	gag	ttc	aac	3914
Tyr	Thr	Gln	Thr	Leu	Gln	Asp	His	Leu	Asn	Ser	Leu	Lys	Glu	Phe	Asn	
			1250				1255						1260			
ctc	cag	aac	atg	gga	ttg	cca	gac	ttc	cac	atc	cca	gaa	aac	ctc	ttc	3962
Leu	Gln	Asn	Met	Gly	Leu	Pro	Asp	Phe	His	Ile	Pro	Glu	Asn	Leu	Phe	
		1265					1270					1275				
tta	aaa	agc	gat	ggc	cgg	gtc	aaa	tat	acc	ttg	aac	aag	aac	agt	ttg	4010
Leu	Lys	Ser	Asp	Gly	Arg	Val	Lys	Tyr	Thr	Leu	Asn	Lys	Asn	Ser	Leu	
		1280			1285					1290						
aaa	att	gag	att	cct	ttg	cct	ttt	ggt	ggc	aaa	tcc	tcc	aga	gat	cta	4058
Lys	Ile	Glu	Ile	Pro	Leu	Pro	Phe	Gly	Gly	Lys	Ser	Ser	Arg	Asp	Leu	
		1295			1300				1305					1310		
aag	atg	tta	gag	act	gtt	agg	aca	cca	gcc	ctc	cac	ttc	aag	tct	gtg	4106
Lys	Met	Leu	Glu	Thr</												

-continued

Asp Gly Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser	
1425 1430 1435	
cat gta gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata	4490
His Val Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile	
1440 1445 1450	
ttc gat gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat	4538
Phe Asp Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His	
1455 1460 1465 1470	
ttg gac tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att	4586
Leu Asp Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile	
1475 1480 1485	
gat ggg cag ttc aga gtc tct tcg ttc tat gct aaa ggc aca tat ggc	4634
Asp Gly Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly	
1490 1495 1500	
ctg tct tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc	4682
Leu Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser	
1505 1510 1515	
aac ctg agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca	4730
Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr	
1520 1525 1530	
gga aga tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg	4778
Gly Arg Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu	
1535 1540 1545 1550	
caa agt ggc atc att aaa aat act gct tcc cta aag tat gag aac tac	4826
Gln Ser Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr	
1555 1560 1565	
gag ctg act tta aaa tct gac acc aat ggg aag tat aag aac ttt gcc	4874
Glu Leu Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala	
1570 1575 1580	
act tct aac aag atg gat atg acc ttc tct aag caa aat gca ctg ctg	4922
Thr Ser Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu	
1585 1590 1595	
cgt tct gaa tat cag gct gat tac gag tca ttg agg ttc ttc agc ctg	4970
Arg Ser Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu	
1600 1605 1610	
ctt tct gga tca cta aat tcc cat ggt ctt gag tta aat gct gac atc	5018
Leu Ser Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile	
1615 1620 1625 1630	
tta ggc act gac aaa att aat agt ggt gct cac aag gcg aca cta agg	5066
Leu Gly Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg	
1635 1640 1645	
att ggc caa gat gga ata tct acc agt gca acg acc aac ttg aag tgt	5114
Ile Gly Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys	
1650 1655 1660	
agt ctc ctg gtg ctg gag aat gag ctg aat gca gag ctt ggc ctc tct	5162
Ser Leu Leu Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser	
1665 1670 1675	
ggg gca tct atg aaa tta aca aca aat ggc cgc ttc agg gaa cac aat	5210
Gly Ala Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn	
1680 1685 1690	
gca aaa ttc agt ctg gat ggg aaa gcc gcc ctc aca gag cta tca ctg	5258
Ala Lys Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu	
1695 1700 1705 1710	
gga agt gct tat cag gcc atg att ctg ggt gtc gac agc aaa aac att	5306
Gly Ser Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile	
1715 1720 1725	
ttc aac ttc aag gtc agt caa gaa gga ctt aag ctc tca aat gac atg	5354
Phe Asn Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met	
1730 1735 1740	
atg ggc tca tat gct gaa atg aaa ttt gac cac aca aac agt ctg aac	5402

-continued

Met	Gly	Ser	Tyr	Ala	Glu	Met	Lys	Phe	Asp	His	Thr	Asn	Ser	Leu	Asn	
		1745					1750					1755				
att	gca	ggc	tta	tca	ctg	gac	ttc	tct	tca	aaa	ctt	gac	aac	att	tac	5450
Ile	Ala	Gly	Leu	Ser	Leu	Asp	Phe	Ser	Ser	Lys	Leu	Asp	Asn	Ile	Tyr	
	1760					1765					1770					
agc	tct	gac	aag	ttt	tat	aag	caa	act	gtt	aat	tta	cag	cta	cag	ccc	5498
Ser	Ser	Asp	Lys	Phe	Tyr	Lys	Gln	Thr	Val	Asn	Leu	Gln	Leu	Gln	Pro	
1775					1780					1785					1790	
tat	tct	ctg	gta	act	act	tta	aac	agt	gac	ctg	aaa	tac	aat	gct	ctg	5546
Tyr	Ser	Leu	Val	Thr	Thr	Leu	Asn	Ser	Asp	Leu	Lys	Tyr	Asn	Ala	Leu	
				1795					1800					1805		
gat	ctc	acc	aac	aat	ggg	aaa	cta	cgg	cta	gaa	ccc	ctg	aag	ctg	cat	5594
Asp	Leu	Thr	Asn	Asn	Gly	Lys	Leu	Arg	Leu	Glu	Pro	Leu	Lys	Leu	His	
		1810						1815					1820			
gtg	gct	ggt	aac	cta	aaa	gga	gcc	tac	caa	aat	aat	gaa	ata	aaa	cac	5642
Val	Ala	Gly	Asn	Leu	Lys	Gly	Ala	Tyr	Gln	Asn	Asn	Glu	Ile	Lys	His	
		1825					1830					1835				
atc	tat	gcc	atc	tct	tct	gct	gcc	tta	tca	gca	agc	tat	aaa	gca	gac	5690
Ile	Tyr	Ala	Ile	Ser	Ser	Ala	Ala	Leu	Ser	Ala	Ser	Tyr	Lys	Ala	Asp	
		1840				1845						1850				
act	gtt	gct	aag	gtt	cag	ggt	gtg	gag	ttt	agc	cat	cgg	ctc	aac	aca	5738
Thr	Val	Ala	Lys	Val	Gln	Gly	Val	Glu	Phe	Ser	His	Arg	Leu	Asn	Thr	
	1855				1860					1865					1870	
gac	atc	gct	ggg	ctg	gct	tca	gcc	att	gac	atg	agc	aca	aac	tat	aat	5786
Asp	Ile	Ala	Gly	Leu	Ala	Ser	Ala	Ile	Asp	Met	Ser	Thr	Asn	Tyr	Asn	
			1875						1880					1885		
tca	gac	tca	ctg	cat	ttc	agc	aat	gtc	ttc	cgt	tct	gta	atg	gcc	ccg	5834
Ser	Asp	Ser	Leu	His	Phe	Ser	Asn	Val	Phe	Arg	Ser	Val	Met	Ala	Pro	
			1890					1895					1900			
ttt	acc	atg	acc	atc	gat	gca	cat	aca	aat	ggc	aat	ggg	aaa	ctc	gct	5882
Phe	Thr	Met	Thr	Ile	Asp	Ala	His	Thr	Asn	Gly	Asn	Gly	Lys	Leu	Ala	
		1905					1910						1915			
ctc	tgg	gga	gaa	cat	act	ggg	cag	ctg	tat	agc	aaa	ttc	ctg	ttg	aaa	5930
Leu	Trp	Gly	Glu	His	Thr	Gly	Gln	Leu	Tyr	Ser	Lys	Phe	Leu	Leu	Lys	
	1920					1925						1930				
gca	gaa	cct	ctg	gca	ttt	act	ttc	tct	cat	tac	aaa	ggc	tcc	aca		5978
Ala	Glu	Pro	Leu	Ala	Phe	Thr	Phe	Ser	His	Asp	Tyr	Lys	Gly	Ser	Thr	
	1935				1940					1945				1950		
agt	cat	cat	ctc	gtg	tct	agg	aaa	agc	atc	agt	gca	gct	ctt	gaa	cac	6026
Ser	His	His	Leu	Val	Ser	Arg	Lys	Ser	Ile	Ser	Ala	Ala	Leu	Glu	His	
			1955						1960					1965		
aaa	gtc	agt	gcc	ctg	ctt	act	cca	gct	gag	cag	aca	ggc	acc	tgg	aaa	6074
Lys	Val	Ser	Ala	Leu	Leu	Thr	Pro	Ala	Glu	Gln	Thr	Gly	Thr	Trp	Lys	
		1970						1975					1980			
ctc	aag	acc	caa	ttt	aac	aac	aat	gaa	tac	agc	cag	gac	ttg	gat	gct	6122
Leu	Lys	Thr	Gln	Phe	Asn	Asn	Asn	Glu	Tyr	Ser	Gln	Asp	Leu	Asp	Ala	
		1985					1990					1995				
tac	aac	act	aaa	gat	aaa	att	ggc	gtg	gag	ctt	act	gga	cga	act	ctg	6170
Tyr	Asn	Thr	Lys	Asp	Lys	Ile	Gly	Val	Glu	Leu	Thr	Gly	Arg	Thr	Leu	
	2000					2005					2010					
gct	gac	cta	act	cta	cta	gac	tcc	cca	att	aaa	gtg	cca	ctt	tta	ctc	6218
Ala	Asp	Leu	Thr	Leu	Leu	Asp	Ser	Pro	Ile	Lys	Val	Pro	Leu	Leu	Leu	
	2015				2020						2025				2030	
agt	gag	ccc	atc	aat	atc	att	gat	gct	tta	gag	atg	aga	gat	gcc	gtt	6266
Ser	Glu	Pro	Ile	Asn	Ile	Ile	Asp	Ala	Leu	Glu	Met	Arg	Asp	Ala	Val	
			2035						2040					2045		
gag	aag	ccc	caa	gaa	ttt	aca	att	gtt	gct	ttt	gta	aag	tat	gat	aaa	6314
Glu	Lys	Pro	Gln	Glu	Phe	Thr	Ile	Val	Ala	Phe	Val	Lys	Tyr	Asp	Lys	
		2050						2055					2060			
aac	caa	gat	gtt	cac	tcc	att	aac	ctc	cca	ttt	ttt	gag	acc	ttg	caa	6362

-continued

Asn	Gln	Asp	Val	His	Ser	Ile	Asn	Leu	Pro	Phe	Phe	Glu	Thr	Leu	Gln	
		2065					2070					2075				
gaa	tat	ttt	gag	agg	aat	cga	caa	acc	att	ata	gtt	gta	gtg	gaa	aac	6410
Glu	Tyr	Phe	Glu	Arg	Asn	Arg	Gln	Thr	Ile	Ile	Val	Val	Val	Glu	Asn	
	2080					2085					2090					
gta	cag	aga	aac	ctg	aag	cac	atc	aat	att	gat	caa	ttt	gta	aga	aaa	6458
Val	Gln	Arg	Asn	Leu	Lys	His	Ile	Asn	Ile	Asp	Gln	Phe	Val	Arg	Lys	
2095					2100					2105					2110	
tac	aga	gca	gcc	ctg	gga	aaa	ctc	cca	cag	caa	gct	aat	gat	tat	ctg	6506
Tyr	Arg	Ala	Ala	Leu	Gly	Lys	Leu	Pro	Gln	Gln	Ala	Asn	Asp	Tyr	Leu	
				2115					2120					2125		
aat	tca	ttc	aat	tggt	gag	aga	caa	gtt	tca	cat	gcc	aag	gag	aaa	ctg	6554
Asn	Ser	Phe	Asn	Trp	Glu	Arg	Gln	Val	Ser	His	Ala	Lys	Glu	Lys	Leu	
		2130					2135						2140			
act	gct	ctc	aca	aaa	aag	tat	aga	att	aca	gaa	aat	gat	ata	caa	att	6602
Thr	Ala	Leu	Thr	Lys	Lys	Tyr	Arg	Ile	Thr	Glu	Asn	Asp	Ile	Gln	Ile	
		2145					2150						2155			
gca	tta	gat	gat	gcc	aaa	atc	aac	ttt	aat	gaa	aaa	cta	tct	caa	ctg	6650
Ala	Leu	Asp	Asp	Ala	Lys	Ile	Asn	Phe	Asn	Glu	Lys	Leu	Ser	Gln	Leu	
	2160					2165						2170				
cag	aca	tat	atg	ata	caa	ttt	gat	cag	tat	att	aaa	gat	agt	tat	gat	6698
Gln	Thr	Tyr	Met	Ile	Gln	Phe	Asp	Gln	Tyr	Ile	Lys	Asp	Ser	Tyr	Asp	
2175					2180					2185					2190	
tta	cat	gat	ttg	aaa	ata	gct	att	gct	aat	att	att	gat	gaa	atc	att	6746
Leu	His	Asp	Leu	Lys	Ile	Ala	Ile	Ala	Asn	Ile	Ile	Asp	Glu	Ile	Ile	
				2195					2200					2205		
gaa	aaa	tta	aaa	agt	ctt	gat	gag	cac	tat	cat	atc	cgt	gta	aat	tta	6794
Glu	Lys	Leu	Lys	Ser	Leu	Asp	Glu	His	Tyr	His	Ile	Arg	Val	Asn	Leu	
		2210						2215					2220			
gta	aaa	aca	atc	cat	gat	cta	cat	ttg	ttt	att	gaa	aat	att	gat	ttt	6842
Val	Lys	Thr	Ile	His	Asp	Leu	His	Leu	Phe	Ile	Glu	Asn	Ile	Asp	Phe	
		2225					2230						2235			
aac	aaa	agt	gga	agt	agt	act	gca	tcc	tggt	att	caa	aat	gtg	gat	act	6890
Asn	Lys	Ser	Gly	Ser	Ser	Thr	Ala	Ser	Trp	Ile	Gln	Asn	Val	Asp	Thr	
	2240					2245						2250				
aag	tac	caa	atc	aga	atc	cag	ata	caa	gaa	aaa	ctg	cag	cag	ctt	aag	6938
Lys	Tyr	Gln	Ile	Arg	Ile	Gln	Ile	Gln	Glu	Lys	Leu	Gln	Gln	Leu	Lys	
	2255					2260				2265					2270	
aga	cac	ata	cag	aat	ata	gac	atc	cag	cac	cta	gct	gga	aag	tta	aaa	6986
Arg	His	Ile	Gln	Asn	Ile	Asp	Ile	Gln	His	Leu	Ala	Gly	Lys	Leu	Lys	
			2275					2280					2285			
caa	cac	att	gag	gct	att	gat	gtt	aga	gtg	ctt	tta	gat	caa	ttg	gga	7034
Gln	His	Ile	Glu	Ala	Ile	Asp	Val	Arg	Val	Leu	Leu	Asp	Gln	Leu	Gly	
		2290						2295					2300			
act	aca	att	tca	ttt	gaa	aga	ata	aat	gat	gtt	ctt	gag	cat	gtc	aaa	7082
Thr	Thr	Ile	Ser	Phe	Glu	Arg	Ile	Asn	Asp	Val	Leu	Glu	His	Val	Lys	
		2305					2310						2315			
cac	ttt	gtt	ata	aat	ctt	att	ggg	gat	ttt	gaa	gta	gct	gag	aaa	atc	7130
His	Phe	Val	Ile	Asn	Leu	Ile	Gly	Asp	Phe	Glu	Val	Ala	Glu	Lys	Ile	
	2320					2325					2330					
aat	gcc	ttc	aga	gcc	aaa	gtc	cat	gag	tta	atc	gag	agg	tat	gaa	gta	7178
Asn	Ala	Phe	Arg	Ala	Lys	Val	His	Glu	Leu	Ile	Glu	Arg	Tyr	Glu	Val	
	2335				2340					2345					2350	
gac	caa	caa	atc	cag	gtt	tta	atg	gat	aaa	tta	gta	gag	ttg	acc	cac	7226
Asp	Gln	Gln	Ile	Gln	Val	Leu	Met	Asp	Lys	Leu	Val	Glu	Leu	Thr	His	
			2355					2360					2365			
caa	tac	aag	ttg	aag	gag	act	att	cag	aag	cta	agc	aat	gtc	cta	caa	7274
Gln	Tyr	Lys	Leu	Lys	Glu	Thr	Ile	Gln	Lys	Leu	Ser	Asn	Val	Leu	Gln	
		2370						2375					2380			
caa	gtt	aag	ata	aaa	gat	tac	ttt	gag	aaa	ttg	gtt	gga	ttt	att	gat	7322

-continued

Gln	Val	Lys	Ile	Lys	Asp	Tyr	Phe	Glu	Lys	Leu	Val	Gly	Phe	Ile	Asp	
	2385						2390					2395				
gat	gct	gtg	aag	aag	ctt	aat	gaa	tta	tct	ttt	aaa	aca	ttc	att	gaa	7370
Asp	Ala	Val	Lys	Lys	Leu	Asn	Glu	Leu	Ser	Phe	Lys	Thr	Phe	Ile	Glu	
	2400						2405					2410				
gat	gtt	aac	aaa	ttc	ctt	gac	atg	ttg	ata	aag	aaa	tta	aag	tca	ttt	7418
Asp	Val	Asn	Lys	Phe	Leu	Asp	Met	Leu	Ile	Lys	Lys	Leu	Lys	Ser	Phe	
	2415						2420					2425			2430	
gat	tac	cac	cag	ttt	gta	gat	gaa	acc	aat	gac	aaa	atc	cgt	gag	gtg	7466
Asp	Tyr	His			Phe	Val	Asp	Glu	Thr	Asn	Asp	Lys	Ile	Arg	Glu	Val
							2435					2440			2445	
act	cag	aga	ctc	aat	ggg	gaa	att	cag	gct	ctg	gaa	cta	cca	caa	aaa	7514
Thr	Gln	Arg	Leu	Asn	Gly	Glu	Ile	Gln	Ala	Leu	Glu	Leu	Pro	Gln	Lys	
							2450								2460	
gct	gaa	gca	tta	aaa	ctg	ttt	tta	gag	gaa	acc	aag	gcc	aca	gtt	gca	7562
Ala	Glu	Ala	Leu	Lys	Leu	Phe	Leu	Glu	Glu	Thr	Lys	Ala	Thr	Val	Ala	
							2465								2475	
gtg	tat	ctg	gaa	agc	cta	cag	gac	acc	aaa	ata	acc	tta	atc	atc	aat	7610
Val	Tyr	Leu	Glu	Ser	Leu	Gln	Asp	Thr	Lys	Ile	Thr	Leu	Ile	Ile	Asn	
							2480								2490	
tgg	tta	cag	gag	gct	tta	agt	tca	gca	tct	ttg	gct	cac	atg	aag	gcc	7658
Trp	Leu	Gln	Glu	Ala	Leu	Ser	Ser	Ala	Ser	Leu	Ala	His	Met	Lys	Ala	
							2495								2510	
aaa	ttc	cga	gag	act	cta	gaa	gat	aca	cga	gac	cga	atg	tat	caa	atg	7706
Lys	Phe	Arg	Glu	Thr	Leu	Glu	Asp	Thr	Arg	Asp	Arg	Met	Tyr	Gln	Met	
							2515								2525	
gac	att	cag	cag	gaa	ctt	caa	cga	tac	ctg	tct	ctg	gta	ggc	cag	gtt	7754
Asp	Ile	Gln	Gln	Glu	Leu	Gln	Arg	Tyr	Leu	Ser	Leu	Val	Gly	Gln	Val	
							2530								2540	
tat	agc	aca	ctt	gtc	acc	tac	att	tct	gat	tgg	tgg	act	ctt	gct	gct	7802
Tyr	Ser	Thr	Leu	Val	Thr	Tyr	Ile	Ser	Asp	Trp	Trp	Thr	Leu	Ala	Ala	
							2545								2555	
aag	aac	ctt	act	gac	ttt	gca	gag	caa	tat	tct	atc	caa	gat	tgg	gct	7850
Lys	Asn	Leu	Thr	Asp	Phe	Ala	Glu	Gln	Tyr	Ser	Ile	Gln	Asp	Trp	Ala	
							2560								2570	
aaa	cgt	atg	aaa	gca	ttg	gta	gag	caa	ggg	ttc	act	ggt	cct	gaa	atc	7898
Lys	Arg	Met	Lys	Ala	Leu	Val	Glu	Gln	Gly	Phe	Thr	Val	Pro	Glu	Ile	
							2575								2590	
aag	acc	atc	ctt	ggg	acc	atg	cct	gcc	ttt	gaa	gtc	agt	ctt	cag	gct	7946
Lys	Thr	Ile	Leu	Gly	Thr	Met	Pro	Ala	Phe	Glu	Val	Ser	Leu	Gln	Ala	
							2595								2605	
ctt	cag	aaa	gct	acc	ttc	cag	aca	cct	gat	ttt	ata	gtc	ccc	cta	aca	7994
Leu	Gln	Lys	Ala	Thr	Phe	Gln	Thr	Pro	Asp	Phe	Ile	Val	Pro	Leu	Thr	
							2610								2620	
gat	ttg	agg	att	cca	tca	ggt	cag	ata	aac	ttc	aaa	gac	tta	aaa	aat	8042
Asp	Leu	Arg	Ile	Pro	Ser	Val	Gln	Ile	Asn	Phe	Lys	Asp	Leu	Lys	Asn	
							2625								2635	
ata	aaa	atc	cca	tcc	agg	ttt	tcc	aca	cca	gaa	ttt	acc	atc	ctt	aac	8090
Ile	Lys	Ile	Pro	Ser	Arg	Phe	Ser	Thr	Pro	Glu	Phe	Thr	Ile	Leu	Asn	
							2640								2650	
acc	ttc	cac	att	cct	tcc	ttt	aca	att	gac	ttt	gtc	gaa	atg	aaa	gta	8138
Thr	Phe	His	Ile	Pro	Ser	Phe	Thr	Ile	Asp	Phe	Val	Glu	Met	Lys	Val	
							2655								2670	
aag	atc	atc	aga	acc	att	gac	cag	atg	cag	aac	agt	gag	ctg	cag	tgg	8186
Lys	Ile	Ile	Arg	Thr	Ile	Asp	Gln	Met	Gln	Asn	Ser	Glu	Leu	Gln	Trp	
							2675								2685	
ccc	gtt	cca	gat	ata	tat	ctc	agg	gat	ctg	aag	gtg	gag	gac	att	cct	8234
Pro	Val	Pro	Asp	Ile	Tyr	Leu	Arg	Asp	Leu	Lys	Val	Glu	Asp	Ile	Pro	
							2690								2700	
cta	gcg	aga	atc	acc	ctg	cca	gac	ttc	cgt	tta	cca	gaa	atc	gca	att	8282

-continued

Leu	Ala	Arg	Ile	Thr	Leu	Pro	Asp	Phe	Arg	Leu	Pro	Glu	Ile	Ala	Ile		
	2705						2710					2715					
cca	gaa	ttc	ata	atc	cca	act	ctc	aac	ctt	aat	gat	ttt	caa	gtt	cct	8330	
Pro	Glu	Phe	Ile	Ile	Pro	Thr	Leu	Asn	Leu	Asn	Asp	Phe	Gln	Val	Pro		
	2720						2725					2730					
gac	ctt	cac	ata	cca	gaa	ttc	cag	ctt	ccc	cac	atc	tca	cac	aca	att	8378	
Asp	Leu	His	Ile	Pro	Glu	Phe	Gln	Leu	Pro	His	Ile	Ser	His	Thr	Ile		
	2735						2740					2745			2750		
gaa	gta	cct	act	ttt	ggc	aag	cta	tac	agt	att	ctg	aaa	atc	caa	tct	8426	
Glu	Val	Pro	Thr	Phe	Gly	Lys	Leu	Tyr	Ser	Ile	Leu	Lys	Ile	Gln	Ser		
							2755				2760				2765		
cct	ctt	ttc	aca	tta	gat	gca	aat	gct	gac	ata	ggg	aat	gga	acc	acc	8474	
Pro	Leu	Phe	Thr	Leu	Asp	Ala	Asn	Ala	Asp	Ile	Gly	Asn	Gly	Thr	Thr		
							2770					2775			2780		
tca	gca	aac	gaa	gca	ggg	atc	gca	gct	tcc	atc	act	gcc	aaa	gga	gag	8522	
Ser	Ala	Asn	Glu	Ala	Gly	Ile	Ala	Ala	Ser	Ile	Thr	Ala	Lys	Gly	Glu		
							2785					2790			2795		
tcc	aaa	tta	gaa	gtt	ctc	aat	ttt	gat	ttt	caa	gca	aat	gca	caa	ctc	8570	
Ser	Lys	Leu	Glu	Val	Leu	Asn	Phe	Asp	Phe	Gln	Ala	Asn	Ala	Gln	Leu		
							2800					2805			2810		
tca	aac	cct	aag	att	aat	ccg	ctg	gct	ctg	aag	gag	tca	gtg	aag	ttc	8618	
Ser	Asn	Pro	Lys	Ile	Asn	Pro	Leu	Ala	Leu	Lys	Glu	Ser	Val	Lys	Phe		
							2815					2820			2825		2830
tcc	agc	aag	tac	ctg	aga	acg	gag	cat	ggg	agt	gaa	atg	ctg	ttt	ttt	8666	
Ser	Ser	Lys	Tyr	Leu	Arg	Thr	Glu	His	Gly	Ser	Glu	Met	Leu	Phe	Phe		
							2835					2840			2845		
gga	aat	gct	att	gag	gga	aaa	tca	aac	aca	gtg	gca	agt	tta	cac	aca	8714	
Gly	Asn	Ala	Ile	Glu	Gly	Lys	Ser	Asn	Thr	Val	Ala	Ser	Leu	His	Thr		
							2850					2855			2860		
gaa	aaa	aat	aca	ctg	gag	ctt	agt	aat	gga	gtg	att	gtc	aag	ata	aac	8762	
Glu	Lys	Asn	Thr	Leu	Glu	Leu	Ser	Asn	Gly	Val	Ile	Val	Lys	Ile	Asn		
							2865					2870			2875		
aat	cag	ctt	acc	ctg	gat	agc	aac	act	aaa	tac	ttc	cac	aaa	ttg	aac	8810	
Asn	Gln	Leu	Thr	Leu	Asp	Ser	Asn	Thr	Lys	Tyr	Phe	His	Lys	Leu	Asn		
							2880					2885			2890		
atc	ccc	aaa	ctg	gac	ttc	tct	agt	cag	gct	gac	ctg	cgc	aac	gag	atc	8858	
Ile	Pro	Lys	Leu	Asp	Phe	Ser	Ser	Gln	Ala	Asp	Leu	Arg	Asn	Glu	Ile		
							2895					2900			2905		2910
aag	aca	ctg	ttg	aaa	gct	ggc	cac	ata	gca	tgg	act	tct	tct	gga	aaa	8906	
Lys	Thr	Leu	Leu	Lys	Ala	Gly	His	Ile	Ala	Trp	Thr	Ser	Ser	Gly	Lys		
							2915					2920			2925		
ggg	tca	tgg	aaa	tgg	gcc	tgc	ccc	aga	ttc	tca	gat	gag	gga	aca	cat	8954	
Gly	Ser	Trp	Lys	Trp	Ala	Cys	Pro	Arg	Phe	Ser	Asp	Glu	Gly	Thr	His		
							2930					2935			2940		
gaa	tca	caa	att	agt	ttc	acc	ata	gaa	gga	ccc	ctc	act	tcc	ttt	gga	9002	
Glu	Ser	Gln	Ile	Ser	Phe	Thr	Ile	Glu	Gly	Pro	Leu	Thr	Ser	Phe	Gly		
							2945					2950			2955		
ctg	tcc	aat	aag	atc	aat	agc	aaa	cac	cta	aga	gta	aac	caa	aac	ttg	9050	
Leu	Ser	Asn	Lys	Ile	Asn	Ser	Lys	His	Leu	Arg	Val	Asn	Gln	Asn	Leu		
							2960					2965			2970		
gtt	tat	gaa	tct	ggc	tcc	ctc	aac	ttt	tct	aaa	ctt	gaa	att	caa	tca	9098	
Val	Tyr	Glu	Ser	Gly	Ser	Leu	Asn	Phe	Ser	Lys	Leu	Glu	Ile	Gln	Ser		
							2975					2980			2985		2990
caa	gtc	gat	tcc	cag	cat	gtg	ggc	cac	agt	gtt	cta	act	gct	aaa	ggc	9146	
Gln	Val	Asp	Ser	Gln	His	Val	Gly	His	Ser	Val	Leu	Thr	Ala	Lys	Gly		
							2995					3000			3005		
atg	gca	ctg	ttt	gga	gaa	ggg	aag	gca	gag	ttt	act	ggg	agg	cat	gat	9194	
Met	Ala	Leu	Phe	Gly	Glu	Gly	Lys	Ala	Glu	Phe	Thr	Gly	Arg	His	Asp		
							3010					3015			3020		
gct	cat	tta	aat	gga	aag	gtt	att	gga	act	ttg	aaa	aat	tct	ctt	ttc	9242	

-continued

Ala His Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe	
3025 3030 3035	
ttt tca gcc cag cca ttt gag atc acg gca tcc aca aac aat gaa ggg	9290
Phe Ser Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly	
3040 3045 3050	
aat ttg aaa gtt cgt ttt cca tta agg tta aca ggg aag ata gac ttc	9338
Asn Leu Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe	
3055 3060 3065 3070	
ctg aat aac tat gca ctg ttt ctg agt ccc agt gcc cag caa gca agt	9386
Leu Asn Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser	
3075 3080 3085	
tggt caa gta agt gct agg ttc aat cag tat aag tac aac caa aat ttc	9434
Trp Gln Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe	
3090 3095 3100	
tct gct gga aac aac gag aac att atg gag gcc cat gta gga ata aat	9482
Ser Ala Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn	
3105 3110 3115	
gga gaa gca aat ctg gat ttc tta aac att cct tta aca att cct gaa	9530
Gly Glu Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu	
3120 3125 3130	
atg cgt cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc	9578
Met Arg Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe	
3135 3140 3145 3150	
tct cta tgg gaa aaa aca ggc ttg aag gaa ttc ttg aaa acg aca aag	9626
Ser Leu Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys	
3155 3160 3165	
caa tca ttt gat tta agt gta aaa gct cag tat aag aaa aac aaa cac	9674
Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His	
3170 3175 3180	
agg cat tcc atc aca aat cct ttg gct gtg ctt tgt gag ttt atc agt	9722
Arg His Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser	
3185 3190 3195	
cag agc atc aaa tcc ttt gac agg cat ttt gaa aaa aac aga aac aat	9770
Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn	
3200 3205 3210	
gca tta gat ttt gtc acc aaa tcc tat aat gaa aca aaa att aag ttt	9818
Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe	
3215 3220 3225 3230	
gat aag tac aaa gct gaa aaa tct cac gac gag ctc ccc agg acc ttt	9866
Asp Lys Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe	
3235 3240 3245	
caa att cct gga tac act gtt cca gtt gtc aat gtt gaa gtg tct cca	9914
Gln Ile Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro	
3250 3255 3260	
ttc acc ata gag atg tcg gca ttc ggc tat gtg ttc cca aaa gca gtc	9962
Phe Thr Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val	
3265 3270 3275	
agc atg cct agt ttc tcc atc cta ggt tct gac gtc cgt gtg cct tca	10010
Ser Met Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro Ser	
3280 3285 3290	
tac aca tta atc ctg cca tca tta gag ctg cca gtc ctt cat gtc cct	10058
Tyr Thr Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro	
3295 3300 3305 3310	
aga aat ctc aag ctt tct ctt cca cat ttc aag gaa ttg tgt acc ata	10106
Arg Asn Leu Lys Leu Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile	
3315 3320 3325	
agc cat att ttt att cct gcc atg ggc aat att acc tat gat ttc tcc	10154
Ser His Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser	
3330 3335 3340	
ttt aaa tca agt gtc atc aca ctg aat acc aat gct gaa ctt ttt aac	10202

-continued

Phe	Lys	Ser	Ser	Val	Ile	Thr	Leu	Asn	Thr	Asn	Ala	Glu	Leu	Phe	Asn	
	3345						3350					3355				
cag	tca	gat	att	gtt	gct	cat	ctc	ctt	tct	tca	tct	tca	tct	gtc	att	10250
Gln	Ser	Asp	Ile	Val	Ala	His	Leu	Leu	Ser	Ser	Ser	Ser	Ser	Val	Ile	
	3360						3365				3370					
gat	gca	ctg	cag	tac	aaa	tta	gag	ggc	acc	aca	aga	ttg	aca	aga	aaa	10298
Asp	Ala	Leu	Gln	Tyr	Lys	Leu	Glu	Gly	Thr	Thr	Arg	Leu	Thr	Arg	Lys	
	3375					3380				3385					3390	
agg	gga	ttg	aag	tta	gcc	aca	gct	ctg	tct	ctg	agc	aac	aaa	ttt	gtg	10346
Arg	Gly	Leu	Lys	Leu	Ala	Thr	Ala	Leu	Ser	Leu	Ser	Asn	Lys	Phe	Val	
				3395					3400					3405		
gag	ggt	agt	cat	aac	agt	act	gtg	agc	tta	acc	acg	aaa	aat	atg	gaa	10394
Glu	Gly	Ser	His	Asn	Ser	Thr	Val	Ser	Leu	Thr	Thr	Lys	Asn	Met	Glu	
			3410					3415					3420			
gtg	tca	gtg	gca	aaa	acc	aca	aaa	gcc	gaa	att	cca	att	ttg	aga	atg	10442
Val	Ser	Val	Ala	Lys	Thr	Thr	Lys	Ala	Glu	Ile	Pro	Ile	Leu	Arg	Met	
			3425				3430					3435				
aat	ttc	aag	caa	gaa	ctt	aat	gga	aat	acc	aag	tca	aaa	cct	act	gtc	10490
Asn	Phe	Lys	Gln	Glu	Leu	Asn	Gly	Asn	Thr	Lys	Ser	Lys	Pro	Thr	Val	
	3440					3445					3450					
tct	tcc	tcc	atg	gaa	ttt	aag	tat	gat	ttc	aat	tct	tca	atg	ctg	tac	10538
Ser	Ser	Ser	Met	Glu	Phe	Lys	Tyr	Asp	Phe	Asn	Ser	Ser	Met	Leu	Tyr	
	3455				3460				3465						3470	
tct	acc	gct	aaa	gga	gca	gtt	gac	cac	aag	ctt	agc	ttg	gaa	agc	ctc	10586
Ser	Thr	Ala	Lys	Gly	Ala	Val	Asp	His	Lys	Leu	Ser	Leu	Glu	Ser	Leu	
			3475						3480					3485		
acc	tct	tac	ttt	tcc	att	gag	tca	tct	acc	aaa	gga	gat	gtc	aag	ggg	10634
Thr	Ser	Tyr	Phe	Ser	Ile	Glu	Ser	Ser	Thr	Lys	Gly	Asp	Val	Lys	Gly	
			3490					3495					3500			
tcg	gtt	ctt	tct	cgg	gaa	tat	tca	gga	act	att	gct	agt	gag	gcc	aac	10682
Ser	Val	Leu	Ser	Arg	Glu	Tyr	Ser	Gly	Thr	Ile	Ala	Ser	Glu	Ala	Asn	
		3505					3510					3515				
act	tac	ttg	aat	tcc	aag	agc	aca	cgg	tct	tca	gtg	aag	ctg	cag	ggc	10730
Thr	Tyr	Leu	Asn	Ser	Lys	Ser	Thr	Arg	Ser	Ser	Val	Lys	Leu	Gln	Gly	
	3520					3525					3530					
act	tcc	aaa	att	gat	gat	atc	tgg	aac	ctt	gaa	gta	aaa	gaa	aat	ttt	10778
Thr	Ser	Lys	Ile	Asp	Asp	Ile	Trp	Asn	Leu	Glu	Val	Lys	Glu	Asn	Phe	
	3535				3540				3545					3550		
gct	gga	gaa	gcc	aca	ctc	caa	cgc	ata	tat	tcc	ctc	tgg	gag	cac	agt	10826
Ala	Gly	Glu	Ala	Thr	Leu	Gln	Arg	Ile	Tyr	Ser	Leu	Trp	Glu	His	Ser	
			3555					3560						3565		
acg	aaa	aac	cac	tta	cag	cta	gag	ggc	ctc	ttt	ttc	acc	aac	gga	gaa	10874
Thr	Lys	Asn	His	Leu	Gln	Leu	Glu	Gly	Leu	Phe	Phe	Thr	Asn	Gly	Glu	
			3570					3575				3580				
cat	aca	agc	aaa	gcc	acc	ctg	gaa	ctc	tct	cca	tgg	caa	atg	tca	gct	10922
His	Thr	Ser	Lys	Ala	Thr	Leu	Glu	Leu	Ser	Pro	Trp	Gln	Met	Ser	Ala	
		3585					3590					3595				
ctt	gtt	cag	gtc	cat	gca	agt	cag	ccc	agt	tcc	ttc	cat	gat	ttc	cct	10970
Leu	Val	Gln	Val	His	Ala	Ser	Gln	Pro	Ser	Ser	Phe	His	Asp	Phe	Pro	
	3600					3605					3610					
gac	ctt	ggc	cag	gaa	gtg	gcc	ctg	aat	gct	aac	act	aag	aac	cag	aag	11018
Asp	Leu	Gly	Gln	Glu	Val	Ala	Leu	Asn	Ala	Asn	Thr	Lys	Asn	Gln	Lys	
	3615				3620				3625					3630		
atc	aga	tgg	aaa	aat	gaa	gtc	cgg	att	cat	tct	ggg	tct	ttc	cag	agc	11066
Ile	Arg	Trp	Lys	Asn	Glu	Val	Arg	Ile	His	Ser	Gly	Ser	Phe	Gln	Ser	
			3635					3640					3645			
cag	gtc	gag	ctt	tcc	aat	gac	caa	gaa	aag	gca	cac	ctt	gac	att	gca	11114
Gln	Val	Glu	Leu	Ser	Asn	Asp	Gln	Glu	Lys	Ala	His	Leu	Asp	Ile	Ala	
			3650				3655					3660				
gga	tcc	tta	gaa	gga	cac	cta	agg	ttc	ctc	aaa	aat	atc	atc	cta	cca	11162

-continued

Gly	Ser	Leu	Glu	Gly	His	Leu	Arg	Phe	Leu	Lys	Asn	Ile	Ile	Leu	Pro	
		3665					3670					3675				
gtc	tat	gac	aag	agc	tta	tg	gat	ttc	cta	aag	ctg	gat	gta	acc	acc	11210
Val	Tyr	Asp	Lys	Ser	Leu	Trp	Asp	Phe	Leu	Lys	Leu	Asp	Val	Thr	Thr	
		3680					3685					3690				
agc	att	ggt	agg	aga	cag	cat	ctt	cgt	gtt	tca	act	gcc	ttt	gtg	tac	11258
Ser	Ile	Gly	Arg	Arg	Gln	His	Leu	Arg	Val	Ser	Thr	Ala	Phe	Val	Tyr	
		3695					3700					3705			3710	
acc	aaa	aac	ccc	aat	ggc	tat	tca	ttc	tcc	atc	cct	gta	aaa	gtt	ttg	11306
Thr	Lys	Asn	Pro	Asn	Gly	Tyr	Ser	Phe	Ser	Ile	Pro	Val	Lys	Val	Leu	
					3715					3720					3725	
gct	gat	aaa	ttc	att	act	cct	ggg	ctg	aaa	cta	aat	gat	cta	aat	tca	11354
Ala	Asp	Lys	Phe	Ile	Thr	Pro	Gly	Leu	Lys	Leu	Asn	Asp	Leu	Asn	Ser	
			3730						3735						3740	
gtt	ctt	gtc	atg	cct	acg	ttc	cat	gtc	cca	ttt	aca	gat	ctt	cag	gtt	11402
Val	Leu	Val	Met	Pro	Thr	Phe	His	Val	Pro	Phe	Thr	Asp	Leu	Gln	Val	
			3745					3750							3755	
cca	tcg	tgc	aaa	ctt	gac	ttc	aga	gaa	ata	caa	atc	tat	aag	aag	ctg	11450
Pro	Ser	Cys	Lys	Leu	Asp	Phe	Arg	Glu	Ile	Gln	Ile	Tyr	Lys	Lys	Leu	
			3760				3765								3770	
aga	act	tca	tca	ttt	gcc	ctc	aac	cta	cca	aca	ctc	ccc	gag	gta	aaa	11498
Arg	Thr	Ser	Ser	Phe	Ala	Leu	Asn	Leu	Pro	Thr	Leu	Pro	Glu	Val	Lys	
					3775		3780				3785				3790	
ttc	cct	gaa	gtt	gat	gtg	tta	aca	aaa	tat	tct	caa	cca	gaa	gac	tcc	11546
Phe	Pro	Glu	Val	Asp	Val	Leu	Thr	Lys	Tyr	Ser	Gln	Pro	Glu	Asp	Ser	
					3795					3800					3805	
ttg	att	ccc	ttt	ttt	gag	ata	acc	gtg	cct	gaa	tct	cag	tta	act	gtg	11594
Leu	Ile	Pro	Phe	Phe	Glu	Ile	Thr	Val	Pro	Glu	Ser	Gln	Leu	Thr	Val	
					3810					3815					3820	
tcc	cag	ttc	acg	ctt	cca	aaa	agt	gtt	tca	gat	ggc	att	gct	gct	ttg	11642
Ser	Gln	Phe	Thr	Leu	Pro	Lys	Ser	Val	Ser	Asp	Gly	Ile	Ala	Ala	Leu	
			3825					3830							3835	
gat	cta	aat	gca	gta	gcc	aac	aag	atc	gca	gac	ttt	gag	ttg	ccc	acc	11690
Asp	Leu	Asn	Ala	Val	Ala	Asn	Lys	Ile	Ala	Asp	Phe	Glu	Leu	Pro	Thr	
			3840				3845								3850	
atc	atc	gtg	cct	gag	cag	acc	att	gag	att	ccc	tcc	att	aag	ttc	tct	11738
Ile	Ile	Val	Pro	Glu	Gln	Thr	Ile	Glu	Ile	Pro	Ser	Ile	Lys	Phe	Ser	
					3855						3865				3870	
gta	cct	gct	gga	att	gtc	att	cct	tcc	ttt	caa	gca	ctg	act	gca	cgc	11786
Val	Pro	Ala	Gly	Ile	Val	Ile	Pro	Ser	Phe	Gln	Ala	Leu	Thr	Ala	Arg	
					3875						3880				3885	
ttt	gag	gta	gac	tct	ccc	gtg	tat	aat	gcc	act	tg	agt	gcc	agt	ttg	11834
Phe	Glu	Val	Asp	Ser	Pro	Val	Tyr	Asn	Ala	Thr	Trp	Ser	Ala	Ser	Leu	
					3890					3895					3900	
aaa	aac	aaa	gca	gat	tat	gtt	gaa	aca	gtc	ctg	gat	tcc	aca	tgc	agc	11882
Lys	Asn	Lys	Ala	Asp	Tyr	Val	Glu	Thr	Val	Leu	Asp	Ser	Thr	Cys	Ser	
			3905							3910					3915	
tca	acc	gta	cag	ttc	cta	gaa	tat	gaa	cta	aat	gtt	ttg	gga	aca	cac	11930
Ser	Thr	Val	Gln	Phe	Leu	Glu	Tyr	Glu	Leu	Asn	Val	Leu	Gly	Thr	His	
					3920										3930	
aaa	atc	gaa	gat	gg	acg	tta	gcc	tct	aag	act	aaa	gga	aca	ctt	gca	11978
Lys	Ile	Glu	Asp	Gly	Thr	Leu	Ala	Ser	Lys	Thr	Lys	Gly	Thr	Leu	Ala	
					3935										3950	
cac	cgt	gac	ttc	agt	gca	gaa	tat	gaa	gaa	gat	ggc	aaa	ttt	gaa	gga	12026
His	Arg	Asp	Phe	Ser	Ala	Glu	Tyr	Glu	Glu	Asp	Gly	Lys	Phe	Glu	Gly	
					3955						3960				3965	
ctt	cag	gaa	tg	gaa	gga	aaa	gcg	cac	ctc	aat	atc	aaa	agc	cca	gcg	12074
Leu	Gln	Glu	Trp	Glu	Gly	Lys	Ala	His	Leu	Asn	Ile	Lys	Ser	Pro	Ala	
					3970						3975				3980	
ttc	acc	gat	ctc	cat	ctg	cgc	tac	cag	aaa	gac	aag	aaa	ggc	atc	tcc	12122

-continued

Phe	Thr	Asp	Leu	His	Leu	Arg	Tyr	Gln	Lys	Asp	Lys	Lys	Gly	Ile	Ser	
		3985					3990						3995			
acc	tca	gca	gcc	tcc	cca	gcc	gta	ggc	acc	gtg	ggc	atg	gat	atg	gat	12170
Thr	Ser	Ala	Ala	Ser	Pro	Ala	Val	Gly	Thr	Val	Gly	Met	Asp	Met	Asp	
		4000					4005					4010				
gaa	gat	gac	gac	ttt	tct	aaa	tgg	aac	ttc	tac	tac	agc	cct	cag	tcc	12218
Glu	Asp	Asp	Asp	Phe	Ser	Lys	Trp	Asn	Phe	Tyr	Tyr	Ser	Pro	Gln	Ser	
		4015				4020				4025					4030	
tct	cca	gat	aaa	aaa	ctc	acc	ata	ttc	aaa	act	gag	ttg	agg	gtc	cgg	12266
Ser	Pro	Asp	Lys	Lys	Leu	Thr	Ile	Phe	Lys	Thr	Glu	Leu	Arg	Val	Arg	
				4035					4040					4045		
gaa	tct	gat	gag	gaa	act	cag	atc	aaa	gtt	aat	tgg	gaa	gaa	gag	gca	12314
Glu	Ser	Asp	Glu	Glu	Thr	Gln	Ile	Lys	Val	Asn	Trp	Glu	Glu	Glu	Ala	
			4050					4055						4060		
gct	tct	ggc	ttg	cta	acc	tct	ctg	aaa	gac	aac	gtg	ccc	aag	gcc	aca	12362
Ala	Ser	Gly	Leu	Leu	Thr	Ser	Leu	Lys	Asp	Asn	Val	Pro	Lys	Ala	Thr	
		4065					4070					4075				
ggg	gtc	ctt	tat	gat	tat	gtc	aac	aag	tac	cac	tgg	gaa	cac	aca	ggg	12410
Gly	Val	Leu	Tyr	Asp	Tyr	Val	Asn	Lys	Tyr	His	Trp	Glu	His	Thr	Gly	
		4080				4085					4090					
ctc	acc	ctg	aga	gaa	gtg	tct	tca	aag	ctg	aga	aga	aat	ctg	cag	aac	12458
Leu	Thr	Leu	Arg	Glu	Val	Ser	Ser	Lys	Leu	Arg	Arg	Asn	Leu	Gln	Asn	
		4095			4100					4105					4110	
aat	gct	gag	tgg	gtt	tat	caa	ggg	gcc	att	agg	caa	att	gat	gat	atc	12506
Asn	Ala	Glu	Trp	Val	Tyr	Gln	Gly	Ala	Ile	Arg	Gln	Ile	Asp	Asp	Ile	
			4115					4120						4125		
gac	gtg	agg	ttc	cag	aaa	gca	gcc	agt	ggc	acc	act	ggg	acc	tac	caa	12554
Asp	Val	Arg	Phe	Gln	Lys	Ala	Ala	Ser	Gly	Thr	Thr	Gly	Thr	Tyr	Gln	
			4130					4135					4140			
gag	tgg	aag	gac	aag	gcc	cag	aat	ctg	tac	cag	gaa	ctg	ttg	act	cag	12602
Glu	Trp	Lys	Asp	Lys	Ala	Gln	Asn	Leu	Tyr	Gln	Glu	Leu	Leu	Thr	Gln	
		4145				4150						4155				
gaa	ggc	caa	gcc	agt	ttc	cag	gga	ctc	aag	gat	aac	gtg	ttt	gat	ggc	12650
Glu	Gly	Gln	Ala	Ser	Phe	Gln	Gly	Leu	Lys	Asp	Asn	Val	Phe	Asp	Gly	
		4160				4165					4170					
ttg	gta	cga	gtt	act	caa	aaa	ttc	cat	atg	aaa	gtc	aag	cat	ctg	att	12698
Leu	Val	Arg	Val	Thr	Gln	Lys	Phe	His	Met	Lys	Val	Lys	His	Leu	Ile	
	4175				4180					4185					4190	
gac	tca	ctc	att	gat	ttt	ctg	aac	ttc	ccc	aga	ttc	cag	ttt	ccg	ggg	12746
Asp	Ser	Leu	Ile	Asp	Phe	Leu	Asn	Phe	Pro	Arg	Phe	Gln	Phe	Pro	Gly	
			4195						4200					4205		
aaa	cct	ggg	ata	tac	act	agg	gag	gaa	ctt	tgc	act	atg	ttc	ata	agg	12794
Lys	Pro	Gly	Ile	Tyr	Thr	Arg	Glu	Leu	Cys	Thr	Met	Phe	Ile	Arg		
			4210					4215					4220			
gag	gta	ggg	acg	gta	ctg	tcc	cag	gta	tat	tcg	aaa	gtc	cat	aat	ggg	12842
Glu	Val	Gly	Thr	Val	Leu	Ser	Gln	Val	Tyr	Ser	Lys	Val	His	Asn	Gly	
		4225				4230						4235				
tca	gaa	ata	ctg	ttt	tcc	tat	ttc	caa	gac	cta	gtg	att	aca	ctt	cct	12890
Ser	Glu	Ile	Leu	Phe	Ser	Tyr	Phe	Gln	Asp	Leu	Val	Ile	Thr	Leu	Pro	
		4240				4245					4250					
ttc	gag	tta	agg	aaa	cat	aaa	cta	ata	gat	gta	atc	tcg	atg	tat	agg	12938
Phe	Glu	Leu	Arg	Lys	His	Lys	Leu	Ile	Asp	Val	Ile	Ser	Met	Tyr	Arg	
	4255				4260					4265					4270	
gaa	ctg	ttg	aaa	gat	tta	tca	aaa	gaa	gcc	caa	gag	gta	ttt	aaa	gcc	12986
Glu	Leu	Leu	Lys	Asp	Leu	Ser	Lys	Glu	Ala	Gln	Glu	Val	Phe	Lys	Ala	
			4275						4280					4285		
att	cag	tct	ctc	aag	acc	aca	gag	gtg	cta	cgt	aat	ctt	cag	gac	ctt	13034
Ile	Gln	Ser	Leu	Lys	Thr	Thr	Glu	Val	Leu	Arg	Asn	Leu	Gln	Asp	Leu	
			4290					4295					4300			
tta	caa	ttc	att	ttc	caa	cta	ata	gaa	gat	aac	att	aaa	cag	ctg	aaa	13082

-continued

Leu	Gln	Phe	Ile	Phe	Gln	Leu	Ile	Glu	Asp	Asn	Ile	Lys	Gln	Leu	Lys		
	4305						4310					4315					
gag	atg	aaa	ttt	act	tat	ctt	att	aat	tat	atc	caa	gat	gag	atc	aac	13130	
Glu	Met	Lys	Phe	Thr	Tyr	Leu	Ile	Asn	Tyr	Ile	Gln	Asp	Glu	Ile	Asn		
	4320					4325				4330							
aca	atc	ttc	aat	gat	tat	atc	cca	tat	gtt	ttt	aaa	ttg	ttg	aaa	gaa	13178	
Thr	Ile	Phe	Asn	Asp	Tyr	Ile	Pro	Tyr	Val	Phe	Lys	Leu	Leu	Lys	Glu		
	4335				4340				4345					4350			
aac	cta	tgc	ctt	aat	ctt	cat	aag	ttc	aat	gaa	ttt	att	caa	aac	gag	13226	
Asn	Leu	Cys	Leu	Asn	Leu	His	Lys	Phe	Asn	Glu	Phe	Ile	Gln	Asn	Glu		
			4355				4360					4365					
ctt	cag	gaa	gct	tct	caa	gag	tta	cag	cag	atc	cat	caa	tac	att	atg	13274	
Leu	Gln	Glu	Ala	Ser	Gln	Glu	Leu	Gln	Gln	Ile	His	Gln	Tyr	Ile	Met		
			4370			4375						4380					
gcc	ctt	cgt	gaa	gaa	tat	ttt	gat	cca	agt	ata	gtt	ggc	tgg	aca	gtg	13322	
Ala	Leu	Arg	Glu	Glu	Tyr	Phe	Asp	Pro	Ser	Ile	Val	Gly	Trp	Thr	Val		
	4385					4390				4395							
aaa	tat	tat	gaa	ctt	gaa	gaa	aag	ata	gtc	agt	ctg	atc	aag	aac	ctg	13370	
Lys	Tyr	Tyr	Glu	Leu	Glu	Lys	Ile	Val	Ser	Leu	Ile	Lys	Asn	Leu			
	4400				4405				4410								
tta	gtt	gct	ctt	aag	gac	ttc	cat	tct	gaa	tat	att	gtc	agt	gcc	tct	13418	
Leu	Val	Ala	Leu	Lys	Asp	Phe	His	Ser	Glu	Tyr	Ile	Val	Ser	Ala	Ser		
	4415			4420				4425				4430					
aac	ttt	act	tcc	caa	ctc	tca	agt	caa	gtt	gag	caa	ttt	ctg	cac	aga	13466	
Asn	Phe	Thr	Ser	Gln	Leu	Ser	Ser	Gln	Val	Glu	Gln	Phe	Leu	His	Arg		
			4435				4440					4445					
aat	att	cag	gaa	tat	ctt	agc	atc	ctt	acc	gat	cca	gat	gga	aaa	ggg	13514	
Asn	Ile	Gln	Glu	Tyr	Leu	Ser	Ile	Leu	Thr	Asp	Pro	Asp	Gly	Lys	Gly		
	4450				4455					4460							
aaa	gag	aag	att	gca	gag	ctt	tct	gcc	act	gct	cag	gaa	ata	att	aaa	13562	
Lys	Glu	Lys	Ile	Ala	Glu	Leu	Ser	Ala	Thr	Ala	Gln	Glu	Ile	Ile	Lys		
	4465				4470				4475								
agc	cag	gcc	att	gcg	acg	aag	aaa	ata	att	tct	gat	tac	cac	cag	cag	13610	
Ser	Gln	Ala	Ile	Ala	Thr	Lys	Lys	Ile	Ile	Ser	Asp	Tyr	His	Gln	Gln		
	4480			4485				4490									
ttt	aga	tat	aaa	ctg	caa	gat	ttt	tca	gac	caa	ctc	tct	gat	tac	tat	13658	
Phe	Arg	Tyr	Lys	Leu	Gln	Asp	Phe	Ser	Asp	Gln	Leu	Ser	Asp	Tyr	Tyr		
	4495			4500				4505				4510					
gaa	aaa	ttt	att	gct	gaa	tcc	aaa	aga	ttg	att	gac	ctg	tcc	att	caa	13706	
Glu	Lys	Phe	Ile	Ala	Glu	Ser	Lys	Arg	Leu	Ile	Asp	Leu	Ser	Ile	Gln		
		4515				4520			4525								
aac	tac	cac	aca	ttt	ctg	ata	tac	atc	acg	gag	tta	ctg	aaa	aag	ctg	13754	
Asn	Tyr	His	Thr	Phe	Leu	Ile	Tyr	Ile	Thr	Glu	Leu	Leu	Lys	Lys	Leu		
		4530			4535					4540							
caa	tca	acc	aca	gtc	atg	aac	ccc	tac	atg	aag	ctt	gct	cca	gga	gaa	13802	
Gln	Ser	Thr	Thr	Val	Met	Asn	Pro	Tyr	Met	Lys	Leu	Ala	Pro	Gly	Glu		
	4545			4550				4555									
ctt	act	atc	atc	ctc	taa	ttttttaaaa	gaaatcttca	tttattcttc								13850	
Leu	Thr	Ile	Ile	Leu	*												
	4560																
ttttccaatt	gaactttcac	atagcacaga	aaaaattcaa	actgcctata	ttgataaaac											13910	
catcacgtga	gccagccttg	cagtaggcag	tagactataa	gcagaagcac	atatgaactg											13970	
gacctgcacc	aaagctggca	ccagggtctg	gaaggtctct	gaactcagaa	ggatggcatt											14030	
ttttgcaagt	taaagaaaat	caggatctga	gttatcttgc	taaacttggg	ggaggaggaa											14090	
caaataaatg	gagtccttat	tgtgtatcat	a													14121	

<210> SEQ ID NO 4

<211> LENGTH: 21

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 4

tgctaaaggc acatatggcc t 21

<210> SEQ ID NO 5
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 5

ctcaggttgg actctccatt gag 23

<210> SEQ ID NO 6
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Probe

<400> SEQUENCE: 6

cttgctcagag ggatcctaac actggccg 28

<210> SEQ ID NO 7
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 7

gaaggtgaag gtcggagtc 19

<210> SEQ ID NO 8
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 8

gaagatggtg atgggatttc 20

<210> SEQ ID NO 9
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Probe

<400> SEQUENCE: 9

caagcttccc gttctcagcc 20

<210> SEQ ID NO 10
 <211> LENGTH: 2354
 <212> TYPE: DNA
 <213> ORGANISM: Mus musculus

<400> SEQUENCE: 10

gaattccaac ttcctcacct ctcacatata attgaaatac ctgcttttgg caaactgcat 60

agcatcctta agatccaatc tcctctcttt atattagatg ctaatgcaa catacagaat 120

-continued

gtaacaactt cagggaaacaa agcagagatt gtggcttctg tcaactgctaa aggagagtcc	180
caatttgaag ctctcaattt tgattttcaa gcacaagctc aattcctgga gttaaatcct	240
catcctccag tcctgaagga atccatgaac ttctccagta agcatgtgag aatggagcat	300
gagggtgaga tagtatttga tggaaaggcc attgagggga aatcagacac agtcgcaagt	360
ttacacacag agaaaaatga agtagagttt aataatggta tgactgtcaa agtaaacaat	420
cagctcacc ttgacagtca cacaaagtac ttccacaagt tgagtgttcc taggctggac	480
ttctccagta aggtcttctc taataatgaa atcaagacac tattagaagc tggacatgtg	540
gcattgacat cttcagggac aggggtcatgg aactgggcct gtcccaactt ctcggtgaa	600
ggcatacatt cgtcccaaat tagctttact gtggatggtc ccattgcttt tgttggacta	660
tccaataaca taaatggcaa acacttacgg gtcacccaaa aactgactta tgaatctggc	720
ttctcaact attctaagtt tgaagttgag tcaaaagttg aatctcagca cgtgggctcc	780
agcattctaa cagccaatgg tcgggcactg ctcaaggacg caaaggcaga aatgactgg	840
gagcacaatg ccaacttaaa tggaaaagt attggaactt tgaaaaattc tctcttctt	900
tcagcacaac catttgagat tactgcatcc acaataatg aaggaaattt gaaagtgggt	960
tttccactaa agctgactgg gaaaatagac ttctgaata actatgcatt gtttctgagt	1020
ccccgtgcc aacaagcaag ctggcaagcg agtaccagat tcaatcagta caaatacaat	1080
caaaactttt ctgctataaa caatgaacac aacatagaag ccagtatagg aatgaatgga	1140
gatgccaaac tggattttct aaacatacct ttaacaattc ctgaaattaa ctgaccttac	1200
acggagtcca aaactccctt actgaaggat ttctccatat gggagaagac aggttgaaa	1260
gaatttttga agacaacaaa gcaatcattt gatttgagtg taaaggctca atataaaaag	1320
aacagtgaca agcattccat tgttgctcct ctgggtatgt tttatgaatt tattctcaac	1380
aatgtcaatt cgtgggacag aaaatttgag aaagtcagaa acaatgcttt acattttctt	1440
accacctcct ataatgaagc aaaaattaag gttgataagt acaaaactga aaattccctt	1500
aatcagccct ctgggacctt tcaaaatcat ggctacacta tcccagttgt caacattgaa	1560
gtatctccat ttgctgtaga gacactggct tccaggcatg tgatccccac agcaataagc	1620
accccaagt tcaacaatcc tggctcctaac atcatggtgc cttcatacaa gttagtctg	1680
ccaccctgg agttgccagt tttccatggc cctgggaatc tattcaagtt tttctccca	1740
gatttcaagg gattcaacac tattgacaat atttatattc cagccatggg caactttacc	1800
tatgactttt cttttaaatc aagtgtcatc aactgaata ccaatgctgg actttataac	1860
caatcagata tcgttgccca tttctttctc tctcttcat ttgtcactga cgcctgcag	1920
tacaaattag agggaaacac acgtctgatg cgaaaaaggg gattgaaact agccacagct	1980
gtctctctaa ctaacaaatt tgtaaagggc agtcatgaca gcaccattag ttttaaccaag	2040
aaaaacatgg aagcatcagt gagaacaact gccaacctcc atgctcccat attctcaatg	2100
aacttcaagc aggaacttaa tggaaatacc aagtcaaac ccactgtttc atcatccatt	2160
gaactaaact atgacttcaa ttctcctaaag ctgcactcta ctgcaacagg aggcattgat	2220
cacaagttca gcttagaaaag tctcacttcc tacttttcca ttgagtcatt caccaaaagga	2280
aatatcaaga gttccttctc ttctcaggaa tattcaggaa gtgttgccaa tgaagccaat	2340
gtatatctga attc	2354

<210> SEQ ID NO 11

<211> LENGTH: 19

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 11

cgtgggctcc agcattcta

19

<210> SEQ ID NO 12
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 12

agtcatttct gcctttgcgt c

21

<210> SEQ ID NO 13
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Probe

<400> SEQUENCE: 13

ccaatggtcg ggcactgctc aa

22

<210> SEQ ID NO 14
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 14

ggcaaattca acggcacagt

20

<210> SEQ ID NO 15
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 15

gggtctcgct cctggaagat

20

<210> SEQ ID NO 16
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Probe

<400> SEQUENCE: 16

aaggccgaga atgggaagct tgatcatc

27

<210> SEQ ID NO 17
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 17

ccgcaggtcc cggtgggaat

20

-continued

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 18

accgagaagg gcactcagcc

20

<210> SEQ ID NO 19
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 19

gcctcggcct cgcggccctg

20

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 20

tccatcgcca gctgcggtgg

20

<210> SEQ ID NO 21
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 21

cagcgccagc agcgccagca

20

<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 22

gcccgccagc agcagcagca

20

<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 23

cttgaatcag cagtcccagg

20

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 24

cttcagcaag gctttgccct

20

<210> SEQ ID NO 25

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 25

tttctgttgc cacattgccc

20

<210> SEQ ID NO 26

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 26

ggaagagggtg ttgctccttg

20

<210> SEQ ID NO 27

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 27

tgtgctacca tcccatactt

20

<210> SEQ ID NO 28

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 28

tcaaatgcga ggcccatctt

20

<210> SEQ ID NO 29

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 29

ggacacctca atcagctgtg

20

<210> SEQ ID NO 30

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 30

tcagggccac caggtaggtg

20

<210> SEQ ID NO 31

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 31

gtaatcttca tccccagtgc 20

<210> SEQ ID NO 32
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 32

tgctccatgg tttggcccat 20

<210> SEQ ID NO 33
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 33

gcagccagtc gcttatctcc 20

<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 34

gtatagccaa agtgggccac 20

<210> SEQ ID NO 35
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 35

cccaggagct ggaggctcatg 20

<210> SEQ ID NO 36
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 36

ttgagccctt cctgatgacc 20

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 37

atctggaccc cactcctagc 20

-continued

<210> SEQ ID NO 38
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 38

cagaccgcgac tcgtggaaga

20

<210> SEQ ID NO 39
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 39

gccctcagta gattcatcat

20

<210> SEQ ID NO 40
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 40

gccatgccac cctcttgga

20

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 41

aaccacgtg ccgaaagtc

20

<210> SEQ ID NO 42
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 42

actccagat gccttctgaa

20

<210> SEQ ID NO 43
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 43

atgtggtaac gagccgaag

20

<210> SEQ ID NO 44
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 44

ggcgtagaga cccatcacat

20

<210> SEQ ID NO 45

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 45

gtgttaggat ccctctgaca

20

<210> SEQ ID NO 46

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 46

cccagtgata gctctgtgag

20

<210> SEQ ID NO 47

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 47

atttcagcat atgagcccat

20

<210> SEQ ID NO 48

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 48

ccctgaacct tagcaacagt

20

<210> SEQ ID NO 49

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 49

gctgaagcca gccacgcat

20

<210> SEQ ID NO 50

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 50

acagctgccc agtatgttct

20

<210> SEQ ID NO 51

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 51

cccaataaga ttataacaa                20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 52

tggcctacca gagacaggta                20

<210> SEQ ID NO 53
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 53

tcatacgttt agccaatct                20

<210> SEQ ID NO 54
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 54

gcatggtccc aaggatggtc                20

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 55

agtgatggaa gctgcgatac                20

<210> SEQ ID NO 56
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 56

atgagcatca tgcctcccag                20

<210> SEQ ID NO 57
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 57

gaacacatag ccgaatgccg                20

```

-continued

<210> SEQ ID NO 58
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 58

gtggtgccct ctaatttga

20

<210> SEQ ID NO 59
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 59

cccgagaaag aaccgaaccc

20

<210> SEQ ID NO 60
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 60

tgccctgcag cttcactgaa

20

<210> SEQ ID NO 61
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 61

gaaatcccat aagctcttgt

20

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 62

agaagctgcc ttttttccc

20

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 63

tcagggtgag ccctgtgtgt

20

<210> SEQ ID NO 64
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 64

ctaattggccc cttgataaac

20

<210> SEQ ID NO 65

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 65

acgttatacct tgagtccttg

20

<210> SEQ ID NO 66

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 66

tatatcccag gtttccccgg

20

<210> SEQ ID NO 67

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 67

acctgggaca gtaccgtccc

20

<210> SEQ ID NO 68

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 68

ctgcctactg caaggctggc

20

<210> SEQ ID NO 69

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 69

agagaccttc cgagccctgg

20

<210> SEQ ID NO 70

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 70

atgatacaca ataaagactc

20

<210> SEQ ID NO 71

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 71
attgtatgtg agaggtgagg                20

<210> SEQ ID NO 72
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 72
gaggagattg gatcttaagg                20

<210> SEQ ID NO 73
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 73
cttcaaattg ggactctcct                20

<210> SEQ ID NO 74
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 74
tccaggaatt gagcttgtgc                20

<210> SEQ ID NO 75
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 75
ttcaggactg gaggatgagg                20

<210> SEQ ID NO 76
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 76
tctcacctc atgctccatt                20

<210> SEQ ID NO 77
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 77
tgactgtcaa gggtagctg                20

```


-continued

<210> SEQ ID NO 78
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 78

gtccagccta ggaacactca

20

<210> SEQ ID NO 79
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 79

atgtcaatgc cacatgtcca

20

<210> SEQ ID NO 80
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 80

ttcatccgag aagttgggac

20

<210> SEQ ID NO 81
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 81

atttgggacg aatgtatgcc

20

<210> SEQ ID NO 82
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 82

agttgaggaa gccagattca

20

<210> SEQ ID NO 83
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 83

ttcccagtcg gcttttagtgg

20

<210> SEQ ID NO 84
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 84

agcttgcttg ttgggcacgg

20

<210> SEQ ID NO 85

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 85

cctatactgg cttctatgtt

20

<210> SEQ ID NO 86

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 86

tgaactccgt gtaaggcaag

20

<210> SEQ ID NO 87

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 87

gagaaatcct tcagtaaggg

20

<210> SEQ ID NO 88

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 88

caatggaatg cttgtcactg

20

<210> SEQ ID NO 89

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 89

gcttcattat aggaggtggt

20

<210> SEQ ID NO 90

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 90

acaactggga tagtgtagcc

20

<210> SEQ ID NO 91

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 91

gttaggacca gggattgtga

20

<210> SEQ ID NO 92
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 92

accatggaaa actggcaact

20

<210> SEQ ID NO 93
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 93

tgggaggaaa aacttgaata

20

<210> SEQ ID NO 94
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 94

tgggcaacga tatctgattg

20

<210> SEQ ID NO 95
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 95

ctgcaggcg tcagtgacaa

20

<210> SEQ ID NO 96
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 96

gcatcagacg tgatgttccc

20

<210> SEQ ID NO 97
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 97

cttggttaaa ctaatggtgc

20

-continued

<210> SEQ ID NO 98
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 98

atgggagcat ggaggttggc

20

<210> SEQ ID NO 99
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 99

aatggatgat gaaacagtgg

20

<210> SEQ ID NO 100
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 100

atcaatgcct cctgttgcag

20

<210> SEQ ID NO 101
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 101

ggaagtgaga ctttctaagc

20

<210> SEQ ID NO 102
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 102

aggaaggaac tcttgatatt

20

<210> SEQ ID NO 103
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 103

attggcttca ttggcaacac

20

<210> SEQ ID NO 104
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 104

aggtgaggaa gttggaattc

20

<210> SEQ ID NO 105

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 105

ttgttccttg aagttgttac

20

<210> SEQ ID NO 106

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 106

gttcattgat tccttcagga

20

<210> SEQ ID NO 107

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 107

atgctccatt ctcacatgct

20

<210> SEQ ID NO 108

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 108

tgcgactgtg tctgatttcc

20

<210> SEQ ID NO 109

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 109

gtccctgaag atgtcaatgc

20

<210> SEQ ID NO 110

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 110

aggcccagtt ccatgaccct

20

<210> SEQ ID NO 111

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 111

ggagcccacg tgctgagatt 20

<210> SEQ ID NO 112
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 112

cgtccttgag cagtgccga 20

<210> SEQ ID NO 113
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 113

cccatatgga gaaatccttc 20

<210> SEQ ID NO 114
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 114

catgcctgga agccagtgtc 20

<210> SEQ ID NO 115
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 115

gtgttgaatc ccttgaaatc 20

<210> SEQ ID NO 116
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 116

ggtaaagttg cccatggctg 20

<210> SEQ ID NO 117
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 117

gttataaagt ccagattgg 20

-continued

<210> SEQ ID NO 118
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 118

catcagacgt gatgttcct

20

<210> SEQ ID NO 119
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 119

tggctagttt caatccccctt

20

<210> SEQ ID NO 120
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 120

ctgtcatgac tgccctttac

20

<210> SEQ ID NO 121
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 121

gcttgaagtt cattgagaat

20

<210> SEQ ID NO 122
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 122

ttcctgagaa aggaaggaac

20

<210> SEQ ID NO 123
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 123

tcagatatac attggcttca

20

<210> SEQ ID NO 124
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 124

ttcctcttcg gccctggcgc

20

<210> SEQ ID NO 125

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 125

ctccactgga actctcagcc

20

<210> SEQ ID NO 126

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 126

cctccagctc aaccttgag

20

<210> SEQ ID NO 127

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 127

gggttgaagc catacacctc

20

<210> SEQ ID NO 128

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 128

ccagcttgag ctcatacctg

20

<210> SEQ ID NO 129

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 129

ccctcttgat gtccaggatg

20

<210> SEQ ID NO 130

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 130

gagcagtttc catacacggt

20

<210> SEQ ID NO 131

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 131

cccttctctcg tcttgacggt                20

<210> SEQ ID NO 132
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 132

ttgaagcgat cacactgccc                20

<210> SEQ ID NO 133
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 133

gcctttgatg agagcaagtg                20

<210> SEQ ID NO 134
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 134

tcctcttagc gtccagtgtg                20

<210> SEQ ID NO 135
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 135

cctctcagct cagtaaccag                20

<210> SEQ ID NO 136
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 136

gcactgaggc tgtccacact                20

<210> SEQ ID NO 137
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 137

cgctgatccc tcgccatgtt                20

```

-continued

<210> SEQ ID NO 138
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 138

gttgaccgcg tggctcagcg

20

<210> SEQ ID NO 139
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 139

gcagctcctg ggtccctgta

20

<210> SEQ ID NO 140
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 140

cccatggtag aatttgaca

20

<210> SEQ ID NO 141
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 141

aatctcgatg aggtcagctg

20

<210> SEQ ID NO 142
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 142

gacaccatca ggaactgac

20

<210> SEQ ID NO 143
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 143

gctcctctcc caagatgcgg

20

<210> SEQ ID NO 144
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 144

ggcaccatc agaagcagct

20

<210> SEQ ID NO 145

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 145

agtcggaat gatgatgcc

20

<210> SEQ ID NO 146

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 146

ctgagcagct tgactggtct

20

<210> SEQ ID NO 147

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 147

cccggtcagc ggatagtagg

20

<210> SEQ ID NO 148

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 148

tgtcacaact taggtggccc

20

<210> SEQ ID NO 149

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 149

gtctggcaat cccatgttct

20

<210> SEQ ID NO 150

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 150

cccacagact tgaagtggag

20

<210> SEQ ID NO 151

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 151

gaactgccca tcaatcttga 20

<210> SEQ ID NO 152
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 152

cccagagagg ccaagctctg 20

<210> SEQ ID NO 153
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 153

tgtgttcctt gaagcgcca 20

<210> SEQ ID NO 154
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 154

accagaatc atggcctgat 20

<210> SEQ ID NO 155
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 155

ggtgcctgtc tgctcagctg 20

<210> SEQ ID NO 156
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 156

atgtgaaact tgtctctccc 20

<210> SEQ ID NO 157
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 157

tatgtctgca gttgagatag 20

-continued

<210> SEQ ID NO 158
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 158

ttgaatccag gatgcagtac

20

<210> SEQ ID NO 159
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 159

gagtctctga gtcacctcac

20

<210> SEQ ID NO 160
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 160

gatagaatat tgctctgcaa

20

<210> SEQ ID NO 161
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 161

cccttgctct accaatgctt

20

<210> SEQ ID NO 162
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 162

tccattccct atgtcagcat

20

<210> SEQ ID NO 163
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 163

gactccttca gagccagcgg

20

<210> SEQ ID NO 164
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 164

cccatgctcc gttctcaggt

20

<210> SEQ ID NO 165

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 165

cgcaggtcag cctgactaga

20

<210> SEQ ID NO 166

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 166

cagttagaac actgtggccc

20

<210> SEQ ID NO 167

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 167

cagtgtgatg acacttgatt

20

<210> SEQ ID NO 168

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 168

ctgtggctaa cttcaatccc

20

<210> SEQ ID NO 169

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 169

cagtactgtt atgactaccc

20

<210> SEQ ID NO 170

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 170

cactgaagac cgtgtgctct

20

<210> SEQ ID NO 171

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 171

tcgtactgtg ctcccagagg 20

<210> SEQ ID NO 172
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 172

aagaggccct ctagctgtaa 20

<210> SEQ ID NO 173
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 173

aagaccaga atgaatccgg 20

<210> SEQ ID NO 174
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 174

gtctacctca aagcgtgcag 20

<210> SEQ ID NO 175
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 175

tagaggctaa cgtaccatct 20

<210> SEQ ID NO 176
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 176

ccatatccat gccacgggtg 20

<210> SEQ ID NO 177
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 177

agtttctca tcagattccc 20

-continued

<210> SEQ ID NO 178
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 178

cccagtggta cttgttgaca

20

<210> SEQ ID NO 179
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 179

cccagtgggtg ccactgggtg

20

<210> SEQ ID NO 180
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 180

gtcaacagtt cctggtacag

20

<210> SEQ ID NO 181
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 181

ccctagtgtatcccaggt

20

<210> SEQ ID NO 182
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 182

ctgaagatta cgtagcacct

20

<210> SEQ ID NO 183
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 183

gtccagccaa ctatacttgg

20

<210> SEQ ID NO 184
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 184

cctggagcaa gcttcattgta

20

<210> SEQ ID NO 185

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 185

tggacagacc aggctgacat

20

<210> SEQ ID NO 186

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 186

atgtgtactt ccggagggtgc

20

<210> SEQ ID NO 187

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 187

tcttcaggat gaagctgcag

20

<210> SEQ ID NO 188

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 188

tcagcaaggc ttgacctca

20

<210> SEQ ID NO 189

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 189

ctgcttcctt tctggaatgg

20

<210> SEQ ID NO 190

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 190

tgccacattg cccttcctcg

20

<210> SEQ ID NO 191

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 191

gctgatcaga gttgacaagg                20

<210> SEQ ID NO 192
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 192

tactgacagg actggctgct                20

<210> SEQ ID NO 193
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 193

gatggcttct gccacatgct                20

<210> SEQ ID NO 194
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 194

gatgtggatt tgggtgctctc              20

<210> SEQ ID NO 195
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 195

tgactgcttc atcactgagg                20

<210> SEQ ID NO 196
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 196

ggtaggtgac cacatctatc                20

<210> SEQ ID NO 197
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 197

tcgcagctgc tgtgctgagg                20

```

-continued

<210> SEQ ID NO 198
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 198

ttccaatgac ccgcagaatc

20

<210> SEQ ID NO 199
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 199

gatcatcagt gatggctttg

20

<210> SEQ ID NO 200
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 200

agcctggatg gcagctttct

20

<210> SEQ ID NO 201
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 201

gtctgaagaa gaacctctg

20

<210> SEQ ID NO 202
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 202

tatctgcctg tgaaggactc

20

<210> SEQ ID NO 203
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 203

ctgagttcaa gatattggca

20

<210> SEQ ID NO 204
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 204

cttccaagcc aatctcgatg

20

<210> SEQ ID NO 205

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 205

tgcaactgta atccagctcc

20

<210> SEQ ID NO 206

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 206

ccagttcagc ctgcatgttg

20

<210> SEQ ID NO 207

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 207

gtagagacca aatgtaatgt

20

<210> SEQ ID NO 208

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 208

cgttggagta agcgcttgag

20

<210> SEQ ID NO 209

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 209

cagctctaata ctggtgtccc

20

<210> SEQ ID NO 210

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 210

ctgtcctctc tctggagctc

20

<210> SEQ ID NO 211

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 211
caaggtcata ctctgccgat                20

<210> SEQ ID NO 212
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 212
gtatggaaat aacacccttg                20

<210> SEQ ID NO 213
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 213
taagctgtag cagatgagtc                20

<210> SEQ ID NO 214
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 214
tagatctctg gaggatttgc                20

<210> SEQ ID NO 215
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 215
gtctagaaca cccaggagag                20

<210> SEQ ID NO 216
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 216
accacagagt cagccttcat                20

<210> SEQ ID NO 217
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 217
aagcagacat ctgtggtccc                20

```

-continued

<210> SEQ ID NO 218
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 218

ctctccattg agccggccag

20

<210> SEQ ID NO 219
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 219

cctgatattc agaacgcagc

20

<210> SEQ ID NO 220
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 220

cagtgccctaa gatgtcagca

20

<210> SEQ ID NO 221
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 221

agcaccagga gactacactt

20

<210> SEQ ID NO 222
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 222

cccatccaga ctgaattttg

20

<210> SEQ ID NO 223
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 223

ggttctagcc gtagtttccc

20

<210> SEQ ID NO 224
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 224

aggttaccag ccacatgcag

20

<210> SEQ ID NO 225

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 225

atgtgcatcg atggtcacgg

20

<210> SEQ ID NO 226

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 226

ccagagagcg agtttcccat

20

<210> SEQ ID NO 227

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 227

ctagacacga gatgatgact

20

<210> SEQ ID NO 228

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 228

tccaagtcct ggctgtattc

20

<210> SEQ ID NO 229

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 229

cgtccagtaa gctccacgcc

20

<210> SEQ ID NO 230

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 230

tcaacggcat ctctcatctc

20

<210> SEQ ID NO 231

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 231

tgatagtgct catcaagact 20

<210> SEQ ID NO 232
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 232

gattctgatt tggtagcttag 20

<210> SEQ ID NO 233
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 233

ctctcgatta actcatggac 20

<210> SEQ ID NO 234
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 234

atacactgca actgtggcct 20

<210> SEQ ID NO 235
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 235

gcaagagtcc accaatcaga 20

<210> SEQ ID NO 236
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 236

agagcctgaa gactgacttc 20

<210> SEQ ID NO 237
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 237

tccctcatct gagaatctgg 20

-continued

<210> SEQ ID NO 238
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 238

cagtgcacatca atgacagatg

20

<210> SEQ ID NO 239
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 239

ccgaaccctt gacatctcct

20

<210> SEQ ID NO 240
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 240

gcctcactag caatagttcc

20

<210> SEQ ID NO 241
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 241

gacatttgcc atggagagag

20

<210> SEQ ID NO 242
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 242

ctgtctccta ccaatgctgg

20

<210> SEQ ID NO 243
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 243

tctgcactga agtcacggtg

20

<210> SEQ ID NO 244
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 244

tcccggaccc tcaactcagt

20

<210> SEQ ID NO 245

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 245

gcaggtcag ttcataatgtg

20

<210> SEQ ID NO 246

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 246

gccatccttc tgagttcaga

20

<210> SEQ ID NO 247

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 247

gcctcagtct gcttcgcacc

20

<210> SEQ ID NO 248

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 248

ccccgcaggt cccggtggga

20

<210> SEQ ID NO 249

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 249

cagccccgca ggtcccggtg

20

<210> SEQ ID NO 250

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 250

caaccgagaa gggcactcag

20

<210> SEQ ID NO 251

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 251

cctcagcggc agcaaccgag                20

<210> SEQ ID NO 252
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 252

tcctcagcgg cagcaaccga                20

<210> SEQ ID NO 253
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 253

ctcctcagcg gcagcaaccg                20

<210> SEQ ID NO 254
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 254

ggctcctcag cggcagcaac                20

<210> SEQ ID NO 255
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 255

ggcggggtcc tcagcggcag                20

<210> SEQ ID NO 256
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 256

ggtccatcgc cagctgcggt                20

<210> SEQ ID NO 257
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 257

ggcgggtcca tcgccagctg                20

```

-continued

<210> SEQ ID NO 258
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 258

tagaggatga tagtaagttc

20

<210> SEQ ID NO 259
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 259

aaatgaagat ttcttttaaa

20

<210> SEQ ID NO 260
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 260

tatgtgaaag ttcaattgga

20

<210> SEQ ID NO 261
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 261

atataggcag tttgaatttt

20

<210> SEQ ID NO 262
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 262

gctcactgta tggttttatc

20

<210> SEQ ID NO 263
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 263

ggctcactgt atggttttat

20

<210> SEQ ID NO 264
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 264

ggctggctca ctgtatggtt

20

<210> SEQ ID NO 265

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 265

aggctggctc actgtatggt

20

<210> SEQ ID NO 266

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 266

aaggctggct cactgtatgg

20

<210> SEQ ID NO 267

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 267

ctactgcaag gctggctcac

20

<210> SEQ ID NO 268

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 268

actgcctact gcaaggctgg

20

<210> SEQ ID NO 269

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 269

tgcttatagt ctactgccta

20

<210> SEQ ID NO 270

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 270

ttctgcttat agtctactgc

20

<210> SEQ ID NO 271

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 271

tttgggtgcag gtccagttca                20

<210> SEQ ID NO 272
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 272

cagcttttggc gcaggtccag                20

<210> SEQ ID NO 273
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 273

gccagcttttg gtgcaggtcc                20

<210> SEQ ID NO 274
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 274

tgggtgccagc tttggtgcag                20

<210> SEQ ID NO 275
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 275

gccctggtgac cagcttttggc                20

<210> SEQ ID NO 276
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 276

gagttcagag accttccgag                20

<210> SEQ ID NO 277
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 277

aaatgccatc cttctgagtt                20

```

-continued

<210> SEQ ID NO 278
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 278

aaaaatgcc a tccttctgag 20

<210> SEQ ID NO 279
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 279

aaaataactc agatcctgat 20

<210> SEQ ID NO 280
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 280

agcaaaaataa ctcagatcct 20

<210> SEQ ID NO 281
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 281

agtttagcaa aataactcag 20

<210> SEQ ID NO 282
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 282

tcccccaagt ttagcaaat 20

<210> SEQ ID NO 283
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 283

ttcctcctcc cccaagttta 20

<210> SEQ ID NO 284
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 284

agactccatt tatttgttcc

20

<210> SEQ ID NO 285

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 285

cttctgcttg agttacaaac

20

<210> SEQ ID NO 286

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 286

accttctgct tgagttacaa

20

<210> SEQ ID NO 287

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 287

gcaccttctg cttgagttac

20

<210> SEQ ID NO 288

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 288

tcgcaccttc tgcttgagtt

20

<210> SEQ ID NO 289

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 289

cttcgcacct tctgcttgag

20

<210> SEQ ID NO 290

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 290

tgcttcgcac cttctgcttg

20

<210> SEQ ID NO 291

<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 291

tctgcttcgc accttctgct 20

<210> SEQ ID NO 292
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 292

agtctgcttc gcaccttctg 20

<210> SEQ ID NO 293
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 293

tcagtctgct tcgcaccttc 20

<210> SEQ ID NO 294
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 294

cctcagtcctg cttcgcacct 20

<210> SEQ ID NO 295
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 295

agcctcagtc tgcttcgcac 20

<210> SEQ ID NO 296
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 296

gtagcctcag tctgcttcgc 20

<210> SEQ ID NO 297
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 297

tggtagcctc agtctgcttc 20

-continued

<210> SEQ ID NO 298
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 298

catggtagcc tcagtctgct

20

<210> SEQ ID NO 299
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 299

gtcatggtag cctcagtctg

20

<210> SEQ ID NO 300
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 300

atgtcatggt agcctcagtc

20

<210> SEQ ID NO 301
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 301

gaatgtcatg gtagcctcag

20

<210> SEQ ID NO 302
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 302

ttgaatgtca tggtagcctc

20

<210> SEQ ID NO 303
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 303

atttgaatgt catggtagcc

20

<210> SEQ ID NO 304
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 304

atatttgaat gtcattgtag

20

<210> SEQ ID NO 305

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 305

cagccacatg cagcttcagg

20

<210> SEQ ID NO 306

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 306

accagccaca tgcagcttca

20

<210> SEQ ID NO 307

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 307

ttaccagcca catgcagctt

20

<210> SEQ ID NO 308

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 308

ggttaccagc cacatgcagc

20

<210> SEQ ID NO 309

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 309

taggttacca gccacatgca

20

<210> SEQ ID NO 310

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 310

tttaggttac cagccacatg

20

<210> SEQ ID NO 311

<211> LENGTH: 20

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 311

cttttaggtt accagccaca                20

<210> SEQ ID NO 312
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 312

tccttttagg ttaccagcca                20

<210> SEQ ID NO 313
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 313

gctcctttta ggttaccagc                20

<210> SEQ ID NO 314
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 314

aggctccttt taggttacca                20

<210> SEQ ID NO 315
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 315

gtaggctcct tttaggttac                20

<210> SEQ ID NO 316
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 316

tggtaggctc ctttttaggt                20

<210> SEQ ID NO 317
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 317

tttggtaggc tccttttagg                20

```

-continued

<210> SEQ ID NO 318
 <211> LENGTH: 13993
 <212> TYPE: DNA
 <213> ORGANISM: H. sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1).. (13692)

<400> SEQUENCE: 318

atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg cct gcg	48
Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu Pro Ala	
1 5 10 15	
ctg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa atg ctg	96
Leu Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu Met Leu	
20 25 30	
gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc aag cac	144
Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe Lys His	
35 40 45	
ctc cgg aag tac aca tac aac tat gag gct gag agt tcc agt gga gtc	192
Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser Gly Val	
50 55 60	
cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc aag gtt	240
Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys Lys Val	
65 70 75 80	
gag ctg gag gtt ccc cag ctc tgc agc ttc atc ctg aag acc agc cag	288
Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr Ser Gln	
85 90 95	
tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa gcc ttg	336
Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys Ala Leu	
100 105 110	
ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg tcc agg	384
Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Met Ser Arg	
115 120 125	
tat gag ctc aag ctg gcc att cca gaa ggg aag cag gtt ttc ctt tac	432
Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe Leu Tyr	
130 135 140	
ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg ggc atc	480
Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg Gly Ile	
145 150 155 160	
att tct gcc ctc ctg gtt ccc cca gag aca gaa gaa gcc aag caa gtg	528
Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys Gln Val	
165 170 175	
ttg ttt ctg gat acc gtg tat gga aac tgc tcc act cac ttt acc gtc	576
Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe Thr Val	
180 185 190	
aag acg agg aag ggc aat gtg gca aca gaa ata tcc act gaa aga gac	624
Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu Arg Asp	
195 200 205	
ctg ggg cag tgt gat cgc ttc aag ccc atc cgc aca ggc atc agc cca	672
Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile Ser Pro	
210 215 220	
ctt gct ctc atc aaa ggc atg acc cgc ccc ttg tca act ctg atc agc	720
Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu Ile Ser	
225 230 235 240	
agc agc cag tcc tgt cag tac aca ctg gac gct aag agg aag cat gtg	768
Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys His Val	
245 250 255	
gca gaa gcc atc tgc aag gag caa cac ctc ttc ctg cct ttc tcc tac	816
Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe Ser Tyr	
260 265 270	

-continued

aag aat aag tat ggg atg gta gca caa gtg aca cag act ttg aaa ctt	864
Lys Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu Lys Leu	
275 280 285	
gaa gac aca cca aag atc aac agc cgc ttc ttt ggt gaa ggt act aag	912
Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly Thr Lys	
290 295 300	
aag atg ggc ctc gca ttt gag agc acc aaa tcc aca tca cct cca aag	960
Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro Pro Lys	
305 310 315 320	
cag gcc gaa gct gtt ttg aag act ctc cag gaa ctg aaa aaa cta acc	1008
Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys Leu Thr	
325 330 335	
atc tct gag caa aat atc cag aga gct aat ctc ttc aat aag ctg gtt	1056
Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys Leu Val	
340 345 350	
act gag ctg aga ggc ctc agt gat gaa gca gtc aca tct ctc ttg cca	1104
Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu Leu Pro	
355 360 365	
cag ctg att gag gtg tcc agc ccc atc act tta caa gcc ttg gtt cag	1152
Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu Val Gln	
370 375 380	
tgt gga cag cct cag tgc tcc act cac atc ctc cag tgg ctg aaa cgt	1200
Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu Lys Arg	
385 390 395 400	
gtg cat gcc aac ccc ctt ctg ata gat gtg gtc acc tac ctg gtg gcc	1248
Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu Val Ala	
405 410 415	
ctg atc ccc gag ccc tca gca cag cag ctg cga gag atc ttc aac atg	1296
Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe Asn Met	
420 425 430	
gcg agg gat cag cgc agc cga gcc acc ttg tat gcg ctg agc cac gcg	1344
Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser His Ala	
435 440 445	
gtc aac aac tat cat aag aca aac cct aca ggg acc cag gag ctg ctg	1392
Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu Leu Leu	
450 455 460	
gac att gct aat tac ctg atg gaa cag att caa gat gac tgc act ggg	1440
Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys Thr Gly	
465 470 475 480	
gat gaa gat tac acc tat ttg att ctg cgg gtc att gga aat atg ggc	1488
Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn Met Gly	
485 490 495	
caa acc atg gag cag tta act cca gaa ctc aag tct tca atc ctg aaa	1536
Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile Leu Lys	
500 505 510	
tgt gtc caa agt aca aag cca tca ctg atg atc cag aaa gct gcc atc	1584
Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala Ala Ile	
515 520 525	
cag gct ctg cgg aaa atg gag cct aaa gac aag gac cag gag gtt ctt	1632
Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu Val Leu	
530 535 540	
ctt cag act ttc ctt gat gat gct tct ccg gga gat aag cga ctg gct	1680
Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg Leu Ala	
545 550 555 560	
gcc tat ctt atg ttg atg agg agt cct tca cag gca gat att aac aaa	1728
Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile Asn Lys	
565 570 575	
att gtc caa att cta cca tgg gaa cag aat gag caa gtg aag aac ttt	1776
Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys Asn Phe	
580 585 590	

-continued

gtg gct tcc cat att gcc aat atc ttg aac tca gaa gaa ttg gat atc	1824
Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu Asp Ile	
595 600 605	
caa gat ctg aaa aag tta gtg aaa gaa gct ctg aaa gaa tct caa ctt	1872
Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser Gln Leu	
610 615 620	
cca act gtc atg gac ttc aga aaa ttc tct cgg aac tat caa ctc tac	1920
Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln Leu Tyr	
625 630 635 640	
aaa tct gtt tct ctt cca tca ctt gac cca gcc tca gcc aaa ata gaa	1968
Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys Ile Glu	
645 650 655	
ggg aat ctt ata ttt gat cca aat aac tac ctt cct aaa gaa agc atg	2016
Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu Ser Met	
660 665 670	
ctg aaa act acc ctc act gcc ttt gga ttt gct tca gct gac ctc atc	2064
Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp Leu Ile	
675 680 685	
gag att ggc ttg gaa gga aaa ggc ttt gag cca aca ttg gag gct cct	2112
Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu Ala Pro	
690 695 700	
ttt ggg aag caa gga ttt ttc cca gac agt gtc aac aaa gct ttg tac	2160
Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala Leu Tyr	
705 710 715 720	
tgg gtt aat ggt caa gtt cct gat ggt gtc tct aag gtc tta gtg gac	2208
Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu Val Asp	
725 730 735	
cac ttt ggc tat acc aaa gat gat aaa cat gag cag gat atg gta aat	2256
His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met Val Asn	
740 745 750	
gga ata atg ctc agt gtt gag aag ctg att aaa gat ttg aaa tcc aaa	2304
Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys Ser Lys	
755 760 765	
gaa gtc ccg gaa gcc aga gcc tac ctc cgc atc ttg gga gag gag ctt	2352
Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu Glu Leu	
770 775 780	
ggt ttt gcc agt ctc cat gac ctc cga ctc ctg gga aag ctg ctt ctg	2400
Gly Phe Ala Ser Leu His Asp Leu Arg Leu Leu Gly Lys Leu Leu Leu	
785 790 795 800	
atg ggt gcc cgc act ctg cag ggg atc ccc cag atg att gga gag gtc	2448
Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly Glu Val	
805 810 815	
atc agg aag ggc tca aag aat gac ttt ttt ctt cac tac atc ttc atg	2496
Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile Phe Met	
820 825 830	
gag aat gcc ttt gaa ctc ccc act gga gct gga tta cag ttg caa ata	2544
Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu Ile	
835 840 845	
tct tca tct gga gtc att gct ccc gga gcc aag gct gga gta aaa ctg	2592
Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val Lys Leu	
850 855 860	
gaa gta gcc aac atg cag gct gaa ctg gtg gca aaa ccc tcc gtg tct	2640
Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser Val Ser	
865 870 875 880	
gtg gag ttt gtg aca aat atg ggc atc atc att ccg gac ttc gct agg	2688
Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe Ala Arg	
885 890 895	
agt ggg gtc cag atg aac acc aac ttc ttc cac gag tcg ggt ctg gag	2736
Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly Leu Glu	
900 905 910	

-continued

gct cat gtt gcc cta aaa gct ggg aag ctg aag ttt atc att cct tcc	2784
Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile Pro Ser	
915 920 925	
cca aag aga cca gtc aag ctg ctc agt gga ggc aac aca tta cat ttg	2832
Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu His Leu	
930 935 940	
gtc tct acc acc aaa acg gag gtc atc cca cct ctc att gag aac agg	2880
Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu Asn Arg	
945 950 955 960	
cag tcc tgg tca gtt tgc aag caa gtc ttt cct ggc ctg aat tac tgc	2928
Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn Tyr Cys	
965 970 975	
acc tca ggc gct tac tcc aac gcc agc tcc aca gac tcc gcc tcc tac	2976
Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala Ser Tyr	
980 985 990	
tat ccg ctg acc ggg gac acc aga tta gag ctg gaa ctg agg cct aca	3024
Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg Pro Thr	
995 1000 1005	
gga gag att gag cag tat tct gtc agc gca acc tat gag ctc cag aga	3072
Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu Gln Arg	
1010 1015 1020	
gag gac aga gcc ttg gtg gat acc ctg aag ttt gta act caa gca gaa	3120
Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln Ala Glu	
1025 1030 1035 1040	
ggc gcg aag cag act gag gct acc atg aca ttc aaa tat aat cgg cag	3168
Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn Arg Gln	
1045 1050 1055	
agt atg acc ttg tcc agt gaa gtc caa att ccg gat ttt gat gtt gac	3216
Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp Val Asp	
1060 1065 1070	
ctc gga aca atc ctc aga gtt aat gat gaa tct act gag ggc aaa acg	3264
Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly Lys Thr	
1075 1080 1085	
tct tac aga ctc acc ctg gac att cag aac aag aaa att act gag gtc	3312
Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr Glu Val	
1090 1095 1100	
gcc ctc atg ggc cac cta agt tgt gac aca aag gaa gaa aga aaa atc	3360
Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg Lys Ile	
1105 1110 1115 1120	
aag ggt gtt att tcc ata ccc cgt ttg caa gca gaa gcc aga agt gag	3408
Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg Ser Glu	
1125 1130 1135	
atc ctc gcc cac tgg tgc cct gcc aaa ctg ctt ctc caa atg gac tca	3456
Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met Asp Ser	
1140 1145 1150	
tct gct aca gct tat ggc tcc aca gtt tcc aag agg gtg gca tgg cat	3504
Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala Trp His	
1155 1160 1165	
tat gat gaa gag aag att gaa ttt gaa tgg aac aca ggc acc aat gta	3552
Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr Asn Val	
1170 1175 1180	
gat acc aaa aaa atg act tcc aat ttc cct gtg gat ctc tcc gat tat	3600
Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser Asp Tyr	
1185 1190 1195 1200	
cct aag agc ttg cat atg tat gct aat aga ctc ctg gat cac aga gtc	3648
Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His Arg Val	
1205 1210 1215	
cct caa aca gac atg act ttc cgg cac gtg ggt tcc aaa tta ata gtt	3696
Pro Gln Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu Ile Val	
1220 1225 1230	

-continued

gca atg agc tca tgg ctt cag aag gca tct ggg agt ctt cct tat acc	3744
Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro Tyr Thr	
1235 1240 1245	
cag act ttg caa gac cac ctc aat agc ctg aag gag ttc aac ctc cag	3792
Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn Leu Gln	
1250 1255 1260	
aac atg gga ttg cca gac tcc cac atc cca gaa aac ctc ttc tta aaa	3840
Asn Met Gly Leu Pro Asp Ser His Ile Pro Glu Asn Leu Phe Leu Lys	
1265 1270 1275 1280	
agc gat ggc cgc gtc aaa tat acc ttg aac aag aac agt ttg aaa att	3888
Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu Lys Ile	
1285 1290 1295	
gag att cct ttg cct ttt ggt ggc aaa tcc tcc aga gat cta aag atg	3936
Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu Lys Met	
1300 1305 1310	
tta gag act gtt agg aca cca gcc ctc cac ttc aag tct gtg gga ttc	3984
Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val Gly Phe	
1315 1320 1325	
cat ctg cca tct cga gag ttc caa gtc cct act ttt acc att ccc aag	4032
His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile Pro Lys	
1330 1335 1340	
ttg tat caa ctg caa gtg cct ctc ctg ggt gtt cta gac ctc tcc acg	4080
Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu Ser Thr	
1345 1350 1355 1360	
aat gtc tac agc aac ttg tac aac tgg tcc gcc tcc tac agt ggt ggc	4128
Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser Gly Gly	
1365 1370 1375	
aac acc agc aca gac cat ttc agc ctt cgg gct cgt tac cac atg aag	4176
Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His Met Lys	
1380 1385 1390	
gct gac tct gtg gtt gac ctg ctt tcc tac aat gtg caa gga tct gga	4224
Ala Asp Ser Val Val Asp Leu Ser Tyr Asn Val Gln Gly Ser Gly	
1395 1400 1405	
gaa aca aca tat gac cac aag aat acg ttc aca cta tca tgt gat ggg	4272
Glu Thr Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys Asp Gly	
1410 1415 1420	
tct cta cgc cac aaa ttt cta gat tcg aat atc aaa ttc agt cat gta	4320
Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser His Val	
1425 1430 1435 1440	
gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata ttc gat	4368
Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile Phe Asp	
1445 1450 1455	
gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat ttg gac	4416
Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His Leu Asp	
1460 1465 1470	
tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att gat ggg	4464
Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile Asp Gly	
1475 1480 1485	
cag ttc aga gtc tct tcg ttc tat gct aaa ggc aca tat ggc ctg tct	4512
Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly Leu Ser	
1490 1495 1500	
tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc aac ctg	4560
Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser Asn Leu	
1505 1510 1515 1520	
agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca gga aga	4608
Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr Gly Arg	
1525 1530 1535	
tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg caa agt	4656
Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu Gln Ser	
1540 1545 1550	

-continued

ggc atc att aaa aat act gct tcc cta aag tat gag aac tac gag ctg	4704
Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr Glu Leu	
1555 1560 1565	
act tta aaa tct gac acc aat ggg aag tat aag aac ttt gcc act tct	4752
Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala Thr Ser	
1570 1575 1580	
aac aag atg gat atg acc ttc tct aag caa aat gca ctg ctg cgt tct	4800
Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu Arg Ser	
1585 1590 1595 1600	
gaa tat cag gct gat tac gag tca ttg agg ttc ttc agc ctg ctt tct	4848
Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu Leu Ser	
1605 1610 1615	
gga tca cta aat tcc cat ggt ctt gag tta aat gct gac atc tta ggc	4896
Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile Leu Gly	
1620 1625 1630	
act gac aaa att aat agt ggt gct cac aag gcg aca cta agg att ggc	4944
Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg Ile Gly	
1635 1640 1645	
caa gat gga ata tct acc agt gca acg acc aac ttg aag tgt agt ctc	4992
Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys Ser Leu	
1650 1655 1660	
ctg gtg ctg gag aat gag ctg aat gca gag ctt ggc ctc tct ggg gca	5040
Leu Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser Gly Ala	
1665 1670 1675 1680	
tct atg aaa tta aca aca aat ggc cgc ttc agg gaa cac aat gca aaa	5088
Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn Ala Lys	
1685 1690 1695	
ttc agt ctg gat ggg aaa gcc gcc ctc aca gag cta tca ctg gga agt	5136
Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu Gly Ser	
1700 1705 1710	
gct tat cag gcc atg att ctg ggt gtc gac agc aaa aac att ttc aac	5184
Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile Phe Asn	
1715 1720 1725	
ttc aag gtc agt caa gaa gga ctt aag ctc tca aat gac atg atg ggc	5232
Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met Met Gly	
1730 1735 1740	
tca tat gct gaa atg aaa ttt gac cac aca aac agt ctg aac att gca	5280
Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn Ile Ala	
1745 1750 1755 1760	
ggc tta tca ctg gac ttc tct tca aaa ctt gac aac att tac agc tct	5328
Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile Tyr Ser Ser	
1765 1770 1775	
gac aag ttt tat aag caa act gtt aat tta cag cta cag ccc tat tct	5376
Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu Gln Pro Tyr Ser	
1780 1785 1790	
ctg gta act act tta aac agt gac ctg aaa tac aat gct ctg gat ctc	5424
Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu Asp Leu	
1795 1800 1805	
acc aac aat ggg aaa cta cgg cta gaa ccc ctg aag ctg cat gtg gct	5472
Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His Val Ala	
1810 1815 1820	
ggt aac cta aaa gga gcc tac caa aat aat gaa ata aaa cac atc tat	5520
Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His Ile Tyr	
1825 1830 1835 1840	
gcc atc tct tct gct gcc tta tca gca agc tat aaa gca gac act gtt	5568
Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp Thr Val	
1845 1850 1855	
gct aag gtt cag ggt gtg gag ttt agc cat ggg ctc aac aca gac atc	5616
Ala Lys Val Gln Gly Val Glu Phe Ser His Gly Leu Asn Thr Asp Ile	
1860 1865 1870	

-continued

gct ggg ctg gct tca gcc att gac atg agc aca aac tat aat tca gac Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn Ser Asp 1875 1880 1885	5664
tca ctg cat ttc agc aat gtc ttc cgt tct gta atg gcc ccg ttt acc Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro Phe Thr 1890 1895 1900	5712
atg acc atc gat gca cat aca aat ggc aat ggg aaa ctc gct ctc tgg Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala Leu Trp 1905 1910 1915 1920	5760
gga gaa cat act ggg cag ctg tat agc aaa ttc ctg ttg aaa gca gaa Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys Ala Glu 1925 1930 1935	5808
cct ctg gca ttt act ttc tct cat gat tac aaa ggc tcc aca agt cat Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr Ser His 1940 1945 1950	5856
cat ctc gtg tct agg aaa agc atc agt gca gct ctt gaa cac aaa gtc His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His Lys Val 1955 1960 1965	5904
agt gcc ctg ctt act cca gct gag cag aca ggc acc tgg aaa ctc aag Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys Leu Lys 1970 1975 1980	5952
acc caa ttt aac aac aat gaa tac agc cag gac ttg gat gct tac aac Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala Tyr Asn 1985 1990 1995 2000	6000
act aaa gat aaa att ggc gtg gag ctt act gga cga act ctg gct gac Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu Ala Asp 2005 2010 2015	6048
cta act cta cta gac tcc cca att aaa gtg cca ctt tta ctc agt gag Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu Ser Glu 2020 2025 2030	6096
ccc atc aat atc aat gat gct tta gag atg aga gat gcc gtt gag aag Pro Ile Asn Ile Asn Asp Ala Leu Glu Met Arg Asp Ala Val Glu Lys 2035 2040 2045	6144
ccc caa gaa ttt aca att gtt gct ttt gta aag tat gat aaa aac caa Pro Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys Asn Gln 2050 2055 2060	6192
gat gtt cac tcc att aac ctc cca ttt ttt gag acc ttg caa gaa tat Asp Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln Glu Tyr 2065 2070 2075 2080	6240
ttt gag agg aat cga caa acc att ata gtt gta ctg gaa aac gta cag Phe Glu Arg Asn Arg Gln Thr Ile Ile Val Val Leu Glu Asn Val Gln 2085 2090 2095	6288
aga aac ctg aag cac atc aat att gat caa ttt gta aga aaa tac aga Arg Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys Tyr Arg 2100 2105 2110	6336
gca gcc ctg gga aaa ctc cca cag caa gct aat gat tat ctg aat tca Ala Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu Asn Ser 2115 2120 2125	6384
ttc aat tgg gag aga caa gtt tca cat gcc aag gag aaa ctg act gct Phe Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu Thr Ala 2130 2135 2140	6432
ctc aca aaa aag tat aga att aca gaa aat gat ata caa att gca tta Leu Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile Ala Leu 2145 2150 2155 2160	6480
gat gat gcc aaa atc aac ttt aat gaa aaa cta tct caa ctg cag aca Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu Gln Thr 2165 2170 2175	6528
tat atg ata caa ttt gat cag tat att aaa gat agt tat gat tta cat Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp Leu His 2180 2185 2190	6576

-continued

gat ttg aaa ata gct att gct aat att att gat gaa atc att gaa aaa Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile Glu Lys 2195 2200 2205	6624
tta aaa agt ctt gat gag cac tat cat acc cgt gta aat tta gta aaa Leu Lys Ser Leu Asp Glu His Tyr His Thr Arg Val Asn Leu Val Lys 2210 2215 2220	6672
aca atc cat gat cta cat ttg ttt att gaa aat att gat ttt aac aaa Thr Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe Asn Lys 2225 2230 2235 2240	6720
agt gga agt agt act gca tcc tgg att caa aat gtg gat act aag tac Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr Lys Tyr 2245 2250 2255	6768
caa atc aga atc cag ata caa gaa aaa ctg cag cag ctt aag aga cac Gln Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys Arg His 2260 2265 2270	6816
ata cag aat ata gac atc cag cac cta gct gga aag tta aaa caa cac Ile Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys Gln His 2275 2280 2285	6864
att gag gct att gat gtt aga gtg ctt tta gat caa ttg gga act aca Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly Thr Thr 2290 2295 2300	6912
att tca ttt gaa aga ata aat gat gtt ctt gag cat gtc aaa cac ttt Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys His Phe 2305 2310 2315 2320	6960
gtt ata aat ctt att ggg gat ttt gaa gta gct gag aaa atc aat gcc Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile Asn Ala 2325 2330 2335	7008
ttc aga gcc aaa gtc cat gag tta atc gag agg tat gaa gta gac caa Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val Asp Gln 2340 2345 2350	7056
caa atc cag gtt tta atg gat aaa tta gta gag ttg gcc cac caa tac Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Ala His Gln Tyr 2355 2360 2365	7104
aag ttg aag gag act att cag aag cta agc aat gtc cta caa caa gtt Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln Gln Val 2370 2375 2380	7152
aag ata aaa gat tac ttt gag aaa ttg gtt gga ttt att gat gat gct Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp Asp Ala 2385 2390 2395 2400	7200
gtc aag aag ctt aat gaa tta tct ttt aaa aca ttc att gaa gat gtt Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu Asp Val 2405 2410 2415	7248
aac aaa ttc ctt gac atg ttg ata aag aaa tta aag tca ttt gat tac Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe Asp Tyr 2420 2425 2430	7296
cac cag ttt gta gat gaa acc aat gac aaa atc cgt gag gtg act cag His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val Thr Gln 2435 2440 2445	7344
aga ctc aat ggt gaa att cag gct ctg gaa cta cca caa aaa gct gaa Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys Ala Glu 2450 2455 2460	7392
gca tta aaa ctg ttt tta gag gaa acc aag gcc aca gtt gca gtg tat Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala Val Tyr 2465 2470 2475 2480	7440
ctg gaa agc cta cag gac acc aaa ata acc tta atc atc aat tgg tta Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn Trp Leu 2485 2490 2495	7488
cag gag gct tta agt tca gca tct ttg gct cac atg aag gcc aaa ttc Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala Lys Phe 2500 2505 2510	7536

-continued

cga gag act cta gaa gat aca cga gac cga atg tat caa atg gac att Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met Asp Ile 2515 2520 2525	7584
cag cag gaa ctt caa cga tac ctg tct ctg gta ggc cag gtt tat agc Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val Tyr Ser 2530 2535 2540	7632
aca ctt gtc acc tac att tct gat tgg tgg act ctt gct gct aag aac Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala Lys Asn 2545 2550 2555 2560	7680
ctt act gac ttt gca gag caa tat tct atc caa gat tgg gct aaa cgt Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala Lys Arg 2565 2570 2575	7728
atg aaa gca ttg gta gag caa ggg ttc act gtt cct gaa atc aag acc Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile Lys Thr 2580 2585 2590	7776
atc ctt ggg acc atg cct gcc ttt gaa gtc agt ctt cag gct ctt cag Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala Leu Gln 2595 2600 2605	7824
aaa gct acc ttc cag aca cct gat ttt ata gtc ccc cta aca gat ttg Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr Asp Leu 2610 2615 2620	7872
agg att cca tca gtt cag ata aac ttc aaa gac tta aaa aat ata aaa Arg Ile Pro Ser Val Gln Ile Asn Phe Lys Asp Leu Lys Asn Ile Lys 2625 2630 2635 2640	7920
atc cca tcc agg ttt tcc aca cca gaa ttt acc atc ctt aac acc ttc Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn Thr Phe 2645 2650 2655	7968
cac att cct tcc ttt aca att gac ttt gta gaa atg aaa gta aag atc His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val Lys Ile 2660 2665 2670	8016
atc aga acc att gac cag atg ctg aac agt gag ctg cag tgg ccc gtt Ile Arg Thr Ile Asp Gln Met Leu Asn Ser Glu Leu Gln Trp Pro Val 2675 2680 2685	8064
cca gat ata tat ctc agg gat ctg aag gtg gag gac att cct cta gcg Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp Ile Pro Leu Ala 2690 2695 2700	8112
aga atc acc ctg cca gac ttc cgt tta cca gaa atc gca att cca gaa Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu Ile Ala Ile Pro Glu 2705 2710 2715 2720	8160
ttc ata atc cca act ctc aac ctt aat gat ttt caa gtt cct gac ctt Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp Phe Gln Val Pro Asp Leu 2725 2730 2735	8208
cac ata cca gaa ttc cag ctt ccc cac atc tca cac aca att gaa gta His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His Thr Ile Glu Val 2740 2745 2750	8256
cct act ttt ggc aag cta tac agt att ctg aaa atc caa tct cct ctt Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys Ile Gln Ser Pro Leu 2755 2760 2765	8304
ttc aca tta gat gca aat gct gac ata ggg aat gga acc acc tca gca Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly Asn Gly Thr Thr Ser Ala 2770 2775 2780	8352
aac gaa gca ggt atc gca gct tcc atc act gcc aaa gga gag tcc aaa Asn Glu Ala Gly Ile Ala Ala Ser Ile Thr Ala Lys Gly Glu Ser Lys 2785 2790 2795 2800	8400
tta gaa gtt ctc aat ttt gat ttt caa gca aat gca caa ctc tca aac Leu Glu Val Leu Asn Phe Asp Phe Gln Ala Asn Ala Gln Leu Ser Asn 2805 2810 2815	8448
cct aag att aat ccg ctg gct ctg aag gag tca gtg aag ttc tcc agc Pro Lys Ile Asn Pro Leu Ala Leu Lys Glu Ser Val Lys Phe Ser Ser 2820 2825 2830	8496

-continued

aag tac ctg aga acg gag cat ggg agt gaa atg ctg ttt ttt gga aat Lys Tyr Leu Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe Gly Asn 2835 2840 2845	8544
gct att gag gga aaa tca aac aca gtg gca agt tta cac aca gaa aaa Ala Ile Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr Glu Lys 2850 2855 2860	8592
aat aca ctg gag ctt agt aat gga gtg att gtc aag ata aac aat cag Asn Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn Asn Gln 2865 2870 2875 2880	8640
ctt acc ctg gat agc aac act aaa tac ttc cac aaa ttg aac atc ccc Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn Ile Pro 2885 2890 2895	8688
aaa ctg gac ttc tct agt cag gct gac ctg cgc aac gag atc aag aca Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile Lys Thr 2900 2905 2910	8736
ctg ttg aaa gct ggc cac ata gca tgg act tct tct gga aaa ggg tca Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys Gly Ser 2915 2920 2925	8784
tggtg aaa tgg gcc tgc ccc aga ttc tca gat gag gga aca cat gaa tca Trp Lys Trp Ala Ser Pro Arg Phe Ser Asp Glu Gly Thr His Glu Ser 2930 2935 2940	8832
caa att agt ttc acc ata gaa gga ccc ctc act tcc ttt gga ctg tcc Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly Leu Ser 2945 2950 2955 2960	8880
aat aag atc aat agc aaa cac cta aga gta aac caa aac ttg gtt tat Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn Leu Val Tyr 2965 2970 2975	8928
gaa tct ggc tcc ctc aac ttt tct aaa ctt gaa att caa tca caa gtc Glu Ser Gly Ser Leu Asn Phe Ser Lys Leu Glu Ile Gln Ser Gln Val 2980 2985 2990	8976
gat tcc cag cat gtg ggc cac agt gtt cta act gct aaa ggc atg gca Asp Ser Gln His Val Gly His Ser Val Leu Thr Ala Lys Gly Met Ala 2995 3000 3005	9024
ctg ttt gga gaa ggg aag gca gag ttt act ggg agg cat gat gct cat Leu Phe Gly Glu Gly Lys Ala Glu Phe Thr Gly Arg His Asp Ala His 3010 3015 3020	9072
tta aat gga aag gtt att gga act ttg aaa aat tct ctt ttc ttt tca Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe Phe Ser 3025 3030 3035 3040	9120
gcc cag cca ttt gag atc acg gca tcc aca aac aat gaa ggg aat ttg Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly Asn Leu 3045 3050 3055	9168
aaa gtt cgt ttt cca tta agg tta aca ggg aag ata gac ttc ctg aat Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe Leu Asn 3060 3065 3070	9216
aac tat gca ctg ttt ctg agt ccc agt gcc cag caa gca agt tgg caa Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser Trp Gln 3075 3080 3085	9264
gta agt gct agg ttc aat cag tat aag tac aac caa aat ttc tct gct Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe Ser Ala 3090 3095 3100	9312
gga aac aac gag aac att atg gag gcc cat gta gga ata aat gga gaa Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn Gly Glu 3105 3110 3115 3120	9360
gca aat ctg gat ttc tta aac att cct tta aca att cct gaa atg cgt Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu Met Arg 3125 3130 3135	9408
cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc tct cta Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe Ser Leu 3140 3145 3150	9456

egg	gaa	aaa	aca	ggc	ttg	aag	gaa	ttc	ttg	aaa	acg	aca	aag	caa	tca	9504																																															
Trp	Glu	Lys	Thr	Gly	Leu	Lys	Glu	Phe	Leu	Lys	Thr	Thr	Lys	Gln	Ser																																																
3155																3160																3165																															
ttt	gat	tta	agt	gta	aaa	gct	cag	tat	aag	aaa	aac	aaa	cac	agg	cat	9552																																															
Phe	Asp	Leu	Ser	Val	Lys	Ala	Gln	Tyr	Lys	Lys	Asn	Lys	His	Arg	His																																																
3170																3175																3180																															
tcc	atc	aca	aat	cct	ttg	gct	gtg	ctt	tgt	gag	ttt	atc	agt	cag	agc	9600																																															
Ser	Ile	Thr	Asn	Pro	Leu	Ala	Val	Leu	Cys	Glu	Phe	Ile	Ser	Gln	Ser																																																
3185																3190																3195																3200															
atc	aaa	tcc	ttt	gac	agg	cat	ttt	gaa	aaa	aac	aga	aac	aat	gca	tta	9648																																															
Ile	Lys	Ser	Phe	Asp	Arg	His	Phe	Glu	Lys	Asn	Arg	Asn	Asn	Ala	Leu																																																
3205																3210																3215																															
gat	ttt	gtc	acc	aaa	tcc	tat	aat	gaa	aca	aaa	att	aag	ttt	gat	aag	9696																																															
Asp	Phe	Val	Thr	Lys	Ser	Tyr	Asn	Glu	Thr	Lys	Ile	Lys	Phe	Asp	Lys																																																
3220																3225																3230																															
tac	aaa	gct	gaa	aaa	tct	cac	gac	gag	ctc	ccc	agg	acc	ttt	caa	att	9744																																															
Tyr	Lys	Ala	Glu	Lys	Ser	His	Asp	Glu	Leu	Pro	Arg	Thr	Phe	Gln	Ile																																																
3235																3240																3245																															
cct	gga	tac	act	gtt	cca	gtt	gtc	aat	gtt	gaa	gtg	tct	cca	ttc	acc	9792																																															
Pro	Gly	Tyr	Thr	Val	Pro	Val	Val	Asn	Val	Glu	Val	Ser	Pro	Phe	Thr																																																
3250																3255																3260																															
ata	gag	atg	tcg	gca	ttc	ggc	tat	gtg	ttc	cca	aaa	gca	gtc	agc	atg	9840																																															
Ile	Glu	Met	Ser	Ala	Phe	Gly	Tyr	Val	Phe	Pro	Lys	Ala	Val	Ser	Met																																																
3265																3270																3275																3280															
cct	agt	ttc	tcc	atc	ata	ggc	tct	gac	gtc	cgt	gtg	cct	tca	tac	aca	9888																																															
Pro	Ser	Phe	Ser	Ile	Ile	Gly	Ser	Asp	Val	Arg	Val	Pro	Ser	Tyr	Thr																																																
3285																3290																3295																															
tta	atc	ctg	cca	tca	tta	gag	ctg	cca	gtc	ctt	cat	gtc	cct	aga	aat	9936																																															
Leu	Ile	Leu	Pro	Ser	Leu	Glu	Leu	Pro	Val	Leu	His	Val	Pro	Arg	Asn																																																
3300																3305																3310																															
ctc	aag	ctt	tct	ctt	cca	gat	ttc	aag	gaa	ttg	tgt	acc	ata	agc	cat	9984																																															
Leu	Lys	Leu	Ser	Leu	Pro	Asp	Phe	Lys	Glu	Leu	Cys	Thr	Ile	Ser	His																																																
3315																3320																3325																															
att	ttt	att	cct	gcc	atg	ggc	aat	att	acc	tat	gat	ttc	tcc	ttt	aaa	10032																																															
Ile	Phe	Ile	Pro	Ala	Met	Gly	Asn	Ile	Thr	Tyr	Asp	Phe	Ser	Phe	Lys																																																
3330																3335																3340																															
tca	agt	gtc	atc	aca	ctg	aat	acc	aat	gct	gaa	ctt	ttt	aac	cag	tca	10080																																															
Ser	Ser	Val	Ile	Thr	Leu	Asn	Thr	Asn	Ala	Glu	Leu	Phe	Asn	Gln	Ser																																																
3345																3350																3355																3360															
gat	att	gtt	gct	cat	ctc	ctt	tct	tca	tct	tca	tct	gtc	att	gat	gca	10128																																															
Val	Ala	Val	Ala	His	Leu	Leu	Ser	Ser	Ser	Ser	Ser	Val	Ile	Asp	Ala																																																
3365																3370																3375																															
ctg	cag	tac	aaa	tta	gag	ggc	acc	aca	aga	ttg	aca	aga	aaa	agg	gga	10176																																															
Leu	Gln	Tyr	Lys	Leu	Glu	Gly	Thr	Thr	Arg	Leu	Thr	Arg	Lys	Arg	Gly																																																
3380																3385																3390																															
ttg	aag	tta	gcc	aca	gct	ctg	tct	ctg	agc	aac																																																					

-continued

gct aaa gga gca gtt gac cac aag ctt agc ttg gaa agc ctc acc tct Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu Thr Ser 3475 3480 3485	10464
tac ttt tcc att gag tca tct acc aaa gga gat gtc aag ggt tcg gtt Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly Ser Val 3490 3495 3500	10512
ctt tct cgg gaa tat tca gga act att gct agt gag gcc aac act tac Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn Thr Tyr 3505 3510 3515 3520	10560
ttg aat tcc aag agc aca cgg tct tca gtg aag ctg cag gcc act tcc Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly Thr Ser 3525 3530 3535	10608
aaa att gat gat atc tgg aac ctt gaa gta aaa gaa aat ttt gct gga Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe Ala Gly 3540 3545 3550	10656
gaa gcc aca ctc caa cgc ata tat tcc ctc tgg gag cac agt acg aaa Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser Thr Lys 3555 3560 3565	10704
aac cac tta cag cta gag gcc ctc ttt ttc acc aac gga gaa cat aca Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu His Thr 3570 3575 3580	10752
agc aaa gcc acc ctg gaa ctc tct cca tgg caa atg tca gct ctt gtt Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala Leu Val 3585 3590 3595 3600	10800
cag gtc cat gca agt cag ccc agt tcc ttc cat gat ttc cct gac ctt Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro Asp Leu 3605 3610 3615	10848
ggc cag gaa gtg gcc ctg aat gct aac act aag aac cag aag atc aga Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys Ile Arg 3620 3625 3630	10896
tgg aaa aat gaa gtc cgg att cat tct ggg tct ttc cag agc cag gtc Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser Gln Val 3635 3640 3645	10944
gag ctt tcc aat gac caa gaa aag gca cac ctt gac att gca gga tcc Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala Gly Ser 3650 3655 3660	10992
tta gaa gga cac cta agg ttc ctc aaa aat atc atc cta cca gtc tat Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro Val Tyr 3665 3670 3675 3680	11040
gac aag agc tta tgg gat ttc cta aag ctg gat gtc acc acc agc att Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr Ser Ile 3685 3690 3695	11088
ggt agg aga cag cat ctt cgt gtt tca act gcc ttt gtg tac acc aaa Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr Thr Lys 3700 3705 3710	11136
aac ccc aat ggc tat tca ttc tcc atc cct gta aaa gtt ttg gct gat Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu Ala Asp 3715 3720 3725	11184
aaa ttc att att cct ggg ctg aaa cta aat gat cta aat tca gtt ctt Lys Phe Ile Ile Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser Val Leu 3730 3735 3740	11232
gtc atg cct acg ttc cat gtc cca ttt aca gat ctt cag gtt cca tcg Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val Pro Ser 3745 3750 3755 3760	11280
tgc aaa ctt gac ttc aga gaa ata caa atc tat aag aag ctg aga act Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu Arg Thr 3765 3770 3775	11328
tca tca ttt gcc ctc acc cta cca aca ctc ccc gag gta aaa ttc cct Ser Ser Phe Ala Leu Thr Leu Pro Thr Leu Pro Glu Val Lys Phe Pro 3780 3785 3790	11376

-continued

gaa gtt gat gtg tta aca aaa tat tct caa cca gaa gac tcc ttg att Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser Leu Ile 3795 3800 3805	11424
ccc ttt ttt gag ata acc gtg cct gaa tct cag tta act gtg tcc cag Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val Ser Gln 3810 3815 3820	11472
ttc acg ctt cca aaa agt gtt tca gat ggc att gct gct ttg gat cta Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu Asp Leu 3825 3830 3835 3840	11520
aat gca gta gcc aac aag atc gca gac ttt gag ttg ccc acc atc atc Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr Ile Ile 3845 3850 3855	11568
gtg cct gag cag acc att gag att ccc tcc att aag ttc tct gta cct Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser Val Pro 3860 3865 3870	11616
gct gga att gtc att cct tcc ttt caa gca ctg act gca cgc ttt gag Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg Phe Glu 3875 3880 3885	11664
gta gac tct ccc gtg tat aat gcc act tgg agt gcc agt ttg aaa aac Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu Lys Asn 3890 3895 3900	11712
aaa gca gat tat gtt gaa aca gtc ctg gat tcc aca tgc agc tca acc Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser Ser Thr 3905 3910 3915 3920	11760
gta cag ttc cta gaa tat gaa cta aat gtt ttg gga aca cac aaa atc Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His Lys Ile 3925 3930 3935	11808
gaa gat ggt acg tta gcc tct aag act aaa gga aca ctt gca cac cgt Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala His Arg 3940 3945 3950	11856
gac ttc agt gca gaa tat gaa gaa gat ggc aaa tat gaa gga ctt cag Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Tyr Glu Gly Leu Gln 3955 3960 3965	11904
gaa tgg gaa gga aaa gcg cac ctc aat atc aaa agc cca gcg ttc acc Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala Phe Thr 3970 3975 3980	11952
gat ctc cat ctg cgc tac cag aaa gac aag aaa ggc atc tcc acc tca Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser Thr Ser 3985 3990 3995 4000	12000
gca gcc tcc cca gcc gta ggc acc gtg ggc atg gat atg gat gaa gat Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp Glu Asp 4005 4010 4015	12048
gac gac ttt tct aaa tgg aac ttc tac tac agc cct cag tcc tct cca Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser Ser Pro 4020 4025 4030	12096
gat aaa aaa ctc acc ata ttc aaa act gag ttg agg gtc cgg gaa tct Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg Glu Ser 4035 4040 4045	12144
gat gag gaa act cag atc aaa gtt aat tgg gaa gaa gag gca gct tct Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala Ala Ser 4050 4055 4060	12192
ggc ttg cta acc tct ctg aaa gac aac gtg ccc aag gcc aca ggg gtc Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr Gly Val 4065 4070 4075 4080	12240
ctt tat gat tat gtc aac aag tac cac tgg gaa cac aca ggg ctc acc Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly Leu Thr 4085 4090 4095	12288
ctg aga gaa gtg tct tca aag ctg aga aga aat ctg cag aac aat gct Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn Asn Ala 4100 4105 4110	12336

-continued

gag tgg gtt tat caa ggg gcc att agg caa att gat gat atc gac gtg Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile Asp Val 4115 4120 4125	12384
agg ttc cag aaa gca gcc agt ggc acc act ggg acc tac caa gag tgg Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln Glu Trp 4130 4135 4140	12432
aag gac aag gcc cag aat ctg tac cag gaa ctg ttg act cag gaa ggc Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln Glu Gly 4145 4150 4155 4160	12480
caa gcc agt ttc cag gga ctc aag gat aac gtg ttt gat ggc ttg gta Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly Leu Val 4165 4170 4175	12528
cga gtt act caa aaa ttc cat atg aaa gtc aag aag ctg att gac tca Arg Val Thr Gln Lys Phe His Met Lys Val Lys Lys Leu Ile Asp Ser 4180 4185 4190	12576
ctc att gat ttt ctg aac ttc ccc aga ttc cag ttt ccg ggg aaa cct Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly Lys Pro 4195 4200 4205	12624
ggg ata tac act agg gag gaa ctt tgc act atg ttc atg agg gag gta Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Met Arg Glu Val 4210 4215 4220	12672
ggg acg gta ctg tcc cag gta tat tcg aaa gtc cat aat ggt tca gaa Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly Ser Glu 4225 4230 4235 4240	12720
ata ctg ttt tcc tat ttc caa gac cta gtg att aca ctt cct ttc gag Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro Phe Glu 4245 4250 4255	12768
tta agg aaa cat aaa cta ata gat gta atc tcg atg tat agg gaa ctg Leu Arg Lys His Lys Leu Ile Asp Val Ile Ser Met Tyr Arg Glu Leu 4260 4265 4270	12816
ttg aaa gat tta tca aaa gaa gcc caa gag gta ttt aaa gcc att cag Leu Lys Asp Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala Ile Gln 4275 4280 4285	12864
tct ctc aag acc aca gag gtg cta cgt aat ctt cag gac ctt tta caa Ser Leu Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu Leu Gln 4290 4295 4300	12912
ttc att ttc caa cta ata gaa gat aac att aaa cag ctg aaa gag atg Phe Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys Glu Met 4305 4310 4315 4320	12960
aaa ttt act tat ctt att aat tat atc caa gat gag atc aac aca atc Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn Thr Ile 4325 4330 4335	13008
ttc aat gat tat atc cca tat gtt ttt aaa ttg ttg aaa gaa aac cta Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu Asn Leu 4340 4345 4350	13056
tgc ctt aat ctt cat aag ttc aat gaa ttt att caa aac gag ctt cag Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu Leu Gln 4355 4360 4365	13104
gaa gct tct caa gag tta cag cag atc cat caa tac att atg gcc ctt Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met Ala Leu 4370 4375 4380	13152
cgt gaa gaa tat ttt gat cca agt ata gtt ggc tgg aca gtg aaa tat Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val Lys Tyr 4385 4390 4395 4400	13200
tat gaa ctt gaa gaa aag ata gtc agt ctg atc aag aac ctg tta gtt Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn Leu Leu Val 4405 4410 4415	13248
gct ctt aag gac ttc cat tct gaa tat att gtc agt gcc tct aac ttt Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser Ala Ser Asn Phe 4420 4425 4430	13296

-continued

act tcc caa ctc tca agt caa gtt gag caa ttt ctg cac aga aat att	13344
Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe Leu His Arg Asn Ile	
4435 4440 4445	
cag gaa tat ctt agc atc ctt acc gat cca gat gga aaa ggg aaa gag	13392
Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro Asp Gly Lys Gly Lys Glu	
4450 4455 4460	
aag att gca gag ctt tct gcc act gct cag gaa ata att aaa agc cag	13440
Lys Ile Ala Glu Leu Ser Ala Thr Ala Gln Glu Ile Ile Lys Ser Gln	
4465 4470 4475 4480	
gcc att gcg acg aag aaa ata att tct gat tac cac cag cag ttt aga	13488
Ala Ile Ala Thr Lys Lys Ile Ile Ser Asp Tyr His Gln Gln Phe Arg	
4485 4490 4495	
tat aaa ctg caa gat ttt tca gac caa ctc tct gat tac tat gaa aaa	13536
Tyr Lys Leu Gln Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr Glu Lys	
4500 4505 4510	
ttt att gct gaa tcc aaa aga ttg att gac ctg tcc att caa aac tac	13584
Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln Asn Tyr	
4515 4520 4525	
cac aca ttt ctg ata tac atc acg gag tta ctg aaa aag ctg caa tca	13632
His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser	
4530 4535 4540	
acc aca gtc atg aac ccc tac atg aag ctt gct cca gga gaa ctt act	13680
Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu Leu Thr	
4545 4550 4555 4560	
atc atc ctc taa tttttttaaa agaaatcttc atttattctt cttttccaat	13732
Ile Ile Leu *	
tgaactttca catagcacag aaaaaattca aactgcctat attgataaaa ccatacagtg	13792
agccagcctt gcagtaggca gtagactata agcagaagca catatgaact ggacctgcac	13852
caaagctggc accaggggctc ggaagggtctc tgaactcaga aggatggcat tttttgcaag	13912
ttaaagaaaa tcaggatctg agttattttg ctaaacttgg gggaggagga acaaataaat	13972
ggagtcttta ttgtgtatca t	13993

<210> SEQ ID NO 319
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 319

gcctcagtct gcttcgcgcc 20

<210> SEQ ID NO 320
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 320

gctcactggt cagcatctgg 20

<210> SEQ ID NO 321
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 321

tgagaatctg ggcgaggccc 20

-continued

<210> SEQ ID NO 322
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 322

gtccttcata ttgccatct

20

<210> SEQ ID NO 323
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 323

cctccctcat gaacatagtg

20

<210> SEQ ID NO 324
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 324

gacgtcagaa cctatgatgg

20

<210> SEQ ID NO 325
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 325

tgagtgagtc aatcagcttc

20

<210> SEQ ID NO 326
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 326

gccttctgct tgagttacaa

20

<210> SEQ ID NO 327
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 327

gcgccttctg cttgagttac

20

<210> SEQ ID NO 328
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 328

tcgcgccttc tgettgagtt

20

<210> SEQ ID NO 329

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 329

cttcgcgcct tctgcttgag

20

<210> SEQ ID NO 330

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 330

agtctgcttc gcgccttctg

20

<210> SEQ ID NO 331

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 331

tcagtctgct tcgcgccttc

20

<210> SEQ ID NO 332

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 332

cctcagttctg cttcgcgcct

20

<210> SEQ ID NO 333

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 333

agcctcagtc tgcttcgcgc

20

<210> SEQ ID NO 334

<211> LENGTH: 43445

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 334

accaagacag cgctcaggac tggttctcct cgtggctccc aattcagtc aggagaagca

60

gagatattgt ccccatgggt ggtcatctga agaaggcacc cctggtcagg gcaggcttct

120

cagaccctga ggcgctggcc atggcccccac tgagacacag gaagggccgc gccagagcac

180

tgaagacgct tggggaaggg aaccacactg ggaccacgcc cctggtggct gcggctgcat

240

-continued

cccaggtggg cccctccccc gaggtctctc aaggctcaaa gagaagccag tgtagaaaag	300
caaacaggtc aggcccgga ggcgccttt ggaccttttg caatcctggc gctcttgag	360
cctgggcttc ctataaatgg ggtgcgggcg cggccgcgc attcccaccg ggacctgcgg	420
ggctgagtgc cttctcggg tgcgtccgt gaggagcccg ccagccagc cagggccgcg	480
aggccgaggc cagggccgag ccagaggcc gcccaccgc agctggcgat ggaccgcgcg	540
aggccgcgc tgcggcgct gctggcgctg cctgcgtgc tgcgtcgtc gctggcgggc	600
gccagggccg gtgagtgcgc ggccgctctg cgggcgcaga gggagcggga gggagccggc	660
ggcacgaggt tggccggggc agcctgggccc taggcagag ggagggcagc cacagggtcc	720
agggcgagtg ggggattgg accagctggc ggccctgca ggctcaggat gggggcgcg	780
ggatggagg gctgaggagg gggctctccg agcctgcctc cctcctgaaa ggtgaaacct	840
gtcccggtgg tccccctgc gggccctagc acccgctggg aagacgtggg aagctcacag	900
atttctttct cctgtcttac agaagaggaa atgctggaaa atgtcagcct ggtctgtcca	960
agtaaggcat ctgcgcattg ggcgtggaag ggcgccagc ccgctgcact ctctacacc	1020
cgggtccctg agggcctccc actctacagg gctgagatgg catcgtgggtg tgccttgctc	1080
tgacccagg aagcaagtc cctgagctc tgcacacacc caagggatgc caactctctt	1140
ctacctggcc ttctgttctg tcccaaaagt tcagcctggg ggcgggggag ggaagggatt	1200
gtctctccgc tggcctgtgc acactttgaa gaaacatcac tgcctgttt atcagtgcact	1260
agtcattgat tcgaagcatg tgagggtgag gaaatactga ctttaacctt tgtgaagaaa	1320
tcgaacctcc acccccttcc tatttacctg acccctgggg gttaaaggaa ctggcctcca	1380
agcgcgaccc tgtgtgctgg agccgcgggg cggacttctg atggggcagc accgccatct	1440
agtggcgcgc tgcctcact gcagctggac tcaggaccca gatgttcttt ttcttcaatt	1500
gttcagaaaa ttctctcaa ctacagtga aacctccaga aattcttttc taggagtttg	1560
ttaagttagt tacgcttaat gcttaatgaa ctttgcctta agtatttggg agtccttagag	1620
tcacggaatt acggcgtgtt caagctaaaa aagcattaga gatagtacta ttgctgaat	1680
gttgtcatct cttaatttgc cagaggtct ctcctgcaga tttctgagc cccattactt	1740
gacactgtgc actcccttcc ctgtgcctca gatgagatat tcaagacatg ccagccaatt	1800
taaacattag cctcagcaaa aacataatgg agaagtcaaa tctataaagg aaaattaagt	1860
ataaagtcaa ttaaaaaata atttgagttg aattaccatt ttaattctc tatgccactg	1920
ccccctctg cccagaattg gctgtcctg ggagagctat ttctgctatg tggctgacgt	1980
atttctcccc acgttagaag atgcgacctg attcaagcac ctccggaagt acacatacaa	2040
ctatgaggct gagagttcca gtggagtccc tgggactgct gattcaagaa gtgccaccag	2100
gatcaactgc aaggatgga ggatgcaggc aggggggacc tagagccac agctttcccc	2160
cagccctgtt ccagcgggcg cccaacacgc gaccttcccg gaggtgtgt actgagcaaa	2220
cgcagaacat ccagaactg ttgtaactg atcaaagcac tgggactttg cctctgtttg	2280
taagtcagcc acattgctga gatgtggtct gccccacca aatttcgcaa gtcagaagta	2340
ttttcccggt aacttcccag atgcaatagg aatccatgat ctagattagc agcagtgtgg	2400
gtctgtagat ttcagcgtga gagagggcca gtaggtgagc tatgggaggc aggcaactcg	2460
gaatcgact gtgaaatgca gtttttataa tttaagtcaa acagaatctg ttgctgaaaa	2520
atgaatggaa agaagaaaaa aatataaaca tacagtttgt tctaaaataa aactttgctt	2580
attattgaga ctggtgttac tcatgttaca tacatgtgga gcagatctac aggtgtctat	2640

-continued

tgggggttgg	gtggggaaga	gaagtcaagc	tgagcagtea	ccttttttta	gagagtaccg	2700
tagctcttgt	atgtgctgtc	caatatggta	gacatgagcc	acattgggct	atttaaatgg	2760
aatgaaatta	aaaattcata	ttcgttgtca	cattagctgc	atttcaactg	ctcaacagcc	2820
accctggcta	ctggctccca	tattgaacag	cacacatgta	caacatttct	ataaagttat	2880
ttgaatagtg	ctggataata	agtaggaatc	cgttgaaaact	ccagctatat	gcaaagctct	2940
aaataggccc	taatagatat	aaccagtttt	ttgggtgaca	ttaaggagac	atttgctgtg	3000
gaaacgaagg	atggccctct	tcctgcttct	tgtttttctt	cttcactttc	actcctagtc	3060
tgcagcgctt	ctatttaacc	acagctcttt	ataattaag	tgagtaactt	tagaaccaat	3120
aaaaggacat	cctccttccc	atgcctaggg	gcaaaactta	gaaatgtgtt	acccgggagg	3180
gggaaaaact	cagcaatagg	actaagtcta	ggttggtgca	cagagaaccc	aggaggcatg	3240
ttgataaggc	atgtggtgtt	gaggcgacag	cagtgggtgtt	cccagcacca	ttccctttgg	3300
tgctctgatt	agagattaag	ccctgggctt	caggggccac	ctctcattct	tgatagacaa	3360
cctcaatgct	ctgctaccct	gaattctcag	gttgagctgg	aggttcccca	gctctgcagc	3420
ttcatcctga	agaccagcca	gtgcaccctg	aaagaggtgt	atggcttcaa	ccctgagggc	3480
aaagccttgc	tgaagaaaac	caagaactct	gaggagtttg	ctgcagccat	gtccaggtaa	3540
gtcatgttgt	acatgagcac	acgcatgtgt	gtgtgtccgc	tgaggatga	acttgtgtgt	3600
ttgcaccagg	cacggatgtg	actgtaagta	tttgtattcc	gtatccatcg	tggatcaggg	3660
aattactgag	ttttcacaat	catcaaaaag	agagaagcat	tagttaacct	tccttagtta	3720
ggttccttta	attatcattt	tcattgtgtt	ctaaaaatct	catgctttaa	acttcttgag	3780
attataaaac	tgagatgctt	tgtttaaaca	agtgaattct	tatttaaaaga	actagtcaag	3840
actagtgcct	ggtggtcctt	ggtgtggggg	cccagaggca	ctggctgctg	tggccggcac	3900
atggcggggc	agggctctgt	caccgcaggg	cagaggagca	ccaaggcttc	ggtggctccc	3960
cctcctaggc	tggcattcag	ccactgcacg	ctgatcggcc	actgcagctg	catctctgct	4020
gactggtcag	ggcccatgtc	gcaccatttg	taaatatatt	caacatcacc	cctgcctcat	4080
cctcaatcac	agtttgtagg	gtcctaggtg	tgtatgaata	caggcaggat	agagttgtta	4140
acttggtagc	atcagaaaac	tctgtctgta	ttagtctgtt	ttcatgctgc	tgataaagac	4200
atacctgaga	ctgggcaatt	tacaaaagaa	aggtttattg	gactcacagt	tccacgtggc	4260
tggggaggtc	tcacaatcat	ggcggaaggt	gaggggacagc	aagtcacatc	ttatgtagat	4320
ggtggctggc	aaagagagct	tgtgcagaga	aactcctggt	tttagaacca	tcagatctcc	4380
cgacacccat	ctgcaatcac	gagaacagca	cgggaaagac	ctgcccccat	gattcaatca	4440
cctccccccc	ggtccctccc	acaacacgtg	ggaattatga	gagctacgag	acgaaatttg	4500
ggtggggacg	cagagccaaa	ccatatcacc	atccttgccc	atttttcagt	tttgctaaac	4560
attagattca	gatgccagtc	ctttcttgcc	aaaataggct	gtgaggcttc	tttctttcct	4620
atgctttatt	ttctccaaga	cttaactgta	tatgaggagg	aggggtatgg	tggcaggagg	4680
aaagagtggg	ttattttttg	gtccttggtc	ttctccaaat	acagaagaga	ctcctgttct	4740
tgaaaaggag	ggctttccat	gtttgcatct	tcatgacttt	aactgtcttt	tttaaaaaatt	4800
gacatacaat	aattatacat	atttattgag	aacatagtga	tattttgata	catgtaatgt	4860
atgggtgatca	gatcagagta	attagcatac	ccatcatctc	aaacatttat	catttcttcg	4920
tgttgggaac	tttctgagag	agtgtaggct	gtgggagata	agtccgtcac	cttttcctcc	4980
tgatgtaacc	agagtggctg	cagccaggtc	ctcagaaaact	cagagagtac	ccagtgggaa	5040

-continued

atccctaaga ccaaagtcag catgggcttc agccatggcc tgacaccata caaaagaatg	5100
actgtccaac aagtgtatga aaataagctc caattcactg gtagtcaaga aatgcgaatt	5160
aatgtaacaa caagatattt atctgctttt acccatcata ctgcaaaact ggaaaacagt	5220
gatagcacct gttgtcggca ggccagttag gaaaagtgtg ctgtcctgag ctgctgggtg	5280
aaacgagagc catcaggcaa tatctactgt aatttaaaat acttaatacc ctttgacaca	5340
gatatttttag tctttgggac tctagcccat gaaaaataaa gcagtaaatgt gtgaagatag	5400
gcacataagg atgtttgttt tggattgttt tgtgtggttt aaaaaaaatc cagaaagaga	5460
gagggcaaat gccatcaaat ggggcaatgt gtgaataaat tataatttagc catggaatgg	5520
aatgttctgc atgcagcttt taaaaaaatc tgttagagct gtaccaagtg actcagaagg	5580
atttttgtga agtataatta agtgagaaaa acaagataaa agtatgcata atacaatgcc	5640
acttgtataa aacaaacaat ggcaaaatct ttgtatgact ctgtttgcac taccatgt	5700
ttacagagga ttgtatgagt gtgcagaaac aaatggaaca accactcggg tgtccgtatg	5760
gggaggatgg gcaaagagac tgatatgggt ggagaacaga gcagggtctg atgagccaag	5820
caaaaaaagt taaaacacag ctggacctgg tggctcatgc ctgtagtccc agcactttgg	5880
gagggccgag aggagaaatc acctgaggtc aggagtttga gaccagcctg gccaacatgg	5940
tgaaaactgt ctctactaaa aatacaaaaa ttagctgggt gtgatggcac atgccagtag	6000
tcctagctac tccggaggct gaggcaggag aatcacttga tcccaggagg tggaggttgc	6060
agtgagctga ggttgcgcca ttgcactcca gcccgggcga ccgagcgaga ctccatttca	6120
aaaaaagaaa aagaaaaaag aaaaaaagaa aaaaaaagaa tcacaaaaac ttatgtatat	6180
gtgcatactt ttttgaaaat gtatgtctat gtgtagctat attctatatt tacaaataaa	6240
tgatgtcaga agaacaattg gttaaaaaaa tatgagaaaa gaaacttcag tgccaccag	6300
cttacttcca gcaagtgtga atggagaagg acatttccgt gaccatcctc tctctgggac	6360
aggatgagc tcaagctggc cattccagaa gggaagcagg ttttccttta cccggagaaa	6420
gatgaacctt cttacatcct gaacatcaag aggggcatca tttctgcct cctggttccc	6480
ccagagacag aagaagccaa gcaagtgtg tttctggtga ggatttagaa agctgatagc	6540
agtggccctt gaaactcatc ttcattgttt agagaccagt cctaccatat acaaagcaga	6600
tcactgagtc agctccatga ctagttagat aggaagccct ggattggcgt gaaatactgg	6660
tgcccgaggt tcctcctgcc ccttaggtgc actgacagat catcccaagc aggettatca	6720
ggttgggtct aattttaaaa cagtcattga ggagtcctgg ccccccacc cctgcttttg	6780
tttgatgctt cacctgtgtt tgctgggtta tgggtgtcac agtaaatcct gtgtgtat	6840
taaacaccaa aaataatggg atctgttctt ggtctctttt acgaatttca ggtttcactg	6900
tgagacagaa ttcatttcac ctcatgtcca tgagcacttt tgtgtgttct aatttctcta	6960
cgacaccata atgggagaag acaccgatgc aacctgcgga ggcctttctg cagaccacc	7020
tttaactggt tttctctctc ccaacttggg ctggccaggc actagcaaga ccacactctg	7080
cataggaaga aaaagaaagt ccctcccaa gctagattcc ttctgctttt tctttcacga	7140
tccccacccc atccctccca agtacccaag gatgttgccc gtgttgaata catgtggttg	7200
catcttcttc ctccatagga tacctgttat ggaaactgct ccactcactt taccgtcaag	7260
acgaggaagg gcaatgtggc aacagaaata tccactgaaa gagacctggg gcagtgtgat	7320
cgcttcaagc ccatccgcac aggcacagc ccaactgtct tcatcaaagg catggtaagt	7380
ccatgtcag cactgtcgtg cacagcaagg agcatcctct tattaatata attccagAAC	7440

-continued

ttttgagcta	gtgggcacct	ttgaggacag	cctgccctgg	ctgtttttta	tacagactag	7500
agataggacc	ctgagcaggc	acgggaaggt	ctgcccaggc	ttcacggcct	gggatcagtt	7560
gagccaaggc	ttgagtcagg	ctcctccctc	ccagcccaga	gctctgtctt	tectcctgtc	7620
cttctgtcac	tggcaccaaa	ctgcctctaa	tctcatcact	tgagagtaat	gactactcac	7680
ctctgagaag	gttccgggga	tggatgtagg	gcagcaaaac	caccttctgt	tcttttctgc	7740
acaaggactc	cttgtgccag	ctccaagcct	ctggcctttg	aagaagtccc	aagacctgtg	7800
tttccccct	ctccctcctc	ccatgaagtg	gagtgactta	gagtgtctca	gcttcttctc	7860
cttcaccccc	cagtaccacc	ctgaccaaac	atggccccac	tgccaccggc	ctggagcacc	7920
ctctcctctc	tgtaactgg	ggccatggag	caccatatta	cctgagcctg	cctgacccct	7980
gcaacatctt	ccctgatatg	agccccagcc	tgtctcagtg	aacatgaata	acttgggcaa	8040
tcactgtcat	gctgggcgct	gttctctgtc	attgtcctta	gggttgaaaa	cagggagtct	8100
gatgaccatg	agtgccacag	tcagaagagg	ataatgcact	ggcttagggg	tcttttctga	8160
gcatctgctg	tttgtcaac	cccactctgg	gcagcaccaa	ggaagggaca	gtggcagatg	8220
aaccatggac	cttccccctc	ggatgcttcc	agtctaagtc	aggagccagg	tcaataaagt	8280
atacgtggta	tactcaataa	ggtgataagc	tgaacagtgc	agacaagaag	tcttgggcct	8340
gaccaggaag	gagaaagaat	tattcatgta	gctcagcggg	caacatttca	tggaagatgt	8400
ggagcaggaa	cccaaaaaat	gcaaagaata	tgtaaatgaa	agagacatgt	aagaatgggc	8460
ttttgggcaa	agaaaagtta	ctgagcaggt	gtgtgagggg	ctatgtgggtg	ggatgggcat	8520
gtggaggata	caaagttag	acattgtcca	gtgaggggtg	aaaagagga	gtctacagct	8580
tgactcagct	ttggggatgc	cgacttgttg	caccccctgg	tctaaatgtc	aagtaccag	8640
ttatcttctt	tctctgagtt	tatctagtgg	tacaggactc	ctgtccctt	ctaccttgaa	8700
ggtaaatgct	tttaacagaa	gatacaggga	ctgatcaaaa	tgctcgtctc	caatctcttt	8760
catagaccgc	ccccttgtca	actctgatca	gcagcagcca	gtcctgtcag	tacacactgg	8820
acgctaagag	gaagcatgtg	gcagaagcca	tctgcaagga	gcaacacctc	ttcctgcctt	8880
tctcctacaa	gtaggtcatg	tgatgcaccc	ctgatttctc	atttaatggg	tcagtgtgaa	8940
ctgaacactt	ctcaagtgtc	ctgttccagg	caaacctgtg	cctgggaggg	aggaatggag	9000
agggataaaa	tgccgccctt	ccctgtcccc	ctttttaagc	gaacaggcca	tttggcagaa	9060
aagtcctagg	catgcaaaac	aatccaagac	caacaaaaga	tatctaagac	ccattcttta	9120
agggctgtag	atccagaaaa	cctgaggatc	actgcagggt	acccgtgtta	gaaaagggtt	9180
catggaagat	ttgggatact	gactggaaac	ttgtgtatcc	aaatccactt	tgaactga	9240
taatcaatga	atatatatgt	agtaactgcc	atattcttgg	ctctatgttg	tggaagatac	9300
gaaagaatgt	tgagacattg	cactagtctc	tacctctggc	cactccagac	tagtgagag	9360
tataaggcac	gcatgtcttt	ttgatgggag	gataactagc	gtgaccagga	agaggtggat	9420
gttattcatt	cagggccaac	aatggctgga	tttaccctag	ctttgaaaga	tgggcaggac	9480
ttgggtagat	gcagagacag	ggaaaacctt	caacatggaa	agaatagtat	gttctggcca	9540
tccgtgacat	ggtgtgcttc	cttggttacc	aggaataagt	atgggatggg	agcacaagt	9600
acacagactt	tgaacttga	agacacacca	aagatcaaca	gccgcttctt	tggtgaaggt	9660
aagagtttct	gtccacatag	ttgctggaaa	atctactcaa	gatgtgccta	tcattgctta	9720
gccacttgct	gagccctgtt	aaatgtctgc	tgactaacia	gtgatacaga	cactgggtgt	9780
ctggctacct	ctagtgaaga	agcaaacctc	tttcatgatg	tcaagttgca	atggcataaa	9840

-continued

```

ggaaaagaag ttcccaaagc tacttaggca tttgtaaata gaaaactgga atcctaagtt 9900
taacatgaca tatttgatag aactgacatc acccatcctg tgataagatc cagagctgtc 9960
ccagacgagg tggaccaagt gggagagaac cttcagagtc tggccagata gtaacctcag 10020
gagtcagtct ttagaggtag aaggaaactc aacaatctca agtccaaccc ttaccagta 10080
ttgtattgta ttatatctg tccaaattcc ttcttgtaaca ttacctcatt gtcctttttg 10140
ctcatagcaa cctgtgatgt cagggtgtag agatgtgatt ttatacctat tctacagagg 10200
agacagtgc acagagaggc ttagagtttg atgtagtcaa ggcgcagaa tattagaggg 10260
gggaaaataa gtgccagggt gtaatctaag ccaggactat tctcattaca ccacatttcc 10320
atgatgactt ttacctctct tcctggcata ggtcacagta ggtggtggag aggatacaaa 10380
agtgtctccc ctcccacaa gctgctgta gaccaatta gaagaaatgg tgataagcac 10440
ccatgtgcct ggtcccagtt gtaaccatgt caacagtagc acctcctcac caattatttc 10500
aagctaaggg taacctgatg atagactcag acaagtctgg attccacttt agctctacct 10560
cttagacct gagagctctt gggaaacctc agttgctcat ctctgggtca cacttcctca 10620
tctctgggtc tcatctcttt gtctcatctc tgggactcag agctgagatc cagggatgag 10680
caatttcat ggcccaaaaa ctctgtgggt ctgagaagca gggctgaatt tatcattaaa 10740
ttgaacaata atgccacccc acagggatag gatgatgagt cagtgaatac aagtcaatca 10800
cctatggcag agccagatct agcaggcatt gaatacagga tagtttcttt cccttttccc 10860
ctgtgctgat actccacaat ttccagcttc cagtagacaa agatatggtt gagatgaaga 10920
aagctagagt tcctttgaca ctttccatct tccaggtact aagaagatgg gcctcgcatt 10980
tgagagcacc aaatccacat cacctccaaa gcaggccgaa gctgttttga agactctcca 11040
ggaaactgaaa aaactaacca tctctgagca aaatatccag agagctaata tcttcaataa 11100
gctggttact gagctgagag gcctcagtga tgaagcagtc acatctctct tggccagct 11160
gattgaggtg tccaggtatc taatggttac agtcaactt tttataaaac tgatggtaac 11220
tgactgaact ttcaaactt ggccaaatgg agaactctcag ggaccatttg gatatcaatc 11280
cagttaatca attagtcaat cagttcatga ttgctggata gagaactatc agctgctgcg 11340
ctgagttcca tgaaacacac acgcgcatac tgtgttcaag gcagctatgt atttgtgtgt 11400
taaaacagaa ggagaatagt tcccacattt tgatgggtaa cttttaattc ctaggctctat 11460
tgcaggtgct ctccagaagc ttataggctg gtggagagag aactcagacg aaaaatataa 11520
tatgatttct ctacccttca aggcactggc tttaagtct atgaaggatga gagaaggac 11580
tgaggccagg aatgagaccc agctaagtgt ggccaggcat attctgtgtg ctggccaaag 11640
gactgtgata acagtcttct tgttctaca gatccacagt cccctcttgg aacttttctc 11700
gattgggctt cttctgtggg taatatctct aaggaaagca tcatggttct gagctccaag 11760
ttgggttttg aagttagatt tgaatagtga atgaggtgat taagggtct cctggcagag 11820
gacacaccat gagcaatatt ttatgtgccc tgaaggtggt ctgtataact ttatccatgt 11880
ctttcttctc agccccatca ctttacaagc cttggttcag tgtggacagc ctgagtgctc 11940
cactcacatc ctccagtggc tgaaacgtgt gcatgccaac ccccttctga tagatgtggt 12000
cacctacctg gtggccctga tccccagcc ctgagcacag cagctgcgag agatcttcaa 12060
catggcgagg gatcagcgca gccgagccac cttgtatgct ctgagccacg cggtcaacaa 12120
gtgagtttcc aactgtatt tctctctcta ggagcagagg aacatcttgc acctctgtgc 12180
atctctgtat taaaactgaa cccctccttc cactttcaaa ctctgctcct tactcttgtg 12240

```

-continued

```

ttttttcttg atcatttttg gggtaatgac ttgaataag aaatcagcaa acacaaattg 12300
aatttttaaa aatattttct ctacattata ttataaaagt ttttgaacat agcaaagtgtg 12360
acagaatttc acagggaaaa cccctagaaa accagctatc tcctactatt taagtgttat 12420
tatatttgct ttatcacata tacatccatc cattaattca tcttattttc tgaagcattt 12480
caaagtaaat tgcaaacatc aacacacttt cccctaagta ttacagcttg catattatta 12540
acttcagttc aatattagtt agcagttttt tcctctgaat ttttttgttt gtttgttttg 12600
tttttttttg ttgttgttgt ttttttgaga tgggtctcact gtgtcaccca ggctggagtg 12660
cagtgatgca gtcacggctc actgaagcct caaattcctg ggctgaagtg atcctcccac 12720
ctcagcctcc tgagtagctg ggaccacagg tgcattgtac catgccctgg ctaatttttg 12780
tattcttggt agatacaggg tttcaccatg ttgctcaggc tagcaggttt ttcctttgat 12840
gaaatttttt ggctttttct tttttacatt tttatataaa tttatgtgga acaagtgtaa 12900
ttttgttaca tgaatagatt gtgcagtagt taagtccagg ctttcagggt atccatcacc 12960
cagacaacat atagtgtacc cactaagtaa tttctcacca tccatctccc tccacttcca 13020
caccttctga gtctcaattg tctatcattc cacacactat gtccttggtg gcacattatt 13080
tcaactccac ttataaatga caacacgcaa tatttgtctt tctgtgactg tctgttttca 13140
cttaagacaa tgacctccag ttccatccat gttgctgcaa atgacatgat tttattcttt 13200
ttatggccga atagtatttt attgcctata catttcacat ttttaatcca atcgtccatt 13260
gatagacact taggttgatt ccattgtctt gctatttgta atagtgtgtg gataaacata 13320
tgggtgcagg tttccttttg atataatgat ttcttttctt ttaggtatat acccagtaat 13380
gggattgttg gatttatttg tagttctatt tttagttctt tgagaaatct ctgtattgtt 13440
ttccatagtg gttgtactta tttacaatcc catcaacagt gattaactgt ttccttttct 13500
ctgtatctcc accaacaact gttatttttt gtcttttgaa taatggccct cctgactctt 13560
gtaagatggt atctcattgt ggttttaatt tacatttctc taatgattag taatgttatg 13620
cattttttca tatgcctatt gccatttgta tgtcttcttt tgaaaaaat gtctattcat 13680
gtcctttgcc tactttttta tgggattatt tgggggattt tttgttgag ttgtttgaat 13740
tgcttgtaaa ttccggatat tagtaccoca ttggatgaat agtttgcaa tattttctcc 13800
cattctgcag gttaccaccc tgttgattat ttgttttact gtgcagaaac tttttacttt 13860
aattaagttc tatttgtcta ttttttgttt ttgttgcctt tgccttgag gtcttattca 13920
cgaattcttt gtctaggcca atgtccagag aagttttccc taggttttct tcttgcatth 13980
ttatagtctc aggtcttata ttttaagctt tgatccatct tgagttgatt tttttatatg 14040
gtgacagata ggagtcacgt tttattcttc tgcattggc aatccatctt tcccagcacc 14100
acttattgaa aagggtgtcc tttccctagt gtatgttttt gtcaattttg tcaaagatcc 14160
gttgactgta agtatgtgac tttatttctg ggttcagtat tctgttccat tgatctatgt 14220
gtctattttt atgccagta catgtgtttt agattactat agccttggtg tataactctga 14280
agtcaggtaa tgtgatgctc ccagctatgt tctttttgct taaaaatgct tcagctattc 14340
aggctctttt tggattccat atgaatttta taattatttt ttctaattca caagtttggg 14400
ttttaagaca aacctaaact ggggtaccaa gtcctgactc tcttctctta ttctgtagct 14460
atcataagac aaacctaca gggaccacgg agctgctgga cattgctaata taccatgatg 14520
aacagattca agatgactgc actggggatg aagattacac ctatttgatt ctgcgggtaa 14580
tctcagttct ttatatgaca tacatcattt cagaagcact tttcctggac accttttact 14640

```

-continued

tcctctctct	gcacctgat	gggttcttgt	ttcttttctt	caatgcaggt	cattggaaat	14700
atgggcaaaa	ccatggagca	gttaactcca	gaactcaagt	cttcaatcct	gaaatgtgtc	14760
caaagtacaa	agccatcact	gatgatccag	aaagctgcca	tccaggctct	gcggaaaatg	14820
gagcctaaa	acaaggtaaa	gtccacaaga	agaggtctga	aagtgaagt	ttattaacaa	14880
ggatttgga	ggtactagg	gaatgagact	ctagatttca	tctactgact	ttattctgct	14940
gtttctttcc	ttctcttct	tccttcttcc	cttcttctct	ccctccctcc	ctttcttctt	15000
tccttcttcc	cttcttctt	tcgagatgga	atctcactct	attgccagg	ctggagtgc	15060
gtggcatgat	ctcggtcac	tgcaacttct	gcctcctggg	ttcaagcaat	tctctctgcc	15120
tcagcctcct	gagtaactgg	gattacaggc	atgtgccatt	acaccagct	aatttttgta	15180
tttttagta	gagatggagt	tttgccatgt	tggccaggct	ggtcttgagc	tctgacctc	15240
aggtgatccg	cctgcctcag	ccttgcaaa	tgctgggatt	acaggcgtga	gccactgcac	15300
ctggcctcta	ctgttttcta	attgcaaatt	tcaacaagcc	tattgacttg	actgcctagc	15360
agtatgtgac	gtgagagaaa	tacttgactt	tgctgctatg	tcaacatgca	gaacgtgaga	15420
tgtttttgct	tcctaccgtc	cacctaccag	attgaccatc	cctctcatca	tggaataaca	15480
tgcttaattt	tcctcccaata	agcttaggct	aggatagcca	acttggtccc	ctcttaggtg	15540
caaagactcc	agaactttgg	aaactaccct	atcttattagc	cccaaactct	tactaccctt	15600
ttctctcttt	atcctcacat	taaaataact	tacgttaaaa	caacttgatt	ttcacttagt	15660
ggtggatctc	caaacaaatc	acaacttggc	cataatttat	gtgttttaat	ggaattgaat	15720
tcaacaggca	ttccacaggc	ttttctctgg	aacccttact	tgatagtgtc	ctaggaacaa	15780
ctggcaagaa	gattcaatac	cagcatttga	agaacgatta	cagagaaatt	agacctgtgc	15840
ttaagaaaga	gctagcagac	aatgccagtg	tttgccaggc	atgttctgtg	ttctgaccac	15900
aggacagtga	taaccatctc	ctcttttgac	tgcaggacca	ggaggttctt	cttcagactt	15960
tccttgatga	tgcttctccg	ggagataagc	gactggctgc	ctatcttatg	ttgatgagga	16020
gtccttcaca	ggcagatatt	aacaaaattg	tccaaattct	accatgggaa	cagaatgagc	16080
aagtgaagaa	ctttgtggct	tcccatattg	ccaatatctt	gaactcagaa	gaattggata	16140
tccaagagta	agtaagagct	attcacccca	tataccactg	agggccctga	gctggaattc	16200
caaccctagg	ttttggcata	gccactgtct	gcccttgett	ctgaaacaaa	cacttgtgca	16260
aatgtgtagc	agatctagac	ccaaagactt	agggtcaatg	aatcaagac	attttggtag	16320
tgattggaaa	tcctatattt	cttgggggtc	aagagtcaaa	ggataataac	atgggtgtgtc	16380
agctcaaaat	atacttcttc	ttatcttagtc	tgaaaaagtt	agtgaagaa	gctctgaaag	16440
aatctcaact	tccaactgtc	atggacttca	gaaaattctc	tcggaactat	caactctaca	16500
aatctgtttc	tcttccatca	cttgaccctg	cctcagccaa	aatagaaggg	aatcttatat	16560
ttgatccaaa	taactacctt	cctaaagaaa	gcattgctgaa	aactaccctc	actgcctttg	16620
gatttgcttc	agctgacctc	atcgaggtaa	gtgtgaagag	tttgaggttc	tctagcccat	16680
tttgtagcgc	atcataaaca	gagagtcctt	gggagccagg	agctaccctg	aggaaaacta	16740
agaaccacca	ggcacttctt	accatgattc	tgaggctttc	ttctttccct	ccttccccgc	16800
cttctctctt	ccccgctagg	ggtcacctga	agcatgactt	cttaacatta	atagaaatgc	16860
aggcctggcg	aggtggctca	ctcctgtaat	cccagcactt	tggaggcccg	aggcgggtgg	16920
atcatgaggt	caggatatcg	acaccatcct	ggctaacacg	gtgaaagccc	atctctacta	16980
aaaaatacaa	aaattagccg	ggcgtgggtg	caggcacctg	tagtcccagc	tacttgggag	17040

-continued

gatgaggcag	gagaatggcg	tgaaccacag	aggctgagct	tgcagtgcgc	cgagagattg	17100
cgccactgcg	ctccagcctg	ggcgacagag	caagactcca	tctcaaaaaa	aaaaaaaaaa	17160
aaaaaaattg	aatgcaaat	gtctcgtctt	taagtcccaa	agccaaggaa	gcataatgtgc	17220
tgccatagca	gatctgcttc	aaatctcaaa	tcaactccaa	ctctgaatcc	tttgttgaat	17280
tatttgcctc	atctgaacct	tagctgcctc	ttctagaaaa	aagcaagtaa	taaggccaag	17340
attctagtga	gattttaata	aagcagctcc	tgtgaaatgc	taaggtcagc	tccctggcctg	17400
tggtattcaa	atacttgttt	agataaatgg	acatcaagag	tggggactac	taggctggca	17460
tacaacaaag	aaacctgatg	ccattttctt	gtctgatttt	ctttctcaga	ttggcttgga	17520
aggaaaaggc	tttgagccaa	cattggaagc	tctttttggg	aagcaaggat	ttttcccaga	17580
cagtgtcaac	aaagctttgt	actgggttaa	tggccaagtt	cctgatggtg	tctctaaggt	17640
cttagtggac	cactttggct	ataccaaaga	tgataaacat	gagcaggtgt	gtatttgtga	17700
agtatcttct	taaggaaagc	tttgggtctc	aatgcaaaaa	caattctttt	ctaagcatgg	17760
aagtctctca	aatactatct	aactgaaggg	ataactatgg	tttttatcaa	ccagacctgc	17820
tggggaagg	gccagtatcc	tctgcagtta	aagatctcct	gaattcagtg	tgcccagaaa	17880
ccagactcac	aataagtact	ctaggataac	aagagtatga	actctgggct	gggtgtgggtg	17940
gttcatgcct	gtaatcccag	cactttggga	ggccaagggtg	ggcagatcac	aaggtcagga	18000
atttgagacc	agcctggcca	acatactgaa	accccgctctc	tactaaaaat	acaaaaaaac	18060
tagctgggca	tggtagtggg	tgccgtgaat	cctagctact	cgggaggctg	agacaggaga	18120
attgcttgaa	cccgaggagt	ggaggttgca	gtgagccgag	atcacgccgt	tacactccag	18180
cccggtgac	agtgtgagac	tgtatcttaa	aaaaaaaaaa	agtatgaact	ctgggcatag	18240
atttaattct	aacttccctg	tcttgaagct	gtgcgcactt	ggggaagttg	gttgatatta	18300
tgtgtatctg	tttctgtctg	tatcccagac	tactaataac	agtccaaacc	tcacaagggt	18360
atttaaagac	aatgaaataa	ggcatctaaa	atgccaaagca	cagtgcctga	tgctggcatt	18420
ggttgttcaa	taagcagaca	ctattacgag	ttctaaatta	atattttcat	tattattaac	18480
tgctgtcttt	ggtctctact	cccacagtg	cactagcaaa	tgagacccaa	cttccacttt	18540
gaagctagca	atgagcccc	atttaaggag	ggaaataggt	tgtatgatct	ggagcttatt	18600
cttgaatttt	ttgctaccca	aagtgtggtc	tggtcagaaa	tacagcttct	catgcttcac	18660
ccacaatcta	ctgaatcaga	agcgcatttt	agcaagacct	catgtgactt	gtatgcacat	18720
tcaactttgc	agagcaaggc	agtaatttac	ccctccaggc	tactgttgga	gcacgagctc	18780
catcttctaa	tttcttgacc	cccacttgag	gccgaggatc	tttgatctgc	tttgagtctg	18840
tcagtttcac	attttttttt	tcccaatgcc	tgggcaccca	tctctgagat	tcttcttctc	18900
tctgagaaga	acttgtctag	gatcaagtgt	ttttcaaact	tctgggtgaat	ttatataaca	18960
gctacatttt	cttaagaaac	accttgtagt	cttcactggg	caaagaagag	aaggctaagc	19020
agggaaacggg	tgggggatag	aggatcttct	aatcttgagg	atcctggcat	actggagaat	19080
agggacccct	cctctcatcc	caccacatct	tactatgtct	acagattttt	taattaagaa	19140
tagcttttagg	agtgccacta	tccctgacaa	gaccttagtt	ctttaatctc	tgcttagagg	19200
aattagcctg	gacttcagtg	tctccctgtt	cctcacctgg	agcatttttt	aggcccatcc	19260
tggctgcac	agacagggtc	cacattggga	actgaaaggt	gtttgacatt	gctgacatct	19320
cactggccat	tttattacta	aactctcagg	atatggtaaa	tggaaataatg	ctcagtgttg	19380
agaagctgat	taaagatttg	aaatccaaag	aagtcccggg	agccagagcc	tacctccgca	19440

-continued

tcttgggaga	ggagcttggt	tttgccagtc	tccatgacct	ccagctcctg	ggaaagctgc	19500
ttctgatggg	tgcccgcaact	ctgcagggga	tccccagat	ggtaagtcag	caggcccccac	19560
tgggggccca	tgagaccaga	cgttgggttt	tttttagatc	gccagactc	ccttacgac	19620
ccagctgcac	aagcccgaaa	agatgcttgt	actttcttca	gagatggagg	tttgccctga	19680
atttcactga	agatgactct	tggatcacat	ggaaatgtta	acatttagaa	attaagctat	19740
tcataatggt	agctgtatgt	ttaagagcat	taatttatct	atctggaaaa	caatgttcgg	19800
tataccttcc	tctacctttg	ctgaagggtc	ttttattttt	atttttatct	ttttaatttt	19860
ttgagatgga	gtcttgctcc	caggctggag	tgcagtgata	caatctcggc	tcactgcaac	19920
tctgccttcc	gggttcaagc	aattctcctg	cctcagcctc	ccaagtagct	gggactgtgg	19980
acgtgcacca	gcatgcccgg	ctaattttgt	tatctttagt	agagacaagc	ctgttgacaa	20040
ccatgtcagg	ctggtttcga	actcctgacc	tcaagtgtac	ctccagcctg	ggcctccccc	20100
agtgtctgga	taacagggtg	gagccactgc	acctgacctg	aaggtccttt	taagattgaa	20160
atgatacaat	gattataaaa	gaaagtattt	ggcaaaactat	aattcactat	ctaaatatgc	20220
tataattttt	attattaatt	cataaaaagga	aatatataaa	tgtactccta	tggtctgatt	20280
aaaaaaatgt	tgactttaag	aaaacaggtc	tcaagctatt	ttattgaaat	attattttaa	20340
aaataaaacc	caatgcgaat	tgatatgtac	atcatctcaa	taggcctttg	gtttcaaaaa	20400
attgatttta	tcataatata	atacatttca	agtacacctt	cacttacagt	cagactccag	20460
aacaccagaa	ttaagccatg	gcatatatga	tacttaaagt	ccataaagct	ctgaggccca	20520
gcaatattct	taagagcctt	ctgagtccac	ttgaaaatga	catgatatct	atctagttaa	20580
atttcttata	tcctgattca	ctgaaaacgg	taaaaacatc	agtttgatct	ttatttatca	20640
aactattcag	ctcatcaaaa	tatgctagtc	cttcctttcc	agataaagag	gaattactct	20700
ccaatgtatg	ggaggttgta	attaacaaaa	cgcactttaa	aaagacttac	ttttatttgc	20760
tctcccttgt	tggtgtctaca	gattggagag	gtcatcagga	agggtcctaa	gaatgacttt	20820
tttcttctact	acatcttcat	ggagaatgcc	tttgaactcc	ccactggagc	tggtattacag	20880
ttgcaaatat	cttcattctg	agtcattgct	cccggagcca	aggctggagt	aaaactggaa	20940
gtagccaacg	taagattctg	tttgcccttt	gatttcttag	gttattactt	tcttccaggg	21000
tgcatcttct	gttaaaacat	atttaaaaaat	gtgtttccac	ttcaagacaa	aatgcttcat	21060
cattgtaatc	acctcattat	ttttttatga	aaaacttcaa	gcttccacca	gaatgcacta	21120
cctcactagc	tccagtagtg	gtatggccat	aagacaagaa	ctcagttctc	tcaacaaatg	21180
agtattccta	tcattctttt	aatctgggtt	tgcttcacgt	taactcaggt	gctttctagt	21240
tctgggtagt	atactccaac	tctagagaac	tgagaactcg	ctttccttct	tccaaacaaa	21300
tcccagtaat	gtttccaaa	gtctgagtta	tccaggaaat	ctttgcccgg	aggtagagaa	21360
gggtggttga	tctgactgac	aggggactga	agtatttaat	gaatctgaat	aggttgtttt	21420
ctgacttata	gatgcaggct	gaactgggtg	caaaaccctc	cgtgtctgtg	gagtttgtga	21480
caaatatggg	catcatcatt	cgggacttcg	ctaggagtgg	gggtccagatg	aacaccaact	21540
tcttccacga	gtcgggtctg	gaggctcatg	ttgccctaaa	agctgggaag	ctgaagttta	21600
tcattctctc	cccaaagaga	ccagtcaagc	tgctcagtgg	agggtaatct	tttcagccaa	21660
gtctgcctag	ccagtttgaa	agagagaaca	gagaatgtac	ctgcagaatt	ttgccaggct	21720
aaacagttga	ttgagatcat	tcaggtcctg	aggaagcagg	agaggagttag	aaaggaaaga	21780
ttccgggtta	cctattttta	ttctagccta	gacttactac	ataactacat	aattaccttt	21840

-continued

```

cttctacttt tcacatttta ctaaactgtc ctttatcttt ctgctttgag acttattaag 21900
acctactgct taattagttt ttattaagtt gtgatttttt gttatctatt tgttttgaga 21960
atgaagaaac aatagctctg gagagatcat ctttggaata ttaatatatt ccccccaaa 22020
aaatacctaa gaacatattg atttgaggta gctaggtagg taaagcatga aactcctaac 22080
ctcgtgataa tggaatacac cctcttttgg agagttccat ttaagtggc accctcaacc 22140
attgatttgc cttagttttc atattttaga cacattcatg tgttcattca aaaataatat 22200
ttaattggcc agccacgggt gttcatgcct gtaatcctag cactttggga gcccaggtg 22260
gatggatcgc ttgagccctg gtgtttgat accagcctgg gcaacatggc aaaaccccat 22320
ctctacaaaa aaaattaaat aaataacaaa attagccagt cgtggtggca catgcctgta 22380
gtccagccta ctcaagaggc tgagatggga ggatcaactg agcccaagag ttcaagcctt 22440
cagtgaacca tgcttcacac actgcactcc agcctgggag acagagcaag atcctgtctc 22500
acaaaaaaca aaaaatagta tatttaattg cctaataatat accacgtatg ttgagtgaga 22560
cacacaaggt ccctgacctt tgaacgctta cattttataa gggagacaca caattaagca 22620
agcagtaatc atagagtaag ggctaagtta tagaaagtat tagagtacca tgaaatttta 22680
tatcatgtag cctgtgctag tcagggaatg cattctgaag caagtgtact tgacctgata 22740
actgaggact gtgtcagagt catttaggca aaggagaaag gagtgagtgt tccaggcaaa 22800
aggaaaagca tgtaattggc tgaaggtaaa ggaatatggt tcaaggaact ggaagaagtg 22860
cagaatggta aggggctcag agatgatggg gagaggtagg caggggagag agcatgcca 22920
gtcgcaaaag ccacctaag gagtttggac tcttttgaag gcacaggagt tgaaaagggg 22980
agcagaaata agataggggt gatgttttag aagaaatact ctgactctag tgtggaagat 23040
gggtgagaag gaggcacagc tggacacgaa gagaccattg gacatctctt acgatcctat 23100
gtggctaaga gctgataatg gcctgcagtg gagaaaagcc aggtatagaa aggagtgagc 23160
agattctaca actttctaag aggcagaatc ataagtactg ggtgattaac tgggtatggg 23220
gacaaggcaa aagaaagaag aaaagaggaa ggaggcgccc ttcattttta taagaactac 23280
agtgggagag cttctggttt caaggaaagt gacaaattca gttttggatg tgctgtattt 23340
gatgtcctcc tatgaaacaa ccagttttag aatctagctg tcaaatagac ctatggatct 23400
gagcccagta aagaggcttg ggctcccat atggatttgg gaatcattag tatacagagg 23460
ttgttgtggt taaacagcaa ctggtataga gtgagacatg agagatgagg acagaaatat 23520
ggagaagaca aacatataaa ggaagaaggg gaataaccag caatgagtta gaagaagtga 23580
ccagagaagc agaaggagaa ccaaagccat aaaaggtcac agaagccaaa ggcagccac 23640
aggggagatc accccatggg taggcgaaag ctggcattag gactccagca catcagcaaa 23700
gcttggtctt gtggcaccac caacttgag aaacaatact tggaggaaaa tgtgctattt 23760
caaagaaagc atccttagaa aaaaccaggc caatgttgaa ctttcttaca tgtactaagt 23820
ttttaagtac acacttgaa ggaaggtgcc atcatctctt cagatgtgag aggtccagc 23880
gtcttagtct ggatcatgag gcgcaactct atggaaggct tctgggaggt caaggaagat 23940
gaaacctaaa tatgcccatt ggatgtagga gcaaggaggg cattagagac attgatgaaa 24000
gcattttcag gagatggagt gagcagtcag agcacattgg gaggaagtag agactgcaaa 24060
ggcagacaac tcttgatggt gaggaagatg agaaagcaag aaaagaaaga aaggagcata 24120
ggggaggggc acagggaag agacttgagc gtgcttaatg caggtggaag gaagcaggta 24180
gagagttaga gatttcatat gaaagagaca gtttctcttg ccctgcattg taggaaggaa 24240

```

-continued

```

ggggcacact gaagttcagc cccagtgate agctatttaa catctctgag cctctgcttc 24300
tgtaaaatga gaaccataag cctactgttg tggggattac aggtaacaga tggaaagaac 24360
tcagccagaa gcttcagagt cactctcatg gcttgatcatg ttgatgttct ttctaataatt 24420
atttgtttct cagtaaatta aatagttaga gataggtgtg gactgaggga agacaggagg 24480
ataagggggg atttgcaccc tgagaatttg tgatgtccat ttgattcat gacttggcaa 24540
taactcaggt atttttgttc ttcaccagca acacattaca ttgggtctct accacaaaaa 24600
cggaggtgat cccacctctc attgagaaca ggcagtcttg gtcagtttgc aagcaagtct 24660
ttcctggcct gaattactgc acctcaggcg cttactccaa cgccagctcc acagactccg 24720
cctcactacta tccgctgacc ggggacacca ggtagagat gctcagtgcc tgaccagca 24780
ttttctcacc ttccacatca tggccaccta gcatggcaca gaaaaaata ctctgtgttg 24840
taagaccctg tcactagcct tctgggtttg caccatcttt gggatttaa agcagggtcc 24900
tctggccaac acattgggtg tcaccttttg cttccttctg catgggatgg gatcacagca 24960
cagatcccaa ttgtctcta attcagtgtc catgtttctg agcctccaga cccatcgcta 25020
tgagcttctt ggagcccacc aatgtgcttg aagccttcac cgtacttagg tggctccctg 25080
tcttcagccc ccaagttcca gtgcttgttc tcagctttgc tgaacaacc agccaactcc 25140
tgctctgctt gtccaaagtc ttgggaatcc tgggtgtctg ccttgcttg ggttcttgta 25200
ggactgaggg atcaaaaaga tcatcttagt taagggaag agacaatgtt aaaataagga 25260
ccatattttt gttgcatttg aggetgaatt gttttgggaa cataatcacc atccttga 25320
gctctaacaat tatgactgtt cttcattgta atgtctttag attagagctg gaactgaggc 25380
ctacaggaga gattgagcag tattctgtca gcgcaaccta tgagctccag agagaggaca 25440
gagccttggt ggataccctg aagtttgtaa ctcaagcaga aggtgagtat tcaaacacac 25500
gctgcctcat ctctgctcgc agtctcaggt tcagaattca tgaggagaag acatgtaatt 25560
taacctattt aacaaatagg ttaactgagt acccactaag cggcaggcct attctaagac 25620
ctgggttaac tgagtaccca ataagcggca ggctattct aagacctggg gctagaacag 25680
tgaacaatgg agtctctgcc ttcattggaag ttacagtga caaccaaca agttaataatt 25740
tggaatatca gataagtact gaggaggaaa acagagcgta gactgggtcta tggagggcta 25800
ggagtaggag ggaggaagaa gggcagggaa agcagtgcac ttggaataat aagggaagt 25860
ctccctggta aagtgagcat aaggagacct atcagaaata agaggagaag ccgtgtggta 25920
agactgttaa caggcagagg gaccagcaag tgcaaaggcc ctgaggctga cacactacta 25980
ccatgtttca aggaaaggaa ggaagacagt atggctggag cagaaagacc agggagaaaa 26040
gaggtagaag atgaggacag agagatatgg agaggtgaag gaaggataat ctcataggcc 26100
atggtaagaa ctttgctctt ttctatgaat taaacgaaag ccattgggga gtccctcatga 26160
tttgatttat gtttatgttg agaaaagact atgggcagac aagggcagag aaactaatat 26220
gtaggttatc acaataatcc aggcaggaat cagtgttgtt ttggatcagg gcaatggcag 26280
aagagatatg agaaggggat ggattctggc catattttga agattaggct gacaagattt 26340
gctgatacag tggatgttga gtgtaagagg aaaaggggaa tgaagacaaa cctaaggttt 26400
ttggcccggg caactgaaaa atggaacttc cattatttga gatggaaagg gctactggag 26460
gagcaggttt tagggaatgg gagaaattta ggtgttctact ttggaaaaaa aattatatag 26520
ggatagcgag gagcaggttt tagggaatgg ggcacattta ggtgttctact ttggaaaaat 26580
tttatatag ggatagcata tcacagaatt aaactaggaa gaaaatccca tgatagaaag 26640

```


-continued

cactggagga	gcagggcacg	ctggggaaat	agtgtttggt	aaacattgtt	ttacgaagga	26700
tataaaatgg	accagcctat	ggattgaagg	acgcccggga	atcttggttac	aaagaaaggg	26760
ggagttgggg	agatggagcc	cagggcaagg	gcagcaagga	accaggacag	gcattctggg	26820
tagaaagtaa	tatagagatg	tcgtgtcttc	ctggcccaga	agggtgcga	gcctttgctg	26880
ttccacaaac	aagctaagtg	ctccccattt	cagggccttt	gcattcctga	ccttctgcct	26940
ggaatgtgct	cctcccagaa	ctcagcgtgg	ctccaacctc	ttttcattct	ggtctctgcc	27000
cacatgtgcc	cttatcagag	agaattttct	tgaccaccaa	gtatgaaata	acattctctt	27060
tatccctttt	ttttatcctt	gtatccagtt	ttactcttct	tcataacatt	cattaccatc	27120
tgacatgagc	aagttaactg	tttattgcct	gtacacctcc	cccactagaa	ggtaagcccc	27180
atgaaagcaa	ggattcccca	gtaccaagag	cagtgccccag	cacacaatag	gctcataaca	27240
ggcaatccat	aaagacttgc	atacatgaac	acaactgagt	ttaaaattat	cagtaaatga	27300
gaccatttaa	aaaattttta	tgagaaaaaa	aaaattcagt	aaaatcctga	actgtgtttt	27360
tgtttaagca	cattgattcc	ttggagtctc	tctacctttt	cctctctttc	cttccaaaac	27420
atagcttctt	tattttattt	tttatttatt	tgtttgttta	tttatttatt	tattttattt	27480
tttttttttt	gagatggagt	ctcgtctctt	tgcccaggct	gcagtgcagt	ggtgccatct	27540
cggtcactg	caagccccgc	ctcccgggtt	catgccattc	tctgcctca	gcctcctgag	27600
tagctgggac	tacaggcacc	caccaacgcg	cccggcta	ttttgtatt	tttagtagag	27660
acggggtttc	accatgttag	ccagaatggt	cttgatctcc	tgacctcatg	atctgcccgc	27720
cttggcctcc	caaagtgcgt	ggattacagg	tgtgagccac	cgcacccggc	ccaaaacata	27780
gcttcttacc	acacatctct	tgattctctt	atacactcgt	ccagggtcga	agcagactga	27840
ggctaccatg	acattcaaat	ataatcgga	gagtatgacc	ttgtccagt	aagtccaaat	27900
tccgattttt	gatgttgacc	tcggaacaat	cctcagagtt	aatgatgaat	ctactgaggg	27960
caaaacgtct	tacagactca	ccctggacat	tcagaacaag	aaaattactg	aggtcgccct	28020
catggggccac	ctaaggtaaa	gaaggccgag	ggtcatctga	cctgcactgc	aggcctgggt	28080
ggttcttttc	attattctct	ttccacttca	tacctgacca	agccatgttc	tcccctagtc	28140
tacaatcaga	gtggcagaga	gagccctcaa	caattttttt	tttttttgag	atggagtctc	28200
actctgtcac	caggctggag	tgcagtggca	caatctcggc	tcaactgcaac	ctccgcctcc	28260
cgagttcaag	tgattctcct	gcttaagcct	cccaaggagc	tggaactata	ggtgcatgcc	28320
accacaccca	gctaattttt	atatttttag	tagagacagg	gtttcaccat	attgaccagg	28380
atggtctcga	tctcctgacc	tcgtgatcca	cctgccttgg	cctcccaaag	tgtggggatt	28440
acaggtgtaa	gccactgcac	ccggccaagc	tctcaacatt	ttaaccctct	gcgcattgtc	28500
agttggattt	tcctaccatt	tatcaggcac	ttactattca	tgtatcaagc	acagtgcctg	28560
gtgctttaa	gaaattatct	cggtcctcac	aataaactgc	gaggtcactg	tgagttttcc	28620
tgtttcatgg	ataaggaaat	ggtagctcag	aggggttaaa	tcatttggtc	aaaatcacag	28680
agctagtaaa	tagcagagca	ggattcaaac	agttttcaaa	aaacttctct	ttctcctaaa	28740
cctgtttgca	aagtccttaa	tttgtgctga	atgttggtt	tagaagttga	tgagtttgat	28800
ctgtggctgt	ttctctgaac	catccttgta	tctggttttg	atcaccacaa	atggaacttc	28860
tgtttaatcc	tgcatatctc	cattgaaagg	acaaaatcat	tggtgccaac	tgattttctt	28920
taccatagtt	gtgacacaaa	ggaagaaaga	aaaatcaagg	gtgttatttc	cataccccg	28980
ttgcaagcag	aagccagaag	tgagatcctc	gcccactgg	cgctgccaa	actgcttctc	29040

-continued

caaatggact catctgctac agcttatggc tccacagttt ccaagagggt ggcattggcat	29100
tatgggtatgt gtctcttccc ctgtgtgagc acttccaaag taatgcagggt gttgagacct	29160
gtggttacag gctgaactag taccattcac aactatttcc tacgtatttt cagatgaaga	29220
gaagattgaa tttgaatgga acacaggcac caatgtagat accaaaaaaa tgacttccaa	29280
ttccctgtg gatctctccg attatcctaa gagcttgcat atgtatgcta atagactcct	29340
ggatcacaga gtccctcaaa cagacatgac tttccggcac gtgggttcca aattaatagt	29400
tgtaagtatg agtctgccag tcaataaata catggatata agtgctaatt acatcctcaa	29460
ctctgagcta ggtgcaggaa ggtttccaaa gatgtataag gcatgcttcc tccccccag	29520
ggaattcttg gggagaaaaa aaaactttca caagtgtgta gttaccaggt tacacaaagc	29580
tgaatgtgat acatatcaaa gagatgctac taagtagaac agttctttgc ctagtgggtat	29640
caaaggaagc ttcaggacac cagctaggag gctgactatg ttagacattc cttttataaa	29700
tatggacagt gatcagtgc tggcaacgaa gattcataat tttctgttat ttatttttaa	29760
ctttcagtgc attgtccagc ttaataatta acttgtcaaa tcggtatttt tgcctaattg	29820
tcattgtctt ttgaggctca tccaagccca ttaccttaaa aatctcctgt cattttgtag	29880
gcaatgagct catggcttca gaaggcatct gggagtcttc cttataccca gactttgcaa	29940
gaccacctca atagcctgaa ggagtccaac ctccagaaca tgggattgcc agacttccac	30000
atccagaaa acctcttctt aaaaaggtaa aagaagaaag cagcaaggct tcttgaacca	30060
tgcaaagtaa atgaaagatt ttacatagca tgatttagac atttttttaa atttttaaag	30120
gaaataattt aagcatttta aggagattaa taactatagc acaaacactg tggcatcttt	30180
gcattagtaa acatgagaac accaaccttg tcaggaagaa tctaagaaag tcattagagg	30240
attctggtac tttcacccta agatatttta ttcagtacaa cctgttataa gcaaattctc	30300
cctctgactg tgaagaattc agaattggcta gaggcgttat tgactacagg cttgctgtta	30360
agctagagag agtcagaaca gccattgagc actaaatgga ggcagcattc tgagaaaata	30420
ctttaacca ggcttactga cttccatacc tatgttcttt ccacaaatca agttgtctca	30480
attcagttta gcaaatttgt atcaagtatc ccctatgtgc aaaatgctag actaggtaca	30540
gtgagaagat agaaactggg taagggtatag ccttttcttt caagaagata ccatggagac	30600
atcaacaaat gagaaataat taattatata agcaaaatta tgacatgctc tttgagaaag	30660
gtgcaaggga ctatgtaact gtaagaatga gacaaattgg ctatgactta ggtgggatgg	30720
taatgataag gagtggccct tagaagagct ttgtcaggat ttgagtgttt gacagggtga	30780
ggtaaaagca aaggggtcca ggcattaggag tagcaciaag aaaagtgcag agtggctttg	30840
ggaatggggc aagtacaata ttgttgtgaa ggtcagaggc agagaacttt gaatgactga	30900
tgtctgactg tggggatgtt atctttgttg ttcatttcag cgatggccgg gtcaaatata	30960
ccttgaacaa gaacagtttg aaaattgaga ttcctttgcc ttttgggtggc aaatcctcca	31020
gagatctaaa gatgttagag actgttagga caccagccct ccacttcaag tctgtgggat	31080
tccatctgcc atctcgagag ttccaagtcc ctacttttac cattcccaag ttgtatcaac	31140
tgcaagtgcc tctcctgggt gttctagacc tctccacgaa tgtctacagc aacttgtaca	31200
actggctccg ctctacaggt ggtggcaaca ccagcacaga ccatttcagc ctctgggctc	31260
gttaccacat gaaggctgac tctgtggttg acctgcttcc ctacaatgtg caaggtgagc	31320
tatgctcagg taaaggggtgc accgggctag ttcattggcag gctctaagag gagagcctcc	31380
tccagggagg aaaggacttt ggctttctag cagataatct tccttgctac ttggaagtct	31440

-continued

```

tttattttat tcaacaaata gaaatattta ttaaaccatat cacgtgtatt aaatattcta 31500
gtaggcagta acagaaagta gacagataag ccagcaatta taattcagtg tgagaggtgc 31560
tatgataaag ttagtatat aagtataagg tagagtggaa gcaactcaaca agggaaacct 31620
aacaagcct gtggtggta ggcaaggctt cctggaggaa tgccttttgc tatcagattt 31680
tatctttgca ttacagatgg aggagtctat tgcacaattg gccagaaaa atggggcttt 31740
attattgaaa gactttcaac atagagattg ctctggaaat gtactgctta atttaaccaa 31800
tgtcttttca tttttatgtt aggatctgga gaaacaacat atgaccacaa gaatacgttc 31860
acactatcat atgatgggct tctacgccac aaatttctag attcgaatat caaattcagt 31920
catgtagaaa aacttggaac caaccagtc tcaaaagggt tactaatatt cgatgcatct 31980
agttcctggg gaccacagat gtctgcttca gttcatttgg actccaaaaa gaaacagcat 32040
ttgtttgtca aagaagtcaa gattgatggg cagttcagag tctcttcgtt ctatgctaaa 32100
ggcacatatg gcctgtcttg tcagagggat cctaactctg gccggctcaa tggagagtcc 32160
aacctgaggt ttaactctc ctacctcaa ggcaccaacc agataacagg aagatatgaa 32220
gatggaaccc tctccctcac ctccacctct gatctgcaa gtggcatcat taaaaatact 32280
gcttcctcaa agtatgagaa ctacgagctg actttaaat ctgacaccaa tgggaagtat 32340
aagaactttg ccacttctaa caagatggat atgaccttct ctaagcaaaa tgcactgctg 32400
cgttctgaat atcaggctga ttacgagtc ttgaggttct tcagcctgct tcttgatca 32460
ctaaattccc atggtcttga gttaaatgct gacatcttag gcaactgaaa aattaatagt 32520
ggtgctcaca aggcgacct aaggattggc caagatggaa tatctaccag tgcaacgacc 32580
aacttgaagt gtagtctcct ggtgctggag aatgagctga atgcagagct tggcctctct 32640
ggggcatcta tgaaattaac aacaaatggc cgcttcaggg aacacaatgc aaaattcagt 32700
ctggatggga aagccgccct cacagagcta tcaactggaa gtgcttatca ggccatgatt 32760
ctgggtgtcg acagcaaaaa cattttcaac ttcaaggta gtcaagaagg acttaagctc 32820
tcaaagaca tgatgggctc atatgctgaa atgaaatttg accacacaaa cagtctgaac 32880
attgcaggct tatcactgga cttctcttca aaacttgaca acatttacag ctctgacaag 32940
ttttataagc aaactgttaa ttacagcta cagccctatt ctctggtaac tactttaaac 33000
agtgcactga aatacaatgc tctggatctc accaacaatg ggaaactacg gctagaaccc 33060
ctgaagctgc atgtggctgg taacctaaaa ggagcctacc aaaataatga aataaacac 33120
atctatgcca tctcttctgc tgccttatca gcaagctata aagcagacac tgttgctaag 33180
gttcagggtg tggagttag ccatcggtc aacacagaca tcgtggggtt ggttcagcc 33240
attgacatga gcacaaacta taattcagac tcaactgcatt tcagcaatgt cttccgttct 33300
gtaatggccc cgtttaccat gaccatgat gcacatacaa atggcaatgg gaaactcgct 33360
ctctggggag aacatactgg gcagctgtat agcaaatcc tgttgaaagc agaacctctg 33420
gcatttactt tctctcatga ttacaaaggc tccacaagtc atcatctcgt gtctaggaaa 33480
agcatcagtg cagctcttga acacaaagtc agtgccctgc ttactccagc tgagcagaca 33540
ggcacctgga aactcaagac ccaatttaac aacaatgaat acagccagga cttggatgct 33600
tacaacacta aagataaaat tggcgtggag cttactggac gaactctggc tgacctaaat 33660
ctactagact ccccaattaa agtgccactt ttactcagtg agcccatcaa tatcattgat 33720
gctttagaga tgagagatgc cgttgagaag cccaagaat ttacaattgt tgcctttgta 33780
aagtatgata aaaaccaaga tgttactccc attaacctcc cattttttga gaccttgcaa 33840

```

-continued

gaatattttg agaggaatcg acaaaccatt atagttgtac tggaaaacgt acagagaaac	33900
ctgaagcaca tcaatattga tcaatttgta agaaaatata gagcagccct gggaaaactc	33960
ccacagcaag ctaatgatta tctgaattca ttcaattggg agagacaagt ttcacatgcc	34020
aaggagaaac tgactgctct cacaaaaaag tatagaatta cagaaaatga tatacaaat	34080
gcattagatg atgccaaaat caactttaat gaaaaactat ctcaactgca gacatatatg	34140
atacaatttg atcagtatat taaagatagt tatgatttac atgatttgaa aatagctatt	34200
gctaataatta ttgatgaaat cattgaaaaa ttaaaaagtc ttgatgagca ctatcatatc	34260
cgtgtaaatt tagtaaaaac aatccatgat ctacatttgt ttattgaaaa tattgatttt	34320
aacaaaagtg gaagtagtac tgcacactgg attcaaaatg tggatactaa gtaccaaatc	34380
agaatccaga tacaagaaaa actgcagcag cttaagagac acatacagaa tatagacatc	34440
cagcacctag ctggaaaagt aaaacaacac attgaggcta ttgatgttag agtgctttta	34500
gatcaattgg gaactacaat ttcatttgaa agaataaatg acattcttga gcatgtcaaa	34560
cactttgtta taaatcttat tggggatttt gaagtagctg agaaaatcaa tgccttcaga	34620
gccaaagtcc atgagttaat cgagaggatg gaagtagacc aacaaatcca ggttttaatg	34680
gataaattag tagagttggc ccaccaatag aagttgaagg agactattca gaagctaagc	34740
aatgtcttac aacaagttaa gataaaagat tactttgaga aattggttgg atttattgat	34800
gatgctgtca agaagcttaa tgaattatct tttaaaacat tcattgaaga tgttaacaaa	34860
ttccttgaca tgttgataaa gaaattaaag tcatttgatt accaccagtt tgtagatgaa	34920
accaatgaca aaatccgtga ggtgactcag agactcaatg gtgaaattca ggctctggaa	34980
ctaccacaaa aagctgaagc attaaaactg tttttagagg aaaccaaggc cacagttgca	35040
gtgtatctgg aaagcctaca ggacacacaa ataaccttaa tcatcaattg gttacaggag	35100
gctttaagtt cagcatcttt ggctcacatg aaggccaaat tccgagagac cctagaagat	35160
acacgagacc gaatgtatca aatggacatt cagcaggaac ttcaacgata cctgtctctg	35220
gtaggccagg tttatagcac acttgtcacc tacattttctg attggtggac tcttgctgct	35280
aagaacctta ctgactttgc agagcaatat tctatccaag attgggctaa acgtatgaaa	35340
gcattggtag agcaagggtt cactgttctc gaaatcaaga ccatccttgg gaccatgcct	35400
gcctttgaag tcagtcttca ggctcttcag aaagctacct tccagacacc tgattttata	35460
gtccccctaa cagatttgag gattccatca gttcagataa acttcaaaga cttaaaaaat	35520
ataaaaaatcc catccagggt tccacacca gaatttacca tccttaacac ctccacatt	35580
ccttccttta caattgactt tgtagaaatg aaagtaaaga tcatcagaac cattgaccag	35640
atgctgaaca gtgagctgca gtggcccggt ccagatatat atctcaggga tctgaagggtg	35700
gaggacattc ctctagcgag aatcacccctg ccagacttcc gtttaccaga aatcgcaatt	35760
ccagaattca taatcccaac tctcaacctt aatgattttc aagttcctga ccttcacata	35820
ccagaattcc agcttcccca catctcacac acaattgaag tacctacttt tggcaagcta	35880
tacagtattc tgaataatcca atctcctctt ttcacattag atgcaaatgc tgacataggg	35940
aatggaacca cctcagcaaa cgaagcaggt atcgcagctt ccatcactgc caaaggagag	36000
tccaaattag aagttctcaa ttttgatttt caagcaaatg cacaactctc aaaccctaa	36060
attaatccgc tggctctgaa ggagtcagtg aagttctcca gcaagtacct gagaacggag	36120
catgggagtg aaatgctgtt ttttggaat gctattgagg gaaaatcaaa cacagtggca	36180
agtttacaca cagaaaaaaa tacactggag cttagtaatg gagtgttgt caagataaac	36240

-continued

```

aatcagctta ccttgatag caactactaa tacttccaca aattgaacat ccccaactg 36300
gacttctcta gtcaggctga cctgcgcaac gagatcaaga cactgttgaa agctggccac 36360
atagcatgga cttcttctgg aaaaggggtca tggaaatggg cctgccccag attctcagat 36420
gagggaaacac atgaatcaca aattagtctt accatagaag gacccctcac ttcctttgga 36480
ctgtccaata agatcaatag caaacaccta agagtaaacc aaaacttggg ttatgaatct 36540
ggctccctca acttttctaa acttgaaatt caatcacaag tcgattccca gcatgtgggc 36600
cacagtgttc taactgctaa aggcattgga ctgtttggag aagggaaggc agagtctact 36660
gggaggcatg atgctcattt aaatggaaag gttattggaa ctttgaaaaa ttctcttttc 36720
ttttcagccc agccatttga gatcacggca tccacaaaca atgaagggaa tttgaaagtt 36780
cgttttccat taaggttaac agggaagata gacttcctga ataactatgc actgtttctg 36840
agtcccagtg cccagcaagc aagttggcaa gtaagtgcta ggttcaatca gtataagtac 36900
aaccaaaatt tctctgctgg aaacaacgag aacattatgg aggccatgt aggaataaat 36960
ggagaagcaa atctggattt cttaaacatt cctttaacaa ttcttgaaat gcgtctacct 37020
tacacaataa tcacaactcc tccactgaaa gatttctctc tatgggaaaa aacaggcttg 37080
aaggaattct tgaaaacgac aaagcaatca tttgatttaa gtgtaaaagc tcagtataag 37140
aaaaaacaac acaggcatc catcacaaat cctttggctg tgctttgtga gtttatcagt 37200
cagagcatca aatcctttga caggcatttt gaaaaaaaca gaaacaatgc attagatttt 37260
gtcaccaaat cctataatga aacaaaaatt aagtttgata agtacaaagc tgaaaaatct 37320
cacgacgagc tccccaggac ctttcaaatt cctggataca ctgttccagt tgccaatgtt 37380
gaagtgtctc cattcaccat agagatgtcg gcattcggct atgtgttccc aaaagcagtc 37440
agcatgccta gtttctccat cctaggttct gacgtccgtg tgccttcata cacattaatc 37500
ctgccatcat tagagctgcc agtccttcat gtccttagaa atctcaagct ttctcttcca 37560
gatttcaagg aattgtgtac cataagccat atttttatc ctgccatggg caatattacc 37620
tatgatttct cctttaaatc aagtgtcatc aactgaata ccaatgctga actttttaac 37680
cagtcagata ttgttgctca tctcctttct tcattctcat ctgtcattga tgcactgcag 37740
tacaaaattag agggcaccac aagattgaca agaaaaaggg gattgaagtt agccacagct 37800
ctgtctctga gcaacaaatt tgtggagggt agtcataaca gtactgtgag ctttaaccacg 37860
aaaaatatgg aagtgtcagt ggcaacaacc acaaaagccc aaattccaat tttgagaatg 37920
aatttcaagc aagaacttaa tggaaatacc aagtcaaaac ctactgtctc ttctccatg 37980
gaatttaagt atgatttcaa ttcttcaatg ctgtactcta ccgctaaagg agcagttgac 38040
cacaagctta gcttgaaaag cctcaactct tacttttcca ttgagtcac taccaaagga 38100
gatgtcaagg gttcggttct ttctcgggaa tattcaggaa ctattgctag tgaggccaac 38160
acttacttga attccaagag cacacggtct tcagtgaagc tgcagggcac ttccaaaatt 38220
gatgatattc ggaaccttga agtaaaagaa aattttgctg gagaagccac actccaacgc 38280
atatattccc tctgggagca cagtacgaaa aaccacttac agctagaggg cctctttttc 38340
accaacggag aacatacaag caaagccacc ctggaactct ctccatggca aatgtcagct 38400
cttgttcagg tccatgcaag tcagcccatg tccttccatg atttccctga ccttgccag 38460
gaagtggccc tgaatgctaa cactaagaac cagaagatca gatggaaaaa tgaagtccgg 38520
attcattctg ggtctttcca gagccaggtc gagctttcca atgaccaaga aaaggcacac 38580
cttgacattg caggatcctt agaaggacac ctaagggttc tcaaaaatat catcctacca 38640

```

-continued

```

gtctatgaca agagcttatg ggatttccta aagctggatg taaccaccag cattggtagg 38700
agacagcatc ttcgtgtttc aactgccttt gtgtacacca aaaaccccaa tggctattca 38760
ttctccatcc ctgtaaaagt tttggctgat aaattcatta ttctgggct gaaactaaat 38820
gatctaaatt cagttcttgt catgcctacg ttccatgtcc catttacaga tcttcagggt 38880
ccatcgtgca aacttgactt cagagaaata caaatctata agaagctgag aacttcatca 38940
tttgcctca acctaccaac actccccgag gtaaaattcc ctgaagtga tgtgttaaca 39000
aaatattctc aaccagaaga ctccctgatt ccttttttg agataaccgt gcctgaatct 39060
cagttaactg tgtcccagt cagccttcca aaaagtgttt cagatggcat tgcgtctttg 39120
gatctaaatg cagtatgcaa caagatcgca gactttgagt tgcccaccat catcgtgcct 39180
gagcagacca ttgagattcc ctccattaag ttctctgtac ctgctggaat tgctattcct 39240
tcctttcaag cactgactgc acgctttgag gtagactctc ccgtgtataa tgccacttgg 39300
agtgccagtt tgaaaaacaa agcagattat gttgaaacag tcctggattc cacatgcagc 39360
tcaaccgtac agttcctaga atatgaacta aatggtaaga aatatcctgc ctctctcct 39420
agatactgta tttttcaat gagagttagt agtaataat tatgtattta gttgtgagta 39480
gatgtacaat tactcaatgt cacaaaattt taagtaagaa aagagataca tgtataccct 39540
acacgtaaaa accaaactgt agaaaatcta gtgtcattca agacaaacag ctttaaagaa 39600
aatggatttt tctgtaatta ttttaggact aacaatgtct tttactatt tttttaaaa 39660
taagtgtgag ctgtacattg catattttta acacaagtga aatatctggt taggatagaa 39720
ttctcccagt tttcacatg aaaacatcaa cgtcctactg ttatgaatct aataaaatac 39780
aaaaatctct ctatacagtt ttgggaacac acaaatcga agatggtagc ttagcctcta 39840
agactaaagg aacatttgca caccgtgact tcagtgcaga atatgaagaa gatggcaaat 39900
atgaaggact tcagtatgga gcttttattg aattgaaacc ttataccttt tgaaaactca 39960
ttgtgatttt ctctctctcc atacccttt cgtgatagct catctgtttt tctgctttca 40020
gggaatggga aggaaaagcg cacctcaata tcaaaagccc agcgttcacc gatctccatc 40080
tgcgtacca gaaagacaag aaaggcatct ccacctcagc agcctccca gccgtaggca 40140
ccgtgggcat ggatatggat gaagatgacg acttttctaa atggaacttc tactacagcc 40200
ctcaggtaaa taccacctaa tgagtgcac gcccccaaga gcgagtggag aattggggca 40260
gatacattta attcaggacc aaatatctag agattccca aactaggtga aagacaggcg 40320
gtaagcaact tcttctctga ggaaatattc tctagaaagt attacaatga gtccttgatt 40380
gattttaatg tttagatgca cacatgacat cccatcagca ctattattta ttaattctgg 40440
gcaaattccg gaagatgagg gttatacctc atcatctaaa tcataggcaa gctcagccat 40500
aggcagggta ttttttctag agaggactgg tttctgtagt atttaaaact ttaaaattct 40560
tcccccaat agaattgcta gatgagatc atcaaattcc tctcatgtca tttacaagct 40620
ctgccagggc caaatcaagg gtgacattac cagaggagaa gaccaaact ggttctatga 40680
ctgttactaa aagtttgtca tgggcttgga gaatgcgtac tgatgtggg attctgggtc 40740
tctgcagggt gggctccaac ttgccttttt tgctatttct tcttttcta tctgtcattt 40800
cctgaactct ctctctctc ctctctctc tctctctctc actctctctc cagttttcag 40860
tcctaggaag gctttaattt taagtgtcac aatgtaaatg acaaacagca agcgtttttg 40920
ttaaatcctt tctggggcat gtgataaaga gaaattaaca acagtagact tatttaacca 40980
taaaacaaac acatgaactg acatatgaaa gataaatccc tttcagtata tgaaagattc 41040

```

-continued

tctgatcttt	atttttaact	gctaatagaag	tttttagtgta	ctatatgtg	taattggagt	41100
aattgaaaac	atgttatttt	tttttttctc	tctgtttagt	cctctccaga	taaaaaactc	41160
accatattca	aaactgagtt	gaggggccgg	gaatctgatg	aggaaactca	gatcaaagtt	41220
aattgggaag	aagaggcagc	ttctggcttg	ctaactctc	tgaagacaa	cgtgcccaag	41280
gccacagggg	tcctttatga	ttatgtcaac	aagtaccact	gggaacacac	agggctcacc	41340
ctgagagaag	tgtcttcaaa	gctgagaaga	aatctgcaga	acaatgctga	gtgggtttat	41400
caaggggcca	ttaggc aaat	tgatgatatc	gacgtgaggt	tccagaaagc	agccagtggc	41460
accactggga	cctaccaaga	gtggaaggac	aaggcccaga	atctgtacca	ggaactgttg	41520
actcaggaag	gccaaagccag	tttccaggga	ctcaaggata	acgtgtttga	tggcttggtg	41580
cgagttactc	aagaattcca	tatgaaagtc	aagcatctga	ttgactcact	cattgatttt	41640
ctgaacttcc	ccagattcca	gtttccgggg	aaacctggga	tataactag	ggaggaactt	41700
tgcaactatgt	tcataagggg	ggtagggacg	gtactgtccc	aggtatatcc	gaaagtccat	41760
aatgggttcag	aaatactgtt	ttcctatttc	caagacctag	tgattacact	tcctttcgag	41820
ttaaggaaac	ataaactaat	agatgtaatc	tcgatgtata	gggaactgtt	gaaagattta	41880
tcaaaagaag	cccaagaggt	atttaaagcc	attcagcttc	tcaagaccac	agaggtgcta	41940
cgtaactcttc	aggacctttt	acaattcatt	ttccaactaa	tagaagataa	cattaacacag	42000
ctgaaagaga	tgaattttac	ttatcttatt	aattatatcc	aagatgagat	caacacaatc	42060
ttcagtgatt	atatcccata	tgtttttaaa	ttgttgaaag	aaaacctatg	ccttaatctt	42120
cataagttca	atgaatttat	tcaaaacgag	cttcaggaag	cttctcaaga	gttacagcag	42180
atccatcaat	acattatggc	ccttcgtgaa	gaatattttg	atccaagtat	agttggctgg	42240
acagtgaat	attatgaact	tgaagaaaag	atagtcagtc	tgatcaagaa	cctgttagtt	42300
gctcttaag	acttccatc	tgaatatatt	gtcagtgcc	ctaactttac	ttcccaactc	42360
tcaagtcaag	ttgagcaatt	tctgcacaga	aatattcagg	aatatcttag	cacocctacc	42420
gatccagatg	gaaaagggaa	agagaagatt	gcagagcttt	ctgccactgc	tcaggaaata	42480
attaaaagcc	aggccattgc	gacgaagaaa	ataattttctg	attaccacca	gcagtttaga	42540
tataaactgc	aagatttttc	agaccaactc	tctgattact	atgaaaaatt	tattgctgaa	42600
tccaaaaagat	tgattgacct	gtccattcaa	aactaccaca	catttctgat	atacatcacg	42660
gagttactga	aaaagctgca	atcaaccaca	gtcatgaacc	cctacatgaa	gcttgctcca	42720
ggagaactta	ctatcatcct	ctaatttttt	aaaagaaaac	ttcatttatt	cttcttttcc	42780
aattgaactt	tcacatagca	cagaaaaaat	tcaaaactgcc	tatattgata	aaaccataca	42840
gtgagccagc	cttgagtag	gcagtagact	ataagcagaa	gcacatatga	actggacctg	42900
caccaaaagct	ggcaccaggg	ctcggaaggt	ctctgaactc	agaaggatgg	cattttttgc	42960
aagttaaaga	aaatcaggat	ctgagttatt	ttgctaaact	tgggggagga	ggaacaaata	43020
aatggagtct	ttattgtgta	tcataccact	gaatgtggct	catttgtatt	gaaagacagt	43080
gaaacgaggg	cattgataaa	atgttctggc	acagcaaaac	ctctagaaca	catagtgtga	43140
tttaagtaac	agaataaaaa	tggaaacgga	gaaattatgg	agggaaatat	tttgcaaaaa	43200
tatttaaaaa	gatgaggtaa	ttgtgttttt	ataattaaat	attttataat	taaaatattt	43260
ataattaaaa	tatttataat	taaatatttt	ataattaaaa	tatttataat	taaatatttt	43320
ataattaaag	tatttataat	taaatatttt	ataattaaaa	tatttataat	taaatatttt	43380
ataattaaaa	tatttataat	taaatatttt	ataattaaaa	tatttataat	taaatatttt	43440

-continued

ataat 43445

<210> SEQ ID NO 335
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 335

tctgtaagac aggagaaaga 20

<210> SEQ ID NO 336
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 336

atttcctctt ctgtaagaca 20

<210> SEQ ID NO 337
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 337

gatgccttac ttggacagac 20

<210> SEQ ID NO 338
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 338

agaaatagct ctccaagga 20

<210> SEQ ID NO 339
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 339

gtcgcattctt ctaacgtggg 20

<210> SEQ ID NO 340
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 340

tcctccatac cttgcagttg 20

<210> SEQ ID NO 341
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 341

tggctcatgt ctaccatatt 20

<210> SEQ ID NO 342
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 342

cagttgaaat gcagctaata 20

<210> SEQ ID NO 343
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 343

tgccagactag gagtgaaagt 20

<210> SEQ ID NO 344
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 344

aggaggatgt ccttttattg 20

<210> SEQ ID NO 345
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 345

atcagagcac caaagggaat 20

<210> SEQ ID NO 346
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 346

ccagctcaac ctgagaattc 20

<210> SEQ ID NO 347
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 347

catgacttac ctggacatgg 20

-continued

<210> SEQ ID NO 348
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 348

cctcagcggg cacacacaca

20

<210> SEQ ID NO 349
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 349

gtcacatccg tgcttggtgc

20

<210> SEQ ID NO 350
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 350

cagtgctctt gggacccac

20

<210> SEQ ID NO 351
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 351

agctgcagtg gccgatcagc

20

<210> SEQ ID NO 352
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 352

gacctcccca gccacgtgga

20

<210> SEQ ID NO 353
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 353

tctgatcacc atacattaca

20

<210> SEQ ID NO 354
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 354

-continued

atttcccaact gggctactctc 20

<210> SEQ ID NO 355
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 355

ggctgaagcc catgctgact 20

<210> SEQ ID NO 356
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 356

gttggacagt cattcttttg 20

<210> SEQ ID NO 357
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 357

cacttggttg acagtcattc 20

<210> SEQ ID NO 358
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 358

atthtaaat acagtagata 20

<210> SEQ ID NO 359
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 359

ctgttctcca cccatatcag 20

<210> SEQ ID NO 360
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 360

gagctcatac ctgtccaga 20

<210> SEQ ID NO 361
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 361

ttcaagggcc actgctatca 20

<210> SEQ ID NO 362
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 362

ccagtatttc acgccaatcc 20

<210> SEQ ID NO 363
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 363

ggcaggagga acctcgggca 20

<210> SEQ ID NO 364
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 364

ttttaaaatt agaccaacc 20

<210> SEQ ID NO 365
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 365

tgactgtttt aaaattagac 20

<210> SEQ ID NO 366
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 366

cccagcaaac acaggtgaag 20

<210> SEQ ID NO 367
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 367

gagtgtggtc ttgctagtgc 20

-continued

<210> SEQ ID NO 368
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 368

ctatgcagag tgtggtcttg

20

<210> SEQ ID NO 369
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 369

agaagatgca accacatgta

20

<210> SEQ ID NO 370
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 370

acacggtatc ctatggagga

20

<210> SEQ ID NO 371
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 371

tgggacttac catgcctttg

20

<210> SEQ ID NO 372
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 372

ggttttgctg ccctacatcc

20

<210> SEQ ID NO 373
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 373

acaaggagtc cttgtgcaga

20

<210> SEQ ID NO 374
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 374

-continued

atgttcactg agacaggctg 20

<210> SEQ ID NO 375
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 375

gaaggtccat ggttcacatg 20

<210> SEQ ID NO 376
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 376

attagactgg aagcatcctg 20

<210> SEQ ID NO 377
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 377

gagattggag acgagcattt 20

<210> SEQ ID NO 378
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 378

catgacctac ttgtaggaga 20

<210> SEQ ID NO 379
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 379

tggatttgga tacacaagtt 20

<210> SEQ ID NO 380
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 380

actcaatata tattcattga 20

<210> SEQ ID NO 381
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 381

caaggaagca caccatgtca 20

<210> SEQ ID NO 382
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 382

atacttattc ctggtaacca 20

<210> SEQ ID NO 383
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 383

ggtagccaga acaccagtgt 20

<210> SEQ ID NO 384
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 384

actagaggta gccagaacac 20

<210> SEQ ID NO 385
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 385

accacctgac atcacaggtt 20

<210> SEQ ID NO 386
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 386

tactgtgacc tatgccagga 20

<210> SEQ ID NO 387
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 387

ggaggtgcta ctgttgacat 20

-continued

<210> SEQ ID NO 388
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 388

tccagacttg tctgagtcta

20

<210> SEQ ID NO 389
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 389

tctaagaggt agagctaaag

20

<210> SEQ ID NO 390
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 390

ccagagatga gcaacttagg

20

<210> SEQ ID NO 391
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 391

ggccatgtaa attgctcatc

20

<210> SEQ ID NO 392
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 392

aaagaaacta tcctgtattc

20

<210> SEQ ID NO 393
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 393

ttcttagtac ctggaagatg

20

<210> SEQ ID NO 394
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 394

-continued

cattagatac ctggacacct 20

<210> SEQ ID NO 395
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 395

gtttcatgga actcagcgca 20

<210> SEQ ID NO 396
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 396

ctggagagca cctgcaatag 20

<210> SEQ ID NO 397
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 397

tgaagggtag agaaatcata 20

<210> SEQ ID NO 398
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 398

ggaaactcac ttgttgaccg 20

<210> SEQ ID NO 399
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 399

aggtgcaaga tggtcctctg 20

<210> SEQ ID NO 400
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 400

tgcaagatgt 20

<210> SEQ ID NO 401
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 401

cacaagagta aggagcagag 20

<210> SEQ ID NO 402
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 402

gatggatggt gagaaattac 20

<210> SEQ ID NO 403
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 403

tagacaattg agactcagaa 20

<210> SEQ ID NO 404
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 404

atgtgcacac aaggacatag 20

<210> SEQ ID NO 405
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 405

acatacaaat ggcaataggc 20

<210> SEQ ID NO 406
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 406

taggcaaagg acatgaatag 20

<210> SEQ ID NO 407
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 407

ttatgatagc tacagaataa 20

-continued

<210> SEQ ID NO 408
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 408

ctgagattac ccgcagaatc

20

<210> SEQ ID NO 409
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 409

gatgtatgtc atataaaaga

20

<210> SEQ ID NO 410
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 410

tttccaatga cctgcattga

20

<210> SEQ ID NO 411
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 411

agggatggtc aatctggtag

20

<210> SEQ ID NO 412
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 412

ggctaataaa tagggtagtt

20

<210> SEQ ID NO 413
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 413

tcctagagca ctatcaagta

20

<210> SEQ ID NO 414
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 414

-continued

cctcctgggtc ctgcagtcaa 20

<210> SEQ ID NO 415
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 415

catttgcaca agtgtttgtt 20

<210> SEQ ID NO 416
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 416

ctgacacacc atgttattat 20

<210> SEQ ID NO 417
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 417

ctttttcaga ctagataaga 20

<210> SEQ ID NO 418
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 418

tcacacttac ctcgatgagg 20

<210> SEQ ID NO 419
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 419

aagaaaatgg catcaggttt 20

<210> SEQ ID NO 420
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 420

ccaagccaat ctgagaaaga 20

<210> SEQ ID NO 421
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 421

aaatacacac ctgctcatgt 20

<210> SEQ ID NO 422
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 422

cttcacaaat acacacctgc 20

<210> SEQ ID NO 423
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 423

agtggaagtt tggctcatt 20

<210> SEQ ID NO 424
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 424

ttgctagctt caaagtggaa 20

<210> SEQ ID NO 425
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 425

tcaagaataa gctccagatc 20

<210> SEQ ID NO 426
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 426

gcatacaagt cacatgaggt 20

<210> SEQ ID NO 427
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 427

tacaaggtgt ttcttaagaa 20

-continued

<210> SEQ ID NO 428
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 428

atgcagccag gatgggccta

20

<210> SEQ ID NO 429
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 429

ttaccatata ctgagagttt

20

<210> SEQ ID NO 430
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 430

gcaaaggtag aggaaggtat

20

<210> SEQ ID NO 431
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 431

aaggaccttc agcaaaggta

20

<210> SEQ ID NO 432
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 432

cataggagta catttatata

20

<210> SEQ ID NO 433
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 433

attatgataa aatcaatttt

20

<210> SEQ ID NO 434
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 434

-continued

agaaatttca ctagatagat 20

<210> SEQ ID NO 435
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 435

agcatatttt gatgagctga 20

<210> SEQ ID NO 436
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 436

gaaaggaagg actagcatat 20

<210> SEQ ID NO 437
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 437

cctctccaat ctgtagaccc 20

<210> SEQ ID NO 438
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 438

ctggataact cagacctttg 20

<210> SEQ ID NO 439
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 439

agtcagaaaa caacctattc 20

<210> SEQ ID NO 440
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 440

cagcctgcat ctataagtca 20

<210> SEQ ID NO 441
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 441

aaagaattac cctccactga 20

<210> SEQ ID NO 442
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 442

tctttcaaac tggctaggca 20

<210> SEQ ID NO 443
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 443

gcctggcaaa attctgcagg 20

<210> SEQ ID NO 444
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 444

ctacctcaaa tcaatatgtt 20

<210> SEQ ID NO 445
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 445

tgetttacct acctagctac 20

<210> SEQ ID NO 446
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 446

accttggtg tctcactcaa 20

<210> SEQ ID NO 447
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 447

atgcattccc tgactagcac 20

-continued

<210> SEQ ID NO 448
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 448

catctctgag ccccttacca

20

<210> SEQ ID NO 449
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 449

gctgggcatg ctctctcccc

20

<210> SEQ ID NO 450
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 450

gcttttcgag ctgggcatgc

20

<210> SEQ ID NO 451
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 451

actcctttct atacctgget

20

<210> SEQ ID NO 452
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 452

attctgcctc ttagaaagtt

20

<210> SEQ ID NO 453
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 453

ccaagcctct ttactgggct

20

<210> SEQ ID NO 454
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 454

-continued

cactcatgac cagactaaga 20

<210> SEQ ID NO 455
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 455

acctcccaga agccttccat 20

<210> SEQ ID NO 456
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 456

ttcatatgaa atctcctact 20

<210> SEQ ID NO 457
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 457

tattttaattt actgagaaac 20

<210> SEQ ID NO 458
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 458

taatgtgttg ctggtgaaga 20

<210> SEQ ID NO 459
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 459

catctctaac ctggtgtccc 20

<210> SEQ ID NO 460
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 460

gtgccatgct aggtggccat 20

<210> SEQ ID NO 461
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 461

agcaaattgg gatctgtgct 20

<210> SEQ ID NO 462
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 462

tctggaggct cagaaacatg 20

<210> SEQ ID NO 463
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 463

tgaagacagg gagccaccta 20

<210> SEQ ID NO 464
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 464

aggattccca agactttgga 20

<210> SEQ ID NO 465
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 465

cagctctaata ctaaagacat 20

<210> SEQ ID NO 466
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 466

gaataactcac cttctgcttg 20

<210> SEQ ID NO 467
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 467

atctctctgt cctcatcttc 20

-continued

<210> SEQ ID NO 468
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 468

ccaactcccc ctttctttgt

20

<210> SEQ ID NO 469
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 469

tctgggccag gaagacacga

20

<210> SEQ ID NO 470
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 470

tattgtgtgc tgggcactgc

20

<210> SEQ ID NO 471
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 471

tgcttcgcac ctggacgagt

20

<210> SEQ ID NO 472
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 472

ccttctttac cttaggtggc

20

<210> SEQ ID NO 473
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 473

gctctctctg ccactctgat

20

<210> SEQ ID NO 474
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 474

-continued

aacttctaaa gccaacattc 20

<210> SEQ ID NO 475
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 475

tgtgtcacaa ctatggtaaa 20

<210> SEQ ID NO 476
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 476

agacacatac cataatgcca 20

<210> SEQ ID NO 477
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 477

ttctcttcat ctgaaaatac 20

<210> SEQ ID NO 478
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 478

tgaggatgta attagcactt 20

<210> SEQ ID NO 479
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 479

agctcattgc ctacaaaatg 20

<210> SEQ ID NO 480
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 480

gttctcatgt ttactaatgc 20

<210> SEQ ID NO 481
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 481

gaattgagac aacttgattt 20

<210> SEQ ID NO 482
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 482

ccggccatcg ctgaaatgaa 20

<210> SEQ ID NO 483
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 483

catagctcac cttgcacatt 20

<210> SEQ ID NO 484
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 484

cggtgcaccc ttacctgag 20

<210> SEQ ID NO 485
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 485

tctccagatc ctaacataaa 20

<210> SEQ ID NO 486
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 486

ttgaatgaca ctagattttc 20

<210> SEQ ID NO 487
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 487

aaaatccatt ttctttaag 20

-continued

<210> SEQ ID NO 488
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 488

cagctcacac ttattttaaa

20

<210> SEQ ID NO 489
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 489

gttcccaaaa ctgtatagga

20

<210> SEQ ID NO 490
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 490

agctccatac tgaagtcctt

20

<210> SEQ ID NO 491
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 491

caattcaata aaagctccat

20

<210> SEQ ID NO 492
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 492

gttttcaaaa ggtataaggt

20

<210> SEQ ID NO 493
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 493

ttcccattcc ctgaaagcag

20

<210> SEQ ID NO 494
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 494

-continued

tggtatttac ctgagggtg 20

<210> SEQ ID NO 495
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 495

ataaataata gtgctgatgg 20

<210> SEQ ID NO 496
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 496

ctatggctga gcttgctat 20

<210> SEQ ID NO 497
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 497

ctctctgaaa aatataccct 20

<210> SEQ ID NO 498
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 498

ttgatgtatc tcatttagca 20

<210> SEQ ID NO 499
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 499

tagaaccatg tttggtcttc 20

<210> SEQ ID NO 500
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 500

tttctcttta tcacatgcc 20

<210> SEQ ID NO 501
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 501

tatagtacac taaaacttca                20

<210> SEQ ID NO 502
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 502

ctggagagga ctaaacagag                20

<210> SEQ ID NO 503
<211> LENGTH: 568
<212> TYPE: DNA
<213> ORGANISM: H. sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 44, 99, 156, 468
<223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 503

ccaaaagatt gattgactgt ccattcaaag ctacacgcaa tttntgatat acatcacgta    60
gttactgaaa aagctgcaat caacacagtt catggaccnc taccatgaag ctgctccag    120
gagaacttct atcattcctc taatttttta aaaganatct tcattttatc ttcttttcca    180
attgaacttt cacatagcac agaaaaaatt caaactgcct atattgataa aaccatacag    240
tgagccagcc ttgcagtagg cagtagacta taagcagaag cacatatgaa ctggacctgc    300
accaaagctg gcaccagggc tcggaaggtc tctgaactca gaaggatggc attttttgca    360
agttaaagaa aatcaggatc tgagttatct tgctaaactt gggggaggag gaacaaataa    420
atggagtctt tattgtgtat cataccactg aatgtggctc atttgtanta aaagacagtg    480
aaacgagggc attgataaaa tgttctggca cagcaaaacc tctagaacac atagtgtgat    540
ttaagtaaca gaataaaaat ggaaacgg                    568

<210> SEQ ID NO 504
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 504

acattttatc aatgccctcg                20

<210> SEQ ID NO 505
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 505

gccagaacat tttatcaatg                20

<210> SEQ ID NO 506
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 506

agaggttttg ctgtgccaga 20

<210> SEQ ID NO 507
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 507

ctagaggttt tgctgtgcca 20

<210> SEQ ID NO 508
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 508

tctagaggtt ttgctgtgcc 20

<210> SEQ ID NO 509
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 509

aatcacacta tgtgttctag 20

<210> SEQ ID NO 510
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 510

aaatcacact atgtgttcta 20

<210> SEQ ID NO 511
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 511

taaatcacac tatgtgttct 20

<210> SEQ ID NO 512
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 512

cttaaatcac actatgtgtt 20

-continued

<210> SEQ ID NO 513
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 513

tattctgtta cttaaatacac

20

<210> SEQ ID NO 514
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 514

tggtagcctc agtctgcttc

20

<210> SEQ ID NO 515
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 515

agtctgcttc gcgccttctg

20

<210> SEQ ID NO 516
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

<400> SEQUENCE: 516

gcgccagggc cgaagaggaa

20

<210> SEQ ID NO 517
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

<400> SEQUENCE: 517

caggtatgag ctcaagctgg

20

<210> SEQ ID NO 518
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

<400> SEQUENCE: 518

catcctgaac atcaagaggg

20

<210> SEQ ID NO 519
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

<400> SEQUENCE: 519

gggcagtgtg atcgcttcaa

20

<210> SEQ ID NO 520
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 520

cacttgctct catcaaaggc

20

<210> SEQ ID NO 521

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 521

cacactggac gctaagagga

20

<210> SEQ ID NO 522

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 522

cgctgagcca cgcggtcaac

20

<210> SEQ ID NO 523

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 523

tgtccaaatt ctaccatggg

20

<210> SEQ ID NO 524

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 524

cagctgacct catcgagatt

20

<210> SEQ ID NO 525

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 525

gtcaagttcc tgatggtgtc

20

<210> SEQ ID NO 526

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 526

agctgcttct gatgggtgcc

20

<210> SEQ ID NO 527

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 527

gggcatcatc attccggact

20

<210> SEQ ID NO 528

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 528

cctactatcc gctgaccggg

20

<210> SEQ ID NO 529

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 529

gggccaccta agttgtgaca

20

<210> SEQ ID NO 530

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 530

agaacatggg attgccagac

20

<210> SEQ ID NO 531

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 531

ctccacttca agtctgtggg

20

<210> SEQ ID NO 532

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 532

cagagcttgg cctctctggg

20

<210> SEQ ID NO 533

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 533

tggccgcttc agggaacaca

20

<210> SEQ ID NO 534

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 534

cagctgagca gacaggcacc

20

<210> SEQ ID NO 535

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 535

gggagagaca agtttcacat

20

<210> SEQ ID NO 536

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 536

gtactgcctc ctggattcaa

20

<210> SEQ ID NO 537

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 537

gtgaggtgac tcagagactc

20

<210> SEQ ID NO 538

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 538

ttgcagagca atattctatc

20

<210> SEQ ID NO 539

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 539

aagcattggt agagcaaggg

20

<210> SEQ ID NO 540

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 540

ccgctggctc tgaaggagtc

20

<210> SEQ ID NO 541

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 541

tctagtcagg ctgacctgcg

20

<210> SEQ ID NO 542

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 542

gggccacagt gttctaactg

20

<210> SEQ ID NO 543

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 543

aatcaagtgt catcacactg

20

<210> SEQ ID NO 544

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 544

gggtagtcat aacagtactg

20

<210> SEQ ID NO 545

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 545

agagcacacg gtcttcagtg

20

<210> SEQ ID NO 546

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 546

ttacagctag agggcctctt

20

<210> SEQ ID NO 547

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 547

caccgtagggc atggatatgg

20

<210> SEQ ID NO 548

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 548

gggaatctga tgaggaaact

20

<210> SEQ ID NO 549

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 549

tgtcaacaag taccactggg

20

<210> SEQ ID NO 550

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 550

acctgggata tacactaggg

20

<210> SEQ ID NO 551

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 551

ccaagtatag ttggctggac

20

<210> SEQ ID NO 552

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 552

tacatgaagc ttgctccagg

20

<210> SEQ ID NO 553

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 553

atgtcagcct ggtctgtcca

20

<210> SEQ ID NO 554

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 554

gcacctccgg aagtacacat

20

<210> SEQ ID NO 555

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 555

ctgcagcttc atcctgaaga

20

<210> SEQ ID NO 556

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 556

tgagggcaaa gccttgctga

20

<210> SEQ ID NO 557

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 557

ccattccaga aggaagcag

20

<210> SEQ ID NO 558

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 558

cgaggaaggg caatgtggca

20

<210> SEQ ID NO 559

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 559

ccttgatcaac tetgatcagc

20

<210> SEQ ID NO 560

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

-continued

<400> SEQUENCE: 560

agcagccagt cctgtcagta

20

<210> SEQ ID NO 561

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 561

agcatgtggc agaagccatc

20

<210> SEQ ID NO 562

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 562

gagagcacca aatccacatc

20

<210> SEQ ID NO 563

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 563

cctcagtgat gaagcagtca

20

<210> SEQ ID NO 564

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 564

gatagatgtg gtcacctacc

20

<210> SEQ ID NO 565

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 565

cctcagcaca gcagctgcga

20

<210> SEQ ID NO 566

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 566

gattctgcgg gtcattggaa

20

<210> SEQ ID NO 567

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 567

caaagccatc actgatgatc

20

<210> SEQ ID NO 568

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 568

agaaagctgc catccaggct

20

<210> SEQ ID NO 569

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 569

caggagggttc ttcttcagac

20

<210> SEQ ID NO 570

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 570

gagtccttca caggcagata

20

<210> SEQ ID NO 571

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 571

tgccaatatc ttgaactcag

20

<210> SEQ ID NO 572

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 572

catcgagatt ggcttggaag

20

<210> SEQ ID NO 573

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 573

ggagctggat tacagttgca

20

<210> SEQ ID NO 574

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 574

caacatgcag gctgaactgg

20

<210> SEQ ID NO 575

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 575

acattacatt tggctctctac

20

<210> SEQ ID NO 576

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 576

ctcaggcgct tactccaacg

20

<210> SEQ ID NO 577

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 577

gggacaccag attagagctg

20

<210> SEQ ID NO 578

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 578

gagctccaga gagaggacag

20

<210> SEQ ID NO 579

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 579

atcggcagag tatgaccttg

20

<210> SEQ ID NO 580

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 580

caagggtggt atttcatac

20

<210> SEQ ID NO 581

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 581

gactcatctg ctacagctta

20

<210> SEQ ID NO 582

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 582

gcaaatcctc cagagatcta

20

<210> SEQ ID NO 583

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 583

ctctcctggg tggtctagac

20

<210> SEQ ID NO 584

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 584

atgaaggctg actctgtggt

20

<210> SEQ ID NO 585

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 585

gggaccacag atgtctgctt

20

<210> SEQ ID NO 586

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 586

ctggccggct caatggagag

20

<210> SEQ ID NO 587

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 587

gctgcgttct gaatatcagg

20

<210> SEQ ID NO 588

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 588

tgctgacatc ttaggcactg

20

<210> SEQ ID NO 589

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 589

aagtgtagtc tcctggtgct

20

<210> SEQ ID NO 590

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 590

caaaattcag tctggatggg

20

<210> SEQ ID NO 591

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 591

gggaaactac ggctagaacc

20

<210> SEQ ID NO 592

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 592

ctgcatgtgg ctggtaacct

20

<210> SEQ ID NO 593

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 593

ccatgaccat cgatgcacat

20

<210> SEQ ID NO 594

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 594

atgggaaact cgctctctgg

20

<210> SEQ ID NO 595

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 595

agtcacatc tcgtgtctag

20

<210> SEQ ID NO 596

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 596

gaatacagcc aggacttgga

20

<210> SEQ ID NO 597

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 597

ggcgtggagc ttactggacg

20

<210> SEQ ID NO 598

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 598

gagatgagag atgccgttga

20

<210> SEQ ID NO 599

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 599

agtcttgatg agcactatca

20

<210> SEQ ID NO 600

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 600

ctaagtacca aatcagaatc

20

<210> SEQ ID NO 601

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 601

gtccatgagt taatcgagag

20

<210> SEQ ID NO 602

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 602

aggccacagt tgcagtgtat

20

<210> SEQ ID NO 603

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 603

tctgattggt ggactcttgc

20

<210> SEQ ID NO 604

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 604

gaagtcagtc ttcaggctct

20

<210> SEQ ID NO 605

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 605

ccagattctc agatgagga

20

<210> SEQ ID NO 606

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 606

catctgtcat tgatgcactg

20

<210> SEQ ID NO 607

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 607

aggagatgtc aagggttcgg

20

<210> SEQ ID NO 608

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 608

ggaactattg ctagtgaggc

20

<210> SEQ ID NO 609

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 609

ctctctccat ggcaaatgtc

20

<210> SEQ ID NO 610

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 610

caccgtgact tcagtgacga

20

<210> SEQ ID NO 611

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 611

actgagttga gggtcggga

20

<210> SEQ ID NO 612

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 612

cacatatgaa ctggacctgc

20

<210> SEQ ID NO 613

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 613

tctgaactca gaaggatggc

20

<210> SEQ ID NO 614

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 614

ggcggaagc agactgaggc

20

<210> SEQ ID NO 615

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 615

tcccaccggg acctgcgggg

20

<210> SEQ ID NO 616

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 616

caccgggacc tgcggggctg

20

<210> SEQ ID NO 617

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 617

ctgagtgcc ttctcggttg

20

<210> SEQ ID NO 618

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 618

ctcggttgct gccgctgagg

20

<210> SEQ ID NO 619

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 619

tcggttgctg ccgctgagga

20

<210> SEQ ID NO 620

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 620

cggttgctgc cgctgaggag

20

<210> SEQ ID NO 621

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 621

gttgctgccg ctgaggagcc

20

<210> SEQ ID NO 622

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 622

ctgccgctga ggagcccgcc

20

<210> SEQ ID NO 623

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 623

accgcagctg gcgatggacc

20

<210> SEQ ID NO 624

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 624

cagctggcga tggaccgccc

20

<210> SEQ ID NO 625

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 625

gaacttacta tcatacctcta

20

<210> SEQ ID NO 626

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 626

tccaattgaa ctttcacata

20

<210> SEQ ID NO 627

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 627

aaaattcaaa ctgcctatat

20

<210> SEQ ID NO 628

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 628

gataaaacca tacagtgagc

20

<210> SEQ ID NO 629

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 629

ataaaacccat acagtgagcc

20

<210> SEQ ID NO 630

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 630

aaccatacag tgagccagcc

20

<210> SEQ ID NO 631

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 631

accatacagt gagccagcct

20

<210> SEQ ID NO 632

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 632

ccatacagtg agccagcctt

20

<210> SEQ ID NO 633

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 633

gtgagccagc cttgcagtag

20

<210> SEQ ID NO 634

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 634

ccagccttgc agtaggcagt

20

<210> SEQ ID NO 635

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 635

taggcagtag actataagca

20

<210> SEQ ID NO 636

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 636

gcagtagact ataagcagaa

20

<210> SEQ ID NO 637

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 637

tgaactggac ctgcacaaaa

20

<210> SEQ ID NO 638

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 638

ctggacctgc accaaagctg

20

<210> SEQ ID NO 639

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 639

ggacctgcac caaagctggc

20

<210> SEQ ID NO 640

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 640

ctgcaccaaa gctggcacca

20

<210> SEQ ID NO 641

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 641

accaaagctg gcaccagggc

20

<210> SEQ ID NO 642

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 642

ctcggaaggt ctctgaactc

20

<210> SEQ ID NO 643

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 643

aactcagaag gatggcattt

20

<210> SEQ ID NO 644

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 644

ctcagaagga tggcattttt

20

<210> SEQ ID NO 645

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 645

atcaggatct gagttatttt

20

<210> SEQ ID NO 646

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 646

aggatctgag ttattttgct

20

<210> SEQ ID NO 647

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 647

ctgagttatt ttgctaaact

20

<210> SEQ ID NO 648

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 648

at tt t t g c t a a a c t t g g g g g a

20

<210> SEQ ID NO 649

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 649

t a a a c t t g g g g g a g g a g g a a

20

<210> SEQ ID NO 650

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 650

g g a a c a a a t a a a t g g a g t c t

20

<210> SEQ ID NO 651

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 651

g t t t g t a a c t c a a g c a g a a g

20

<210> SEQ ID NO 652

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 652

t t g t a a c t c a a g c a g a a g g t

20

<210> SEQ ID NO 653

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 653

g t a a c t c a a g c a g a a g g t g c

20

<210> SEQ ID NO 654

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 654

a a c t c a a g c a g a a g g t g c g a

20

<210> SEQ ID NO 655

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

<400> SEQUENCE: 655

c t c a a g c a g a a g g t g c g a a g

20

<210> SEQ ID NO 656

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: *H. sapiens*

-continued

<400> SEQUENCE: 656

caagcagaag gtgcgaagca

20

<210> SEQ ID NO 657

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 657

agcagaaggt gcgaagcaga

20

<210> SEQ ID NO 658

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 658

cagaaggtgc gaagcagact

20

<210> SEQ ID NO 659

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 659

gaaggtgcga agcagactga

20

<210> SEQ ID NO 660

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 660

aggtgcgaag cagactgagg

20

<210> SEQ ID NO 661

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 661

gtgcgaagca gactgaggct

20

<210> SEQ ID NO 662

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 662

gcgaagcaga ctgaggctac

20

<210> SEQ ID NO 663

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 663

gaagcagact gaggctacca

20

<210> SEQ ID NO 664

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 664

agcagactga ggctaccatg

20

<210> SEQ ID NO 665

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 665

cagactgagg ctaccatgac

20

<210> SEQ ID NO 666

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 666

gactgaggct accatgacat

20

<210> SEQ ID NO 667

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 667

ctgaggctac catgacattc

20

<210> SEQ ID NO 668

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 668

gaggctacca tgacattcaa

20

<210> SEQ ID NO 669

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 669

ggctaccatg acattcaaatt

20

<210> SEQ ID NO 670

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 670

ctaccatgac attcaaattat

20

<210> SEQ ID NO 671

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 671

cctgaagctg catgtggctg

20

<210> SEQ ID NO 672

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 672

tgaagctgca tgtggctggt

20

<210> SEQ ID NO 673

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 673

aagctgcatg tggctggtaa

20

<210> SEQ ID NO 674

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 674

gctgcatgtg gctggtaacc

20

<210> SEQ ID NO 675

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 675

tgcatgtggc tggtaaccta

20

<210> SEQ ID NO 676

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 676

catgtggctg gtaacctaaa

20

<210> SEQ ID NO 677

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 677

tgtggctggt aacctaaaag

20

<210> SEQ ID NO 678

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 678

tggctggtaa cctaaaagga

20

<210> SEQ ID NO 679

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 679

gctggtaacc taaaaggagc

20

<210> SEQ ID NO 680

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 680

tggtaaccta aaaggagcct

20

<210> SEQ ID NO 681

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 681

gtaacctaaa aggagcctac

20

<210> SEQ ID NO 682

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 682

aacctaaaag ggcctacca

20

<210> SEQ ID NO 683

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 683

cctaaaagga gcctaccaa

20

<210> SEQ ID NO 684

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 684

ggcggaagc agactgaggc

20

<210> SEQ ID NO 685

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 685

cactatgttc atgagggagg

20

<210> SEQ ID NO 686

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 686

ccatcatagg ttctgacgtc

20

<210> SEQ ID NO 687

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 687

gaagctgatt gactcactca

20

<210> SEQ ID NO 688

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 688

ttgtaactca agcagaaggc

20

<210> SEQ ID NO 689

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 689

gtaactcaag cagaaggcgc

20

<210> SEQ ID NO 690

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 690

aactcaagca gaaggcgcga

20

<210> SEQ ID NO 691

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 691

ctcaagcaga aggcgcgaag

20

<210> SEQ ID NO 692

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 692

cagaaggcgc gaagcagact

20

<210> SEQ ID NO 693

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 693

gaaggcgcga agcagactga

20

<210> SEQ ID NO 694

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 694

aggcgcgaag cagactgagg

20

<210> SEQ ID NO 695

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 695

gcgcgaagca gactgaggct

20

<210> SEQ ID NO 696

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 696

gaagcagact gaggtacca

20

<210> SEQ ID NO 697

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 697

cagaaggcgc gaagcagact

20

<210> SEQ ID NO 698

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 698

tctttctcct gtcttacaga

20

<210> SEQ ID NO 699

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 699

cccacgttag aagatgcgac

20

<210> SEQ ID NO 700

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 700

aatatggttag acatgagcca

20

<210> SEQ ID NO 701

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 701

cattagctgc atttcaactg

20

<210> SEQ ID NO 702

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 702

actttcactc ctagtctgca

20

<210> SEQ ID NO 703

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 703

ccatgtccag gtaagtcag

20

<210> SEQ ID NO 704

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 704

gcaccaggca cggatgtgac

20

<210> SEQ ID NO 705

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 705

gtgggggtccc agaggcactg

20

<210> SEQ ID NO 706

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 706

gctgatcggc cactgcagct

20

<210> SEQ ID NO 707

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 707

tccacgtggc tggggaggtc

20

<210> SEQ ID NO 708

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 708

tgtaatgtat ggtgatcaga

20

<210> SEQ ID NO 709

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 709

gagagtaccc agtgggaaat

20

<210> SEQ ID NO 710

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 710

agtcagcatg ggcttcagcc

20

<210> SEQ ID NO 711

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 711

caaaagaatg actgtccaac

20

<210> SEQ ID NO 712

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 712

gaatgactgt ccaacaagtg

20

<210> SEQ ID NO 713

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 713

tatctactgt aatttaaaat

20

<210> SEQ ID NO 714

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 714

ctgatatggg tggagaacag

20

<210> SEQ ID NO 715

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 715

tctgggacag gtatgagctc

20

<210> SEQ ID NO 716

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 716

tgatagcagt ggcccttgaa

20

<210> SEQ ID NO 717

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 717

ggattggcgt gaaatactgg

20

<210> SEQ ID NO 718

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 718

tgcccgaggt tcctcctgcc

20

<210> SEQ ID NO 719

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 719

gcactagcaa gaccacactc

20

<210> SEQ ID NO 720

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 720

caagaccaca ctctgcatag

20

<210> SEQ ID NO 721

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 721

tcctccatag gataccgtgt

20

<210> SEQ ID NO 722

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 722

ggatgtaggg cagcaaaacc

20

<210> SEQ ID NO 723

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 723

tctgcacaag gactccttgt

20

<210> SEQ ID NO 724

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 724

cagcctgtct cagtgaacat

20

<210> SEQ ID NO 725

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 725

caggatgctt ccagtctaat

20

<210> SEQ ID NO 726

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 726

aaatgctcgt ctccaatctc

20

<210> SEQ ID NO 727

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 727

aacttgtgta tccaaatcca

20

<210> SEQ ID NO 728

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 728

tgacatggtg tgcttccttg

20

<210> SEQ ID NO 729

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 729

acactggtgt tctggctacc

20

<210> SEQ ID NO 730

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 730

gtgttctggc tacctctagt

20

<210> SEQ ID NO 731

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 731

tcctggcata ggtcacagta

20

<210> SEQ ID NO 732

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 732

atgtcaacag tagcacctcc

20

<210> SEQ ID NO 733

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 733

tagactcaga caagtctgga

20

<210> SEQ ID NO 734

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 734

cctaagttgc tcattctctgg

20

<210> SEQ ID NO 735

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 735

tgcgctgagt tccatgaaac

20

<210> SEQ ID NO 736

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 736

ctattgcagg tgctctccag

20

<210> SEQ ID NO 737

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 737

cagaggaaca tcttgacact

20

<210> SEQ ID NO 738

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 738

ctctgctcct tactcttgtg

20

<210> SEQ ID NO 739

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 739

gtaatttctc accatccatc

20

<210> SEQ ID NO 740

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 740

ttctgagtct caattgtcta

20

<210> SEQ ID NO 741

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 741

ctatgtcctt gtgtgcacat

20

<210> SEQ ID NO 742

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 742

gcctattgcc atttgtatgt

20

<210> SEQ ID NO 743

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 743

ctattcatgt cctttgccta

20

<210> SEQ ID NO 744

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 744

gattctgcgg gtaatctcag

20

<210> SEQ ID NO 745

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 745

tcaatgcagg tcattggaaa

20

<210> SEQ ID NO 746

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 746

ctaccagatt gaccatccct

20

<210> SEQ ID NO 747

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 747

tacttgatag tgctctagga

20

<210> SEQ ID NO 748

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 748

ttgactgcag gaccaggagg

20

<210> SEQ ID NO 749

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 749

aacaaacact tgtgcaaatg

20

<210> SEQ ID NO 750

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 750

aatgagacca aacttccact

20

<210> SEQ ID NO 751

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 751

ttccactttg aagctagcaa

20

<210> SEQ ID NO 752

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 752

gatctggagc ttattcttga

20

<210> SEQ ID NO 753

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 753

acctcatgtg acttgatgc

20

<210> SEQ ID NO 754

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 754

ttcttaagaa acaccttgta

20

<210> SEQ ID NO 755

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 755

taggcccac cctggctgcat

20

<210> SEQ ID NO 756

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 756

aaactctcag gatatggtaa

20

<210> SEQ ID NO 757

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 757

ataccttcct ctacctttgc

20

<210> SEQ ID NO 758

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 758

tacctttgct gaaggctcct

20

<210> SEQ ID NO 759

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 759

atctatctag tgaaatttct

20

<210> SEQ ID NO 760

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 760

tcagctcatc aaaatatgct

20

<210> SEQ ID NO 761

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 761

atatgctagt ccttcctttc

20

<210> SEQ ID NO 762

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 762

caaaggtctg agttatccag

20

<210> SEQ ID NO 763

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 763

tgacttatag atgcaggctg

20

<210> SEQ ID NO 764

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 764

tcagtggagg gtaattcttt

20

<210> SEQ ID NO 765

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 765

tgcctagcca gtttgaaaga

20

<210> SEQ ID NO 766

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 766

cctgcagaat ttgccaggc

20

<210> SEQ ID NO 767

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 767

gtagctaggt aggtaaagca

20

<210> SEQ ID NO 768

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 768

ttgagtgaga cacacaaggt

20

<210> SEQ ID NO 769

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 769

gtgctagtca gggaatgcat

20

<210> SEQ ID NO 770

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 770

ggggagagag catgcccagc

20

<210> SEQ ID NO 771

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 771

gcatgcccag ctgcgaaagc

20

<210> SEQ ID NO 772

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 772

agccaggtat agaaaggagt

20

<210> SEQ ID NO 773

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 773

aactttctaa gaggcagaat

20

<210> SEQ ID NO 774

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 774

tcttagtctg gtcagtgtg

20

<210> SEQ ID NO 775

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 775

agtaggagat ttcatatgaa

20

<210> SEQ ID NO 776

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 776

tcttcaccag caacacatta

20

<210> SEQ ID NO 777

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 777

atggccacct agcatggcac

20

<210> SEQ ID NO 778

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 778

catgtttctg agcctccaga

20

<210> SEQ ID NO 779

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 779

taggtggctc cctgtttca

20

<210> SEQ ID NO 780

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 780

tccaaagtct tgggaatcct

20

<210> SEQ ID NO 781

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 781

acaaagaaag ggggagttgg

20

<210> SEQ ID NO 782

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 782

tcgtgtcttc ctggcccaga

20

<210> SEQ ID NO 783

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 783

gcagtgccca gcacacaata

20

<210> SEQ ID NO 784

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 784

actcgtccag gtgcgaagca

20

<210> SEQ ID NO 785

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 785

gccacctaag gtaaagaagg

20

<210> SEQ ID NO 786

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 786

atcagagtgg cagagagagc

20

<210> SEQ ID NO 787

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 787

tttaccatag ttgtgacaca

20

<210> SEQ ID NO 788

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 788

cattttgtag gcaatgagct

20

<210> SEQ ID NO 789

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 789

gcattagtaa acatgagaac

20

<210> SEQ ID NO 790

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 790

ttcatttcag cgatggccgg

20

<210> SEQ ID NO 791

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 791

gaaaatctag tgtcattcaa

20

<210> SEQ ID NO 792

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 792

tcctatacag ttttgggaac

20

<210> SEQ ID NO 793

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 793

aaggacttca gtatggagct

20

<210> SEQ ID NO 794

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 794

atggagcttt tattgaattg

20

<210> SEQ ID NO 795

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 795

ccatcagcac tattatttat

20

<210> SEQ ID NO 796

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 796

ataggcaagc tcagccatag

20

<210> SEQ ID NO 797

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 797

tgctagatga gatacatcaa

20

<210> SEQ ID NO 798

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 798

gaagacaaa catggttcta

20

<210> SEQ ID NO 799

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 799

ctctgtttag tcctctccag

20

<210> SEQ ID NO 800

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

-continued

<400> SEQUENCE: 800

cattgataaa atgttctggc

20

<210> SEQ ID NO 801

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 801

tctggcacag caaacctct

20

<210> SEQ ID NO 802

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 802

tggcacagca aaacctctag

20

<210> SEQ ID NO 803

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 803

tagaacacat agtgtgattt

20

<210> SEQ ID NO 804

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: H. sapiens

<400> SEQUENCE: 804

aacacatagt gtgatttaag

20

<210> SEQ ID NO 805

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 805

ctttccgttg gaccctggg

20

<210> SEQ ID NO 806

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 806

tcccgctgt gacatgcatt

20

<210> SEQ ID NO 807

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 807

ttctacctcg cgcgatttac

20

-continued

<210> SEQ ID NO 808
 <211> LENGTH: 432
 <212> TYPE: DNA
 <213> ORGANISM: O. cuniculus

<400> SEQUENCE: 808

```

gatctttacct tctccagca aaatgcattg ctacgtgctg agtatcaggc tgattacaag      60
tcaactgaggt tcttcacct gctttctggg ttgttgaata cccatggtct tgaattaaat      120
gctgacatct tgggcactga caaatgaat actgctgctc acaaggcaac tctaagaatt      180
ggccaaaatg gagtatctac cagtgcaca accagcttga ggtacagtcc cctgatgctg      240
gagaatgagc tgaacgcaga gcttgccctt tctggggcat ctatgaaatt agcaacaaat      300
ggccgcttca aggaacacaa tgcaaaatc agcctagatg ggaagctac cctcacagag      360
ttatccctgg gaagcgctta ccaggccatg attctgggtg ctgacagcaa gaacattttc      420
aacttcaaga tc                                          432

```

<210> SEQ ID NO 809
 <211> LENGTH: 660
 <212> TYPE: DNA
 <213> ORGANISM: O. cuniculus

<400> SEQUENCE: 809

```

ctgggaaaac tcccacagca agttaatgat tatctgagta cattcaattg ggagagacaa      60
gtttccagtg ccaagagagaa actaactact ttcacaaaaa attataaaat tacagagaat      120
gatatacaaa ctgcattgga taatgccaaa atcaacttaa atgaaaaact gtctcaactt      180
cagacatatg tgatataatt tgatcagtat attaaagata attttgatct acatgatatt      240
aaaaatagcta tagctagtat tatagatcaa atcatggaaa aattaaaaat tcttgatgaa      300
cgttatcata tccgtgcaca tttaattaa tcaatccata atttatattt gtttattgaa      360
gctattgatt ttaacaaaat tggaagtagt actgcatctt ggattcaaaa tgtggatacc      420
aagtatcaag tcagaatctg gatacaagaa atattgcaac agtttaagac acagattcag      480
aatacaaaac tcccatacct ggctgaaaaa ctgaacaac agattgaggc tattgatgtc      540
agagtgtctt tagatcaatt gagaactaca attccatttc gtataataaa ggacattatt      600
gaacatttca aatactttgt tataaatatt attgaaaatt ttgaagtaat tgacaaaatc      660

```

<210> SEQ ID NO 810
 <211> LENGTH: 543
 <212> TYPE: DNA
 <213> ORGANISM: O. cuniculus
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (45)
 <223> OTHER INFORMATION: n = a, c, g, or t
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (118)
 <223> OTHER INFORMATION: n = a, c, g, or t
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (148)
 <223> OTHER INFORMATION: n = a, c, g, or t
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (173)
 <223> OTHER INFORMATION: n = a, c, g, or t
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (180)
 <223> OTHER INFORMATION: n = a, c, g, or t

-continued

<400> SEQUENCE: 810

cagaacatcg gagacaacgc attggatttt ctactaaat cttanaatga agcaaaaatt 60
aagtttgata agtacaaagt tgaaaaatcg ctcaacaggc tccccaggac ctttcagnct 120
cctggataca ttattccaat tttcaatntt gaagtatctc cactcacaat agnagacgtn 180
agcattcagt catgtgatcc caaaatcaat aagcaccccc aatgtcacca tcttgatttc 240
aagcttctat gtgccttcat atacattggc tctgccatcc ctagagctgc cagtcttcca 300
tgtccccagg aatctactca aggtctctct tccagatttc aaggaattga aaaccattaa 360
caatatTTTT attccagcca tgggcaacat tacctatgaa ttttccttca aatcaacgat 420
cattacactg aataccaatg ctggacttta taaccaatca gacattgttg cccatatact 480
ttcttctct tcatctgtca ttgatgcact acagtacaaa tttagaggga cgctcaagtt 540
tga 543

<210> SEQ ID NO 811

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 811

aagcaccccc aatgtcacc 19

<210> SEQ ID NO 812

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 812

gggatggcag agccaatgta 20

<210> SEQ ID NO 813

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 813

tcttgatttc aagcttctat gtgccttca 29

<210> SEQ ID NO 814

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 814

tgcttggaga aggtaagatc 20

<210> SEQ ID NO 815

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 815

-continued

gcgttggtctc cgatgttctg 20

<210> SEQ ID NO 816
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 816

taatcattaa cttgctgtgg 20

<210> SEQ ID NO 817
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 817

tcagcacgta gcaatgcatt 20

<210> SEQ ID NO 818
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 818

gcctgatact cagcacgtag 20

<210> SEQ ID NO 819
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 819

caattgaatg tactcagata 20

<210> SEQ ID NO 820
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 820

acctcagtga cttgtaatca 20

<210> SEQ ID NO 821
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 821

cactggaaac ttgtctctcc 20

<210> SEQ ID NO 822
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 822

agtagttagt ttctccttgg 20

<210> SEQ ID NO 823
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 823

tcagtgccca agatgtcagc 20

<210> SEQ ID NO 824
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 824

attggaataa tgtatccagg 20

<210> SEQ ID NO 825
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 825

ttggcattat ccaatgcagt 20

<210> SEQ ID NO 826
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 826

gttgccttgt gagcagcagt 20

<210> SEQ ID NO 827
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 827

attgtgagtg gagatacttc 20

<210> SEQ ID NO 828
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 828

catatgtctg aagttgagac 20

-continued

<210> SEQ ID NO 829
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 829

gtagatactc cattttggcc

20

<210> SEQ ID NO 830
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 830

ggatcacatg actgaatgct

20

<210> SEQ ID NO 831
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 831

tcaagctggt tgttgactg

20

<210> SEQ ID NO 832
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 832

ggactgtacc tcaagctggt

20

<210> SEQ ID NO 833
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 833

gctcattctc cagcatcagg

20

<210> SEQ ID NO 834
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 834

ttgatctata atactagcta

20

<210> SEQ ID NO 835
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 835

-continued

atggaagact ggcagctcta 20

<210> SEQ ID NO 836
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 836

ttgtgttcct tgaagcggcc 20

<210> SEQ ID NO 837
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 837

tgtgcacgga tatgataacg 20

<210> SEQ ID NO 838
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 838

gaccttgagt agattcctgg 20

<210> SEQ ID NO 839
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 839

gaaatctgga agagagacct 20

<210> SEQ ID NO 840
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 840

gtagctttcc catctaggct 20

<210> SEQ ID NO 841
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 841

gataactctg tgagggtagc 20

<210> SEQ ID NO 842
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 842

atgttgccca tggctggaat 20

<210> SEQ ID NO 843
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 843

aagatgcagt actacttcca 20

<210> SEQ ID NO 844
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 844

gcacccagaa tcatggcctg 20

<210> SEQ ID NO 845
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 845

cttgatactt ggtatccaca 20

<210> SEQ ID NO 846
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 846

cagtgtaatg atcgttgatt 20

<210> SEQ ID NO 847
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 847

taaagtccag cattggtatt 20

<210> SEQ ID NO 848
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 848

caacaatgtc tgattggta 20

-continued

<210> SEQ ID NO 849
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 849

gaagaggaag aaaggatatg

20

<210> SEQ ID NO 850
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 850

tgacagatga agaggaagaa

20

<210> SEQ ID NO 851
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 851

ttgtactgta gtgcatcaat

20

<210> SEQ ID NO 852
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 852

gcctcaatct gttgtttcag

20

<210> SEQ ID NO 853
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 853

acttgagcgt gccctctaata

20

<210> SEQ ID NO 854
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 854

gaaatggaat tgtagttctc

20

<210> SEQ ID NO 855
<211> LENGTH: 479
<212> TYPE: DNA
<213> ORGANISM: *M. fascicularis*
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7)
<223> OTHER INFORMATION: n = A,T,C or G

-continued

```

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (469)..(474)
<223> OTHER INFORMATION: n = A,T,C or G
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (476)..( 479)
<223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 855

tgcgtnaga ctccgcccc tactatccgc tgaccgggga caccagatta gagctggaac      60
tgaggcctac aggagaagtt gagcagtatt ctgtcagtgc aacctatgag ctccagagag      120
aggacagagc cttggtggac accctgaagt ttgtaactca agcagaaggt gtaaagcaga      180
ctgaggctac catgacattc aaatataatc ggcagagtat gaccttgtcc agtgaagtcc      240
aaattccgga ttttgaggtt gaccttgaa caatcctcag agttaatgat gaatctactg      300
agggcagaaa gtcttacaga ctccacctgg acattcagaa ccagaaaatt actgagggtca      360
ccctcatggg ccacctaagt tgtgacacaa aggaagaagg aaaaatcaaa ggtgttattt      420
ccgtaccccg ttgtcaagca gaagccagaa gtgagatcct cgcccacann nnnnnnnnn      479

<210> SEQ ID NO 856
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 856

gtccctcaac atctgaatgc      20

<210> SEQ ID NO 857
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 857

ctgctagcct ctggatttga      20

<210> SEQ ID NO 858
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 858

ccttcctga aggttcctcc      20

<210> SEQ ID NO 859
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 859

ctcttactgt getgtggaca      20

<210> SEQ ID NO 860
<211> LENGTH: 13938
<212> TYPE: DNA
<213> ORGANISM: H. sapiens

```


-continued

<400> SEQUENCE: 860

ctgggattgg gacacacttt ctggacactg ctggccagtc ccaaaatgga acataaggaa	60
gtggttcttc tacttctttt atttctgaaa tcagcagcac ctgagcaaag ccatgtggtc	120
caggattgct accatgggtga tggacagagt tatcgaggca cgtactccac cactgtcaca	180
ggaaggacct gccaaagcttg gtcactctatg acaccacatc aacataatag gaccacagaa	240
aactacccaa atgctggcct gatcatgaac tactgcagga atccagatgc tgtggcagct	300
ccttattgtt atacgaggga tcccgggtgc aggtgggagt actgcaacct gacgcaatgc	360
tcagacgcag aagggactgc cgtcgcgcct cgcactgtta ccccggttcc aagcctagag	420
gtcctctccg aacaagcacc gactgagcaa aggcctgggg tgcaggagtgc ctaccatggt	480
aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaaagct	540
tggtcatcta tgacaccaca ctgcgatagt cggaccccg aatactaccc aaatgctggc	600
ttgatcatga actactgcag gaatccagat gctgtggcag ctcttattg ttatacgagg	660
gatcccggtg tcagggtgga gtactgcaac ctgacgcaat gctcagacgc agaagggact	720
gccgtcgcgc ctccgactgt tccccgggt ccaagcctag aggtctcttc cgaacaagca	780
ccgactgagc aaaggcctgg ggtgcaggag tgctaccatg gtaatggaca gagttatcga	840
ggcacatact ccaccactgt cacaggaaga acctgccaaag cttggtcac tatgacacca	900
cactcgcata gtcggacccc agaatactac ccaaatgctg gcttgatcat gaactactgc	960
aggaatccag atgctgtggc agctccttat tgttatacga gggatcccg tgctcagggtg	1020
gagtactgca acctgacgca atgctcagac gcagaaggga ctgccgtcgc gcctccgact	1080
gttaccctcg ttccaagcct agaggctcct tccgaacaag caccgactga gcaaaggcct	1140
gggggtgcagg agtgctacca tggtaatgga cagagttatc gaggcacata ctccaccact	1200
gtcacaggaa gaacctgcc aaccttggtca tctatgacac cactactgca tagtcggacc	1260
ccagaatact acccaaatgc tggcttgatc atgaactact gcaggaatcc agatgctgtg	1320
gcagctcctt attgttatcc gagggatccc ggtgtcagggt gggagtactg caacctgacg	1380
caatgctcag acgcagaagg gactgccgtc gcgcctccga ctgttaccct ggttccaagc	1440
ctagaggctc ctccgaaca agcaccgact gagcaaaggc ctgggggtgca ggagtgtctac	1500
catggtaatg gacagagtta tcgaggcaca tactccacca ctgtcacagg aagaacctgc	1560
caagcttggt catctatgac accacactcg catagtcgga cccagaata ctaccctaat	1620
gctggcttga tcatgaacta ctgcaggaat ccagatgctg tggcagctcc ttattgttat	1680
acgagggatc ccggtgtcag gtgggagtag tgcaacctga cgcaatgctc agacgcagaa	1740
gggactgccg tcgcgcctcc gactgttacc ccggttccaa gcctagaggc tccttccgaa	1800
caagcaccga ctgagcaaag gcctgggggtg caggagtgtc accatggtaa tggacagagt	1860
tatcgaggca catactccac cactgtcaca ggaagaacct gccaaagcttg gtcactctatg	1920
acaccacact cgcatagtcg gacccagaa tactacccaa atgctggcct gatcatgaac	1980
tactgcagga atccagatgc tgtggcagct ccttattgtt atacgaggga tcccgggtgc	2040
aggtgggagt actgcaacct gacgcaatgc tcagacgcag aagggactgc cgtcgcgcct	2100
ccgactgtta ccccggttcc aagcctagag gctccttccg aacaagcacc gactgagcaa	2160
aggcctgggg tgcaggagtgc ctaccatggt aatggacaga gttatcgagg cacatactcc	2220
accactgtca caggaagaac ctgccaaagct tggtcatcta tgacaccaca ctgcgatagt	2280
cggaccccg aatactaccc aaatgctggc ttgatcatga actactgcag gaatccagat	2340

-continued

gctgtggcag	ctccttattg	ttatacgagg	gatcccggtg	tcagggtggga	gtactgcaac	2400
ctgacgcaat	gctcagacgc	agaagggact	gccgtcgcgc	ctccgactgt	taccccggtt	2460
ccaagcctag	aggctccttc	cgaacaagca	cgcactgagc	aaaggcctgg	ggtgcaggag	2520
tgctaccatg	gtaatggaca	gagttatcga	ggcacatact	ccaccactgt	cacaggaaga	2580
acctgccaa	cttggtcata	tatgacacca	cactcgcata	gtcggacccc	agaatactac	2640
ccaaatgctg	gcttgatcat	gaactactgc	aggaatccag	atgctgtggc	agctccttat	2700
tgttatacga	gggatcccg	tgtcagggtg	gagtactgca	acctgacgca	atgctcagac	2760
gcagaaggga	ctgccgtcgc	gcctccgact	gttaccgccg	ttccaagcct	agaggctcct	2820
tccgaacaag	caccgactga	gcaaaggcct	ggggtgcagg	agtgtacca	tggtaatgga	2880
cagagttatc	gaggcacata	ctccaccact	gtcacaggaa	gaacctgcca	agcttggtca	2940
tctatgacac	cacactcgca	tagtcggacc	ccagaatact	acccaaatgc	tggcttgatc	3000
atgaactact	gcaggaatcc	agatgctgtg	gcagctcctt	attgttatac	gagggatccc	3060
ggtgtcagg	gggagtactg	caacctgacg	caatgctcag	acgcagaagg	gactgccgtc	3120
gcgcctccga	ctgttaccgc	ggttccaagc	ctagaggctc	cttccgaaca	agcaccgact	3180
gagcaaaagg	ctggggtgca	ggagtgttac	catggtaatg	gacagagtta	tcgaggcaca	3240
tactccacca	ctgtcacagg	aagaacctgc	caagcttggt	catctatgac	accacactcg	3300
catagtcgga	ccccagaata	ctacccaat	gctggcttga	tcatgaacta	ctgcaggaat	3360
ccagatgctg	tggcagctcc	ttattgttat	acgagggatc	ccggtgtcag	gtgggagtac	3420
tgcaacctga	cgcaatgctc	agacgcagaa	gggactgccg	tcgcgcctcc	gactgttacc	3480
ccggttccaa	gcctagaggc	tccttcgaa	caagcaccca	ctgagcaaag	gcctgggggtg	3540
caggagtgtc	accatggtaa	tggacagagt	tatcgaggca	catactccac	cactgtcaca	3600
ggaagaacct	gccaaagctg	gtcatctatg	acaccacact	cgcatagtcg	gacccagaa	3660
tactacccaa	atgctggctt	gatcatgaac	tactgcagga	atccagatgc	tgtggcagct	3720
ccttattgtt	atcagaggga	tcccgggtgc	agggtggagt	actgcaacct	gacgcaatgc	3780
tcagacgcag	aagggactgc	cgctcgcctc	ccgactgtta	ccccgggtcc	aagcctagag	3840
gctccttcgc	aacaagcacc	gactgagcaa	aggcctgggg	tgcaggagtg	ctaccatggt	3900
aatggacaga	gttatcgagg	cacatactcc	accactgtca	caggaagaac	ctgccaaagct	3960
tggtcatcta	tgacaccaca	ctcgcatagt	cggaccccag	aatactaccc	aatgctggc	4020
ttgatcatga	actactgcag	gaatccagat	gctgtggcag	ctccttattg	ttatacgagg	4080
gatcccggtg	tcagggtggga	gtactgcaac	ctgacgcaat	gctcagacgc	agaagggact	4140
gccgtcgcgc	ctccgactgt	taccccggtt	ccaagcctag	aggctccttc	cgaacaagca	4200
ccgactgagc	aaaggcctgg	ggtgcaggag	tgctaccatg	gtaatggaca	gagttatcga	4260
ggcacatact	ccaccactgt	cacaggaaga	acctgccaa	cttggtcata	tatgacacca	4320
cactcgcata	gtcggacccc	agaatactac	ccaaatgctg	gcttgatcat	gaactactgc	4380
aggaatccag	atgctgtggc	agctccttat	tgttatacga	gggatcccg	tgtcagggtg	4440
gagtactgca	acctgacgca	atgctcagac	gcagaaggga	ctgccgtcgc	gcctccgact	4500
gttaccgccg	ttccaagcct	agaggctcct	tccgaacaag	caccgactga	gcaaaggcct	4560
gggggtgcagg	agtgtacca	tggtaatgga	cagagttatc	gaggcacata	ctccaccact	4620
gtcacaggaa	gaacctgcca	agcttggtca	tctatgacac	cacactcgca	tagtcggacc	4680
ccagaatact	acccaaatgc	tggcttgatc	atgaactact	gcaggaatcc	agatgctgtg	4740

-continued

gcagctcctt attgttatac gagggatccc ggtgtcaggt gggagtactg caacctgacg	4800
caatgctcag acgcagaagg gactgccgtc gcgcctccga ctgttacccc ggttccaagc	4860
ctagaggctc cttccgaaca agcaccgact gagcaaaggc ctgggggtgca ggagtgtac	4920
catggtaatg gacagagtta tcgaggcaca tactccacca ctgtcacagg aagaacctgc	4980
caagcttggc catctatgac accacactcg catagtccga cccagaata ctacccaaat	5040
gctggcttga tcatgaacta ctgcaggaat ccagatgtg tggcagctcc ttattgttat	5100
acgagggatc ccggtgtcag gtgggagtac tgcaacctga cgcaatgtc agacgcagaa	5160
gggactgccg tcgcgcctcc gactgttacc ccggttccaa gcctagaggc tccttccgaa	5220
caagcaccga ctgagcaaag gcctgggggtg caggagtgt accatggtaa tggacagagt	5280
tatcgaggca catactccac cactgtcaca ggaagaacct gccaaagtgt gtcactatg	5340
acaccacact cgcatagtcg gacccagaa tactaccaa atgctggctt gatcatgaac	5400
tactgcagga atccagatgc tgtggcagct ccttattgtt atacgaggga tcccggtgtc	5460
aggtgggagt actgcaacct gacgcaatgc tcagacgcag aagggtgtc cgtcgcct	5520
ccgactgtta ccccggttcc aagcctagag gctccttccg aacaagcacc gactgagcaa	5580
aggctgggg tgcaggagt ctaccatggt aatggacaga gttatcgagg cacatactcc	5640
accactgtca caggaagaac ctgccaaagt tggatcatcta tgacaccaca ctgcatagt	5700
cggacccag aatactaccc aatgctggc ttgatcatga actactgcag gaatccagat	5760
gctgtggcag ctcttattg ttatacgagg gatcccggtg tcagggtgga gtactgcaac	5820
ctgacgcaat gctcagacgc agaagggtact gccgtcgcgc ctccgactgt taccgggt	5880
ccaagcctag aggtccttc cgaacaagca ccgactgagc aaaggcctgg ggtgcaggag	5940
tgctaccatg gtaatggaca gaggttatcga ggcacatact ccaccactgt cacaggaaga	6000
acctgccaa cttggtcac tatgacacca cactgcata gtcggacccc agaatactac	6060
ccaaatgctg gcttgatcat gaactactgc aggaatccag atgctgtggc agtccttat	6120
tgttatcaga gggatcccg tgtcagggtg gactactgca acctgacgca atgctcagac	6180
gcagaaggga ctgccgtcgc gcctccgact gttaccccg ttccaagcct agaggctcct	6240
tccgaacaag caccgactga gcaaaggcct ggggtgcagg agtgctacca tggtaatgga	6300
cagagttatc gaggcacata ctccaccact gtcacaggaa gaacctgcca agcttggtca	6360
tctatgacac cacactgcga tagtcggacc ccagaatact acccaaatgc tggcttgatc	6420
atgaactact gcaggaatcc agatgctgtg gcagctcctt attgttatac gagggatccc	6480
ggtgtcaggt gggagtactg caacctgacg caatgctcag acgcagaagg gactgccgtc	6540
gcgcctccga ctgttacccc ggttccaagc ctgagggctc cttccgaaca agcaccgact	6600
gagcaaaggc ctgggggtgca ggagtgtac catggtaatg gacagagtta tcgaggcaca	6660
tactccacca ctgtcacagg aagaacctgc caagcttggc catctatgac accacactcg	6720
catagtccga cccagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat	6780
ccagatgctg tggcagctcc ttattgttat acgagggatc ccggtgtcag gtgggagtac	6840
tgcaacctga cgcaatgtc agacgcagaa gggactgccg tcgcgcctcc gactgttacc	6900
ccggttccaa gcctagaggc tccttccgaa caagcaccga ctgagcaaag gcctgggggtg	6960
caggagtgt accatggtaa tggacagagt tatcgaggca catactccac cactgtcaca	7020
ggaagaacct gccaaagtgt gtcactatg acaccacact cgcatagtcg gacccagaa	7080
tactaccaa atgctggctt gatcatgaac tactgcagga atccagatgc tgtggcagct	7140

-continued

ccttattggt atacgagggg tcccgggtgc aggtgggagt actgcaacct gacgcaatgc	7200
tcagacgcag aagggactgc cgtcgcgcct cgcactgtta ccccggttcc aagcctagag	7260
gctccttccg aacaagcacc gactgagcaa aggcctgggg tgcaggagtgc ctaccatggt	7320
aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaaagct	7380
tggtcatcta tgacaccaca ctgcgcatagt cggaccccag aatactaccc aaatgctggc	7440
ttgatcatga actactgcag gaatccagat gctgtggcag ctccctattg ttatacgagg	7500
gatcccgggt tcagggtgga gtactgcaac ctgacgcaat gctcagacgc agaagggact	7560
gccgtcgcgc ctccgactgt taccgcggtt ccaagcctag aggtcccttc cgaacaagca	7620
ccgactgagc aaaggcctgg ggtgcaggag tgctaccatg gtaatggaca gagttatcga	7680
ggcacatact ccaccactgt cacaggaaga acctgccaaag cttggtcatc tatgacacca	7740
cactcgcata gtcggacccc agaatactac ccaaagtctg gcttgatcat gaactactgc	7800
aggaatccag atgctgtggc agctccttat tgttatacga gggatcccgg tgtcagggtg	7860
gagtactgca acctgacgca atgctcagac gcagaaggga ctgccgtcgc gcctccgact	7920
gttaccgccg ttccaagcct agaggctcct tccgaacaag caccgactga gcagaggcct	7980
ggggtgcagg agtgcataca cggtaatgga cagagttatc gaggcacata ctccaccact	8040
gtcactggaa gaacctgcc aacctgtgca tctatgacac cacactcgca tagtcggacc	8100
ccagaatact acccaaatgc tggcttgatc atgaactact gcaggaatcc agatgctgtg	8160
gcagtcctt attgttatac gagggatccc ggtgtcagggt gggagtactg caacctgacg	8220
caatgctcag acgcagaagg gactgcgcgc gcgcctccga ctgttaccgc ggttccaagc	8280
ctagaggctc ctccgaaca agcaccgact gagcaaaggc ctgggggtgca ggagtgcctac	8340
catggtaatg gacagagtta tcgaggcaca tactccacca ctgtcacagg aagaacctgc	8400
caagcttggt catctatgac accacactcg catagtcgga cccagaata ctacccaa	8460
gctggcttga tcatgaacta ctgcaggaat ccagatgctg tggcagctcc ttattgttat	8520
acgagggatc ccggtgtcag gtgggagtac tgcaacctga cgcaatgctc agacgcagaa	8580
gggactgccg tcgcgcctcc gactgttacc ccggttccaa gcctagaggc tccttccgaa	8640
caagcaccga ctgagcaaag gcctgggggtg caggagtgcct accatggtaa tggacagagt	8700
tatcgaggca catactccac cactgtcaca ggaagaacct gccaaagcttg gtcactctatg	8760
acaccacact cgcatagtcg gaccccgaa tactacccaa atgctggctt gatcatgaac	8820
tactgcagga atccagatgc tgtggcagct ccttattggt atacgagggg tcccgggtgc	8880
aggtgggagt actgcaacct gacgcaatgc tcagacgcag aagggactgc cgtcgcgcct	8940
ccgactgtta ccccggttcc aagcctagag gctccttccg aacaagcacc gactgagcag	9000
aggcctgggg tgcaggagtgc ctaccacggt aatggacaga gttatcgagg cacatactcc	9060
accactgtca ctggaagaac ctgccaaagct tggatcatcta tgacaccaca ctgcgcatagt	9120
cggaccccag aatactaccc aaatgctggc ttgatcatga actactgcag gaatccagat	9180
gctgtggcag ctccctattg ttatacgagg gatcccgggt tcagggtgga gtactgcaac	9240
ctgacgcaat gctcagacgc agaagggact gccgtcgcgc ctccgactgt taccgcggtt	9300
ccaagcctag aggtcccttc cgaacaagca ccgactgagc agaggcctgg ggtgcaggag	9360
tgctaccacg gtaatggaca gagttatcga ggcacatact ccaccactgt cactggaaga	9420
acctgccaa cttggtcatc tatgacacca cactcgcata gtcggacccc agaatactac	9480
ccaaatgctg gcttgatcat gaactactgc aggaatccag atgctgtggc agctccttat	9540

-continued

tggtatacga	gggatccccg	tgtcaggtgg	gagtactgca	acctgacgca	atgctcagac	9600
gcagaaggga	ctgccgtcgc	gcctccgact	gttaccgccg	ttccaagcct	agaggctcct	9660
tccgaacaag	caccgactga	gcagaggcct	ggggtgcagg	agtgctacca	cggtaatgga	9720
cagagttatc	gaggcacata	ctccaccact	gtcactggaa	gaacctgcca	agcttgggtca	9780
tctatgacac	cacactcgca	tagtcggacc	ccagaatact	acccaaatgc	tggcttgatc	9840
atgaactact	gcaggaatcc	agatgctgtg	gcagctcctt	attgttatac	gagggatccc	9900
ggtgtcaggt	gggagtactg	caacctgacg	caatgctcag	acgcagaagg	gactgccgtc	9960
gcgcctccga	ctgttaccgc	ggttccaagc	ctagaggctc	cttccgaaca	agcaccgact	10020
gagcagaggc	ctgggggtgca	ggagtgtctac	cacggtaatg	gacagagtta	tcgaggcaca	10080
tactccacca	ctgtcactgg	aagaacctgc	caagcttggg	catctatgac	accacactcg	10140
catagtcgga	ccccagaata	ctacccaaat	gctggcttga	tcatgaacta	ctgcaggaat	10200
ccagatcctg	tggcagcccc	ttattgttat	acgagggatc	ccagtgtcag	gtgggagtac	10260
tgcaacctga	cacaatgctc	agacgcagaa	gggactgccg	tcgcgcctcc	aactattacc	10320
ccgattccaa	gcctagaggc	tccttctgaa	caagcaccaa	ctgagcaaag	gcctgggggtg	10380
caggagtgtc	accacggaaa	tggacagagt	tatcaaggca	catacttcat	tactgtcaca	10440
ggaagaacct	gccaaagctg	gtcatctatg	acaccacact	cgcatagtcg	gaccccagca	10500
tactacccaa	atgctggctt	gatcaagaac	tactgccgaa	atccagatcc	tgtggcagcc	10560
ccttggtgtt	atacaacaga	tcccagtgtc	aggtgggagt	actgcaacct	gacacgatgc	10620
tcagatgcag	aatggactgc	cttcgtccct	ccgaatgtta	ttctggctcc	aagcctagag	10680
gctttttttg	aacaagcact	gactgaggaa	acccccgggg	tacaggactg	ctactaccat	10740
tatggacaga	gttaccgagg	cacatactcc	accactgtca	caggaagaac	ttgccaaagct	10800
tggtcatcta	tgaccaccac	ccagcatagt	cggaccccag	aaaactaccc	aaatgctggc	10860
ctgaccagga	actactgcag	gaatccagat	gctgagattc	gcccttgggtg	ttacaccatg	10920
gatcccagtg	tcagggtggga	gtactgcaac	ctgacacaa	gcctgggtgac	agaatcaagt	10980
gtccttgcaa	ctctcacggt	ggtcccagat	ccaagcacag	aggcttcttc	tgaagaagca	11040
ccaacggagc	aaagccccgg	ggtccaggat	tgctaccatg	gtgatggaca	gagttatcga	11100
ggctcattct	ctaccactgt	cacaggaagg	acatgtcagt	cttggctctc	tatgacacca	11160
cactggcatc	agaggacaac	agaatattat	ccaaatggtg	gcctgaccag	gaactactgc	11220
aggaatccag	atgctgagat	tagtccttgg	tggtatacca	tggatcccaa	tgtcagatgg	11280
gagtactgca	acctgacaca	atgtccagtg	acagaatcaa	gtgtccttgc	gacgtccacg	11340
gctgtttctg	aacaagcacc	aacggagcaa	agccccacag	tccaggactg	ctaccatggt	11400
gatggacaga	gttatcgagg	ctcattctcc	accactgtta	caggaaggac	atgtcagtct	11460
tggtcctcta	tgaccaccac	ctggcatcag	agaaccacag	aatactaccc	aaatgggtggc	11520
ctgaccagga	actactgcag	gaatccagat	gctgagattc	gcccttgggtg	ttataccatg	11580
gatcccagtg	tcagatggga	gtactgcaac	ctgacgcaat	gtccagtgat	ggaatcaact	11640
ctcctcacia	ctcccacggt	ggtcccagtt	ccaagcacag	agcttctctc	tgaagaagca	11700
ccaactgaaa	acagcactgg	ggtccaggac	tgctaccgag	gtgatggaca	gagttatcga	11760
ggcacactct	ccaccactat	cacaggaaga	acatgtcagt	cttggctcgtc	tatgacacca	11820
cattggcatc	ggaggatccc	attatactat	ccaaatgctg	gcctgaccag	gaactactgc	11880
aggaatccag	atgctgagat	tcgcccttgg	tggtacacca	tggatcccag	tgtcaggtgg	11940

-continued

```

gagtactgca acctgacacg atgtccagtg acagaatcga gtgtectcac aactcccaca 12000
gtggccccgg ttccaagcac agaggctcct tctgaacaag caccacctga gaaaagccct 12060
gtggtccagg attgctacca tgggtgatgga cggagttatc gaggcataatc ctccaccact 12120
gtcacaggaa ggacctgtca atcttgggtca tctatgatac cacactggca tcagaggacc 12180
ccagaaaact acccaaatgc tggcctgacc gagaactact gcaggaatcc agattctggg 12240
aaacaaccct ggtgttacac aaccgatccg tgtgtgaggt gggagtactg caatctgaca 12300
caatgctcag aaacagaatc aggtgtccta gagactccca ctgttgttcc agttccaagc 12360
atggaggctc attctgaagc agcaccaact gagcaaaccc ctgtgggtccg gcagtgtctac 12420
catggtaatg gccagagtta tcgaggcaca ttctccacca ctgtcacagg aaggacatgt 12480
caatcttggg catccatgac accacaccgg catcagagga cccagaaaaa ctacccaaat 12540
gatggcctga caatgaacta ctgcaggaat ccagatgccg atacaggccc ttggtgtttt 12600
accatggacc ccagcatcag gtgggagtag tgcaacctga cgcgatgtc agacacagaa 12660
gggactgtgg tcgtctctcc gactgtcatc caggttccaa gcctagggcc tccttctgaa 12720
caagactgta tgtttgggaa tgggaaagga taccggggca agaaggcaac cactgttact 12780
gggagcccat gccaggaatg ggctgccacg gagccccata gacacagcac gttcattcca 12840
gggacaaaata aatgggcagg tctggaaaaa aattactgcc gtaaccctga tggtagacatc 12900
aatggtcctt ggtgtcacac aatgaatcca agaaaacttt ttgactactg tgatatccct 12960
ctctgtgcat cctcttcatt tgattgtggg aagcctcaag tggagccgaa gaaatgtcct 13020
ggaagcattg tagggggggt tgtggccac ccacattcct ggccctggca agtcagtctc 13080
agaacaaggt ttggaagca cttctgtgga ggcaccttaa tatcccaga gtgggtgctg 13140
actgtgtctc actgcttgaa gaagtctca aggccttcat cctacaaggt catcctgggt 13200
gcacaccaag aagtgaacct cgaatctcat gttcaggaaa tagaagtgtc taggctgttc 13260
ttggagccca cacaagcaga tattgccttg ctaaagctaa gcaggcctgc cgtcatcact 13320
gacaaaagta tgccagcttg tctgccatcc ccagactaca tggtcaccgc caggactgaa 13380
tgttacatca ctggctgggg agaaacccaa ggtacctttg ggactggcct tctcaaggaa 13440
gcccagctcc ttgttattga gaatgaagt tgcaatcact ataagtatat ttgtgtgag 13500
catttggcca gaggcactga cagttgccag ggtgacagtg gagggcctct ggtttgcttc 13560
gagaaggaca aatacathtt acaaggagtc acttcttggg gtcttggtg tgcacgcccc 13620
aataagcctg gtgtctatgc tcgtgtttca aggtttgtta cttggattga gggaaatgatg 13680
agaaataatt aattggacgg gagacagagt gaagcatcaa cctacttaga agctgaaacg 13740
tgggtaagga tttagcatgc tggaaataat agacagcaat caaacgaaga cactgttccc 13800
agctaccagc tatgccaaac cttggcattt ttggtatttt tgtgtataag cttttaaggt 13860
ctgactgaca aattctgtat taaggtgtca tagctatgac atttgttaaa aataaactct 13920
gcacttattt tgatttga                                     13938

```

<210> SEQ ID NO 861

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 861

cagctcctta ttgttatagc aggga

-continued

<210> SEQ ID NO 862
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 862

tgcgctctgag cattgcgt

18

<210> SEQ ID NO 863
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Probe

<400> SEQUENCE: 863

cccgggtgtca ggtgggagta ctgc

24

<210> SEQ ID NO 864
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 864

gcctcagtct tcttcgcacc

20

<210> SEQ ID NO 865
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 865

gcctcagtct tattcgcacc

20

<210> SEQ ID NO 866
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 866

gcctcagtat tattcgcacc

20

<210> SEQ ID NO 867
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 867

gcctcattat tattcgcacc

20

<210> SEQ ID NO 868
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 868

gcctcattat tattagcacc

20

<210> SEQ ID NO 869

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 869

gcctcattat tattatcacc

20

<210> SEQ ID NO 870

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 870

gcctaattat tattatcacc

20

<210> SEQ ID NO 871

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 871

gcctcagtct gcttcgcac

19

<210> SEQ ID NO 872

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 872

gcctcagtct gcttcgca

18

<210> SEQ ID NO 873

<211> LENGTH: 15

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 873

gcctcagtct gcttc

15

<210> SEQ ID NO 874

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 874

cctcagtctg cttcgcac

18

<210> SEQ ID NO 875

<211> LENGTH: 16

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 875

ctcagtctgc ttcgca                                16

<210> SEQ ID NO 876
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 876

tcagtctgct tcgc                                14

<210> SEQ ID NO 877
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 877

gcctcagtct                                10

<210> SEQ ID NO 878
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 878

gcttcgcacc                                10

<210> SEQ ID NO 879
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 879

uugaagccau acaccuuuu                            20

<210> SEQ ID NO 880
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 880

ugaccaggac ugccuguucu                            20

<210> SEQ ID NO 881
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 881

gaauagggcu guagcuguaa                            20

```

-continued

<210> SEQ ID NO 882
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 882

uauacugauc aaauuguauc

20

<210> SEQ ID NO 883
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 883

uggaaauucug guaugugaag

20

<210> SEQ ID NO 884
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 884

aaaucaaaug auugcuuugu

20

<210> SEQ ID NO 885
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 885

gugaugacac uugauuuaaa

20

<210> SEQ ID NO 886
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 886

gaagcugccu cuucuuucca

20

<210> SEQ ID NO 887
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 887

gagaguuggu cugaaaaauc

20

<210> SEQ ID NO 888
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Oligonucleotide

-continued

<400> SEQUENCE: 888

gtgcgcgcgga gcccgaatc

20

<210> SEQ ID NO 889

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 889

cuucuggcau ccgguuuagt t

21

<210> SEQ ID NO 890

<211> LENGTH: 466

<212> TYPE: DNA

<213> ORGANISM: M. fascicularis

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: 9

<223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 890

ggatcggcng accctgagct gcatatggct ggtaatctaa aaggagccta ccaaaataat

60

gaaataaaac acatctatac catctcttct gctgccttat cagcaagcta caaagcagac

120

actgttgcta aggttcagggtgtggagttt agccatcggc tcaacacaga catcgctggg

180

ctggcttcag ccattgacat tagcacaaac tataattcag actcattgca tttcagcaat

240

gtcttcatt ctgtaatggtccattttacc atgaccattg atacacatac aaatggcaac

300

gggaaacttg ttctctgggg agaacatact gggcagctgt atagcaaatt cctgttgaaa

360

gcagaacctc tggcattcac ttctctcat gattacaaag gctccacgag tcatcatctc

420

atgtctagga aaagcatcag tgcagctctt gaacacaaag tcagta

466

<210> SEQ ID NO 891

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 891

gcctcagtct gctttacacc

20

<210> SEQ ID NO 892

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Antisense Oligonucleotide

<400> SEQUENCE: 892

agattaccag ccatatgcag

20

<210> SEQ ID NO 893

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 893

cgagaggcgg acgggaccg

19

-continued

<210> SEQ ID NO 894
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 894

cgagaggcgg acgggaccgt t

21

<210> SEQ ID NO 895
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 895

ttgctctcgg cctgccttgg c

21

<210> SEQ ID NO 896
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 896

gctctccggc tgccctggc

19

<210> SEQ ID NO 897
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: M. musculus

<400> SEQUENCE: 897

agattaccag ccatatgcag

20

What is claimed is:

1. An antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises at least one modified sugar moiety.

2. The antisense compound of claim 1, wherein said antisense compound is fully complementary within the range of nucleotides 5582-5625 of SEQ ID NO:3.

3. The antisense compound of claim 1, wherein said antisense compound is targeted to the range of nucleotides 5589-5608 of SEQ ID NO:3 and is fully complementary over its length to SEQ ID NO: 3.

4. The antisense compound of claim 1, wherein said antisense compound comprises at least 8 contiguous nucleobases of SEQ ID NO: 224.

5. The antisense compound of claim 1, wherein said antisense compound comprises SEQ ID NO: 224.

6. The antisense compound of claim 1, wherein the antisense compound comprises an antisense oligonucleotide.

7. The antisense compound of claim 1, wherein the antisense compound further comprises one or more modifications selected from the group consisting of a modified backbone and a modified nucleobase.

8. The antisense compound of claim 1, wherein the modified sugar moiety is selected from the group consisting of a 2'-methoxyethoxy modified sugar moiety, a 2'-methoxy

modified sugar moiety, a 2'-O-alkyl modified sugar moiety, and a bicyclic nucleic acid sugar moiety.

9. The antisense compound of claim 1, wherein the antisense compound is single-stranded.

10. The antisense compound of claim 1, wherein the antisense compound is double-stranded.

11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. The antisense compound of claim 1, wherein the antisense compound is covalently linked to a lipid moiety.

13. The antisense compound of claim 12 wherein the lipid moiety comprises a cholesterol.

14. The antisense compound of claim 1, wherein the antisense compound is 20 to 30 nucleobases in length.

15. The antisense compound of claim 1, wherein the antisense compound is 20 nucleobases in length.

16. The antisense compound of claim 1, wherein the antisense compound is a chimeric antisense compound.

17. An antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and at least one modified sugar moiety, wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

18. The antisense compound of claim 17, wherein the antisense compound is 20 nucleobases in length.

19. The antisense compound of claim 17, wherein the modified sugar moiety is a 2'-methoxyethoxy modified sugar

535

moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, or a bicyclic nucleic acid sugar moiety.

20. The antisense compound of claim 17, wherein the antisense compound is an antisense oligonucleotide.

21. The antisense compound of claim 20, wherein the antisense oligonucleotide is a chimeric antisense oligonucleotide.

22. The antisense compound of claim 21, wherein the chimeric antisense oligonucleotide comprises a gap segment of 2'-deoxynucleotides positioned between wing segments, wherein each nucleotide of each wing segment comprises a 2'-methoxyethoxy sugar moiety.

23. The antisense compound of claim 22, wherein the gap segment is ten 2'-deoxynucleotides in length and each wing segment comprises from one to nine 2'-methoxyethoxy nucleotides.

24. The antisense compound of claim 22, wherein the gap segment is ten 2'-deoxynucleotides and each wing segment comprises five 2'-methoxyethoxy nucleotides.

25. The antisense compound of claim 17, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

26. The antisense compound of claim 17, wherein each cytosine is a 5-methylcytosine.

27. The antisense compound of claim 17, wherein the antisense compound is covalently linked to a lipid moiety.

28. The antisense compound of claim 27, wherein the lipid moiety is cholesterol.

29. The antisense compound of claim 17, wherein the antisense compound is fully complementary to SEQ ID NO: 3.

30. The antisense compound of claim 17, wherein the antisense compound comprises SEQ ID NO: 224.

31. The antisense compound of claim 17, wherein the antisense compound consists of SEQ ID NO: 224.

32. An antisense oligonucleotide consisting of SEQ ID NO: 224, wherein nucleobases 1-5 and 16-20 comprise 2'-methoxyethoxy nucleotides, nucleobases 6-15 are 2'-deoxynucleotides, each internucleoside linkage is a phosphorothioate internucleoside linkage, and each cytosine is a 5-methylcytosine.

33. The antisense oligonucleotide of claim 32, wherein the antisense oligonucleotide is in a salt form.

34. The antisense oligonucleotide of claim 33, wherein the salt is sodium salt.

35. A composition comprising the antisense oligonucleotide of any of claim 17, 32, 33 or 34 and a pharmaceutically acceptable carrier or diluent.

36. The antisense compound of claim 17, wherein said antisense compound inhibits expression of apolipoprotein B mRNA in HepG2 cells by at least 40% when contacted with the HepG2 cells at a concentration of 50 nM.

37. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises at least one modified sugar moiety.

38. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and at least one modified sugar moiety, wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

536

39. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense oligonucleotide consisting of SEQ ID NO: 224, wherein nucleobases 1-5 and 16-20 comprise 2'-methoxyethoxy nucleotides, nucleobases 6-15 are 2'-deoxynucleotides, each internucleoside linkage is a phosphorothioate internucleoside linkage, and each cytosine is a 5-methylcytosine.

40. A method of inhibiting the expression of apolipoprotein B mRNA in HepG2 cells by at least 40% comprising contacting said cells with an antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and at least one modified sugar moiety, wherein said antisense compound specifically hybridizes to SEQ ID NO:3, wherein the antisense compound is at a concentration of 50 nM, and wherein said mRNA is inhibited by at least 40%.

41. An antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, wherein the antisense compound is chemically modified.

42. An antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224, wherein the antisense compound is chemically modified, and wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

43. An oligomeric compound 12 to 30 nucleobases in length, wherein said oligomeric compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises at least one modified sugar moiety.

44. An oligomeric compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and at least one sugar moiety, and wherein said oligomeric compound specifically hybridizes to SEQ ID NO:3.

45. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, wherein the antisense compound is chemically modified.

46. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224, wherein the antisense compound is chemically modified, and wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

47. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an oligomeric compound 12 to 30 nucleobases in length, wherein said oligomeric compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises at least one modified sugar moiety.

48. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an oligomeric compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and at least one sugar moiety, wherein said oligomeric compound specifically hybridizes to SEQ ID NO:3.

49. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with a conjugate compound, wherein said conjugate compound comprises an antisense compound 12 to

537

30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and wherein said antisense compound is conjugated to an active drug substance.

50. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with a conjugate compound, wherein said conjugate compound comprises an antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224, wherein said antisense compound specifically hybridizes to SEQ ID NO:3, and wherein said antisense compound is conjugated to an active drug substance.

51. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with a conjugate compound, wherein said conjugate compound comprises an oligomeric compound 12 to 30 nucleobases in length, wherein said oligomeric compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and wherein said oligomeric compound is conjugated to an active drug substance.

52. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with a conjugate compound, wherein said conjugate compound comprises an oligomeric compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224, wherein said oligomeric compound specifically hybridizes to SEQ ID NO:3, and wherein said oligomeric compound is conjugated to an active drug substance.

53. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises a modified backbone or modified nucleobase.

54. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and a modified backbone or modified nucleobase, wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

538

bases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and a modified backbone or modified nucleobase, wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

55. A method of inhibiting the expression of apolipoprotein B mRNA in HepG2 cells by at least 40% comprising contacting said cells with an antisense compound at a concentration of 50 nM, wherein said mRNA is inhibited by at least 40%, wherein said antisense compound is 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and a modified backbone or modified nucleobase, and wherein said antisense compound specifically hybridizes to SEQ ID NO:3.

56. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an oligomeric compound 12 to 30 nucleobases in length, wherein said oligomeric compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises a modified backbone or modified nucleobase.

57. A method of inhibiting the expression of apolipoprotein B in human cells or tissues in vivo comprising contacting said cells or tissues with an oligomeric compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and a modified backbone or modified nucleobase, wherein said oligomeric compound specifically hybridizes to SEQ ID NO:3.

58. A method of inhibiting the expression of apolipoprotein B mRNA in HepG2 cells by at least 40% comprising contacting said cells with an oligomeric compound at a concentration of 50 nM, wherein said mRNA is inhibited by at least 40%, wherein said oligomeric compound is 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO: 224 and a modified backbone or modified nucleobase, and wherein said oligomeric compound specifically hybridizes to SEQ ID NO:3.

* * * * *